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outline of the thesis
A disease can be described at various levels, based on its etiology, pathogenesis, 
pathophysiology and phenotype. The etiology and pathogenesis describe the cause 
and disease-specific processes, respectively, that lead to the pathophysiology, i.e. the 
functional changes that accompany a disease. These physiological changes, in turn, lead 
to clinical symptoms, i.e. the phenotype of the disease. Clinical and biological research 
aims at advancing our insights into the etiology, pathogenesis, pathophysiology and 
phenotype of a disease. In this introduction, the increasing understanding of Parkinson’s 
disease (PD) will be summarized according to these four levels of description, starting 
with the clinical description (phenotype; section 1.1), followed by the pathophysiology 
(section 1.2), and the etiology and pathogenesis (section 1.3) of PD. This view into 
knowledge development over time not only gives insights into the workings of science, 
but also provides us an overview of all currently known factors involved in PD and 
enables us to appreciate the complexity of the disease.
In the research described in this thesis, we use (animal) models, generate hypotheses, 
and seek to uncover and further advance the knowledge of the core molecular processes 
underlying PD. It is therefore of crucial importance that we compare the model that we 
apply, or the hypothesis that we pose, with the real-life situation, in this case PD. Is our 
model sufficiently simulating the disease that we want to understand? What are the 
limitations and caveats of the model used? Is our hypothesis in accordance with the 
human situation? To allow such considerations, I believe it is essential to have at least 
a basic understanding of the clinical and biological aspects of the disease.
Further, I shortly discuss current treatments of PD (section 1.4), explain the landscape 
building approach – the method that is used throughout this thesis to integrate and 
interpret large datasets – (section 1.5), and present the specific aims of this thesis and 
a brief outline of each chapter (section 1.6).
1.1 A HISTORICAL WINDOW INTO THE CLINICAL DESCRIPTION OF PD
1.1.1 The cardinal motor features of PD
Until the early 19th century, diseases such as PD, multiple sclerosis, progressive muscle 
atrophy and amyotrophic lateral sclerosis (ALS) were all described as ‘palsies’. A palsy 
referred to any type of paralysis, which was defined by the nosologist Philippe Pinel 
(1745-1826) as:
“…a total or a partial decrease of voluntary movement. The arms and legs 
could be in various states: without any tension, with tremor or in a state of 
contraction.” 1, 2
Therefore, basically all diseases with involuntary motor symptoms were categorized 
in this group, which asked for a more specific definition of the disorders. In 1817, the 




palsy” (Figure 1). In this medical essay, Parkinson described six cases with the shaking 
palsy of which he observed three in his practice and three others from a distance on his 
walks around the neighborhood. In 66 pages, Parkinson described his definition of the 
shaking palsy (or ‘paralysis agitans’) and thereby set it apart from other palsies: 
“Involuntary tremulous motion, 
with lessened muscular power, 
in parts not in action and 
even when supported; with a 
propensity to bend the trunk 
forward, and to pass from a 
walking to a running pace: the 
senses and intellects being 
uninjured.” 
In this way, Parkinson described two 
of the four cardinal features of PD, the 
resting tremor and postural instability. 
The latter causes the propulsion observed 
in PD patients, caused by their inability 
to maintain their balance. In addition to 
these features, Parkinson described non-
motor symptoms such as constipation:
“The bowels, which had been all 
along torpid, now, in most cases, 
demand stimulating medicines 
of very considerable power” 
and drooling: 
“the saliva fails of being directed to the back part of the fauces, and hence is 
continually draining from the mouth, mixed with the particles of food, which 
he is no longer able to clear from the inside of the mouth.” 
Furthermore, Parkinson made a distinction between acute cases of palsy and the cases 
of shaking palsy he described in his essay. He defined an acute palsy as a sudden 
decrease in voluntary muscle action, sometimes in combination with a ‘lessened sense 
of feeling’ and caused by a trauma, or as he put it:
“compression of the brain, or dependent on partial exhaustion of the energy of 
 that organ”
In contrast, in the six cases of shaking palsy described by Parkinson, he saw a longer 





duration of disease onset and progression, eventually resulting in reduced mobility 
with increased speech problems, but without a loss of feeling as seen in the acute cases:
“…the diminution of the influence of the will on the muscles comes on with 
extreme slowness, is always accompanied, and even preceded, by agitations 
of the affected parts, and never by a lessened sense of feeling. (...) he began to 
find a small impediment in uttering some words (...) the difficulty in speaking 
(...) considerably increased (...) a spitting began, and now it was with difficulty 
that he uttered a few words.” 
Parkinson therefore noted that the cases of shaking palsy had a slower progression of 
the disease and other symptoms than was observed in patients with acute palsies.
Lastly, Parkinson defined the tremor and the propulsion as pathognomonic (occurring 
in only one disease) for shaking palsy, distinguishing it from other patients with 
palsies3. However, nowadays these symptoms are not considered to be pathognomonic 
anymore and can overlap with other neurodegenerative diseases such as multiple 
system atrophy and progressive supranuclear palsy4, 5. 
Although Parkinson tried to excite his fellow researchers, it was not until the second 
half of the 19th century that the French internist Armand Trousseau (1801-1867) in 
his lectures at the Hôtel-Dieu in Paris and the neurologist Jean-Martin Charcot (1825-
1893) during his teaching at the Salpêtrière in Paris further defined and elucidated 
the clinical features of the shaking palsy. Trousseau described rigidity in PD patients, 
the third cardinal motor symptom of PD, and also described a progressive slowing 
of repeated hand opening, which is the first account of bradykinesia6 and the fourth 
cardinal feature of PD. Moreover, and in contrast to Parkinson, Trousseau noted that PD 
patients show a cognitive decline:
“The intellect is at first unaffected, but gets weakened at last; the patient loses 
his memory, and his friends soon notice that his mind is not so clear as it was: 
precocious caducity sets in.” 6
Charcot contributed to the systematic examination of neurological diseases, which 
made it possible to distinguish PD from other diseases such as multiple sclerosis7. He 
was the first to provide a clear description of ALS8, and to give a complete overview of 
the clinical symptoms of PD in the 1870s and 1880s, which was eventually published in 
the ‘Leçons sur les maladies du système nerveux, faites à la Salpêtrière’. In this work, 
Charcot, like Parkinson, described the cardinal PD motor features resting tremor:
“the patient closes the fingers on the thumb as though in the act of spinning 
wool (...) The thumb moves over the fingers as when a pencil or paper-ball 
is rolled between them; in others the movements are more complicated and 




and postural instability: 
“a tendency to propulsion or to retropulsion (...) the individual is, in the first 
case, propelled forward, and, as it were, compelled to adopt a quick pace; the 
individual is unable, without extreme difficulty, to stop – being apparently 
forced to follow a flying centre of gravity.”
but also recognized, like Trousseau, the rigidity in the neck, trunk and extremities. 
Moreover, Charcot described slowness in the execution of movement (bradykinesia) as a 
cardinal feature of the disease and noted that this was independent of the rigidity in the 
limps7. In 1925, Jean-René Cruchet (1875-1959) was the first to use the term ‘bradykinesia’ 
for the slow execution of movement and defined this as the most important symptom 
of PD9, 10. In the 1920s, the French Neurologist Jules Froment (1878-1946) showed that 
rigidity in PD depends on the static posture of the body and that in PD ‘maintenance 
stabilization’ of the body is impaired and is compensated by ‘rigidification’ of the body11.
Charcot also noted the ‘poker face’ of PD patients: 
“a fixed look, and immobile features”
Further, he acknowledged PD patients’ complains of pain and sensations:
“They complain of cramps, or rather of a nearly permanent sensation of tension 
and traction in most of the muscles.”
but also their problems with speaking: 
“the utterance is slow, jerky and short of phrase: the pronunciation of each 
word appears to cost a considerable effort (...)the utterance will be tremulous, 
broken, jolted out as it were like that of an inexperienced rider on horseback, 
when the animal is trotting.”
and he studied the problems PD patients have with writing (micrographia) (Figure 2):
“The strokes forming the letters 
are very irregular and sinuous, 
whilst the irregularities and 
sinuosities are of a very limited 
width. (…) the down-strokes are 
all, with the exception of the first 
letter, made with comparative 
firmness and are, in fact, nearly normal – the finer up-strokes, on the contrary, 
are all tremulous in appearance, and it is to the unsteadiness of these lines that 
the peculiar character of the writing here is principally due.”




In describing the cardinal features 
of PD, Charcot recognized the early 
contributions of James Parkinson and 
therefore proposed to name the disease 
“Parkinson’s disease”7, a name that has 
been used ever since. 
In the 1870s, the anatomist Paul Richer 
(1849-1933) started as an assistant of 
Charcot and in 1882 became the head of 
the Salpêtrière’s museum of pathological 
anatomy. Charcot founded this 
museum that was focused on the visual 
representation of different (neurological) 
diseases12. Charcot and Richer had a 
shared interest in the representation 
of diseases in art and wrote two books, 
‘Les Démoniaques dans l’art’ (1887) and 
‘Les Difformes et les Malades dans l’Art’ 
(1889), in which they diagnosed patients 
depicted in artwork12. By creating and 
collecting sculptures and other visual 
representations of pathologies, Charcot and Richer meant to provide an objective, 
three-dimensional alternative for photography12. For the Salpêtrière’s museum of 
pathological anatomy, Richer sculpted a series of very accurate representations 
of patients suffering from e.g. myopathy, hypothyroidism and PD12. In 1895, Richer 
published ‘Étude morphologique sur la maladie 
de Parkinson’, which contains photographs of 
a statue of a 58-year-old female PD patient he 
had sculpted that were compared with photos 
of a male PD patient photographed in the same 
angles and lighting conditions as the statue13 
(Figure 3). In this way, Richer confirmed the 
pathological likeness and objectivity of his 
‘scientific artworks’12, 13. This work by Richer is 
one of the first known depictions of PD. Another 
iconic illustration of a PD patient was published 
in 1888 by the British neurologist William Gowers 
(1845-1915) in his book ‘A Manual of Diseases of 
the Nervous System’ (Figure 4). 
Figure 3. Photographs of a statue (46 cm tall) of a female 
PD patient sculpted by Richer (upper panels) and of 
a male PD patient (lower panels). Photographs are 
adjusted from ref. 13.
Figure 4. Illustration of a PD patient by 




Gowers was the first to recognize the predominance of male PD patients and he also 
reported the high age of onset (50-60 years of age), the joint deformities in PD and an 
increased sense of heat and perspiration. On the treatment of PD patients Gowers said:
“My own experience is to the effect that arsenic and Indian hemp, the latter 
sometimes combined with opium, are of most use” 14
and he also notes that:
 “Electricity in all forms is useless.” 14
These statements probably made him – in comparison to all other used practices 
such as nerve stretching (Westphal), static electricity (Charcot) and voltaic electricity 
(Berger)14 – an attractive physician to consult at that time.
1.1.2 Cognition and psychiatric symptoms in PD
Although some neurologists have reported a cognitive decline in the end stages of the 
disease, the psychiatric symptoms of PD have been less well described. In 1881, the 
first professor of psychiatry in Paris, Benjamin Ball (1833-1893), stated on a medical 
congress in London that:
“(…) a large number of Parkinsonian patients present psychological disorders 
extending from simple irritability to psychosis; far from being an exception I 
would say that a slight degree of cognitive impairment is the rule” 15. 
By doing so, Ball was the first to describe psychiatric symptoms, like depression, 
in association with PD and started a debate among neurologists about psychiatric 
symptoms as an integral part of PD. Charcot and his (former) student Brissaud (1852-
1909) still believed that these symptoms were not part of the disease and irrelevant. 
Moreover, the British neurologists Gowers and Samuel Wilson (1878-1937) believed that 
the depression and irritability observed in PD patients should be regarded a “natural 
outcome, perhaps, of an incurable disease”. This implied that these symptoms would 
have been caused by the frustration of being incurably ill and that these and other 
psychiatric symptoms could be ascribed to other diseases or were incidental15, 16. 
Nevertheless, later Gowers also stated that PD patients had a propensity for mental 
weakness, memory loss and delusions:
“Pronounced mental symptoms are occasionally present, however, in the 
later stages of the disease, commonly limited to mental weakness and loss of 
memory, but sometimes accompanied by a tendency to delusions.” 14 
Therefore, although not fully accepted as part of the disease, the psychiatric symptoms 
were included more and more into the clinical description of PD. However, it was not 





In summary, PD is defined primarily as a motor disorder, exhibiting the cardinal features 
resting tremor, postural instability, rigidity and bradykinesia and is, especially in the 
later stages of disease progression, associated with cognitive decline and psychiatric 
symptoms. In addition, although the clinical depiction of PD has changed over time, 
the initial descriptions by Parkinson and Charcot still form the basis for defining the 
disease. 
1.1.3 Categorization of disease progression
Parkinson described the disease as extremely slow and gradually progressing over 
the course of multiple years. In one of his case descriptions, Parkinson reported the 
progression of the disease as starting with a tremor in the left hand and arm, extending 
three years later to the right arm and hand, and another three years later also to the 
legs3. Charcot gave a more elaborate description of the average clinical progression of 
PD and recognized three disease phases7. The first phase is a ‘slow invasion’ of disease 
symptoms:
“At this stage of the disease the tremor may be merely passing and transitory. It 
breaks out when least expected, the patient enjoying complete repose of mind 
and body, and it frequently occurs without his being conscious of it. (…) Later 
on, it will be no longer so. Moreover, as it augments in intensity and persistence, 
the tremor invades little by little (…)”.
The second phase is a stationary period in which the characteristics of the disease such 
as the tremor are “displayed in all their fullness” and the third phase is the terminal 
period, for which he described the symptoms of the patient as: 
“(…) difficulty of movement increases, and the patients are obliged to remain, 
the whole day long, seated on a chair, or are altogether confined to the bed. 
Then, nutrition suffers, especially the nutrition of the muscular system. (…) the 
patients succumb to the mere progress of their disease, by a sort of exhaustion 
of the nervous system”. 
In addition, Gowers noted that the disease is “always chronic, and usually progressive, 
in its course.” and he described the extension of motor symptoms from one side of 
the body to the opposite site taking place “six months to three or four years after the 
onset.” 14. In 1967, Hoehn and Yahr updated this motor symptoms-based description17, 
and categorized PD patients according to five disease stages:
Stage I:  Unilateral motor symptoms; 
Stage II:  Bilateral motor symptoms; 




but the patient can still cope without assistance; 
Stage IV: Severe and disabling motor symptoms, assistance is often 
necessary during physical movement;
Stage V: Most severe motor symptoms, the patient is unable to perform 
physical movement without assistance, and is confined to a 
bed or wheelchair. 
However, acknowledging the shortcomings of categorizing PD patients solely on their 
motor symptoms, the Movement Disorder Society - Unified Parkinson’s Disease Rating 
Scale (MDS-UPDRS) is currently used to describe PD progression. This detailed rating 
scale describes the various aspects of motor dysfunction and includes the Hoehn and 
Yahr classification of progression as well, but it also takes into account the non-motor 
symptoms seen in (especially late-stage) PD e.g. (impaired) mental functioning, mood, 
pain and other sensations, sleep problems and daily living activities18. As such, the 
categorization of PD disease progression is – by including the non-motor symptoms of 
PD – (again) in accordance with the clinical description of PD.
1.2 TOWARDS THE PATHOPHYSIOLOGY OF PD
In the 19th century, the concept of networks between different brain areas was not known 
yet, and therefore various pathological origins of PD were proposed, and a discussion 
arose about which brain area would cause PD. Parkinson and later also the English 
physiologist Marshall Hall thought that lesions in the medulla caused Parkinson’s 
disease19, 20. Charcot on the other hand thought that PD was caused by neurosis “in this 
sense that it possesses no proper lesion” 7, and the German neuropathologist Oskar 
Berger (1844-1885) suggested that sudden intense emotions (especially sudden terror), 
long exposure to damp cold, or trauma to the peripheral nerves were initiators of PD21. It 
was in 1895 that Brissaud commented in his lesson ‘Nature et Pathogénie de la Maladie 
de Parkinson’ at the Salpêtrière that: 
“a lesion of the locus niger may be the anatomical substrate of Parkinson’s 
disease” 22 (translated from French). 
Brissaud made this clinicopathological association based on a case report by Blocq and 
Marinesco in which they described a patient with unilateral Parkinsonism caused by a 
tumor in the substantia nigra (SN)23. In 1919, the Russian neuropathologist Konstantin 
Tretiakoff (1892-1958) confirmed Brissaud’s remark in his thesis, i.e. Tretiakoff reported a 
loss of pigmented neurons in the SN of six patients with PD and also noted the presence 
of ‘Lewy bodies’ in the remaining SN neurons24. The latter he did in recognition of earlier 
research by Friedrich Lewy (1885-1950) who reported similar inclusions in neurons of 
PD patients25. Tretiakoff ended his thesis with the statement:




substantia nigra and Parkinson’s disease, there is a very close relation. This is 
most likely a causal relation.” 24 (translated from French). 
However, others claimed that lesions in the cerebral cortex26, globus pallidus and 
striatum27, 28 were more relevant. Moreover, although the degeneration of pigmented 
neurons of the SN was consistently found in patients with PD29, 30, Tretiakoff’s findings 
were not widely accepted until they were confirmed by the German pathologist Rolf 
Hassler (1914-1984) in 1938 and by Greenfield and Bosanquet in 1953. Hassler showed 
that all PD patients had a loss of pigmented neurons in the SN, that surviving neurons 
contained Lewy bodies, and that lesions in the striatum or globus pallidus were not 
always present31, whereas Greenfield and Bosanquet provided an extensive pathological 
overview of the lesions observed in PD32.
In subsequent years, the concept of neuronal circuits took hold, with the SN, striatum 
and globus pallidus (all part of the basal ganglia) as key brain nuclei involved in the 
clinical manifestation of PD33. 
In the 1950s, the biochemical changes underlying this neuronal circuit in the basal 
ganglia were identified by, among others, the Swedish researcher Arvid Carlsson. 
Carlsson showed that dopamine (DA) was a neurotransmitter in the brain that could 
be depleted by reserpine – a cardiovascular drug that also has an akinetic effect – and 
restored by levodopa (L-DOPA), a precursor of DA34. Moreover, Bertler and Rosengred, 
medical students in the lab of Carlsson, showed that DA concentrated in the striatum of 
a dog brain35, 36 and they concluded that: 
“The results favour the assumption that dopamine is concerned with the 
function of the corpus striatum and thus with the control of motor function.” 
These observations were also replicated in humans37 and in 1959, Carlsson suggested 
that DA plays a role in PD38. In 2000, Carlsson received the Nobel Prize in Physiology or 
Medicine for his work on signal transduction in the nervous system39.
In 1960, Ehringer and Hornykiewicz found that depletion of striatal DA was specific 
for PD patients and not observed in patients with Huntington’s disease or exhibiting 
extrapyramidal signs – such as tremor, rigidity and hyperkinesias – of unknown 
origin, i.e. neurological diseases that exhibit motor symptoms similar to PD40. Their 
first clinical trial showed that intravenous administration of L-DOPA reduces the motor 
symptoms of PD patients41. In 1967, George Cotzias demonstrated that starting with 
very low doses of L-DOPA that were gradually increased over time not only reduced the 
motor symptoms of PD but also the side-effects of high dosages of L-DOPA42.
The link between striatal DA levels and SN degeneration was confirmed in 1964 by Nils-
Erik Andén (and Carlsson as a co-author) using a fluorescence technique developed 




axons of the SN neurons and showed that an SN lesion causes a loss of fluorescence in 
the striatum and thus reduced striatal DA45.
In conclusion, the pathophysiology of PD is characterized by lesions in basal ganglia 
nuclei, and especially by the loss of DA-producing neurons in the SN, resulting in 
reduced DA release in the striatum. Treatment of PD patients with the DA precursor 
L-DOPA attenuates the motor symptoms caused by low striatal DA.
The presence of non-motor symptoms in PD supports the involvement of 
neurotransmitters other than DA that regulate processes such as memory and learning 
(e.g. glutamate, acetylcholine)46, 47, and mood and sleep (e.g. serotonin)48, or pain (e.g. 
neuropeptides)49, 50. Moreover, the neurological substrate of PD is not limited to the SN 
and involves the degeneration of multiple other brain areas and non-DA pathways that 
contribute to both the motor and non-motor features of PD. The establishment of PD as 
a disease spanning multiple brain areas was further emphasized by a study by Braak in 
2003. In this study, the pathological disease pattern of PD was described in six stages 
starting in the pre-motor period of PD with lesions in the anterior olfactory nucleus and 
brain stem (stages 1-2), ascending to the basal mid- and forebrain nuclei (among which 
the SN) and paralimbic cortex (stages 3-4) and in the final stages (5-6) to the neocortex51, 
52. Lesions in all these areas, other than the basal ganglia nuclei, may contribute to the 
non-motor symptoms of PD and affect e.g. olfactory function, rapid eye movements and 
mood, and this even before the clinical manifestation of motor symptoms. Nevertheless, 
until today, the biochemical changes underlying the pre-motor symptoms in PD have 
been under-investigated compared to such changes underlying the motor symptoms 
and are therefore still largely unresolved53.
To better understand how decreased levels of DA in specific brain areas could lead to 
the diverse clinical manifestations as seen in PD, new models were developed taking 
connections between different brain areas into account. The classic model of basal 
ganglia circuitry is based on a loop between the cortex and the basal ganglia nuclei, 
which is thought to be dysregulated in PD (Figure 5). In this model, the reduced input 
from the SN pars compacta (SNpc) to the striatum results in increased activation of 
the globus pallidus pars interna (GPi) and SN pars reticulata (SNr), and subsequent 
inhibition of the thalamocortical projection. Increased activation of the GPi may occur 
either through the direct pathway (striatum > GPi) or indirect pathway (striatum > 
globus pallidus pars externa > subthalamic nucleus > GPi/SNr). In this way, activation 
of the direct pathway reduces the activity of the GPi and facilitates movement, whereas 
activation of the indirect pathway increases GPi activity and suppresses movement. 
Nevertheless, this model is now regarded as limited, because it cannot explain multiple 
clinical features of PD54. For example, the origin of a rest tremor and rigidity as seen in 




Figure 5. The classic pathophysiological model of the basal ganglia circuit in a healthy person (left) and in a PD 
patient (right). In PD, a reduced DAergic innervations of the striatum (yellow arrow) increases the activity of the 
indirect pathway (striatum-GPe-STN-GPi/SNr) and decreases the activity of the direct pathway (striatum-GPi). 
Green arrows show the excitatory glutamatergic connections and red arrows show the inhibitory GABAergic 
connections between the brain areas. GPe, globus pallidus pars externa; GPi, globus pallidus pars interna; 
SNpc, substantia nigra pars compacta; SNr, substantia nigra pars reticulate; STN, subthalamic nucleus. Figure 
modified from refs. 54 and 55.
Figure 6. The basal ganglia circuitry subdivided in motor, oculomotor, associative and limbic loops. As an 
extension of the classic basal ganglia model (shown left) the basal ganglia circuit is subdivided in four loops 
that each regulate a subset of functions (shown below each loop). These loops are located in more precisely 
defined areas of the cortex and basal ganglia nuclei that are also part of the classic model. GPi, globus pallidus 




lesions of the global pallidus or thalamus do not aggravate the motor function of PD 
patients, and GPi lesions abolish L-DOPA-induced dyskinesias, which is incompatible 
with a model that associates increased inhibition of the GPi with the facilitation of 
movements such as dyskinesias54. Therefore, in the most recent basal ganglia model, 
the basal ganglia circuitry is subdivided into motor, oculomotor, associative and limbic 
loops (Figure 6) that each regulate a subset of functions such as learning, planning, 
memory and emotions. In this respect, the dysregulation of the motor loop in the form 
of abnormal synchronized oscillatory activity – i.e. repetitive activation of groups of 
neurons – results in motor impairment in PD58, whereas the oculomotor loop is involved 
in the control of eye movements which are affected in PD patients59. Further, defects 
in the associative loop result in cognitive inertia and executive dysfunction in PD60, 
and dysregulation of the limbic loop in PD contributes to motivational and emotional 
processes such as impulse control disorders and emotional blunting60, 61. Although 
this current model is still oversimplified, the loops between basal ganglia areas and 
the cortex nevertheless provide a better model for the pathophysiology of PD than 
the classic basal ganglia model, and also better explain the occurrence of non-motor 
symptoms in PD.
1.3 THE ETIOLOGY AND PATHOGENESIS OF PD
Up until now, research on patients with familial PD – i.e. the Mendelian form that is 
passed on from parent to child – has resulted in the identification of 23 genetic risk loci 
and 17 genes that, when mutated, cause PD. The list of familial PD genes, their mode of 
inheritance, and the proteins that they encode can be found in Table 1. The involvement 
of these genes in PD provided an initial idea of the processes and pathways leading to 
the degeneration of neurons in the SN, e.g. the protein encoded by the alpha-synuclein 
(SNCA) PD-familial gene is part of the earlier identified Lewy bodies, while PARK2, PARK7 
and PINK1 encode proteins that regulate mitochondrial quality control and oxidative 
stress, and the proteins encoded by LRRK2 and VPS35 are involved in autophagy 
and protein trafficking, respectively. However, as only 5-10% of the patients have the 
Mendelian forms, PD is predominantly considered a sporadic disease62, 63, i.e. occurring 
‘spontaneously’ in a patient without a family history of PD. In contrast to a ‘one-hit 
model’ like familial PD, sporadic PD is considered to be a multifactorial disease that 
requires ‘multiple hits’ – i.e. by a combination of genetic and environmental risk factors 
– for the disease to manifest itself64, 65. Because these risk factors all contribute to the 
onset of PD for only a small part and they can differ between and within populations, it is 
more difficult to pinpoint them than familial mutations. However, since the completion 
of the human genome project in 200166, 67 the use of genome-wide screening methods 
such as genome-wide association studies (GWASs) and genome-wide expression 
profiling became possible. Using these methods, instead of studying single candidate 




Table 1. PD risk loci and associated familial PD genes. For each PD gene, its protein product and its 
mode of inheritance is shown. The references provide for each gene (or locus when the causative gene 
in the locus is unknown), the study that firstly associated the gene/locus with PD is referred to. AD: 
Autosomal dominant; AR: Autosomal recessive.
Locus Location Gene Protein Inher. Ref.
PARK1 4q22.1 SNCA 
(mutation)
Alpha-synuclein AD 68
PARK2 6q26 Parkin E3 ubiquitin-protein ligase parkin AR 69
PARK3 2p13 Unknown - AD 70
PARK4 4q22.1 SNCA 
(triplication)
Alpha-synuclein AD 71
PARK5 4p13 UCHL1 Ubiquitin carboxyl-terminal 
hydrolase isozyme L1
AD 72
PARK6 1p36.12 PINK1 Serine/threonine-protein kinase 
PINK1
AR 73
PARK7 1p36.23 DJ-1 Protein deglycase DJ-1 AR 74
PARK8 12q12 LRRK2 Leucine-rich repeat serine/
threonine-protein kinase 2
AD 75
PARK9 1p36.13 ATP13A2 Probable cation-transporting 
ATPase 13A2
AR 76
PARK10 1p32 Unknown - - 77
PARK11 2q36-q37 GIGYF2 [1] PERQ amino acid-rich with GYF 
domain-containing protein 2
AD 78
PARK12 Xq21-q25 Unknown - - 79
PARK13 2p13.1 HTRA2 Serine protease HTRA2 AD 80
PARK14 22q13.1 PLA2G6 85/88 kDa calcium-independent 
phospholipase A2
AR 81
PARK15 22q12.3 FBXO7 F-box only protein 7 AR 82
PARK16 1q32 Unknown - - 83
PARK17 16q11.2 VPS35 Vacuolar protein sorting-
associated protein 35
AD 84
PARK18 3q27.1 EIF4G1 [2] Eukaryotic translation initiation 
factor 4 gamma 1
AD 85
PARK19 1p31.3 DNAJC6 Putative tyrosine-protein 
phosphatase auxilin
AR 86
PARK20 21q22.11 SYNJ1 Synaptojanin-1 AR 87
PARK21 3q22 DNAJC13 DnaJ homolog subfamily C 
member 13
AD 88
PARK22 7p11.2 CHCHD2 [3] Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 2
AD 89
PARK23 15q22.2 VPS13C [4] Vacuolar protein sorting-
associated protein 13C
AR 90
[1]  It is questionable whether GIGYF2 mutations actually cause PD. Mutations in GIGYF2 are provisionally 
designated as risk factors for PD91.
[2]  Confirmed as a risk factor for PD92, but not as a familial, causative gene92, 93.
[3]  The mutations in the initial study have not been confirmed, but other putative pathogenic mutations have 
been reported94.




factors or expression differences. GWASs determine if there is an association between 
common variations in the genome, so called single nucleotide polymorphisms (SNPs), 
and a specific trait or disease95. Further, mRNA expression profiling using microarrays 
or RNA sequencing (RNAseq) made it possible to identify genes – or rather the mRNAs 
transcribed by these genes – that show a dysregulated expression and reflect the 
causative and compensatory processes that are involved in the disease. In this way, 
an enormous amount of genetic and expression data for PD has been collected in the 
past years. GWASs identified multiple susceptibility genes for sporadic PD (e.g. SNCA, 
WNT3, FAM190A, GBA, NSF )96-99, whereas genome-wide expression studies showed the 
dysregulation of genes/mRNAs involved in (among others) the ubiquitin-proteasome 
system, oxidative stress, mitochondrial function, vesicular transport, axon guidance, 
synaptic function and the immune response100-105. In addition to the findings from 
genetic and expression studies, environmental risk factors for PD have been thoroughly 
researched, i.e. increased risk for PD has been attributed to pesticides, head injury and 
use of beta-blockers, whereas smoking and caffeine intake have been associated with 
a decreased risk106. Although these different approaches resulted in large datasets and 
have led to the identification of multiple PD candidate genes and proteins exhibiting 
a wide variety of functions, it has proved difficult to integrate these data and find a 
common mechanism leading to sporadic PD. However, as variants within familial PD 
genes (e.g. SNCA, LRRK2) were also identified as susceptibility factors for sporadic 
PD107, 108, the underlying causal mechanisms of familial and sporadic PD are expected 
to – at least partially – overlap. Nevertheless, the absence of clear understanding of the 
underlying molecular pathways hampers the development of effective new therapies 
and drugs to treat PD. This is made clear by the fact that, despite all the research of 
the past decades, symptomatic treatment with L-DOPA is still the gold standard. To 
develop true disease-modifying therapies that not only provide symptomatic relief but 
also slow – or even stop – the progression of the disease, the underlying biological 
processes and causal mechanisms of the disease must be targeted. Therefore, further 
and more in-depth knowledge about the etiology and pathogenesis of PD is essential.
1.4 CURRENT TREATMENTS OF PD
Treatment of PD may consist of dopaminergic medication, neurosurgical methods 
such as deep brain stimulation (DBS) and supportive care such as physiotherapy109. 
Dopaminergic therapy aims to increase DA signaling in the brain by increasing its 
production through the administration of L-DOPA, by using DA agonists that activate 
DA receptors, or by using drugs that inhibit the proteins involved in DA degradation. 
Often these compounds are administrated in different combinations, depending on the 
stage of the disease and side effects experienced by the patient. Dopaminergic therapy 
works very effectively against the motor symptoms of PD, but does not slow down 




degenerated and higher dosages are needed, L-DOPA may induce dyskinesias110-112 and 
DA agonists potentially cause hallucinations113. Therefore, especially in the late stages 
of PD, dopaminergic therapy is complex and needs to be tailored per patient.
DBS is an alternative, established therapy for PD. Usually an electrode is placed in the 
subthalamic nucleus (STN) or the GPi, two hyperactive brain regions in the basal ganglia 
of PD patients109, 114 (see also Figure 5). The electrical stimulation from the electrode is 
thought to disrupt the signaling of these brain areas and block the abnormal signals 
through the basal ganglia circuit115. DBS is used to treat the motor symptoms of PD, 
particularly motor fluctuations – rapid changes between good and poor response to 
dopaminergic therapy – and resting tremor that is resistant to pharmacotherapy. The 
effects of DBS on non-motor symptoms in PD is controversial, i.e. were some studies 
show worsening of cognitive function – i.e. measures of reasoning, memory, executive 
functions and language – after DBS surgery116-119, others suggest that this is due to 
worsening of the disease, and reduction of medication and not as a result of the DBS120-
123. 
Of interest, aerobic exercise (e.g. treadmill exercise, cycling or dancing) or strength 
training (e.g. using a modified fitness counts program or progressive resistance 
exercising) that is used as supportive therapy to treat PD have been demonstrated 
to improve DA signaling in a mouse model124, 125, and motor dysfunction – including 
bradykinesia, rigidity and tremor – in PD patients126-131. Further, physical exercise has 
also been reported to improve mood, cognitive function and sleeping problems in PD 
patients132-134 and therefore improves – in contrast to dopaminergic therapy and DBS – 
not only the motor, but also certain non-motor symptoms of PD. 
Although therapeutic interventions based on the main pathophysiology – e.g. improving 
DA signaling with L-DOPA treatment – or main clinical symptoms – e.g. improvement 
of motor symptoms with physical exercise – may not modulate the underlying disease-
causing processes, they do however provide symptomatic relief. Moreover, further 
insight into the molecular and cellular effects of these treatments may improve our 
understanding of the pathophysiology of PD, and may also enable us to develop more 
effective therapies.
1.5  THE LANDSCAPE BUILDING APPROACH
In this thesis, large genetic and expression datasets are integrated and interpreted 
using the landscape building approach to gain insight into the molecular pathways 
underlying 1) the etiology and pathogenesis of PD, and 2) the beneficial effects of 
physical exercise therapy. An unbiased dataset is used as starting point for the 
landscape building approach – e.g. GWAS or genome wide expression data – to identify 




and expression dataset are visualized, and respectively the SNPs and transcripts that 
represent the candidate genes are indicated. These SNPs and transcripts meet certain 
inclusion criteria that are presented below and are also shown in Figure 8A as the first 
part of the landscape building approach: 
When GWAS data is used as a starting point, only the SNPs with a p-value <0.0001, often 
employed to designate ‘suggestive’ association135-137, are considered. The candidate 
genes either contain one or more of these SNPs within their exonic, intronic or 
untranslated region, or are the nearest gene downstream, or the nearest gene upstream 
within 100 kilobases (kb) of a SNP. The latter is based on the fact that the vast majority 
of expression quantitative trait loci (eQTL; SNPs that are not located in a gene but 
regulate the expression of one or more genes in their (relative) vincinity) for a given 
gene are located within 100 kb down- and/or upstream of this gene138-140 and because 
trait-associated SNPs are more likely to be eQTL141. When candidate gene selection 
is based on expression data e.g. resulting from RNAseq, the transcripts are subjected 
to a cut-off for the RPKM (Reads Per Kilobase of transcript per Million mapped reads; 
a correction for gene length), the adjusted p-value and the fold-change between the 
healthy and the diseased state. In the case of our RNAseq analysis (chapter 4), these 
cut-offs were chosen based on qPCR measurements that indicated which transcripts 
could be detected in the individual samples, and as such, which cut-offs should be used 
as a detection threshold.
In the second stage of the landscape building approach (Figure 8B), the resulting list of 
candidate genes is subjected to an elaborate literature study to establish:
Figure 7. Visualization of GWAS (A) and genome wide expression (B) data. The SNPs respectively the transcripts 




1)  the interactions between the proteins encoded by these genes, and other 
proteins that function as key interactors (e.g. by forming a functional hub),
2)  the interactions with additional proteins that are associated with the 
disease through candidate gene, functional, animal and/or cell line studies,
3)  functional themes, signaling pathways and/or cascades within the set of 
interacting proteins, and
4) identification of putative druggable targets.
Figure 8. Overview of the landscape building approach. Candidate genes potentially involved in the studied 
disease are identified from genome wide association studies (GWASs) or genome wide expression data (A). 
Subsequently, the interactions between the proteins encoded by these candidate genes (red), but also the 
interactions with proteins that function as key interactors (light gray) and/or are disease-associated (dark gray) 
are established. Combined, all these interactions form the molecular landscape in which functional themes 
(red circle), signaling pathways and cascades (red arrows), and putative druggable targets (green marks) can be 
identified (B). FC, fold-change; qPCR, quantitative real-time polymerase chain reaction; RPKM, reads per kilobase 




These interactions, themes and pathways result in a molecular landscape that shows a 
comprehensive overview of biological processes and cascades that may be relevant to 
disease etiology and/or pathophysiology. As such, the molecular landscape generates 
(more) in-depth and new insights into disease etiology and provides hypotheses for the 
development of novel treatments. This landscape building approach has previously also 
been applied to neurodevelopmental disorders such as ADHD142, autism143 and OCD144.
1.6 AIMS AND OUTLINE OF THIS THESIS
This thesis aims to:
(1)  provide insights into the molecular pathways underlying PD etiology and as 
such generate clues as well as hypotheses for the future development of novel 
PD treatment options; 
(2)  improve the understanding of the molecular pathways underlying the beneficial 
effects of physical exercise on PD;
(3)  further establish the landscape building approach as a useful tool to identify 
the molecular pathways underlying complex neurodegenerative diseases.
In chapter 2, the landscape building approach is used to construct a molecular landscape 
of PD based on PD GWAS data, and other genes/proteins implicated in PD through e.g. 
familial candidate gene association and functional studies. This molecular landscape 
gives novel insights into the etiology of PD.
In chapter 3, the validity of the 1-methyl-4-pheynl-1,2,3,6-tetrahydropyridine (MPTP) 
mouse as a model for the molecular mechanisms that underlie human PD is assessed. 
MPTP, a drug that is transported into the brain and subsequently converted to the 
neurotoxin MPP+, causes the degeneration of DA neurons, especially in the SN. The 
MPTP-treated mouse is therefore a widely-used model for PD that enables us to perform 
in vivo studies on a pathology similar to PD. However, although the pathophysiology 
is similar, the underlying molecular pathways have never been directly compared. By 
comparing genome-wide expression data from MPTP-treated mice with expression data 
from both the SN and striatum of human PD patients, the validity of the MPTP-model as 
a model for the molecular pathways underlying human PD is assessed. Subsequently, 
the MPTP mouse model enables us to identify in chapter 4 the underlying molecular 
pathways and therapeutic effects of physical exercise on PD in a preclinical setting. In 
both chapters 3 and 4, the landscape building approach is used as a tool to elucidate the 
underlying molecular pathways and interpret the datasets.
In chapter 5, I analyze whether it is possible to elucidate distinct, disease-specific and 
substrate-specific mechanisms for another neurodegenerative disease – i.e. ALS – by 




degenerate, which results in muscle weakness and ultimately respiratory failure 
within 2-5 years after onset of the first symptoms. As such, ALS exhibits – similar to PD 
– motor symptoms that are caused by the degeneration of a specific neuron population.
Lastly, in chapter 6 the main results and conclusions from this thesis will be summarized, 
compared and discussed.
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2.1 ABSTRACT
Parkinson’s disease (PD) is caused by a complex interplay of genetic and environmental 
factors. Although a number of independent molecular pathways and processes have 
been associated with familial PD, a common mechanism underlying especially sporadic 
PD is still largely unknown. In order to gain further insight into the etiology of PD, we 
here conducted genetic network and literature analyses to integrate the top-ranked 
findings from thirteen published genome-wide association studies (GWASs) of PD 
(involving 13.094 cases and 47.148 controls) and other genes implicated in (familial) PD, 
into a molecular interaction landscape. The molecular PD landscape harbors four main 
biological processes – oxidative stress response, endosomal-lysosomal functioning, 
endoplasmic reticulum stress response, and immune response activation – that 
interact with each other and regulate dopaminergic (DA) neuron function and death, 
the pathological hallmark of PD. Interestingly, lipids and lipoproteins are functionally 
involved in and influenced by all these processes, and affect DA neuron-specific 
signaling cascades. Furthermore, we validate the PD-lipid relationship by GWAS data-
based polygenic risk score analyses that indicate a shared genetic risk between lipid/
lipoprotein traits and PD. Taken together, our findings provide novel insights into 
the molecular pathways underlying the etiology of (sporadic) PD and highlight a key 
role for lipids and lipoproteins in PD pathogenesis, providing important clues for the 
development of disease-modifying treatments of PD.
KEYWORDS:  Parkinson’s Disease, Molecular Landscape, Etiology, Lipids, Lipoproteins, GWAS
2.2 INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative disease, with 
an estimated prevalence of 0.3%, affecting 1-2% of people over 60 years of age1, 2. The 
pathological hallmark of PD is loss of dopaminergic (DA) neurons in the substantia 
nigra (SN), and the presence of protein aggregates (i.e. Lewy bodies) involving 
synuclein alpha (SNCA) in the residual DA neurons3. A number of biological processes 
that contribute to the pathogenesis of PD have been identified, including defects 
in mitochondrial function4, oxidative stress5 and protein aggregation6-8. However, 
detailed insights into the molecular mechanisms underlying these processes, and how 
they interact with each other, are essentially lacking. In many studies exploring PD 
pathogenesis, familial PD genes served as starting point. Thus far, at least eighteen 
genetic loci for familial PD have been found, and twelve familial PD candidate genes 
have been identified (ATP13A2, DJ-1, DNAJC6, EIF4G1, FBXO7, LRRK2, PARK2, PINK1, 
PLA2G6, SNCA, SYNJ1 and VPS35)9, 10. However, as a mutation in one of these familial 
genes is found in only 5-10% of the cases, PD should be considered a predominantly 
sporadic disease11, 12, with both genetic and environmental contributing risk factors. In 




risk factors for sporadic PD13-26 but the functional coupling of the proteins encoded by 
the GWAS-identified candidate genes to PD pathophysiology is often not clear. In the 
present study, we aimed to identify the core mechanisms underlying PD pathogenesis 
by using bioinformatics and extensive literature analyses to integrate (1) the genes 
corresponding to the top-ranked single-nucleotide polymorphisms (SNPs) found in 
published GWASs of sporadic PD, and (2) other PD candidate genes (e.g. familial PD 
genes) into a protein interaction landscape. This molecular landscape allowed us to 
identify the specific biological processes that are key in PD pathogenesis and provides 
clues for the development of novel PD treatment strategies. 
2.3 METHODS
2.3.1 PD GWAS gene selection
The first step of our molecular landscape building approach27-29 is the selection of 
candidate genes based on GWAS single nucleotide polymorphisms (SNPs) and their 
corresponding p-values. All 15 PD GWASs published to date were considered. Criteria 
for inclusion were a publicly available GWAS discovery sample with all SNPs associated 
at p<0.0001. From the GWASs for which these data were available, we then selected the 
SNPs that were associated with PD at p<0.0001 to compile a list of associated genes. 
The selected genes either contained a SNP that was located within an exonic, intronic 
or untranslated region of the gene or were found within 100 kilobases (kb) downstream 
and upstream of the SNP. The latter was based on the fact that the vast majority of 
expression quantitative trait loci (eQTL) for a given gene are located within 100 kb 
downstream and/or upstream of a gene30-32 and because trait-associated SNPs are more 
likely to be eQTL33. The chosen cut-off for association (p<0.0001) is often employed to 
designate ‘suggestive’ association and has been used in GWASs of multiple disorders34-36. 
Subsequently, the literature was searched for additional (genetic) evidence linking the 
selected GWAS candidate genes to PD. 
2.3.2 Genetic network enrichment analysis
To identify enriched protein networks in the PD GWAS candidate genes, a network 
analysis using the Ingenuity Pathway Analysis (IPA) software package (http://www.
ingenuity.com) was performed, using default parameters. In this respect, the analysis 
used the so-called reference set of known genes and endogenous chemicals, which 
is accessible through the ‘Ingenuity Knowledge Base’, a repository of extensive 
information from manually curated published literature as well as many other sources, 
including gene expression databases. In addition, only functional relationships that 
are corroborated by experimental evidence were included in the networks. For each 
network, the Ingenuity software also generates an enrichment score that takes into 
account the number of eligible molecules/proteins in the network and its size, as well 
as the total number of network-eligible molecules analyzed and the total number 
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of molecules in the Ingenuity Knowledge Base that could potentially be included in 
networks. This score is the negative logarithm of the right-tailed Fisher’s exact test 
result.
2.3.3 Molecular landscape building
Following the network enrichment analysis, the literature was extensively searched 
for the functions and interactions of all proteins encoded by the candidate genes 
implicated through PD GWASs as well as other PD candidates implicated via other 
evidence, including genetic association studies, mRNA/protein expression studies 
and/or functional studies. First, we used the UniProt Protein Knowledge Base (http://
www.uniprot.org/uniprot)37 to gather basic information on the functions of all candidate 
genes and their encoded proteins. Subsequently, and starting with the interactions in 
the most enriched genetic network, we used PubMed (http://www.ncbi.nlm.nih.gov/
sites/entrez) to search for all functional, experimental evidence-based interactions 
between all PD candidate genes/proteins. While building the landscape in this way, 
we also included genes/proteins and metabolites that have no known link with PD, but 
have multiple – i.e. at least two different – functional interactions with PD-implicated 
proteins. Based on all gathered information, we generated a protein interaction 
landscape. The figures depicting this landscape were made using the drawing program 
Serif DrawPlus version 4.0 (www.serif.com).”  
2.3.4 Polygenic risk score (PRS) analyses
Our molecular landscape pointed towards an important role for lipids and lipoproteins 
in PD etiology (see below). Therefore, we conducted PRS analyses using the tool 
PRSice38, with summary statistics data from genome-wide association studies (GWASs) 
of blood levels of total cholesterol, total triglycerides, total high density lipoprotein 
(HDL) and total low density lipoprotein (LDL) as ‘base’ samples (GWAS data for 188577 
European-ancestry individuals from the general population)39 and summary statistics 
data from a meta-analytic PD GWAS by the International Parkinson Disease Genomics 
Consortium (IPDGC) as ‘target’ sample (GWAS data for 5333 PD cases and 12019 healthy 
control subjects, all of European ancestry)40. Using the default settings in PRSice we 
calculated the shared genetic etiology between the four lipid/lipoprotein traits and PD 
at seven broad p-value thresholds (indicated by pT) which were used to select the SNPs 
from the base sample that were included in the PRS analysis, i.e. pT < 0.001, 0.05, 0.1, 0.2, 
0.3, 0.4 and 0.5. As such, the seven pT thresholds led to the selection of all SNPs that 
were associated with the base lipid/lipoprotein phenotype at p< 0.001, 0.05, 0.1 etc. 
The calculated p-values indicating the significance of a shared genetic etiology 
between each lipid/lipoprotein trait and PD were aggregated and corrected for 




potential dependencies between p-values41.  To calculate the FDR, we used the mafdr 
function in MATLAB (R2012a, The Mathworks, Natick, MA, USA) using the bootstrap 
selection method for the FDR parameter lambda. FDR was set to not lower p-values 
below uncorrected p-values, which would have occurred due to overall (relatively) low 
uncorrected p-values.
In addition to calculating the shared genetic etiology between the four lipid/lipoprotein 
traits and PD, we performed similar analyses using four ‘combined lipoprotein traits’. 
In order to do this, we first divided the HDL and LDL level summary statistics GWAS 
data into four groups of SNPs, i.e. all SNPs associated with (1) increased HDL levels, 
(2) increased LDL levels, (3) decreased HDL levels and (4) decreased LDL levels (where 
‘increased’ and ‘decreased’ refer to all SNPs that had an effect size-indicating beta > 
0 and beta < 0, respectively). Subsequently, we conducted PRSice analyses with four 
combined data sets as base sample, i.e. (1) all SNPs increasing HDL and LDL levels, (2) 
all SNPs decreasing HDL and LDL levels, (3) all SNPs increasing HDL and decreasing 
LDL levels, and (4), all SNPs decreasing HDL and increasing LDL levels. Before the data 
sets were fed into PRSice, an equivalent, weighted p-value for each SNP in each of the 
four combined HDL/LDL data sets was calculated as: 
2.4 RESULTS
2.4.1 Selected PD GWAS genes and genetic network enrichment analysis       
Thirteen of the fifteen published PD GWASs met our inclusion criteria (Supplementary 
Table 1) and were used to select a total of 451 PD GWAS candidate genes based on SNPs 
with P <0.0001 (Supplementary Table 2). Of the five most significantly enriched IPA 
networks (Supplementary  Table 3), the network with the highest enrichment score 
(P=1.00E-44) and the highest number of PD GWAS candidate gene-encoded proteins 
(28 proteins) served as the starting point for the building of the molecular landscape 
(Supplementary Figure 1).
2.4.2 The molecular landscape of PD
Guided by the most significantly enriched genetic network and extensive literature 
searches, we built a molecular landscape consisting of 260 interacting proteins (i.e. 
encoded by approximately 58% of the 451 PD GWAS genes, Supplementary Table 2), 
128 proteins implicated in PD through other evidence (Supplementary Table 4) and 49 
proteins that have not been directly linked to PD (yet) but have multiple functional 
interactions within the landscape (Supplementary Table 4). Approximately one in 
three landscape proteins are implicated in PD etiology through at least two types of 
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evidence.  
Supplementary Figures 2 and 3 show all relevant protein interactions in the PD 
landscape that are functionally involved in four main biological processes: oxidative 
stress response, endosomal-lysosomal functioning, endoplasmic reticulum (ER) stress 
response, and neuron death and immune response. The Supplementary Information 
provides a detailed and referenced description of the evidence linking all the proteins 
in the landscape. In Supplementary Table 5, we have indicated in which process(es) 
each landscape protein exerts its main effect and where it is located in Supplementary 
Figures 2 and/or 3.
The above being said, we here give a succinct description of the four main biological 
processes and signaling cascades in the PD landscape that are depicted in Figure 1. 
Central in the landscape is signaling involving lipoproteins – i.e. low density lipoprotein 
(LDL), high density lipoprotein (HDL) and very low density lipoprotein (VLDL) – and 
their component lipids and metabolites (e.g. cholesterol, oxysterols, sphingolipids 
such as ceramide and sphingosine, and triglycerides). Lipid and lipoprotein signaling 
represents the ‘common denominator’ that functionally integrates, regulates and 
is regulated by the four landscape processes (Fig. 1A-D). Either by themselves or in 
combination, deficits or impairments in any of these four processes – each composed 
of multiple signaling cascades – can contribute to the degeneration and ultimately 
death of DA neurons. 
First, deficits or impairments in dopamine synthesis and - linked to this - iron 
metabolism can cause an increased oxidative stress response (Fig. 1A). Dopamine can 
be either taken up through active transport or is newly synthesized in neurons and can 
subsequently be re-released (through vesicular exocytosis), degraded or (auto-)oxidized 
into neuromelanin (NM). Further, like erythrocytes (see below), SN DA neurons have a 
high oxygen demand and express oxygen-carrying hemoglobin.
Through oxidation, cytotoxic heme is released from hemoglobin and then converted in 
DA neurons to ferrous iron, Fe(II). Fe(II) increases oxidative stress and together with free 
cholesterol – that is taken up by neurons through lipoproteins (see below) – induces 
mitochondrial oxysterol formation. In turn, this causes mitochondrial dysfunction and 
triggers the release of pro-apoptotic cytochrome c and, eventually, neuron death. 
The second main landscape process centers around the (dys)regulation of endosomal-
lysosomal functioning (Fig. 1B). Neuronal uptake of cholesterol occurs through the 
endosomal system, i.e. after neuronal uptake through vesicular endocytosis, LDL 
particles are processed into their composite parts: proteins, free cholesterol and other 




stored in lysosomes through autophagy. Hence, NM complex formation prevents the 
above described Fe(II)- and cholesterol-induced oxidative stress response. Moreover, 
their ageing-related increase in NM content and the associated increased demands 
on lysosomal function renders DA neurons particularly vulnerable to lysosomal 
defects. Other important lysosomal functions include the degradation of misfolded or 
aggregated proteins (such as pathological SNCA aggregates), the regulation of ceramide 
metabolism and reverse cholesterol transport, i.e. the vesicle-mediated transport and 
exocytosis of cholesterol into HDL particles in the bloodstream (and back to the liver). 
As such, a defect in any of these endosomal-lysosomal system components results in 
disturbed levels of lipids such as cholesterol and ceramide. In turn, these disturbed lipid 
levels affect membrane function in general and more specifically the functioning of so-
called lipid rafts – microdomains of the vesicular, lysosomal and plasma membrane 
Figure 1. Overview of the molecular landscape of PD. The four main biological processes in the PD landscape 
– oxidative stress response (Fig. 1A), endosomal-lysosomal functioning (Fig. 1B), endoplasmic reticulum (ER) 
stress response (Fig. 1C), and neuron death and immune response (Fig. 1D) – are depicted. ECM, extracellular 
matrix; ER, endoplasmic reticulum; UPR, unfolded protein response.
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containing high amounts of cholesterol and sphingolipids and crucial for membrane 
function – and hence processes such as autophagy, endo- and exocytosis. Deficient 
lysosomal function together with reduced degradation by the proteasome also leads to 
misfolded or aggregated protein formation. 
Misfolded/aggregated proteins trigger the ER stress response (Fig. 1C), the third main 
landscape process, and subsequent activation of the protective unfolded protein 
response (UPR) as well as stimulation of cholesterol influx through upregulating the 
expression of key lipoprotein receptors. Prolonged ER stress that can no longer be 
counteracted by the UPR induces mitochondrial dysfunction, which eventually results 
in DA neuron death. 
Lastly, apart from or in addition to dysregulated processes within DA neurons (as 
described above), DA neuron death can be the consequence of external factors such 
as an exaggerated immune response (Fig. 1D), the fourth landscape process. In this 
respect, immune cells are activated and attracted to damaged or already dying DA 
neurons by extracellular factors such as the sphingolipid-derived sphingosine-1-
phosphate (S1P), triglyceride-rich extraneuronal VLDL particles (not shown), heme-
oxidized LDL (oxLDL, see above), and various cytokines. Subsequently, the damaged/
dying DA neurons are removed by the activated immune cells, an essentially normal 
and adequate response that is exaggerated in PD by DA neuron-specific antigens such 
as SNCA aggregates and NM complexes – released by dying DA neurons – creating a 
vicious cycle of DA neuron death and immune cell activation. 
2.4.3 PRS analyses
Because our molecular landscape pointed towards an important role for lipids and 
lipoproteins in PD etiology (see above), we conducted polygenic risk score (PRS) 
analyses using the tool PRSice38, with GWAS data for the blood levels of various lipids and 
lipoproteins39 as base samples and meta-analytic PD GWAS data from the International 
Parkinson Disease Genomics Consortium (IPDGC)40 as target sample. We found 
statistically significant evidence (FDR-corrected p<0.05) for a shared genetic etiology 
between the lipid traits ‘total cholesterol levels’ and ‘total triglyceride levels’ and PD, 
with the most predictive p-value threshold (pT) at 0.001 and 0.05, respectively (Figure 
2). In contrast, the lipoprotein traits ‘total HDL levels’ and ‘total LDL levels’ yielded no 
evidence for a shared genetic risk with PD (Figure 2).  For the various combinations of 
increased or decreased HDL and LDL levels, we found significant evidence for a shared 
genetic etiology between PD and the combined trait ‘increased HDL + increased LDL’ 





In this study, we integrated the available genetic and expression data with data about 
environmental risk factors into a protein interaction landscape that reveals the main 
biological processes and signaling cascades that are affected in PD and occur in DA 
neurons and immune cells. Our PD landscape represents processes and cascades that 
are affected in both the monogenic, familial and the more prevalent polygenic, sporadic 
forms of PD. In this respect, the molecular landscape includes the ‘classic’ processes 
and cascades known to be affected in PD and based on the familial PD candidate 
genes (e.g. SNCA, PARK2, LRRK2): mitochondrial function, oxidative stress and protein 
aggregation. In addition, the landscape harbors more novel processes that have been 
less well studied in relation to PD pathogenesis yet, such as impairments in lysosomal 
Figure 2. Bar plots from PRSice for shared genetic etiology between four lipid and lipoprotein traits (cholesterol, 
triglyceride, HDL and LDL levels) and PD showing results at broad p-value thresholds (pT). The numbers above 
the bars indicate the p-values for shared genetic etiology, and these p-values were corrected using the false 
discovery rate (FDR) method; * denotes FDR-corrected p<0.05, ** denotes FDR-corrected p<0.01
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function and immune response regulation. The landscape does not imply a ‘sequence 
of events’ that leads to DA neuron loss, i.e. a number of (impaired) biological processes 
and cascades that occur in a temporally and/or spatially distinct order. Instead, 
deficits in any of the main landscape processes/cascades, either by themselves or in 
combination with deficits of other processes/cascades, may cause DA neurons to die. 
Moreover, an aging-related decline in the functionality and/or efficiency of landscape 
processes/cascades may play a role in PD onset and progression. For example, a gradual 
buildup of NM or aggregated proteins may disturb lysosomal function in DA neurons42 
or an age-related decrease in the expression and activity of ER folding enzymes can 
compromise proper protein folding43. 
Lipid and lipoprotein signaling functionally integrates, regulates and is regulated by 
the key landscape processes and cascades. Any disturbance of these processes and 
cascades can (eventually) result in DA neuron death, which is further aggravated or 
initiated by an increased (auto-)immune response44. The involvement of deficient 
lipid and lipoprotein signaling in PD pathophysiology is corroborated by a number 
of environmental risk factor studies. Increased plasma levels of total cholesterol are 
associated with a lower PD risk45-47. Nevertheless, a recent meta-analysis did not show 
an effect of higher or lower dietary cholesterol intake on PD risk48, suggesting that direct 
cholesterol intake through food may not play a major role in PD etiology. Further, low 
plasma levels of LDL are linked to a higher PD risk49, 50, whereas high plasma HDL and 
CSF oxysterol levels are associated with increased PD risk and duration51, 52. In addition, 
the levels of oxidized LDL, oxysterols, sphingolipids are increased in the plasma of PD 
patients53-55. Thus, PD patients have a lower LDL:HDL ratio that is associated with a 
lower risk of cardiovascular disease (CVD)56 and could at least to some extent explain 
why the PD population is indeed less susceptible to developing CVD51. Apart from the 
observed dysregulated levels of cholesterol (metabolites) and cholesterol-containing 
lipoproteins in PD patients, lower serum levels of triglycerides – which are highly 
enriched in VLDL particles – associate with an increased PD risk57, 58. 
Intriguingly, we found a significant overlap between the polygenic risk associated with 
total cholesterol and triglyceride levels and PD. We also identified a shared genetic 
etiology between the combined lipoprotein trait ‘increased HDL + increased LDL’ and 
PD. To our knowledge, we are the first to find a shared genetic risk between quantitative 
traits and a neurodegenerative disease but these findings need to be replicated in larger 
data sets, especially for the target sample, i.e. the PD GWAS data set. Together, the 
epidemiological and our PRS analysis findings indicate that the link between specific 
lipid/lipoprotein traits and PD may be the result of both shared environmental and 




Given the converging evidence for lipid and lipoprotein signaling playing a key role in 
PD etiology, compounds that modulate lipid/lipoprotein levels could represent effective 
novel PD treatments. In this respect, statins – inhibitors of peripheral cholesterol 
synthesis that are used to treat hypercholesterolemia and hence prevent cholesterol-
associated CVD – have a neuroprotective effect in the rat brain59, but their effect on PD 
risk remains unclear60-67. Interestingly, the only published prospective study that has 
adjusted for baseline cholesterol levels before statin treatment has found that statin 
use is associated with a significantly higher PD risk47, which is in keeping with the 
observation that higher total plasma cholesterol levels – which are lowered by statins 
– are protective against PD. Other signaling molecules from the landscape that affect 
cholesterol and lipoprotein levels are testosterone and vitamin D3. Caucasian male 
PD patients show significantly reduced testosterone levels68-70, and free testosterone 
levels are positively correlated with LDL, HDL and total cholesterol levels71. Therefore, 
decreased testosterone levels may impact on several key PD landscape processes, 
as testosterone regulates the efflux of LDL and HDL to the circulation72. Hence, 
testosterone could be used for treating PD in male patients and indeed, testosterone 
treatment has some modest beneficial effects in men with PD73, 74. Deficiency of vitamin 
D3 – which affects cholesterol metabolism through downregulating SREBF175, the 
main transcriptional activator of lipid homeostasis and key landscape protein – has 
been consistently associated with an increased PD risk76 and its supplementation may 
stabilize PD symptoms77. 
Lastly, a number of landscape proteins that both regulate lipid/lipoprotein signaling 
and landscape cascades involved in DA neuron death represent attractive (novel) 
drug targets for PD. Examples include HMOX1 that prevents oxidative stress by heme, 
PSAP and its receptor GPR37 that mediate ceramide metabolism, the immunity-related 
ICAM1 that is regulated by extracellular lipids and (oxidized) lipoproteins, and plasmin 
that regulates the degradation of extracellular SNCA and (lipo)proteins. 
In conclusion, our integrated molecular landscape yields detailed insights into the 
mechanisms underlying PD pathogenesis, and highlights the involvement of deficient 
lipid and lipoprotein signaling. These findings warrant future rigorous perturbation 
experiments in PD cell and animal models that may eventually provide validated drug 
target ‘leads’ for the development of novel disease-modifying PD treatments. 
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Supplementary Figure 1. Top enriched Ingenuity genetic network. The network with the highest score 
(P=1.00E-44) and containing the highest number of proteins (28 proteins) obtained by a network enrichment 
analysis of the PD GWAS candidate genes from Supplementary Table 2 using Ingenuity pathway software (www.
ingenuity.com) (Supplementary Table 3). The proteins encoded by a gene that emerged from (at least) one of the 
PD GWASs and that were included in the PD landscape are indicated in red, whereas the PD GWAS gene-encoded 
proteins that are not included in the landscape are depicted in grey. Of note, two molecules – HDL and LDL – did 




































MOLECULAR LANDSCAPE OF PD
Supplementary Figure 2: PD landscape; intracellular pathways constituting processes A-D. The functional interactions between proteins functioning within the processes oxidative stress response (A), endosomal-lysosomal functioning (B), ER stress 
response (C) and neuron death and immune response (D) are shown. The transcription factors and transcription regulators in the nucleus regulate the expression of proteins that are involved in all four processes. These expressed proteins are shown 
in the vicinity of the nucleus (in the light brown band surrounding the nucleus) and will translocate to their cellular destination, i.e. either the cytoplasm, one of the organelles, or the cell membrane. The functional interactions within process D that 




















Supplementary Figure 3: PD landscape; immune cell regulation-related pathways of process D. The functional interactions within process D: ´neuron death and immune response´ that regulate the activation of astroglia, microglia, T cells, B cells and 
dendritic cells are shown. For each individual protein in this figure, Supplementary Table 5 shows the location coordinates and the main process(es) (A-D) in which they exert their main effect.
Supplementary Figure 4. Additional Polygenic Risk Score Analyses. Bar plots from PRSice showing results at 
broad P-value thresholds (PT) for shared genetic etiology between four ‘combined lipoprotein traits’ (increased 
HDL + increased LDL, decreased HDL + decreased LDL, increased HDL + decreased LDL, decreased HDL + 
increased LDL) and PD. The numbers above the bars indicate the P-values for shared genetic etiology, and these 
P-values were corrected using the false discovery rate (FDR) method; * denotes FDR-corrected P < 0.05
51




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 5. Landscape proteins, the main process(es) they are functionally involved in and their location within 
the figures. For each protein (complex) in the landscape, the process(es) oxidative stress response (A), endosomal-lysosomal 
functioning (B), endoplasmic reticulum (ER) stress response (C), and neuron death and immune response (D) in which they 
exert their main effect is indicated in columns A to D. The location of each protein (complex) in the landscape is indicated in 
the column ‘Location coordinates in Figures S2 and S3’ with these coordinates corresponding to the location of the protein 
(complex) in Figure S2 and/or S3. A total of 113, 152, 131 and 208 proteins were assigned to processes A, B, C and D, respectively. 
Between parentheses, protein complex subunits (csu) or protein isoforms (iso) that function within the landscape are indicated. 
NS; not shown.
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
26S (PSMD11) X X S2-3d BDNF X X S2-1b; S3-2b, 3a, 3c, 
4a, 5d
ABCA1 X X X S2-1a, 3a, 3c, 3d BMP7 X X X X S2-2d; S3-2b, 3c, 
3d, 5c
ABCA3 X S2-3b BST1 X S3-1b
ABCA5 X S2-3b BTNL2 X S3-2c
ABCG1 X X X X S2-1a, 3a, 3b, 3c; 
S3-4b
C9 X S3-3d
ACMSD X NS CACNA1A X S2-1a, 2a, 5b; S3-1c
ACSL6 X S2-1c CACNA1B X S2-1a
ACTN4 X X X S2-3c, 3d, 4d; S3-2d CACNA1C X NS
ADAM12 X S2-5b CACNA1D X NS
ADAMTS14 X S2-5b CACNA1E X NS
ADAMTS2 X S2-5b CACNA1F X NS
ADH1C X S2-4d CACNA1S X NS
AGAP1 X X S2-2a CACNA2D3 X S2-1a, 5c; S3-1c
AGTR1 X X X S2-1b, 3a, 5a, 5b; S3-
3d, 4d
CASP3 X X X S2-2b, 2c, 2d, 5a
AICDA X NS CASP9 X X X S2-2b, 3d
AKT1 X X X X S2-2c, 2d, 3b, 4c, 4d CAV1 X X S2-2a, 2b, 3a
AMIGO2 X X S2-2a CCAR2 X X S2-2c, 3c, 4a, 4c, 4d






X X S2-1b, 1d, 2a, 2c, 
3a, 3d
CCR4 X S3-2b, 3b, 4b
ANGPT2 X X X S2-1b, 5b; S3-3a, 3b, 
3d, 4d, 5b
CD163 X S2-1a
AP3 (AP3B1) X S2-2a, 3b CD200 X S3-3c, 4d
APOE X X S2-2a, 2d CD200R1 X S3-3c, 4d
APP X NS CDH2 X S2-1d
AR X S2-2d, 4c, 5c; S3-2c CDH23 X S2-4a
ARHGAP33 X S2-3a CDH6 X S2-4d
ARHGAP44 X S2-3a CDK19 X S2-4c
ARL4A X NS CECR2 X S2-4d
ARMC8 X NS CENPC X S2-4c
ASAH1 X S2-3b, 4b CEP85L X S2-1d
ASCL1 X S2-5c CLVS2 X S2-2a
ATF6 X X S2-3c, 4c; S3-2a CNNM2 X S2-1a
ATG5 X X S2-2b, 5a CNTN1 X S2-5a
ATG7 X X X S2-2b CNTNAP2 X S3-3d
ATP13A2 X X X S2-3b; S3-3c COL18A1 X X X X S2-2a, 4d; S3-1d, 3b, 
3d, 4c, 5d
ATP2B2 X X S2-1d COL2A1 X X X S2-4a, 4d, 5b; S3-
3a, 4a
ATP6V0A1 X S2-3b, 4b COMT X S2-1b, 5b
ATR X X S2-3c, 4c CPNE4 X S2-4a
AXIN1 X S2-2a, 3d, 4d CREM X X X X S2-4c; S3-4b
BAG6 X X X S2-2c, 3b, 3d, 4b, 5b; 
S3-4d
CRH X X X S2-2a; S3-2b, 5c
BAK1 X X S2-3d CRHBP X S3-2b
BAMBI X X X S2-3d CRHR1 X X X S2-2a, 4a; S3-5c
BANK1 X S3-1b CSMD1 X S2-3d
BAT2 X S2-3d, 4d CTNNB1 X X X S2-1a, 2b, 2d, 3c, 3d, 
4c, 4d, 5a
BAT5 X S2-1d CTSD X S2-3b
BAX X X S2-1c, 2c, 3d CUL2 X X S2-3d, 4c, 5a
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Supplementary Table 5. (continued)
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
CXCL12 X S2-5a; S3-1b, 2a, 3a, 
3c, 4c, 5d
GPATCH2 X NS
CXCR4 X X S2-5a; S3-1b, 3a, 3c, 
4b, 5d
GPR37 X S2-4a
CYCS X X S2-1b, 1c, 2b, 2c GSK3B X X X X S2-1b, 1d, 2a, 2b, 2c, 
2d, 3d, 4a, 4b, 4c, 4d, 
5a, 5b, 5c
CYP17A1 X S2-3c, 3d, 5b H1FX X S2-3c
DCUN1D1 X X S2-3d, 4c HAVCR1 X S3-2c
DDIT4 X X S2-2c Hb (HBA1, HBA2, 




DDX3X X S2-4c HCAR1 X S2-2a
DGKQ X X S2-1d, 2c, 3c HIP1R X S2-3a
DLG2 X X S2-1d, 3a, 3d, 4a HK2 X S2-1c, 3b
DNAH11 X S2-4b HLA-B X S3-4b, 5b
DNAJC13 X S2-2a HLA-C X X S3-4b
DNAJC6 X S2-2a HLA-DQA1 X S3-5b
DNM2 X X S2-2a, 2b HLA-DQA2 X S3-5a
DRAM1 X S2-3b HLA-DQB1 X S3-5b
DRD2 X X X S2-2a; S3-5c HLA-DQB2 X S3-5a
DRD3 X S2-3a HLA-DRA X S3-4b, 5b
DRG2 X S3-2c HLA-DRB1 X S3-4b
DSCAM X X S2-4d HLCS X S2-1c
E2F1 X S2-4c HLX X S3-1b, 2c
EFCAB4B X S3-2c HMOX1 X X S2-1a, 1b, 4b, 4d; S3-
3a, 2a
EFCAB6 X S2-5b HMOX2 X NS
EHMT2 X X S2-4c; S3-3a HP X S2-1a
EIF2A X NS HPGD X S2-2a
EIF4E X S2-1b, 3c HS3ST1 X S2-4b
EIF4EBP2 X S2-1b, 3c, 5c HSPA5 X NS
EIF4G1 X S2-1b, 2c, 2d, 3c, 3d HSPA8 X S2-2a, 2b, 2d, 3b, 3c, 
3d, 4a
ENSA X X S2-1b HTRA2 X X X S2-1c, 2c, 2d
ETV6 X S2-4b, 4c; S3-4d HUS1 X X S2-4b; S3-5d
FAM134C X S2-5c ICAM1 X S3-1b, 1d, 2a, 2b, 2c, 
3a, 3b, 3c, 4c, 5b
FAM190A X S2-3a IFNG X S3-3b, 3c, 4c
FBN1 X X S3-3b IGF1 X NS
FBXO25 X S2-3d IL10 X S3-5b
FBXO36 X NS IL12 (IL12A, IL12B) X S3-1b, 1c, 2b, 2c, 3d, 
4c, 5c
FBXO7 X X S2-1c, 3d IL1B X S3-3b, 3c, 3d, 4b, 5b
FER X X S2-3a, 4d, 5b; S3-3c IL2 X S3-2b, 2c, 3b, 3d
FGF12 X S2-1a IL2RA X S3-1b, 2b, 3c
FOXO1 X X X X S2-1d, 2b, 2d, 4b, 4c; 
S3-3d, 4a, 4b, 4d
IL4 X NS
FPR3 X NS IL5 X S3-1b, 2b, 3c, 4c
FRMD4A X S2-5a IL5RA X S3-1b, 4c
GAK X X S2-2a, 2d, 3a, 3b IL6 X S3-3a
GAS2 X S2-5a; S3-3c IL8 X S3-5c
GBA X S2-3b INS X X X X S2-1c, 1d, 2c, 2d, 3a, 
3c, 4a, 5b, 5c; S3-2a, 
2b, 3b, 4a, 4b, 4c
GCH1 X X S2-3c; S3-3b INSR X X X X S2-1d, 2d, 3a, 4b, 5b; 
S3-4a, 4b, 5c
GDNF X X S2-1b, 4a; S3-2a, 
3c, 5c
ITGA6 X S2-4a, 5b; S3-5c
GJB2 X X S2-3a, 3d, 4b, 4d ITGA8 X S2-4a
GLDN X S3-3d ITGA2B X S2-4a; S3-2c, 3a




















Supplementary Table 5. (continued)
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
JARID2 X S2-4c mPTP (STAR) X S2-1b, 1c, 2c
KANSL1 X S2-5b MREG X S2-2a
KCNA5 X S2-2a MRPL18 X S2-1c
KDM2B X S2-4b, 4c; S3-3c MRPL19 X S2-1c
KIF11 X S2-5a MRPL3 X S2-1c
KIF14 X S2-3d MSX1 X X S2-4c
KPNA4 X X S2-3b, 3c, 4b, 5b MTERFD1 X S2-1c
LAMP1 X X S2-1a, 2a, 3b mTORC1 (AKT1S1, 
DEPTOR, MLST8, 
MTOR, RPTOR)
X X X S2-1b, 2c, 3c, 3d, 4b






LAMP3 X X S3-1d MYO1E X S2-2a
LDLR X X S2-3a, 3c, 3d NAPB X NS
LFA-1 (ITGAL, 
ITGB2)
X S3-1b, 1d, 3b, 3c, 4c NCAM2 X S2-5a
LIPC X X S2-2a NDEL1 X S2-3a
LMX1A X S2-5c NDUFAF2 X S2-1c
LMX1B X X S2-4c NEDD4 X S2-2a, 2b
LRP1 X X S2-2a, 2d NEDD8 X X S2-3d, 4c
LRP1B X S3-4d NEDD9 X X S2-2a, 3b, 5c; S3-2b
LRPPRC X S2-1c, 3d NEGR1 X S2-5a
LRRC16A X S2-3c NEO1 X S3-2c, 2d
LRRC25 X S3-1b NEUROG2 X NS
LRRK2 X X X X S2-1c, 1d, 2a, 2b, 2c, 





X X S2-3b, 3c, 4a, 4c, 5a, 
5c; S3-1c, 2c, 3a, 3b, 
4b, 4d, 5d
LSM7 X S2-3c NLGN1 X S2-4a, 5a
LTBP1 X S3-3b, 4d NMT2 X S2-5a, 5c
LXR (LXRA, 
LXRB)
X X S3-3a, 4b NOS1 X S2-1d
MAOA X S2-2b, 3c, 5b NOS2 X X S2-1d, 4d; S3-3a, 
3d, 5d
MAOB X S2-1b NPTX2 X S2-4a; S3-5c
MAP1B X X X S2-1a, 1d, 2b, 3d, 5b; 
S3-1c
NR4A2 X S2-4b, 5c
MAP2K6 X X X S2-2d, 3a, 4c NR5A1 X X X S2-3c
MAP3K7 X X S2-2d, 3a NSF X S2-2b, 3a
MAPT X X S2-1b, 1d, 2b, 2d, 3a, 
3b, 3d
NTF3 X X X S2-4b; S3-4a
MARC1 X S2-1c OCA2 X S2-3b
MARK2 X X S2-1d, 2a, 5a PALD1 X S3-5c
MAS1 X S2-1b, 3a PARD3 X X X S2-3d, 5a; S3-2d
MBNL2 X S2-4b PARK2 X X X X S2-1b, 1c, 2a, 2b, 2c, 
2d, 3b, 3d, 4a, 4b, 5a
MBP X S2-3d, 4d; S3-2b, 
2c, 5b
PARK7 X X X X S2-2b, 2c, 3b, 3c, 4c, 
5a, 5b; S3-3a
MC1R X X S2-1d, 4b PCDH8 X S2-5a
MCC X X X S2-1c, 2a, 2d, 3c, 
3d, 4c
PCM1 X S2-3a
MCCC1 X S2-1c PEO1 X S2-1c
MCFD2 X S2-3c PIK3CD X X S2-1d, 2c, 3c; S3-
1b, 2d
MCPH1 X S2-4c PINK1 X X X X S2-1c, 1d, 2b, 2c, 3d, 
4c, 5a, 5b; S3-1c, 
4b, 5c
MED13 X X S2-4c PITX3 X X S2-5c
MICAL2 X S2-3a PLA2G6 X X X S2-2b; S3-4d
MITF X X X S2-4c; S3-3d PLAT X S3-4c, 4d, 5c
MMRN1 X S3-4d PLAU X S3-3d, 4c, 4d
MPI X S2-5b PLAUR X NS
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Supplementary Table 5. (continued)
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
PLCB4 X S2-1d SEMA3E X NS
PLEKHM1 X X S2-5b SEMA6D X S3-2c
PLG X S3-3c, 4c, 5c SENP7 X S2-4a
PLOD1 X X S2-3d, 5c SEP15 X S2-3c
PLS1 X S2-3b SERPINB5 X NS
POU2F1 X S2-4c; S3-4b SERPINB9 X S2-5b






X S2-3a, 3c, 3d, 4c, 
4d, 5c
SERPING1 X X S2-2a
PRF1 X S3-3d SIK1 X X S2-1b, 2c, 4c
PRKCE X X X S2-1c, 1d, 2c, 3a, 4a, 
5a, 5b; S3-1c, 2b, 3b
SIRT1 X X X X S2-2b, 2c, 2d, 3c, 4a, 
4c, 4d, 5a, 5c; S3-3c, 
3d, 4d
PRKG1 X S2-3a, 3d, 4d SIRT7 X S2-3c, 3d
PRKRIR X X S2-4b SLC11A2 X S2-1a, 1b, 1c
PROK2 X S2-4b SLC18A2 X X S2-2b, 5c
PSAP X S2-2a, 3b, 4a, 4b, 4d SLC24A3 X S2-1a
PSEN1 X S2-2c, 2d SLC2A13 X S2-1d
PSEN2 X S2-2d SLC40A1 X S2-1a
PTEN X X X X S2-1c, 1d, 2b, 2c, 2d, 
4c, 5a, 5c; S3-2c, 
3c, 4d
SLC41A1 X S2-1a
PTPN1 X S2-2c, 2d, 3c, 4a, 4b, 
5a, 5b
SLC45A3 X S2-2d
PTPRT X S2-5b SLC6A3 X X S2-2a, 4a, 5c; S3-5c
RAB7L1 X S2-3c SLCO3A1 X NS
RAC1 X X S2-3b SLIT2 X S2-4a, 5c
RAI1 X S2-3c, 4c; S3-1b, 2c SMAD4 X S2-4d
RAP1A X X S2-2c, 3b, 5a, 5c SMAD5 X X S2-2d, 4d; S3-4d
RAP2A X X S2-2b SMPD1 X S2-3b
RBFOX1 X S2-3d SNCA X X X X S2-1b, 1c, 1d, 2a, 2b, 
2c, 2d, 3b, 3c, 3d, 4a, 
4c, 4d, 5a; S3-1c, 3a, 
3c, 4c, 5c
RCOR1 X S2-4c; S3-3a, 4b SND1 X X S2-2c, 3c, 3d, 4c
RER1 X X S2-2c SNRK X S2-2c
RFX3 X S2-4b SNRPB2 X S2-4c
RFX4 X S2-4b SOD2 X S2-1c, 4c
RGMA X S3-2c, 2d SOX2 X S2-4c
RHOA X NS SP110 X S2-4b, 4c
RIT2 X S2-2a, 3a SPHK1 X X S2-3a; S3-5d
ROBO2 X S2-4a SPNS2 X X S2-3a; S3-5d
RPH3AL X S2-1a SPPL2B X S3-1d
RPL38 X S2-3d SREBF1 X X S2-2c, 2d, 3c, 4b, 4c; 
S3-4b
RPL7A X S2-3d, 4a, 5b STAP1 X S3-1b, 4b
RUFY3 X S2-1a STAT3 X S2-3a, 4b, 4c, 5a; S3-
1b, 3b, 3c, 4d
RUNX3 X X S2-2d, 4d; S3-1b, 3d STK11 X S2-1d, 2c, 3d, 5a; 
S3-3d
RXFP1 X S2-2a STK39 X X S2-3d, 4c, 4d; S3-3d
RXRA X NS SYN3 X S2-2b
SAMD4A X S2-2c SYNJ1 X S2-2a, 2b
SCAMP5 X S2-2a; S3-4b SYT11 X S2-1b
SCARB1 X X S2-2a, 3c, 4d TACC2 X S2-4c
SCARB2 X S2-2b, 3b TBX3 X S2-4c
SCIN X X S2-3b TCF12 X X S2-4b; S3-1b, 2d
SCN2A X S2-1a TF X S2-1a, 1c, 2b
SCNN1A X S2-3c TFR2 X S2-1a



















Supplementary Table 5. (continued)
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
Protein (csu/iso) A B C D Location coordinates 
in Figures S2 and S3
TH X X S2-1b, 1c, 2a, 3d, 
5a, 5c
TYR X S2-3b
TIAL1 X S3-3d UCHL1 X X X X S2-2b, 3b, 3d, 4d, 5b
TIMD4 X S3-2c, 3c ULK2 X X S2-2c, 3c
TLE1 X X S2-4c, 4d UNC13B X S2-1a
TMCC3 X S2-5a USP9X X S2-1a, 2c, 3c, 3d, 4d
TMEM2 X NS VDAC (VDAC1, 
VDAC2, VDAC3)
X S2-1c
TMPRSS3 X X S2-3c VDR X X X S2-3c, 4c; S3-2c, 3c
TMPRSS9 X X S3-3d VLDLR X X S3-4c, 4d
TMX1 X X S2-3d VPS35 X X S2-2c, 2d
TNF X S3-1d, 2c, 3b, 4c, 5c VPS41 X S2-2a
TOM1L2 X S2-2a WDHD1 X S2-4b
TP53 X S2-1b, 3a, 3c, 4b, 4c, 
5a; S3-3a, 3c, 4d, 5b
WNK1 X X S2-3d; S3-3d
TP53BP1 X S2-3a, 3c, 4c WNT3 X S2-4d
TPO X NS WWOX X S2-2d, 4d
TRAF2 X S2-3c, 3d ZAK X X S2-4a
TRAF3 X X S2-3a, 3c, 3d, 5a; 
S3-1b, 1c
ZBTB20 X S2-5c
TRAPPC9 X S2-4a ZNF385B X S3-1b
TRPC6 X S2-1d, 5a ZNF423 X S2-4d
TSPO X S2-1b, 2c
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In Supplementary Figures 2 and 3  all relevant protein interactions that constitute the 
molecular landscape of Parkinson’s disease (PD) are shown. In this description, the 
various interactions operational within the molecular landscape for PD are grouped 
into four main processes, (A) oxidative stress response, (B) endosomal-lysosomal 
functioning, (C) endoplasmic reticulum (ER) stress response, and (D) neuron death 
and immune response. Obviously, these processes overlap, and some of the proteins 
and protein signaling cascades are involved in multiple processes. Nevertheless, 
recurrent description of processes and interactions is avoided as much as possible. In 
Supplementary Figures 2 and 3, these processes are designated with the letters A-D. 
Supplementary Table 5 gives an overview of all the proteins in the PD landscape, where 
they are located in Supplementary Figures S2 and S3 and in which process(es) they 
exert their main effect.
In all descriptions of the PD landscape, names of proteins derived from the genome-
wide association studies (GWASs) are in bold, single-underlined proteins are genetically 
associated with PD, dotted underlined genes encode proteins that are differentially 
expressed in PD and double underlined genes are genetically associated with PD and 
encode a protein that is differentially expressed in PD. Supplementary Table 2 gives an 
overview of all GWAS gene-encoded proteins per GWAS and the corroborating evidence 
for their associations with PD. Supplementary Table 4 shows all other landscape 
proteins and the corroborating evidence for their associations with PD.
Not all GWAS gene-encoded proteins were placed in the landscape, either because 
there were no connections with other landscape proteins or due to lack of annotation, 
or both. However, this does not necessarily mean that they are not involved in PD 
pathophysiology. For example, SPPL2C is one of the genes that is not included in the 
landscape, but is still on the shortlist of highly interesting genes in relation to PD. 
Namely, SPPL2C is one of the most significantly PD-associated genes in four different 
PD GWASs6, 10, 12, 262, which includes association with two non-synonymous coding 
SNPs in SPPL2C. However, due to lack of annotation and knowledge about its protein 
function263 it could not be placed in the landscape. Future research should clarify if 
this highly associated gene indeed encodes a functional active protein263, 264 that is of 
importance in PD pathophysiology.
Overall, two generalization have been made. First, when a knock-out of protein A in a 
cell or animal model increases the expression of protein B, we assume that endogenous 
expression of protein A leads to the opposite effect and decreases the expression of 
protein B. Second, we assumed that all identified protein interactions (in any organism 
and/or cell type) can be extrapolated to the interactions in human DA neurons and 
immune cells.
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In the descriptions below, the gene name abbreviations refer to both the gene and 
the protein. Furthermore, the terms ‘activates’ and ‘inhibits’ are used to indicate the 
activation of a protein (e.g. by (de)phosphorylation) by another protein. To describe a 
difference in abundance of a protein (directly or indirectly) induced by another protein, 
the terms ‘increases the expression of’ or ‘decreases the expression of’ are used. And 
lastly, interactions in the PD landscape that are not shown in the figures are indicated 
with ‘(not shown)’ in the text.
A. OXIDATIVE STRESS RESPONSE
Oxidative stress in DA neurons is increased by cell-specific processes (A1), dysregulation 
of mitochondria  and oxidative phosphorylation (A2) and by dysregulation of regulators 
of oxidative stress (A3). The functional interactions between the proteins within 
process A, ‘oxidative stress response’, are shown in Supplementary Figure 2.
A1.	 Dopamine	(DA)	neuron	specificity
The processes that have been associated with PD, as discussed in this and the next 
sections – such as autophagy, lysosomal degradation, ER stress, mitochondrial 
destabilization and apoptotic cascades – are often generic processes that can occur 
in virtually every cell in the body. However, midbrain dopamine (DA) neuron death 
is a hallmark of PD, implying a cell-specific vulnerability for dysregulation of these 
processes. Therefore, sections A1.1 - A1.3 describe processes that are (highly) specific to 
DA neurons and may play a crucial role in their vulnerability. Subsequently, a genetic 
predisposition for defects in more generic processes such as autophagy, lysosomal 
degradation, ER stress, mitochondrial destabilization or proteasomal degradation 
(as discussed in the next chapters) would increase the vulnerability of these 
neurons beyond that of neurons that do not synthesize DA or other monoaminergic 
neurotransmitters. In this way, a relatively small increase in protein aggregation, 
mitochondrial destabilization and/or lysosomal dysfunctioning may lead to specific 
DA neuron death.
A1.1 DA synthesis, storage and degradation, and neuromelanin (NM) production
In PD patients, monoaminergic neurotransmitter-synthesizing neurons are vulnerable 
and degenerate265. In DA neurons, DA can be spontaneously oxidized to the NM precursor 
aminochrome, an oxidation process that produces oxygen radicals and increases 
oxidative stress266. DA oxidation results in increased reactive oxygen species (ROS), 
that are involved in the formation of oxysterols and in lipid peroxidation. Indeed, PD 
patients show increased lipid peroxidase activity, indicated by the elevated presence of 




















Monoamine oxidase A (MAOA) increases the expression of SLC18A2272, that sequesters 
DA into secretory vesicles. SLC18A2 (that binds to PARK7273) thereby prevents DA 
oxidation274, as is suggested from the inverse association between SLC18A2 expression 
and both NM production in the SN and vulnerability to neuronal degradation in the 
human postmortem brain274, reduced vesicular storage of DA by SLC18A2 causing 
nigrostriatal neurodegeneration in mice275 and association studies showing that gain 
of function polymorphisms in the SLC18A2 gene promotor are protective against PD in 
females229, 230.  Taken together increased sequestration of DA in secretory vesicles by 
SLC18A2 appears to have neuroprotective properties against PD.
Apart from DA loading into secretory vesicles, DA oxidation can also be prevented by 
monoamine oxidase (MAO)-dependent (occurring in two forms, MAOA and MAOB) or 
catechol ortho-methyl transferase (COMT)-dependent degradation of DA266 (all three 
genetically associated with an increased PD risk145, 194, 196, 197). More specifically, MAOA 
variations are associated with PD in males194-196, MAOB variations are associated with 
PD in females198 and a COMT polymorphism with lower age of onset in males146, showing 
that altered DA degradation affects the risk for PD. PARK2 decreases the expression and 
inhibits the activity of both MAOA and MAOB276, whereas AR277 and SIRT1278 increase 
MAOA expression, calcium (Ca2+) increases MAOA activity279 and vitamin D3 decreases 
MAOB expression and activation280. Further, COMT expression is increased by ANGPT2281 
(not shown) and TP53282. Thus, the expression of the DA degradating enzymes MAOA, 
MAOB and COMT is regulated by proteins in the PD landscape.
Taken together, decreased transport into secretory vesicles or decreased degradation 
of DA increases DA auto-oxidation and thus cellular aminochrome levels, which can 
have major effects on cellular processes by inhibiting the proteasome283, increasing 
cellular NM levels266 and binding to the familial PD proteins SNCA284, UCHL1285, PARK2 
(and aminochrome also inhibits PARK2286) and PARK7287. Aminochrome is speculated 
to affect chaperone mediated autophagy (CMA) function (for more on CMA see section 
B3.4) by binding to SNCA and UCHL1266, by inducing formation of SNCA protofibrils284 
that inhibit CMA just like mutated SNCA266 and UCHL1288.
The mRNA and protein levels of tyrosine hydroxylase (TH), the rate-limiting enzyme 
in DA synthesis in the cytoplasm of DA neurons289, are decreased in PD SN neurons246. 
TH expression is normally increased by PARK7290, CRHR1291, NTF3292 (not shown), the DA 
transporter SLC6A3293 and the transcription factor PITX3294, and decreased by SNCA295, 296 
(accumulates in lewy bodies40, 41), PTEN297 and CREM298, and inhibited by the DA receptor 
DRD2299. Cytoplasmic TH binds to SNCA300 and SLC18A2301 (not shown), suggesting a 
direct regulation of TH by SNCA. Further, SLC18A2 is found in a complex together with 
the DA transporter SLC6A3302 (not shown), i.e. in close contact with the DA transporter 
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responsible for DA influx in the cell. SLC6A3, in turn, binds to the familial PD proteins 
SNCA303 and PARK2304.
In summary, monoaminergic neurotransmitter-synthesizing neurons are more 
vulnerable due to aminochrome production that increases the cellular burden by 
inhibiting the proteasome, increasing cellular NM levels and affecting familial PD 
proteins that regulate autophagy, CMA, mitochondrial and lysosomal stabilization and 
proteasomal degradation.
A1.2 Hemoglobin, iron homeostasis and lipoprotein oxidation
Hemoglobin (Hb) is an iron-containing metalloprotein that in the blood transports 
oxygen from the lungs to the rest of the body. Hb is a tetramer of globin subunits (HBA1, 
HBA2, HBB, HBD, HBE1, HBG1, HBG2, HBM, HBQ1 and HBZ) that changes its composition 
during embryonic and fetal development. During adult life the most common Hb is a 
tetramer of two alpha (HBA1 or HBA2) and two beta (HBB) subunits305. Higher levels of 
late-life Hb161 and genotypes of the Hb-binding protein haptoglobin (HP) are associated 
with increased PD risk169. PD patients show an increased number of HBA1 containing 
mitochondria, reduced mitochondrial/cytoplasmic HBB ratios in SN neurons162. HP, 
which also binds HDL306, 307, prevents oxidation of Hb and thereby ensures its transport 
into the cell by the scavenger receptor CD163308. SN DA neurons are (next to red 
blood cells) one of the few cell types in the body that express Hb309, where Hb may be 
involved in iron metabolism, oxygen supply and mitochondrial function309. Oxidation of 
hemeproteins (e.g. Hb) can result in the release of their heme group310, which can become 
cytotoxic in the presence of multiple inflammatory factors310. Heme is also a cofactor 
for the thyroid peroxidase TPO (not shown; necessary for thyroid hormone synthesis 
and reducing hydrogen peroxide to water)311, 312 and essential for NOS1 activation313 and 
therefore affects (anti)oxidative reations. The lipoproteins HDL and LDL are the initial 
heme scavengers in the circulation and get oxidized (to oxHDL and oxLDL, respectively) 
by binding to heme310, which also renders them toxic. Of note, oxLDL is increased in 
the plasma of (L-DOPA treated) PD patients177. Clearance of heme by its conversion into 
biliverdin by the heme oxygenases HMOX1 and HMOX2312 prevents the oxidation of 
HDL and LDL by oxidized Hb. The inducibe heme oxygenase HMOX1 is increased in 
PD serum167, the number of HMOX1-positive astroglia (see main process D) is increased 
in the PD SN166 and lewy bodies in the SN neurons show intense HMOX1 expression166. 
Also, the constitutively active heme oxygenase HMOX2 is genetically associated with 
PD168. EIF4E increases HMOX1 translation314 and HMOX1 expression is increased by 
oxLDL315, ANGPT2316, STAT3317 (not shown), AKT1318, 319 (not shown), FOXO1320, RAC1321 (not 
shown) and SREBF1322 and decreased by ferrous iron (Fe(II))323 and NF-KB324 (not shown). 
Further, HMOX1 activation is increased by TP53325, ER stress326 (not shown), hypoxia327 



















Downregulation of HMOX1 results in increased SNCA aggregation323. Moreover, HMOX1 
increases the expression of BDNF331, GDNF331, TH332, ABCA1333, ABCG1333, PITX3332 (not 
shown), ANGPT2334 and DA332, decreases the expression of CXCL12335 and ICAM1336, 337 
(both part of main process D) and inhibits the accumulation of cholesterol333.
Conversion of heme into biliverdin by HMOX1 results in the production of carbon 
monoxide and the highly oxidative ferrous iron (Fe(II))312. NM binds Fe(II) and is in DA 
neurons the main Fe(II) store338, 339. Fe(II) is also a cofactor for TH in the DA synthesis 
pathway340, but highly cytotoxic and its cytoplasmic levels should therefore be tightly 
controlled. In the SN of PD patients the total iron content is higher than in controls228, 
whereas increased serum iron levels are associated with a decreased risk of developing 
PD341. SLC40A1 transports Fe(II) out of the cell and is upregulated in the PD SN231. SLC11A2, 
another iron transporter, is genetically linked to PD risk227 and its different isoforms are 
differentially expressed in PD228. SLC11A2 isoforms transports Fe(II) from endosomes 
into the cytoplasm and also into the mitochondria342. PARK2 increases proteasomal 
degradation of SLC11A2343, putatively decreasing cytoplasmic and mitochondrial Fe(II). 
Ferric iron (Fe(III)) can be transported into the cell by binding to transferrin (TF344; part 
of the HDL-complex345). TF binds to the transferrin receptor 2 (TFR2, the number of 
TF binding places, as a measure for transferring receptor expression, is lower on PD 
DA SN neurons245 and TFR2 expression is highly specific for SN DA neurons244), and 
is transported into an endosome where the low pH releases Fe(III) from TF346. The PD 
SN shows a dramatic increase of oxidized TF244. This oxidation of TF results in the 
reductive release of Fe(II) from TF244 and increases the oxidative cross-linking of TF to 
other proteins by formation of a disulfide bond, which likely impairs normal trafficking 
of TF244 and thus affects the localization of (cytotoxic) iron ions.
In summary, Hb and iron homeostasis increase the ‘oxidative burden’ of the DA neuron, 
and may also result in an increased oxidation of lipoproteins. Of note, low cholesterol 
intake, especially in combination with high dietary iron intake, increases PD risk347, 
perhaps due to  insufficient (unoxidized) LDL (the major blood cholesterol carrier) in the 
PD brain, affecting the downstream targets and regulation of lipoproteins.
A1.3 Interaction of the DA- and angiotensin-system
The angiotensin II receptor AGTR1 is involved in the renin-angiotensin system (RAS), 
that regulates water homeostasis and hypertension, of which the latter is associated 
with PD348-350. Moreover, overactivation of the RAS results in hypertension, increases 
superoxide formation by activating NADPH-dependent oxidases, increases microglial 
activation and increases oxidative stress as shown in PD animal models351. The DA 
and angiotensin II systems directly counterregulate each other in the ‘classical’ RAS 
in the renal cells352, but also in local RAS in the brain. Namely, in the striatum and 
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SN angiotensin II exacerbates toxin-induced DA neuron death via AGTR1 activation, 
whereas DA depletion increases the expression of the angiotensin receptors353. 
DA depletion may therefore result in increased RAS activation and exacerbate the 
angiotensin II-regulated oxidative stress and microglial inflammatory responses354, 355 
and thereby contribute to the degeneration of DA neurons351.
Aging in general is associated with an increase in RAS activation, which can be reduced 
by angiotensin II antagonists and subsequently prevent SN DA neuron degeneration 
in PD models351. AGTR1 regulates the JAK/STAT pathway356-358, caspase359 and NF-KB 
signaling360, 361, E3 ubiquitin-protein ligase complexes362, coagulation factors (for more 
on coagulation factors see section D2.2.3)363, 364, increases cholesterol esterification365, 
mobilization of intracellular Ca2+ and the production of inositol phosphates366, ER 
stress factors367, 368, autophagy369, 370 and endocytosis371. Thus, dysregulation of the RAS-
dopamine system interaction can affect many cellular processes in the PD landscape. 
The angiotensin 1-7 receptor MAS1 upregulates372, binds and is a functional antagonist 
of AGTR1366. Further, AGTR1 expression is decreased by the secreted vascular 
remodeling protein angtiopoietin-2 (ANGPT2)373 and HDL-cholesterol374 (which levels 
are positively correlated with the duration of PD375) and increased by the oxysterols 
24-hydroxycholesterol (24-OHC, which CSF-levels correlated with the duration of PD376) 
and 27-hydroxycholesterol (27-OHC)377 (for more on 24-OHC and 27-OHC see section 
B4).
In summary, the RAS and DA system counterregulate each other, indicating that the 
regulation of local brain RAS is important for a normal DA system. DA depletion, aging 
and oxysterols increase RAS activation, that in turn regulates multiple pathways in 
the PD landscape leading to increased oxidative stress, microglial activation and DA 
neuron death.
A2. Mitochondrial dysfunction
Mitochondrial dysfunction, increased oxidative stress and release of the apoptosis-
inducing cytochrome c may be caused by imperfect functioning mitochondrial 
proteins e.g., dysregulation of the mitochondrial transcription factor MTERFD1378 
(its inactivation leads to respiratory complex deficiency379), the mitochondrial DNA 
regulator PEO1312, the mitochondrial complex I assembly chaperone NDUFAF2380 or the 
mitochondrial 39S ribosome complex proteins MRPL3, MRPL18 and MRPL19312, which 
may impair mitochondrial protein translation. 
The superoxide dismutase SOD2 (differentially expressed in the PD brain237, 238, 381, 382) 
neutralizes superoxide, the toxic byproduct of the respiratory chain239 and decreases 
release of cytochrome c from the mitochondria383. Further, SOD2 inhibits ATF6384 



















GTP cyclohydrolase GCH1386 (not shown) and binds MCC387. And, SOD2 expression 
is decreased by PARK7388, increased by FOXO1389 and ANGPT2281 (not shown) and 
enzymatic activity of SOD2 is attenuated (up to 50%) by DA neuron specific reactive 
dopamine-quinones239. Further, LRPPRC is an essential posttranscriptional regulator 
of (mitochondrial) mRNA390, localizes predominantly to mitochondria but also to the 
nuclear membrane312. LRPPRC interacts with and its expression is increased by PINK1391, 
392, interacts with PARK2393 (not shown) and binds to MCC387, SIRT7394 (not shown), 
FBXO25395 and CECR2396. Dysregulation of LRPPRC results in defective regulation of 
cytochrome c oxidase subunits392. Thus, both SOD2 and LRPPRC may affect cytochrome 
c production in the mitochondria.
In addition to self-regulation, the mitochondria are also highly regulated by external 
factors from the cytoplasm. The next sections will discuss the regulation of mitochondrial 
(dys)function by familial PD proteins and the mitochondrial permeability transition 
pore (A2.1), by Ca2+ (A2.2) and by cholesterol and oxysterols (A2.3).
A2.1     Regulation of mitochondrial membrane permeability and cytochrome c release
Mitochondrion integrity and degradation is highly regulated by familial PD proteins, 
suggesting a key role in (familial) PD pathogenesis. Loss of the mitochondrial 
transmembrane potential (ΔΨm) results in activation of caspase-independent cell 
death pathway that is controlled by the serine protease HTRA2397 and mitochondrial 
accumulation of PINK1398. HTRA2 degradates denatured mitochondrial proteins and 
promotes apoptosis when released into the cytoplasm399 and accumulated mitochondrial 
PINK1 increases mitochondrial Ca2+ levels and opening of the mitochondrial permeability 
transition pore (mPTP)400 and subsequent cytochrome c release to the cytoplasm401. 
Further, accumulated PINK1 recruits PARK2 to mitochondria to initiate mitophagy398, 
402, 403. This recruition of PARK2 to mitochondria is disturbed in FBXO7 deficient cells404. 
Further, HTRA2 binds and cleaves PARK2 and thereby inhibits its E3 ubiquitin ligase 
activity405 and PARK2 is bound and inhibited (via ubiquitination) by LRRK2406 (binds 
SNCA407). Thus, PINK1, FBXO7, HTRA2 and LRRK2 regulate PARK2 that, by ubiquinating 
BAX, functions as a ‘gateway’ for BAX transport to the mitochondrial membrane and 
subsequent cytochrome c release408.
Cytochrome c (endoded by CYCS) is an essential component in the mitochondrial 
electron transport chain, but is also involved in the initiation of apoptosis when 
release from the mitochondria into the cytoplasm. Cytochrome c release is increased 
by ATP2B2409 (not shown), PTEN410, AMPK411, RAC1412 (not shown), TP53413 (not shown), 
CASP3414, CASP9415 (not shown; activated in TH+ SN neurons of late-onset PD patients138), 
cholesterol416, ceramide417, sphingosine418, NM419 and L-DOPA420 and decreased by EIF4E421, 
SOD2383, PRKCE422 (not shown), MAPT423, ATP13A2424 (not shown), PINK1425, PARK7426 
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(inhibits SNCA aggregation427) and PARK2428. Cytoplasmic cytochrome c increases the 
aggregation of SNCA429 and activates the apoptotic caspase pathway by activating 
CASP9 and subsequently CASP3430-433, which are also regulated by the familial PD 
proteins, i.e. CASP3 is activated by UCHL1434 and HTRA2435 and inhibited by PARK7 and 
PINK1436, 437, whereas CASP9 is activated by HTRA2438 and inhibited by PARK7436.
The proapoptotic proteins BAX and BAK1 bind to the voltage-dependent anion 
channel (VDAC), which results in loss of ΔΨm, mPTP opening, release of cytochrome 
c in the cytoplasm and activation of the caspase pathway by activation of CASP9 and 
CASP3439-444. The VDAC (there are three VDAC isoforms present in humans; VDAC1-3) 
is the major mitochondrial outer membrane channel, that allows ATP/ADP exchange 
between cytoplasm and mitochondria and allows the transport of ions (e.g. Ca2+), 
lipids (e.g. cholesterol) and metabolites over the mitochondrial outer membrane312, 
445, 446. The VDAC opens at low membrane potentials and closes at potentials above 
30mV447-449 and regulates, but is not necessary for mPTP formation450-453. Of note, in 
yeast cells SNCA-toxicity is dependent on VDAC. More precisely, the VDAC is able to 
transport monomeric SNCA into mitochondria and is blocked by SNCA. In this way, 
SNCA disrupts the VDAC-mediated ATP/ADP exchange, decreases ΔΨm and impairs 
oxidative phosphorylation454 (not shown). In addition to BAX and BAK1, VDAC also binds 
to CAV1455 (not shown), cholesterol (may also affect VDAC functioning)456, HLA-B387 (not 
shown), LRRK2457, MCC387, PARK2458, 459, PLAT (on the plasma membrane)460 (not shown), 
PRKCE422 (not shown), SIRT7394 (not shown), SNCA461 and the mPTP components STAR462 
and TSPO463. Further, VDAC accumulation440 and oligomerization induces apoptosis464, 
465 and its expression is increased by COL18A1440 (not shown), IL2466 (not shown) and 
vitamin D467 (not shown) and decreased by TSPO468 (not shown). VDAC recruits PARK2 to 
dysfunctioning mitochondria to induce mitophagy458. Ubiquitinating of VDAC by PARK2 
is PINK1-dependent469, and necessary for PARK2-mediated mitophagy470. Apoptotic 
pathways are activated via regulation of VDAC by BAX471, COL18A1440 and GSK3B472 and 
inhibited by PRKCE422. Of note, DA decreases the ΔΨm and reduces VDAC levels on the 
mitochondrial outer membrane473, 474, but this DA toxicity is not counteracted by (VDAC-
dependent458, 470) mitophagy and thereby enhances oxidative stress, which may possibly 
explain DA neuron death in PD474.
Binding and stabilization of hexokinase 2 (HK2) to VDAC and the mitochondrial 
outer membrane suppresses (BAX-induced) cytochrome c release, CASP3 activation 
and apoptosis475-477, by preventing mitochondrial VDAC accumulation440. HK2 locates 
to the outer membrane of mitochondria and is involved in glucose metabolism 
by phosphorylating glucose to glucose-6-phosphate312. HK2 also protects against 
neurodegeneration in rotenone and MPTP mouse models of PD478 and it is proposed that 



















increase phosphorylation of VDAC, which disrupts binding of the hexokinase HK2 to 
VDAC and decreases ΔΨm440, 472, whereas GSK3B inhibition increases the accumulation 
of HK2 in mitochondria, enhances glycolysis in the cell and increases neuronal 
survival480.
HK2 expression is regulated by binding of STAT3 and SREBF1 to the HK2 gene 
promotor481, 482 and is increased by AKT1483 (not shown), mTORC1484, 485 (not shown), 
CAV1486 (not shown), STAT3487, IFNG488 (not shown), IL1B489 (not shown), insulin (INS)490 
(not shown) and mutant TP53491 (not shown) and decreased by COL18A1440 (not shown). 
HK2 binds to PRKCE422 and PARK2459 and INSR activation results in HK2 translocation 
to mitochondria (via the AKT1 pathway)492 (not shown).
Thus, by regulating VDAC and HK2, cytochrome c release by the mPTP and subsequent 
activation of the caspase pathway can be suppressed. Of note, prevention of apoptosis 
by HK2 stabilization to VDAC and the mitochondrial outer membrane also favours the 
glycolysis pathway followed by lactic acid fermentation and reduces the oxidation 
of pyruvate in mitochondria475, 493. This change in energy production, from aerobic to 
anaerobic, is called the Warburg effect and reduces the production of ROS and is often 
seen in cancer cells494. Further, PARK2 deficiency activates glycolysis and reduces 
aerobic respiration by the mitochondria495.
A2.2 Ca2+-induced mitochondrial dysfunction 
The VDAC (as seen in A2.1) regulates transport of SNCA, metabolites and ions, such 
as Ca2+, over the mitochondrial membrane. However, the rate of their transport into 
the mitochondria also depends on their cytoplasmic levels. High cytoplasmic Ca2+ 
levels increase the transport of Ca2+ into the mitochondria. Therefore, regulation of 
cytoplasmic SNCA and Ca2+ levels is important to maintain homeostasis.
Of note, SN DA neurons are able to generate action potentials in the absence of synaptic 
input. They are autonomously active, which is regulated via Ca2+ entry through L-type 
calcium channels (composed of four subunits; CACNA1C, CACNA1D, CACNA1S and 
CACNA1F312)496. Ca2+ influx is therefore an important factor in regulating the basal 
activity of DA neurons. Further, L-type calcium channel-mediated Ca2+ influx enhances 
the production of DA from L-DOPA497, the use of L-type calcium channel blockers has 
been shown to reduce the risk of developing PD in a Danish population498. Furthermore, 
in the PD SN the number of cells that express CACNA1C and CACNA1D is lower134, but in 
these cells CACNA1D is higher expressed than in controls134. And, the CACNA1D subunit 
is also shown to be higher expressed in the PD SN135. Lastly, also the CACNA1D to 
CACNA1C ratio is increased in PD brains134. Thus, by regulating the intrinsic tonic firing 
typical for DA neurons, Ca2+ ensures that there is a continuous DA supply to target areas 
such as the striatum. This however exposes SN neurons to a higher Ca2+ influx than 
other neurons and it is hypothesized that together with the low Ca2+ buffering capacity 
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of SN neurons, this influx is directly responsible for mitochondrial stress and increased 
ROS production, which makes them more vulnerable499, 500. Increased intracellular 
Ca2+ levels disrupt mitochondrial membrane integrity, which results in cytochrome c 
release and apoptosis501.
Secreted SNCA-toxicity is mediated by an increased Ca2+ influx and deregulation of the 
cellular Ca2+ homeostasis503. And, intracellular Ca2+ levels can also be increased by CXCR4, 
by AGTR1 via activation of G proteins (e.g. GNA12)312, by influx through or mediated by 
the Na+/K+/Ca2+-exchanger SLC24A3312 (highly expressed in nigral DA neurons, and a 
potential role in DA neuron survival504), by the Ca2+-binding protein EFCAB4B (plays a 
key role in store-operated Ca2+ entry in T-cells312) and the voltage-dependent calcium 
channels (such as the L-type calcium channel subunits mentioned above, but also by 
other types of channels consisting of alpha-1 (CACNA1A), alpha-2 (CACNA2D3), beta and 
delta subunits312). These calcium channels are mediated by multiple proteins in the 
landscape i.e., CACNA1A binds to USP9X505, MAP1B505, EHMT2506 (not shown), LRP1506, 
SYNJ1505, CTNNB1505 and AMIGO2506 (activates the NF-KB complex507 (not shown)) and 
is inhibited by the dopamine receptor DRD3508 (not shown). Further, DA decreases the 
expression of CACNA2D3509 (not shown), which is high and highly specific expressed in 
the rat SN and is decreased after 6-OHDA treatment 504.
Other alpha-1 calcium channel subunits are also regulated by proteins in the landscape. 
CACNA1B (increases blood INS level510) binds SCN2A505 (SCN2A also binds to FGF12511), 
CNNM2505, MAP1B505 and the regulator of axonogenesis RUFY3312, 505 and is regulated by 
the dopamine receptor DRD2 (not shown)512. Further, CACNA1E also binds to RUFY3505 
(not shown), CACNA1C binds SIRT1513 and alternative splicing of CACNA1D and CACNA1S 
(both L-type calcium channel subunits) is regulated by RFBOX1514 (not shown).
Administration of Mg2+ reduces Ca2+ mediated microglial DA neurotoxicity in PD515 
and increases the kinase activity of LRRK2516. Mg2+ is transported out of the cell by the 
transporters CNNM2517 and SLC41A1518. Moreover, the magnesium dependent ATPase 
ATP2B2 couples ATPase activity to Ca2+ efflux312 and its overexpression depletes 
intracellular Ca2+ stores and triggers apoptosis409.
Thus, voltage-gated calcium channels regulate Ca2+ levels in the neuron, which 
is important for the intrinsic tonic firing of DA neurons and DA release, and are 
themselves regulated by multiple landscape proteins (e.g. the DA receptors DRD2 and 
DRD3). Increased Ca2+ influx increases mitochondrial dysfunction and increases SNCA-
toxicity.
A2.2.1 ER stress-induced mitochondrial dysfunction
Oxidative stress increases the influx of Ca2+ into the cytoplasm from the ECM, but also 
increases release of Ca2+ from the ER Ca2+-store519. Acute release of Ca2+ from the ER 



















normal ER function, resulting in activation of the unfolded protein response (UPR; see 
also section C1)) results in a perturbed mitochondrial function through a disturbed ER-
mitochondrial Ca2+ homeostasis521-523, i.e. BAX and BAK1 oligomerize in the ER membrane 
and allow Ca2+ release to the cytoplasm524, which is taken up by the mitochondria 
resulting in loss of the ΔΨm522, 524. Further, during ER stress BAX translocates to the 
mitochondrial membrane (increased by mitochondrial lipid rafts525) where it interacts 
with the mPTP leading, together with the loss of ΔΨm, to cytochrome c release in the 
cytoplasm439, 521, 524, 526, which results in caspase activation and apoptosis397.
The relevance of these processes in PD is illustrated by the increased BAX 
immunoreactivity in NM-containing neurons125 and differences in aggregation of BAX-
rich inclusions in PD126. Moreover, BAK1-deficient mice were resistant to paraquat 
neurotoxicity, a model for PD527 and the receptor for humanin, FPR3 (not shown), that 
mediates the anti-apoptotic activity of humanin and suppresses BAX-dependent 
apoptosis312, was found in the GWASs6.
Hence, ER stress results in BAX-dependent apoptosis, through Ca2+ release from the ER 
that is taken up by mitochondria, leading to a loss of ΔΨm, mitochondrial dysfunction, 
cytochrome c release and activation of apoptotic pathways.
A2.2.2 Intracellular Ca2+ release and regulation of inositol phosphates
Ca2+ release from intracellular stores (including the ER) is also increased by the 
secondary messenger inositol triphosphate (IP3)528, which is produced together with 
diacylglycerol (DAG) by cleaving of phosphatidylinositol 4,5-bisphosphate (PIP2) by 
PLCB4312. Myo-inositol serves as an important component of inositol phosphates (e.g. 
PI, PIP2, PIP3 and IP3)  and is transported into the cell by the proton myo-inositol 
cotransporter SLC2A13529 (genetically associated with PD53). PIK3CD generates the 
AKT1 activating PIP3 (phosphatidylinositol (3,4,5)-trisphosphate) by phosphorylating 
PIP2312 and increases intracellular Ca2+530. Further, PIK3CD also inhibits PTEN531, that 
generates PIP2 by dephosphorylating PIP3312 and thereby functions as an antagonist for 
the AKT1 signaling pathway312. The SNCA-binding532 serine/threonine-protein kinase 
PRKCE binds to diacylglycerol kinase theta (DGKQ, associated to PD27-29) and increases 
its translocation to the plasma membrane533. DGKQ phosphorylates DAG and thereby 
produces phosphatidic acid (PA)312. PA quantity is also increased by S1P534 (not shown). 
PA and DAG are both essential for PRKCE activation and translocation to the plasma 
membrane535. Further, PA also activates, and is necessary for mTORC1 signaling536-538, 
binds NR5A1539 (not shown) and increases NR5A1-dependent expression539, inhibits 
PPP1CA540, activates SPHK1541 (and increases its translocation to the plasma 
membrane542), activates AGAP1543 (GTPase activity stimulated by PIP3 and PIP2, whereas 
PA potentiates PIP2 activation543), activates the reverse activity of ASAH1 (resulting in 
ceramide production)544 (part of main process B), increases MAPT phosphorylation (via 
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MTOR activation)545  (not shown), binds HIP1R546 (not shown) and MBP547 (not shown) 
and induces fibrillization of SNCA548. Thus, inositol phosphate regulation affects Ca2+ 
release and production of PA affects among others, energy and redox sensing (mTORC1), 
sphingosine regulation (ASAH1, SPHK1) and SNCA aggregation as seen in PD.
A2.3 Cholesterol- and oxysterol-induced mitochondrial dysfunction
Several findings suggest that lipid metabolism is involved in PD pathogenesis. 
For example, high dietary intake of (poly)unsaturated fatty acids and plasma 
hypercholesterolemia are associated with lowering the risk of PD350, 549, 550, low plasma 
levels of LDL-cholesterol and total cholesterol are associated with an increased 
PD risk551-554 and PD disease duration is positively correlated with plasma HDL-
cholesterol375. Dietary cholesterol increases nicotinamide adenine dinucleotide (NAD) 
synthesis from tryptophan by inhibiting the decarboxylase ACMSD555 (not shown), that 
is also downregulated by long chain fatty acids556. NAD+ is reduced to NADH in the 
citric acid cycle or during β-oxidation or glycolysis, which is subsequently used during 
ATP production through oxidative phosphorylation in the mitochondria557. Activation 
of the lactate receptor HCAR1 inhibits lipolysis and thus the hydrolysis of triglycerides 
into glycerol and fatty acids558, 559 (its expression is inhibited by inflammation560). The 
mitochondrial oxidoreductase MARC1 catalyzes the NADH-dependent nitrite reduction 
to nitric oxide (NO) under anaerobic conditions561, is associated with LDL cholesterol 
levels562 and binds PARK2459. Maintaining a balance between (oxLDL-generated) reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) such as NO is important in 
preventing apoptosis563.
Plasma levels of oxidized cholesterol derivates are associated with PD. Patients have 
higher plasma oxLDL177 and 7-ketocholesterol (7-KC)564 (the main cholesterol oxidation 
product in oxLDL565). Statins, inhibitors of cholesterol synthesis, decrease oxysterol 
levels in the brain566 and reduce the aggregation of SNCA in vitro and in SNCA transgenic 
mice567, 568. Whereas high plasma LDL-cholesterol levels are protective, cellular LDL is 
oxidized in mitochondria569, increases ROS formation570 and impairs the activity of 
the mitochondrial oxidative complexes571. OxLDL consists of multiple oxysterols572, 573 
and results in ΔΨm disruption and release of the pro-apoptotic proteins cytochrome 
c and HTRA2574. Further, high cytoplasmic free cholesterol levels are toxic575 and can 
cause mitochondrial dysfunction416, 576, i.e. increased mitochondrial cholesterol levels 
increase oxidative stress577, resulting in increased oxysterol formation578. Oxysterols 
can be generated by either auto-oxidation or by ER or mitochondrial cholesterol 
hydroxylases579 and regulate lipid metabolism (via SREBF1, see also main process C), 
receptor function, immune response and apoptosis579 and cause SNCA aggregation568, 580, 
581 and lysosomal and mitochondrial destabilization582-584.



















(see section A2.2.1) but also by cholesterol regulation in the ER. Namely, SREBF1 
inhibition or knockdown reduces cholesterol-dependent stabilization of PINK1 on the 
mitochondrial membrane, PARK2 translocation to the mitochondria and subsequent 
mitophagy585. Further, the familial PD protein PLA2G6222, 223 catalyzes fatty acids release 
from phospholipids and associates with mitochondria during cholesterol-induced ER 
stress586, whereas sustained PLA2G6 activation leads to disruption of the mitochondrial 
outer membrane and cytochrome c release587. 
Expression of the outer mitochondrial membrane translocator protein (TSPO) is 
increased in PD striatum and midbrain, and correlates with motor disease serverity252. 
It is uncertain if TSPO is part of the mPTP or only associated to this complex578. TSPO 
transports cholesterol into the mitochondria578, 588, 589. TSPO expression is increased by 
S1P590 and in a 6OHDA rat  PD model591 and is activated during microglia activation252. 
In addition to TSPO, also the steroidogenic acute regulatory protein (STAR; part of the 
mPTP) binds cholesterol592 and increases cholesterol transport into the mitochondria593, 
594. STAR expression is increased by angiotensin II595, 596 (not shown), NR5A1597, 598 (not 
shown), CREM599 (not shown), LDL600 (not shown), HDL600 (not shown), 27-OHC601, 602, S1P590 
(not shown) and SREBF1603, 604 (not shown) and decreased by AMPK605, SIK1606, BMP7607, 608 
(not shown), NF-KB609 (not shown), LXRA/RXRA610 (not shown) and ASAH1611 (not shown). 
Furthermore, STAR binds to the vitamin D receptor (VDR)612 (not shown) and PRKG1613 
(not shown) and increases transport of VDR into mitochondria 612 (not shown). Thus, 
cellular lipoprotein (LDL, HDL), cholesterol-related (27-OHC, SREBF1) and sphingosine-
related (S1P, ASAH1) proteins affect cholesterol uptake by the mitochondria. STAR-
mediated mitochondrial cholesterol transport increases mitochondrial accumulation614 
of the apoptotic cholesterol derivate 27-OHC615. 27-OHC is increased in the plasma of 
PD patients564, decreases TH expression and increases SNCA expression616, 617 and is 
involved in reverse cholesterol transport (see section B4).
Cholesterol transport into mitochondria is required for the formation of steroid 
hormones. TSPO and STAR transport cholesterol into the mitochondria for conversion 
to pregnenolone and eventually to testosterone594, 618-622 by CYP17A1 in the ER623, 624. Thus, 
TSPO and STAR are indirectly important in production of testosterone. Testosterone 
decreases the expression of STAR620 (not shown), and thereby functions as a feedback 
loop on cholesterol transport into the mitochondria and subsequent testosterone 
synthesis, but may also increase the formation of 27-OHC and oxysterols. For more on 
testosterone function in PD pathogenesis see section C4.
A3. FOXO1 and SIRT1: Transcriptional regulators of oxidative stress
The transcription factor FOXO1 mediates cellular homeostasis during oxidative 
stress312, is inhibited by INS signaling312 and promotes neuronal cell death312. FOXO1 
105

















has a key role as it is connected with many proteins in the landscape. FOXO1 binds 
STAT3625, is activated by CXCL12626 (not shown), its expression is increased by TCF12627 
and PIK3CD increases FOXO1 degradation628. Further, FOXO1 increases expression of 
NF-KB629, ATP6V0A1630, HUS1629, SOD2389, INSR631, SCARB1632, the mTORC2 complex633 (not 
shown; mTORC2 consists of MTOR, RICTOR, MLST8, PRR5, MAPKAP1 and DEPTOR312, 
binds PINK1634, EHMT2 and BAT5635 and increases the expression of PTEN636), LAMP2632, 
SIRT1637 and decreases the expression of SREBF1632, ANGPT2638, PRF1630 and SERPINE1639 
and regulates CCL5 release640. Furthermore, deacetylated FOXO1 increases expression 
of ICAM1641. Thus, FOXO1 regulates DNA repair (HUS1), oxidative stress (SOD2), 
acidification of intracellular compartments (ATP6V0A1), INS metabolism (INSR), 
cholesterol metabolism (SCARB1, SREBF1), chaperone-mediated autophagy (LAMP2) 
and the immune response (PRF1, ICAM1, CCL5). 
The PD-linked226 deacetylation factor SIRT1 is a sensor for cellular energy status and is 
activated by an increased NAD/NADH+ ratio, and is subsequently involved in regulation 
of cell cycle, apoptosis and autophagy, and shuttles between the cytoplasm and the 
nucleus312. SIRT1 is, like FOXO1, an important regulator of the main transcriptional 
pathways in the PD landscape (see below) and is involved in cholesterol homeostasis642. 
Mutations in the SIRT1 promotor that may decrease SIRT1 transcription were found in 
some PD patients, but not in controls226. Cytoplasmic SIRT1 binds mTORC1643, MAPT644, 
CTNNB1645, ATG5646, ATG7646, CACNA1C513 and SREBF1647 and binds to and activates 
AMPK648 (another energy sensor, activated in response to low cellular ATP levels, see 
section B3.1). In the nucleus, SIRT1 binds to NF-KB649, TP53650, STAT3651, TLE1652, AR653, 
VDR654, CCAR2655 (inhibits SIRT1655) and NEDD8656. SIRT1 activates PTEN657, 658 and 
AMPK659, and inhibits CASP3660, NF-KB652, SERPINE1661, TP53650 and SREBF1662. Although 
SIRT1 decreases SREBF1 stability via deacetylation662, it also increases the expression 
of the cholesterol transporters ABCA1663 and ABCG1663 and thereby increases reverse 
cholesterol transport663, 664 (see also section B4).
Further, SIRT1 increases expression of MAOA278, regulates expression of SOD2665, 666 and 
decreases expression of the sodium channel SCNN1A667, STAT3668, TP53651, AR653 and the 
production of testosterone669. 
Thus, in response to cellular energy levels, SIRT1 regulates autophagy (AMPK, mTORC1, 
ATG5, ATG7), transcription (FOXO1, STAT3, SREBF1, VDR, TP53), and is involved in the 
regulation of oxidative stress (SOD2) and apoptosis (CASP3, TP53). Finally, FOXO1 
and SIRT1 tightly regulate each other. They bind670, FOXO1 activates671 and increases 
expression of SIRT1637 and SIRT1 inhibits FOXO1672. 
A4. Concluding remarks
The uptake, processing and signaling of lipoproteins and their components (e.g. 



















derivatives (e.g. oxysterol, ceramide, sphingosine, S1P, fatty acids) appear to play a 
crucial role in the PD landscape. Dysregulation of cellular cholesterol levels increase 
oxidative- and mitochondrial stress, which - given the increased oxidative state of DA 
neurons (e.g. due to iron and DA metabolism) – may just tip the scales in DA neurons 
and result in (ER stress-induced) mitochondrial dysfunction, increased cellular stress 
and apoptosis. Of note, familial PD proteins are directly involved in mitochondrial 
membrane quality control and cellular apoptosis and are therefore located at the ‘end 
of the funnel’ of interactions ultimately leading to mitochondrial-mediated DA neuron 
death. Single sporadic variations have a lower impact on the same pathways, but when 
accumulated, will also lead to mitochondrial dysfunction and DA neuron death.
B. ENDOSOMAL-LYSOSOMAL FUNCTIONING
Many of the PD-GWAS-associated proteins regulate endocytosis, autophagy and 
lysosomal function. This section discusses these processes and pathways in detail, 
starting with sphingolipids (B1), as they are important for membrane (and lipid raft) 
function and thus crucial for the regulation of endocytosis, autophagy and lysosomal 
function. Further, section B2 discusses the endocytosis of extracellular proteins and 
lipids into the intracellular endosome-lysosome system, and B3 elaborates on the 
function of the lysosome in autophagy and protein degradation. Lastly, section B4 
covers the role of reverse cholesterol transport and (systemic) regulation of lipoproteins 
and INS in PD. The functional interactions between the proteins within process B, 
‘endosomal-lysosomal functioning’, are shown in Supplementary Figure 2.
B1. Sphingolipids
Sphingolipids are a class of bioactive lipids containing a hydrophobic backbone of a 
long-chain spingoid base that is linked to a fatty acid and an hydrophilic head group 
than may contain hydroxyl groups, phosphates or sugar residues. Simple spingolipids 
include sphingosine (sphingoid base) and ceramide (sphingosine linked to fatty acid 
without additional head groups). More complex sphingolipids include sphingomyelin 
(ceramide with a phosphocholine or phosphoethanolamine head group), cerebrosides 
(ceramide with a single glucose or galactose head group) and gangliosides (ceramide 
with at least three sugars, one of which must be sialic acid). Ceramide, sphingomyelin, 
sphingosine, cerebrosides and gangliosides are discussed in more detail in the next 
paragraphs.
B1.1 Ceramide and sphingomyelin
Ceramide is important for the functioning of cellular membranes and plays a role 
in apoptosis673. Further, plasma ceramide is higher in sporadic PD patients versus 
controls and in PD patients with versus without cognitive impairment674, whereas 
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sphingomyelin is reduced in PD frontal cortex lipid rafts compared to controls675. 
In addition to the de novo synthesis from less complex molecules, ceramide can be 
generated through hydrolysis from sphingomyelin by the lysosomal sphingomyelinase 
SMPD1. SMPD1 is activated by cholesterol676 and induces translocation of PRKCE to the 
cytosol and NF-KB to the nucleus677, 678 (not shown), this is presumably resulting from 
a change in ceramide/sphingomyelin ratio by SMPD1, for ceramide increases cytosolic 
accumulation of PRKCE677, 679 (not shown) and translocation of NF-KB to the nucleus678. 
Moreover, ceramide also increases activation of NF-KB680-683, CASP3684-686, CASP9687 and 
BAX418, 688, inhibits AKT1689-691 and increases ER- Ca2+ and mitochondrial cytochrome C 
release and apoptosis528, 692, 693. The lysosomal glucosylceramidase GBA and ceramidase 
ASAH1 respectively increase and decrease ceramide levels, i.e. GBA converts glucosyl-
ceramide (a cerebroside, and also called glucocerebroside) to ceramide and ASAH1 
catalyzes the conversion of ceramide to sphingosine694, 695. GBA also binds to PARK2696 
and SNCA697 and mutations in, or knockdown of GBA698 increases SNCA aggregation, 
whereas SNCA in turn inhibits GBA activity698.
The transporter ABCG1 is located on the plasma membrane and increases secretion 
of sphingomyelin from the cell699. Further, sphingomyelin may be a substrate for and 
increases the expression of the late-endosomal/lysosomal cholesterol transporter 
ABCA5700 (mRNA expression is increased in the amygdala of PD patients700). Moreover, 
sphingomyelin also increases expression of SNCA700, and decreases expression of the 
cellular cholesterol homeostasis-controlling transcription factor SREBF1701. On the 
other hand, ceramide increases activation and nuclear translocation of SREBF1702, 
suggesting that sphingomyelin and ceramide have opposite effects on cholesterol 
regulation. In turn, cellular sphingolipid levels are affected by lipoproteins, e.g. HDL 
increases ceramide levels703 by binding to SCARB1704, and oxLDL and 7-KC can increase 
ceramide accumulation705 (not shown), but 7-KC in oxLDL can also inhibit lysosomal 
sphingomyelinase706 (not shown).
B1.2 Sphingosine
The sphingosine synthesis pathway is regulated by the precursor protein prosaposin 
(PSAP), whose uptake and transport into endosomal-lysosomal compartments707 and to 
the lysosome is regulated by its binding to LRP1708, 709 and sphingomyelin710 and to the 
PSAP receptor GPR37711. PSAP is increased by CTNNB1712, TP53713 and in the striatum by 
the DA transporters SLC6A3714 and SLC18A2714 (not shown). In the lysosome, PSAP binds 
CTSD715, that regulates the proteolytic processing of PSAP into saposins A, B, C and D716. 
These saposins are associated to PD-related mechanisms i.e. saposin A and B deficient 
mice show altered autophagy717, saposin A and B knockout mice show increased number 
of foot slips in the narrow bridge test (a behavioral test to assess motor balance and 



















and binds720 and activates GBA721-723, whereas saposin D increases ASAH1 activity723, 724. 
Thus, saposin C and D stimulate the conversion of glucocerebroside to ceramide (via 
GBA), to sphingosine (via ASAH1) respectively.
Of note, the PSAP receptor, GPR37 is associated with juvenile parkinsonism157, is 
accumulated in PD lewy bodies156 and its overexpression induces macroautophagy725. 
GPR37 increases ER stress and expression of HSPA5725, 726 (not shown) and PARK2726. GPR37 
binds HSPA8727 and SLC6A3301, 728. Further, PARK2 binds, increases the ubiquitination 
and increases the degradation of GPR37 and thereby prevents its aggregation and 
subsequent ER stress-mediated neuron death157, 727, 729, 730. GPR37 is involved in the 
expression of SLC6A3301 and the uptake and quantity of DA in the striatum728, 731, 732. 
So, overall, PSAP regulation is important for activation of the sphingosine synthesis 
pathway and in maintaining normal DA levels in the striatum.
B1.2.1 Sphingosine-1-phosphate
Sphingosine-1-phosphate (S1P), formed through phosphorylation of sphingosine by 
sphingosine kinase 1 (SPHK1)733, is an immune attractant (see section D2.2.2.1) and 
is transported out of the cell by the transporter SPNS2734. Further, S1P activates the 
UPR and ER stress735, 736 and is, similarly to cholesterol, transported by lipoproteins 
and involved in lipid raft functioning590, 735-737. Sphingosine and cholesterol metabolism 
are linked, illustrated by S1P activation of SREBF1737 (the cholesterol uptake proteins 
SCARB1 and LDLR are upregulated by S1P590) and the regulation of GBA activity by 
cholesterol707.
The S1P receptors bind and increase activation (after activation by S1P) of the G protein 
GNA12 to regulate cell shape and motility738, 739. GNA12 transduces extracellular signals 
over the membrane312 and also binds to CDH2740, CXCR4741, LRRK2742 and the cytoplasmic 
proteins PRKCE743 and AXIN1744. Thus, S1P activates GNA12739 and activates CTNNB1740, 
GSK3B745 and NF-KB746, increases the expression of the immune regulator ITGA6747, the 
diacylglycerol (DAG) activated calcium channel TRPC6 (increasing Ca2+ influx)748 and 
NOS2749. NOS2 expression is also increased by LRRK2750, and SREBF1751 and decreased 
by COL18A1752 (not shown) and NOS2 itself increases the expression of perforin (PRF1)753 
and IL6312, indicating a role in the immune response (part of main process D).
B1.3 Cerebrosides and gangliosides
Cerebrosides are primarily found in nervous tissue and are reduced in lipid rafts of the 
frontal cortex of PD patients675, but increased in the plasma of PD patients compared 
to controls674. Further, GBA, the glucocerebrosidase that converts glucocerebroside to 
ceramide, is downregulated in PD patients compared to controls98, 754. Glucocerebroside 
can be converted into globoside by addition of a galactose, further addition of the 
sugars sialic acid, N-acetylgalactosamine and galactose results in the synthesis of 
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respectively the gangliosides GM3, GM2 and GM1. GM1 is the most common ganglioside 
in the brain and is involved in neuronal plasticity and repair as seen by its protective 
effects after a mechanical lesion of the dopaminergic nigro-striatal system755. 
Development of parkinsonistic features, i.e. motor impairment, striatal DA depletion, 
loss of TH positive neurons and SNCA aggregation were seen in mice devoid of the 
GM1756, 757. Whereas GM1 administration in mice treated with MPTP (a model for PD) 
resulted in partial restoration of DA neurons in the SN758, 759. Further, in a cell model for 
lysosomal disease, characterized by reduced lysosomal activity, lysosomal cytotoxicity, 
and inhibition of the autophagy-lysosomal pathway resulting in SNCA accumulation, 
GM1 administration reversed the phenotype760. Moreover, use of ganglioside GM1 by 
PD patients improves their motor symptoms and slows down symptom progression761, 
even over a five-year period762. And, anti-GM1 ganglioside antibodies are increased 
in the serum of PD patients compared to controls763. Lastly, GM1 content in the brain 
decreases with age, while GM3, a minor brain ganglioside, is increasing764. GM3 has 
a higher binding affinity to SNCA than GM1765 and can specifically regulate SNCA-
induced pore formation766, 767 (not shown). SNCA membrane association, by binding to 
GM3 or GM1, induces folding of an alpha-helix domain that displays a high affinity for 
cholesterol enabling it to get inserted in a cholesterol rich part of the plasma membrane 
(lipid raft) and form an oligomeric ion channel765. In this way, SNCA can form pores in 
the neuronal plasma membrane767 that increase Ca2+ influx, increasing synaptic vesicle 
release and increase synaptotoxicity768. Of note, defects in the endocytic pathway 
and membrane trafficking to the lysosome results in accelerated release of exosome-
associated GM1769 and these exosomes (extracellular vesicles secreted by the cell) 
containing GM1 or GM3 accelerate the aggregation of SNCA770 (not shown). Moreover, 
GM1 binds MBP771 (not shown) and GM3 binds the INSR772 (not shown) and decreases 
expression of ICAM1773 (not shown). Further, the proprotein PSAP binds GM1 and GM3 
and may function as a ganglioside transport protein for transport into the cell774 (not 
shown), whereas its proteolytic cleavage product saposin B increases the degradation 
of GM1 in lysosomes723, 775 (not shown). 
Thus, ganglioside content in plasma or exosome membranes, which is regulated by 
among others the endosomal-lysosomal pathway and PSAP, may affect membrane 
function, but also SNCA membrane association and thereby be important in PD 
pathophysiology.
B2. The endosome-lysosomal system
The endosome-lysosomal system recycles and catabolizes material taken up by 
endocytosis, from the external milieu or from the cytosol by autophagy. The endosomal-
lysosomal system regulates protein trafficking, sorting, recycling and degradation, and 
microtubular motor transport. Moreover, in immune cells, the endosomal-lysosomal 



















subprocesses include clathrin- and caveolae-mediated endocytosis, the trafficking, 
targeting and recycling of vesicles, as well as lipoprotein uptake and processing. 
Particularly, the organization of membrane components in lipid rafts, such as cholesterol 
and sphingolipids (including sphingomyelin and ceramide), regulates the fluidity of the 
membrane676, 776, 777, and is essential for the clustering of receptor molecules, recruitment 
of intracellular signaling molecules778-780, endocytosis, membrane trafficking and 
activation of the immune response781, 782. Lipid rafts, i.e. cholesterol-rich microdomains, 
are located on plasma, endosomal, lysosomal, ER and mitochondrial membranes. 
Interestingly, oxysterols can regulate membrane fluidity783 and the formation of lipid 
rafts777. Further, also the familial PD protein LRRK2 and cholesterol affect lipid raft 
function784-787. Moreover, membrane cholesterol affects the DA uptake/efflux function of 
the PD-associated232-234, 788 DA transporter SLC6A3789-792 that is located in both lipid rafts 
and non-raft membrane regions789 and undergoes clathrin-mediated endocytosis793, 794. 
In lipid rafts SLC6A3 binds to the PD associated28 and SN specific504 RIT2 that regulates 
SLC6A3 internalization and functional downregulation795, and may be involved in the 
survival of DA neurons504.
The next paragraphs will discusse clathrin-independent (B2.1) and -dependent (B2.2) 
endocytosis and their role in cholesterol and lipoprotein uptake, vesicle trafficking and 
sorting.
B2.1 Clathrin-independent endocytosis
Clathrin-independent endocytosis occurs by caveolae, i.e. specialized lipid rafts 
in caveolin-1 (CAV1)-enriched plasma membrane invaginations796, 797. SNCA and 
PRKCE increase the expression of CAV1798, 799 and thus may promote the formation 
of caveolae. CAV1 binds to and increases lipid raft localization of the gap junction 
protein GJB2800. CAV1 also binds to PTEN801, INSR802, SCARB2803, RAC1804 (not shown), 
SCARB1805 (stabilization by PARK2 prevents its degradation806, 807), LRP1808, CTNNB1809, 
JAK2810 and STAT3811, indicating that CAV1 and thus caveolae regulate the JAK2/STAT3 
pathway as well as cholesterol (SCARB1, SCARB2 and LRP1) and INS (INSR) signaling. 
Moreover, CAV1 increases the cholesterol content of lipid rafts812, decreases cholesterol 
esterification813 and increases cholesterol efflux814. In turn, cholesterol increases CAV1 
expression815, 816 (not shown), indicating a complex interaction between CAV1, lipid rafts 
and cholesterol. Further, in lipid rafts sphingosine can be converted into sphingosine-
1-phosphate (S1P) by sphingosine kinase 1 (SPHK1)733. S1P increases the localization of 
CAV1 and actin cytoskeleton-regulating proteins, such as the CAV1-binding COL18A1 
(endostatin)817, to lipid rafts818, enabling cytoskeleton regulation that is necessary for 
caveolae-mediated endocytosis. Defective sphingosine production (as regulated by 
the enzymes GBA and ASAH1) can therefore have major effects on lipid raft function 
and (caveolae-mediated) endocytosis by the cell. The CAV1-binding819, 820 microtubule-
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associated protein DNM2 mediates endocytosis and vesicle budding in caveolae821 and 
further binds to CACNA1A505, MCC387, AMPH822, AMPK387 and DRD2823, and binds to and 
colocalizes with the myosin motor protein MYO1E824 that is involved in freshly-budded 
vesicle trafficking. The caveolae-localized potassium voltage-gated channel subunit 
Kv1.5 (KCNA5) is regulated by angiotensin II825, cholesterol, sphingolipid and oxLDL825-827 
and linked to apoptosis828. And lastly, the transcription factor RFX4 heterodimerizes 
with RFX3829, a transcription factor that binds to the promotor of DNAH11830. DNAH11 is 
a protein that is involved in microtubule motor activity and genetically associated with 
LDL levels831.
B2.2 Clathrin-dependent endocytosis
Clathrin-mediated endocytosis is regulated by the clathrin- and dynamin-binding 
protein amphiphysin (AMPH)822, 832-837 and by the adaptor protein 3-complex (AP3, subunit 
AP3B1) that binds and sorts proteins to endosomes and lysosomes838. Association of the 
endocytic clathrin-coat with the actin cytoskeleton is regulated by the genetically PD-
linked HIP1R77, 839, 840. The myosin motor protein MYO1E (required for actin assembly 
during clathrin-mediated endocytosis)841, AMPH842, but also the cytoplasmic actin-
bundling and calcium-sensitive protein fimbrin (PLS1)843 and RAC1 (necessary for 
actin polymerization during endocytic clathrin-coated pit formation)844 are involved in 
actin formation during endocytosis, whereas the cytoplasmic monooxygenase MICAL2 
promotes depolymerisation of F-actin312. RAC1 binds to and is activated by the familial 
PD proteins LRRK2 (changes the cellular localization of membrane-bound RAC1)845 and 
PARK2846, the Rho GTPases ARHGAP33 and ARHGAP44312, 847, 848, binds to the nuclear 
importin KPNA4848 (not shown), and is activated by RAP1A849, RIT2850 and NEDD9851 and 
inhibited by PTEN852. 
In addition to endocytosis, clathrin is also used for protein sorting towards lysosomes853, 
854. The clathrin-binding proteins CLVS2 and TOM1L2 are required for normal endosome/
lysosome morphology855 and protein trafficking to the lysosome856 respectively. Of note, 
the ubiquitin ligase NEDD4 promotes degradation of SNCA by the endosomal-lysosomal 
pathway and is located in lewy bodies857, 858. NEDD4 binds to SMAD5859 (not shown), 
RAP2A860, ZAK861 (not shown), GBA861 (not shown), TOM1L2861, MRPL19861 (not shown) and 
binds and increases mono-ubiquitination of DCUN1D1862 (not shown).
To uncoat clathrin-coated vesicle – necessary for fission with the target membrane – 
DNAJC6 or its homologue GAK (also referred to as auxilin 1 and 2, respectively) recruit 
the (in the PD SN downregulated171) clathrin uncoating ATPase Hsc70 (HSPA8)863-865. Both 
GAK and HSPA8 bind to the familial PD lysosomal protein ATP13A2866 (found in the lewy 
bodies of remaining PD DA neurons867), which deficiency leads to lysosomal dysfunction 



















mediated endocytosis869 and the GAK-LRRK2 complex promotes golgi-derived vesicle 
clearance through the autophagy–lysosome system870.
B2.2.1	 Vesicle	trafficking	and	recycling
PCM1 and FAM190A are both involved in early vesicle trafficking, by binding the 
dynein-mediated organellar transport regulator NDEL1, the dysfunctioning of which 
results in delayed endocytic-lysosomal compartment formation871. Further, the 
lysosomal trafficking protein VPS41 binds the AP3-complex872, 873, reduces SNCA 
accumulation and caspase activation, and is protective against SNCA overexpression 
and the neurotoxins 6-OHDA and rotenone in PD models874. Lysosomal trafficking by 
AP3B1 (AP3-complex)875 includes the membrane protein SCARB2876 that regulates 
lysosomal targetting of GBA877, enabling GBA to convert glucocerebroside into ceramide 
(see section B1). Further, Localization of LAMP1 (lower expressed in DA neurons in the 
PD SN34) to the endosomal / lysosomal membrane is regulated by AP3875, 878. LAMP1 
decreases expression of LAMP2879 and both LAMP1 and LAMP2 regulate cholesterol 
traffic and decrease cholesterol accumulation880.
Recycling of (endosomal) vesicles is regulated by multiple proteins in the landscape. 
The familial PD protein260 VPS35 is part of the retromer complex for endosome/trans-
golgi network transmembrane receptor recycling and the sorting of cargo proteins881, 
882, e.g. for sorting of the lysosomal acid protease cathepsin-D (CTSD)883. The retromer 
complex interacts with the PD-linked DNAJC13148, an endosomal recycling component 
regulating early-endosome clathrin-coat dynamics148. DNAJC13 binds to GSK3B884 and 
HSPA8885. Further, RER1 regulates retrograde vesicle-mediated transport of proteins 
from the golgi to the ER886. RER1 binds the γ-secretase complex (by bind to e.g. PSEN1) 
and thereby increases the retention and retrieval of this complex and its subunits in 
the ER, preventing γ-secretase activity887-889 (for more on the γ-secretase complex see 
section C2.4). 
The membrane fusion protein NSF is required for endocytic vesicle/golgi fusion890, 
vesicle-mediated ER-golgi transport891, clathrin-coated vesicle/target membrane 
fusion892, 893, thus regulating endocytic recycling894 and exocytosis895. LRRK2 binds 
to NSF (thus controling vesicle recycling)896 and interacts with SNCA (406, 897, 898 that 
inhibits vesicle recycling899. The cytoplasmic protein SYN3 localizes to the membrane 
of cytoplasmic vesicles and decreases release of DA in the striatum900 and is 
downregulated by SNCA901. FER also binds to and phosphorylates NSF, thus inhibiting 
subsequently vesicle fusion902. NSF-attachement protein beta (NAPB) helps NSF 
binding to the SNARE complex903 and is thus involved in vesicle fusion and exocytosis. 
Other exocytosis-regulating proteins are RPH3AL904 (involved in INS secretion905) that 
binds to UNC13B312, 906 and the ER-stress-induced907, CCL5-regulating908 clathrin-coated 
vesicle protein909 SCAMP5908. The PD associated protein SYT1176, 77, 104 regulates Ca2+-
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dependent exocytosis of secretory vesicles312 (the Ca2+-dependent protein SCIN312 also 
regulates exocytosis by regulating the actin cytoskeleton during exocytosis502). SYT11 
binds ATP13A2866 (not shown) and PARK2, that also increases SYT11 degradation910. 
The early-onset Parkinsonism-associated SYNJ1240, 241 is involved in synaptic vesicle 
recycling240 and components of this machinery, i.e. it binds to AMPH911, MYO1E824, 
PARK2912, clathrin913 and the calcium-channel subunit CACNA1A505. The recycling 
endosome membrane protein RAP2A914 binds to the mTORC1 complex915 and the SNCA-
binding phosphoprotein ENSA916-918. Dysfunctioning of the AP3 complex regulator 
AGAP1 (that binds AP3 and regulates AP3-dependent trafficking)919, affects striatal DA 
release, linking endocytic recycling to DA release919, 920.
B2.2.2	 Lipoprotein	uptake	and	processing
Lipoproteins are composed of lipids, triglycerides and proteins. Very low-density 
lipoprotein (VLDL) particles are enriched in triglycerides and the removal of 
triglycerides from VLDL results in the formation of intermediate density lipidprotein 
(IDL)921. IDL is enriched in cholesterol and can subsequently be converted by LIPC into 
LDL312, which is highly enriched in cholesterol. The clathrin-mediated endosomal-
lysosomal system facilitates lipoprotein (e.g. VLDL, LDL) uptake via (among others) the 
VLDL receptor (VLDLR) and LDL receptor (LDLR)312. Early endocytic vesicle acidification 
by the V-ATPase (ATP6V0A1) releases LDL from the LDLR. LDL is then degraded in the 
lysosome, and cholesterol is salvaged for cellular use922 and increases the expression 
of the transporter ABCG1923-925 that subsequently exports cholesterol to HDL926, 927 and 
thereby also inhibits plasma membrane lipid raft formation928. LDLR expression is in 
turn increased by PRKCE929 and its activation inhibited by MAP2K6930 that is activated 
by LRRK2931. Uptake of IDL and HDL is regulated by the receptors SCARB1 (upregulated 
by FOXO1)632 and SREBF1932, and downregulated by ASAH1590 and LRP1 respectively, both 
of which are affected by the extracellular matrix (ECM) lipase LIPC933-935. LIPC deficiency 
increases serum HDL-cholesterol936. The expression of the APOE receptor LRP1 (binds 
to SERPING1708) and APOE itself is increased in early PD117, which may indicate a defect 
in lipoprotein regulation in early PD.
The ER serine protease TMPRSS3, the plasma membrane serine protease TMPRSS9, the 
anti-apoptotic protein937, 938 RXFP1, the pore forming complement system member C9, 
and the lipoprotein uptake receptors VLDLR, LRP1 and LDLR all contain a LDLR class A 
domain that can bind LDL312.
B3. The lysosome-autophagosomal system
B3.1 AMPK and mTORC1 regulated autophagy
The AMP-activated protein kinase (AMPK)-complex and the mTORC1-complex are 
both essential for autophagy functioning939, 940. The mTORC1-complex (composed of 



















synthesis for cell growth and proliferation and is activated by INS, growth factors and 
oxidative stress941, 942. mTORC1 is involved in DA neuron survival, whereas the mTORC1 
inhibitor rapamycin is neuroprotective in in vitro and in vivo PD models943 and blocks 
translation of the MTOR inhibitor DDIT4, a protein that is elevated in PD SN neurons 
and mediates cellular death in PD models147, indicating that inhibition of only certain 
mTORC1 functions is beneficial for neuronal survival. Of note, prolonged treatment 
of PD patients with the DA precursor L-DOPA results in L-DOPA-induced dyskinesia, 
which is associated with persistent activation of mTORC1944.
The AMPK-complex – consisting of an α-subunit (PRKAA1 or PRKAA2), a β-subunit 
(PRKAB1 or PRKAB2) and a γ-subunit (PRKAG1, PRKAG2 or PRKAG3)) –  is a cellular 
energy sensor that is activated when intracellular ATP levels are low940 and subsequently 
tries to restore cellular energy (ATP) levels by stimulation of fatty acid oxidation, 
glycolysis, glucose uptake and ketogenesis and inhibition of synthesis pathways 
for proteins, glycogens, fatty acids and cholesterol945-948. AMPK activation results in 
increased oxidative stress, release of mitochondrial cytochrome c and mitochondrial 
caspase pathway activation949. The mTORC1-complex is regulated by AMPK, i.e. AMPK 
binds mTORC1950 and inhibits mTORC1 activation940, 950, thereby preventing mTORC1-
mediated autophagy inhibition940 and mTORC1-mediated SREBF1 activation951. 
Following mTORC1 inhibition (by AMPK), autophagosomes form952 and fuse with the 
lysosome to degrade their cargo953. The PD-associated proteins ATG5 en ATG7120, 121 are 
involved in autophagosome assembly954. ATG5 binds to the familial PD protein UCHL1387 
and SIRT1646, activates JAK2955, and is essential in T- and B- lymphocyte survival and 
proliferation312 (not shown; part of main process D). Both ATG5 and ATG7 are involved 
in mitochondrial quality control following oxidative damage312. ATG7 increases 
autophagy956, decreases SNCA957 and LRRK2957 aggregation, activates CASP3958, JAK2955 
and STAT3959 and, like ATG5, binds to and is deacetylated by SIRT1646, 960. In a PD mouse 
model, conditional deletion of ATG7 results in age-related loss of DA neurons and loss of 
striatal dopamine961. Together, these results indicate that proper autophagy is important 
to prevent DA neuronal loss and PD.
In addition to inhibition by AMPK, mTORC1 activity is also inhibited by ULK2962, 
GSK3B963, inhibited and decreased by PTEN964, 965 and FOXO1633, 966 and activated by 
ATF6967 and INS968, 969. mTORC1 in turn inhibits GSK3B970, 971 and CASP3972, increases the 
expression of PTEN636, activates and increases the nuclear expression of SREBF1973, 974, 
regulates BAMBI975 (not shown), binds the deubiquitinase USP9X976, the NAD-dependent 
deacetylases SIRT1643 (not shown) and SIRT7394, the transcription factor EIF4E977 
and binds and phosphorylates the repressor of translation initiation EIF4EBP2977, 978. 
Hypophosphorylated EIF4EBP2 competes with the familial PD protein EIF4G1 to interact 
with the translation initiation factor EIF4E312, 979. Thus, mTORC1 favors the binding 
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of EIF4E to EIF4G1979, which results in recognition of the mRNA cap and initiation of 
translation312, 980 (e.g. LSM7 mRNA translation314) (part of main process C).
STK11 is a master upstream kinase that increases the activity of AMPK and AMPK-
related kinases981. Deacetylation of STK11 by SIRT1 increases STK11 activation and 
subsequent AMPK activation982. In addition, STK11 also binds AMPK983-987, the kinase 
SIK1988, 989, SNRK990 (a distant AMPK relative981), PARD3991, GSK3B992, PTEN993, inhibits 
MTOR994, increases the expression of PTEN995, TIAL1995 and NCAM2995, decreases the 
expression of CNTN1995 (CNTN1 binds SNCA461) and binds and activates both TP53996, 997 
and MARK2988, 989. MARK2 is an AMPK-related kinase981 that binds to AMPK998, CEP85L 
999, SNCA461, CACNA1A505, binds and activates PINK11000 and is inactivated by PARD31001.
Further, AMPK also binds to and inhibits NF-KB1002, 1003, binds to SIK1998 (inhibits nuclear 
SREBF11004), SNRK998 and SND1954, regulates BAMBI975 (not shown) and binds to, inhibits 
and increases expression of SIRT1648, 1005, 1006. Furthermore, familial PD proteins VPS35387 
and EIF4G1387 directly bind to AMPK, while LRRK2 (mutations in LRRK2 have been 
associated with autophagy impairment1007) activates AMPK1008, indicating that altered 
AMPK function may be important in PD. The serine/threonine-protein kinase and AMPK 
inhibitor1009 ULK2 is involved in autophagy and is activated following phosphorylation 
by AMPK1010. ULK2 is also both a downstream effector952 and a negative regulator of 
mTORC1 signaling962 and ULK2 expression is increased by SREBF11011. Thus, AMPK and 
SREBF1 regulate autophagy and mTORC1 activation via regulation of ULK2. Moreover, 
ULK2 functions as a negative feedback loop for both AMPK (directly) and SREBF1 (via 
inhibition of mTORC1).
Lastly, after Ser473-phosphorylation, AKT1 activates the mTORC1 activator SAMD4A1012, 
that is necessary for mTORC1 activation. In control brains, AKT1 and Ser473-
phosphorylated AKT1 are expressed at high levels in DA neurons in the SN, whereas 
PD patients show diminished brain levels of both total and Ser473-phosphorylated 
AKT1113. In contrast to neuronal loss of AKT1 in PD, both phosphorylated and 
unphosphorylated AKT1 are increased in glia cells in the PD brain SN113. Further, AKT1 
Ser473-phosphorylation is increased by the familial PD proteins PARK7 (by binding and 
inhibiting the negative AKT1-regulator PTEN)1013, 1014, PINK1 (by activating the mTORC2-
PRKCE-AKT1 pathway)634, 1015 and LRRK2 (that also binds to AKT1)1016. AKT1 is also 
activated by PRKCE1017 (binds SNCA532), PIK3CD1018, 1019, inhibited by PTPN11020, 1021 (which 
is again inhibited by AKT11022) and bound and inhibited by the LRRK2 phosphatase 
PPP1CA (PP1)1023, 1024. 
In summary, activation of the mTORC1 complex is regulated by multiple proteins in the 
PD landscape, either indirectly (via AMPK and AKT1) or directly (via DDIT4, ULK2 and 



















SREBF1), apoptosis (via CASP3) and translation (via EIF4E, EIF4G1 and EIF4EBP2).
B3.2	 Lysosomal	acidification
Lysosomal function and autophagy require organellar acidification that involves 
PLEKHM1 via its Rab7-binding domain RUN1025, 1026. The PD-associated Rab7-like protein 
RAB7L1102, 106 interacts with LRRK2 to modify intraneuronal protein sorting1027 and binds to 
the pre-mRNA splicing factor LSM71028. The familial PD lysosomal ATPase ATP13A21029-1031 
is decreased in PD SN867 and its dysfunctioning leads to lysosomal membrane instability, 
reduced processing of lysosomal proteins, diminished degradation of lysosomal 
substrates, reduced clearance of autophagosomes and impaired lysosomal acidification 
which subsequently may contribute to the formation of Lewy bodies, a hallmark of 
PD867, 1007. ATP6V0A1 is a subunit of the V-ATPase, a proton pump essential for lysosomal 
acidification1032, and binds to SNCA461. Lysosomal V-ATPase activity is regulated by 
DRAM11033, which is activated by TP531034, and activates the lysosomal acid protease 
cathepsin-D (CTSD)1035 (lower expressed in PD SN neurons)33 and autophagy following 
mitochondrial dysfunction1033. CTSD is necessary for lysosomal protease activity, but 
e.g. also for proteolytic cleavage of PSAP into saposin C and D, peptides that activate 
GBA and ASAH1 (see also section B1.1.2). Conversion of ceramide into sphingosine and 
vice versa by ASAH1 in the lysosomes is pH-dependent544, 1036. Therefore, lysosomal 
pH, controlled by the proton V-ATPase (including subunit ATP6V0A1), affects celllular 
ceramide and sphingosine levels, that may affect cellular membrane regulation and 
apoptosis (see section B1.1). Of note, lysosomal acidification (and thus stability) is also 
dependent on lysosomal cholesterol membrane content1037, 1038, again illustrating the 
importance of proper cholesterol regulation for normal lysosomal functioning.
B3.3 (Neuro)melanin regulation
PD is characterized by selective death of SN DA neurons containing neuromelanin (NM), 
suggesting involvement of NM in PD pathogenesis. There is an age-related increase 
in NM in the SN1039, and NM production, through oxidation of DA, increases oxidative 
stress and lipid peroxidation (see section A1.1). NM is cytotoxic419, 1040-1042 and results in 
collapse of mitochondrial transmembrane potential, cytochrome c release and CASP3 
activation419. Therefore, DA neurons need an optimal autophagy and lysosomal function 
to store NM and prevent cytoplasmic NM-toxicity1040. Moreover, cellular increase in NM 
might eventually interfere with the endosomal-lysosomal pathway and lysosomal 
function1040. Release of NM in the ECM, e.g. as a consequence of DA neuron death, 
increases immune cell activation1043, 1044 (see also section D2.2). Nevertheless, due to its 
ability to chelate ferrous iron338, 339 and free radicals, NM may in addition to its toxic 
properties also have neuroprotective functions1043, 1044. 
Of note, NM has the ability to absorb lipids, e.g. cholesterol1045 and associates with 
SNCA1046, 1047 that itself contains two cholesterol-binding domains1048. Further, SREBF1 
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increases the production of both cholesterol and isoprenoid dolichol1049, 1050, both lipid 
components of neuromelanin1051. This indicates that there may be a complex interaction 
between NM, SNCA and lipid accumulation in DA neurons. Dysregulation of either NM, 
SNCA or, for example, cholesterol may increase their aggregation and cytotoxicity.
Proteins regulating the melanin producing melanocytes in the periphery, like MC1R, 
MITF, MREG and TYR, might also be involved in the regulation of neuromelanin in DA 
neurons. Of note, mutations in the melanocyte-stimulating hormone receptor MC1R 
may increase the risk for PD1052, 1053 and MC1R binds to the DA neuron determinant1054 
MSX11055 (not shown, see also section section D1.1). Activation of MC1R triggers 
transcription of MITF1056, a transcription factor involved in melanocyte development 
and melanin production1057. MITF expression is increased by cholesterol1058 and 
decreased by STAT31059. Further, MITF is activated by GSK3B1060, cleaved by CASP3 (this 
cleavage is essential in apoptosis of melanocytes)1061 (not shown), binds to CTNNB11062 
and STAT31063 and increases the transcription of ASAH11064, SCARB11064, PRF11065, MBP1064, 
COL2A11066 (also increased by MSX11067 and KDM2B1068), MC1R1069 (binds to PTEN1070 and its 
expression is decreased by retinoic acid1071 (not shown)) and the melanin producing1072 
TYR1064, 1073. Subsequently, the lysosomal maturation protein melanoregulin (MREG) 
is involved in the transfer of melanin-containing melanosomes from melanocytes to 
keratinocytes, and as such drives skin and hair pigmentation1074-1076. MREG dysfunction 
results in an increased secretion of CTSD1077. The AP3-complex-regulated1078, 1079 
membrane protein OCA2 is involved in melanin synthesis1080 and regulates trafficking 
of TYR1081 that is mediated by the AP3-complex1082. Further, OCA2 binds to the familial 
PD protein ATP13A2866 (ATP13A2 inhibits SNCA aggregation868) and loss of OCA2 
disrupts the unfolded protein response (UPR) and increases resistance to ER stress in 
melanocytes1083. TYR mRNA and protein are expressed in the SN1084-1086 and increased 
TYR levels are toxic for DA neurons and can exacerbate the toxic effect of mutant 
SNCA1086. Of note, decreasing hair color darkness is associated with an increased PD 
risk1052 and familial grey hair frequency is higher in PD patients1087, underscoring a 
possible association between peripheral melanin regulation (e.g. by MITF, MC1R, MREG 
and TYR) and PD.
B3.3.1 Vitamin D3
Active vitamin D3 (calcitriol) increases melanocyte maturation, inhibits their 
proliferation and increases TYR activity (by inducing MITF expression1088) and melanin 
production1088, 1089. Vitamin D3 is synthesized from a cholesterol precursor in the skin 
under influence of UV light1090. Vitamin D3 is lower expressed in PD patients1090-1092 
and its supplementation may stabilize PD for a short period1093. Vitamin D3 regulates 
the expression of PPP1CA1094 (not shown) and NEDD91094 (expression decreased by 



















and SERPINB91100 and decreases the expression of ANGPT21101, IL2RA1102, BMP71103 (not 
shown), LTBP11094 and SREBF11104. Vitamin D3 also activates JAK21105, inhibits SERPINE1 
expression by inhibiting NF-KB activation1106 and inhibits the immune response by 
reducing the production of CCL51107 and IL81107, by inhibiting NF-KB-mediated IL12 
expression1108 and IFNG-activation of macrophages1109.
The vitamin D3 receptor (VDR) is a nuclear transcription factor that is associated 
with PD257-259 and binds to ACTN41110, the transcription factors POU2F11111 and RUNX31112 
and the transcription regulators SIRT1654 and MED13 (also activates VDR)1113. The VDR 
is transported into the mitochondria by the mPTP612 and its expression is increased 
by MAP2K61114. The active vitamin D3, binds to the VDR and thereby regulates gene 
expression in the nucleus of the cell. The VDR (bound by vitamin D3) inhibits CREM1117 
and decreases the expression of the immune response-associated proteins CCL51115 and 
ICAM11116.
Thus, vitamin D3 and its receptor VDR regulate transcription (via NF-KB, POU2F1, 
SIRT1, SREBF1, RUNX3, MED13), pigmentation (via MITF,  cholesterol homeostasis (via 
SREBF1), coagulation (via BMP7, LTBP1, SERPINE1, PLAT), and the immune response 
(e.g. via JAK2/STAT3, NF-KB, CCL5, ICAM1). Moreover, as vitamin D3 and its receptor VDR 
can regulate production of melanin in the skin, they might also affect neuromelanin 
production and indirectly DA production in DA neurons in PD as indicated by decreased 
DA neuron death1118 and partially restored TH expression1099 by vitamin D3 in PD models.
B3.4 Chaperone-mediated autophagy
Chaperone-mediated autophagy (CMA) is the targeting of cytosolic proteins to the 
lysosomal membrane by chaperone HSPA8. The HSPA8-substrate complex binds to the 
lysosomal-associated membrane protein type 2A (LAMP2), so they can be translocated 
over the lysosomal membrane and subsequently degraded1119. LAMP2 is reduced in 
peripheral leukocytes of PD patients192 and both LAMP2 and HSPA8 are reduced in the 
PD SN171. LAMP2 is degraded in cholesterol-rich lipid rafts1119, 1120. Cholesterol depletion of 
lysosomal lipid rafts therefore enhances CMA activity, whereas lysosomal cholesterol 
loading reduces CMA activity1119, 1120. LAMP2 also decreases cholesterol accumulation880 
and its reduced expression may thus affect cholesterol regulation in PD patients. 
Moreover, reduced levels of LAMP2 and HSPA8 affect MHC class II molecules1121 and 
therefore immune cell activity. Of note, the lysosomal membrane protein LAMP3, is 
involved in adjusting lysosomal function after the transfer of peptide-MHC class II 
molecules to the surface of dendritic cells1122 and increases autophagy1123. 
HSPA8 also binds to (and increases degradation of) ATP13A2866, LRRK21124, SNCA918, 
1125, PARK2727, 1126, UCHL11127, MAPT1128, TP531129, AKT11130, AMPK1131, the NF-KB-complex 
subunits REL, RELA, RELB and NFKB11132, LIPC1133, NEDD81134 (is associated with PD lewy 
bodies200, binds RPL7A1135 and UCHL1846 and binds PARK2 and PINK1 and increases their 
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ligase activity and stabilization respectively200), DNAJC61136, FBXO25395 (not shown), 
HLA-DRA1137, AR1138, AP3-complex1139, BAG61140, JAK21141, GAK863, 1142, MAP3K71132, GSK3B1131, 
CCAR21143, BAX1144 (not shown) and LAMP21145. LAMP2 also binds to UCHL1288, TP531146 and 
SNCA1147, and its expression is increased by FOXO1632 and the AP3-complex875 (not shown) 
and is mediated by the NF-KB-complex1148 (not shown). Thus, HSPA8 and LAMP2 bind 
to at least five familial PD proteins and interacts with several key landscape proteins. 
Overall the CMA proteins HSPA8 and LAMP2 are required for a normal degradation of 
(aggregated) SNCA1149, 1150. This notion is underscored by mutant  LRRK21124 and mutant 
UCHL1288 that both inhibit CMA, which in turn results in increased SNCA aggregation288, 
1124. Of note, in contrast to the familial PD proteins LRRK2 and UCHL1, mutant TP53 is 
normaly degraded by CMA1146.
B4. Reverse cholesterol transport
Reverse cholesterol transport is the routing of excess cholesterol and oxysterols back 
to the liver and the subsequently excretion from the body. Several key components 
of the landscape are involved in these processes, which contribute to cholesterol 
homeostasis. First, in the liver, the familial PD protein PARK2 is a lipid-responsive 
regulator of fat uptake and thereby increases hepatic fat uptake806. Second, the 
neuronal ATP-binding cassette transporters ABCA3 and ABCA5 (located on lysosomal/
late endosomal membranes1151-1153) and ABCG1 (located on ER, golgi, late endosome and 
plasma membrane1154-1156) are involved in reverse transport, by transporting cholesterol 
into the lysosomes (ABCA3)1152 and increasing cholesterol efflux to HDL (ABCA5 and 
ABCG1)926, 927, 1153. Of note, the prospective studies that found association of low plasma 
LDL-cholesterol and low total cholesterol with increased PD risk552-554 and the positive 
correlation between PD disease duration and plasma HDL-cholesterol375, indicate that 
lipoprotein-cholesterol levels are affected in PD, which may be due to dysregulation of 
reverse cholesterol transport regulated by these transporters and PARK2.
PD patients have higher plasma oxLDL177 and 7-KC564, the main cholesterol oxidation 
product in oxLDL565. Statins, inhibitors of cholesterol synthesis, also decrease oxysterol 
levels in the brain566 and reduce the aggregation of SNCA in vitro567 and in SNCA 
transgenic mice568. Statin use has been associated with lower PD risk1157, 1158 and even 
prospective studies found lower PD risk when using statins1159, 1160. However, statin use 
has also been reported not to affect PD risk1161-1164, and it is unclear if the PD risk lowering 
is due to statin use, or merely due to high baseline cholesterol levels of these statin 
users. The only prospective study, that did took baseline cholesterol levels before statin 
use and during PD treatment into account, showed association between statin use and 
higher PD risk554.
OxLDL increases expression of ABCA5 and ABCG11153. ABCG1 protects against oxLDL-
induced apoptosis by promoting efflux of 7-KC to HDL565, 1165, as 7-KC activates apoptotic 



















increasing the expression of TP531167. Further, 7-KC inhibits AKT11168, induces ER stress by 
increasing the expression of the ATF6-dependent ER stress chaperone HSPA5967, 1166 (not 
shown), increases the expression of ICAM1 and ITGAL on microglia1169 and is involved 
in inhibition of inflammatory responses1170. Thus, maintaining low intracellular 7-KC 
levels by the regulation of 7-KC efflux by (among others) ABCG1 is therefore important 
in prevention of ER stress, the activation of apoptotic and regulation of immune 
responses.
As opposed to cholesterol, its derivates hydroxycholesterol (24-OHC) and 
27-hydroxycholesterol (27-OHC) can cross the blood brain barrier. 24-OHC originates 
primarily from the brain and is the main cholesterol elimination product of the 
brain1171. 27-OHC is the major oxysterol in the circulation that can cross the blood 
brain barrier and has under normal physiological conditions a steady influx into the 
brain1172. Both 24-OHC and 27-OHC levels are associated with PD, i.e. 24-OHC levels 
in the CSF of PD patients correlate with the duration of PD376, whereas 27-OHC is 
increased in the plasma of PD patients564. An increased 27-OHC flux into the brain, e.g. 
due to hypercholesterolemia, potentially has implications for PD pathogenesis, as 27-
OHC decreases TH and increases SNCA616, 617 expression. Healthy men with low HDL-
cholesterol have a high 27-OHC/total cholesterol ratio, indicating that the production of 
27-OHC and its transport to the liver may represent an alternative pathway for reverse 
cholesterol transport by HDL1173. 
Further, high 24-OHC and 27-OHC concentrations induce apoptosis of neuronal cells616, 
1174 (low 27-OHC concentrations trigger survival and high concentrations apoptosis615) 
and should therefore be thighty controlled. One of these control mechanisms is the 
transport of 24-OHC out of the cell to HDL by the transporter ABCA11174. 24-OHC increases 
the expression of ABCA1, but also that of ABCG11175 and decreases the expression of LDLR 
and SREBF11175. 27-OHC also increases the expression of ABCA11176, 1177 and ABCG11177 and 
is involved in the expression of SREBF11178, 1179 (not shown). Thus, 24-OHC and 27-OHC 
increase the export and decrease the uptake of cholesterol by the cell. 
In addition to regulation of cholesterol homeostasis, 24-OHC and 27-OHC both increase 
activation of STAT3 and increase the expression of the angtiotensin II receptor AGTR1 
via the liver X receptors (LXR)377 (not shown), indicating that there is a relation between 
oxysterol regulation and the brain renin-angiotensin system, that is again known to 
interact with the DA system (see section A1.3). 24-OHC and 27-OHC are both endogenous 
activators of the LXR1178, 1180. LXR, having 2 isoforms, LXRA and LXRB312 is activated by 
27-OHC in response to cholesterol overload in the cell1178 and subsequently inhibits the 
production of IL1B and IL6 and the inflammatory response of microglia and astroglia1181 
(part of process D). 27-OHC also induces production of TNF from macrophages1182 
(not shown), a factor involved in T cell activation (part of process D), and the LXR 
also activates SREBF11183 and redistributes ABCG1 to the plasma membrane where 
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it transports cholesterol out of the cell1154. Further, administration of an LXR agonist 
prevented DA neuron loss in a PD mice model, whereas knockout of LXR-beta increased 
damaged to the DA neurons in the SN. Interestingly, LXR-beta was not expressed in 
the DA neurons, but in the microglia and astroglia of the SN, indicating that LXR-beta 
activation inhibits activation of the microglia  and astroglia in the SN1184. Thus, LXR is a 
mediator of cholesterol homeostasis in the cell, and involved in immune cell regulation 
that is critical for DA neuron survival.
In summary, oxysterols and cholesterol oxidation products are tightly regulated in 
the brain, any disturbance in the levels of 7-KC, 24-OHC and/or 27-OHC can therefore 
induce immunological or apoptotic responses that decrease the viability of DA neurons. 
More precisely, ATF6, SREBF1, STAT3, AGTR1 and expression of TH and SNCA itself are 
regulated by cholesterol derivates, showing that they are regulating the main cascades 
in the PD landscape and fullfil a very important modulating role in PD.
B4.1 Fat uptake and insulin (INS)
Diabetics show an increased risk of developing PD1185, and the frequency of diabetics 
among PD patients is higher than normally expected1087, suggesting an influence of 
glucose metabolism on PD pathogenesis. Indeed, INS, is increased by the familial PD 
protein PLA2G6 (increases INS secretion; not shown)1186, 1187, whereas the ER protein TMX1 
increases cleavage of INS1188 and ZBTB20 increases INS blood levels1095 (not shown). INS 
itself has effects on many components of the PD landscape. First, it activates JAK21189, 
ACTN41190 (not shown), mTORC1968, 969, 978, 1191, TH1192 and SREBF11193 and inhibits AMPK1194. 
Furthermore, INS decreases expression of FOXO11195, PTEN1196 and CCL51197 and increases 
expression of AGTR11198, COL18A11199, CYP17A11200, 1201, SCARB11202, 1203 (not shown), the 
thyroid peroxidase TPO1204 (not shown; binds heme312), NTF31205, MBP1206, FER1207 (not 
shown), ITGA61208 and SREBF11201, 1209. In addition to this, INS increases degradation 
of ABCA11210 and increases binding of FER and STAT31207 and binding of STAT3 to the 
ICAM1 promotor1211 (not shown). Moreover, INS increases binding of INSR and SDC11212 
and binding of EIF4E to EIF4EBP21213 and to EIF4G11214 (not shown).  
The INS receptor (INSR) is a tyrosine kinase receptor that binds INS and regulates 
glucose homeostasis. The INSR is decreased in the SN of PD patients190, 191. The INSR 
is regulated by MBNL2 (by regulating alternative splicing)1215, PRKCE (binds and 
inhibits)1216, FOXO1 (increases expression)631, PALD1 (decreases expression)1217, HLA-C 
(binds and translocates INSR to the membrane)1218, 1219 and PTPN1 (inhibits)1020, 1220, 1221). 
So, the expression of INSR, its alternative splicing and its localization to the membrane 
is part of the PD landscape. In turn, INSR increases the expression of RPL7A1222 and 
SCARB11223 (not shown), regulates expression of SIRT11223, 1224 (not shown), ULK21225 (not 



















activates CYP17A11200. Further, INSR binds SDC11212, PIK3CD1228 and CAV1802, and binds and 
activates JAK21229, 1230 and PTPN11231, 1232.
Of note, INS metabolism has profound effects on fat uptake. INS inhibits HDL-mediated 
cholesterol reverse transport by inhibiting expression of ABCG11233. Further, INS 
(resistance) disturbs cholesterol regulation in the periphery1234, 1235, a high-fat diet and 
INS resistance have been shown to impair nigrostriatal functioning (they attenuated 
release and clearance of DA in the striatum and increased iron deposition in the 
SN)1236 and PD patients show an increased autoimmune reaction towards serum INS189, 
indicating that INS function may affect PD pathogenesis.
In conclusion, INS and its receptor regulate in the PD landscape, among others, four 
important transcription regulators (PTEN, FOXO1, SREBF1 and STAT3), cholesterol 
metabolism (via SCARB1, ABCA1, SREBF1), the rennin-angiotensin system (AGTR1), 
steroid production (CYP17A1), immune responses (CXCR4, SCD1, ICAM1) and mRNA 
translation (EIF4E, EIF4EBP2, EIF4G1).
B5. Concluding remarks
Cholesterol and sphingolipids are important for membrane function and therefore crucial 
for normal functioning of the endosome-lysosomal and the lysosome-autophagosomal 
system that depend heavily on membrane lipid rafts, membrane fission, fusion and 
trafficking. In return, the endosomal-lysosomal and lysosome-autophagosomal system 
are important for normal cholesterol and sphingolipid transport and synthesis. The 
proprotein PSAP regulates the sphingosine synthesis pathway and the trafficking 
of gangliosides and is therefore an important regulator of (membrane) lipids in the 
cell. The endosomal-lysosomal system regulates clathrin-(in)dependent endocytosis 
and recycling and trafficking of vesicles in the cytoplasm. Thereby, the endosomal-
lysosomal system regulates the uptake and the processing of lipoproteins, but also 
the reverse transport of excess lipids out of the cell. Moreover, it also regulates the 
uptake, degradation or recycling of membrane (receptor) proteins and is in immune 
cells required for the uptake and processing of proteins for antigen presentation.
During life NM content increases in the DA neurons, hindering the function of the 
lysosomal compartments and making DA neurons especially vulnerable for defects in 
the endosomal-lysosomal and lysosome-autophagosomal system. Autophagy-related 
pathways (e.g. the AMPK-mTORC1 pathway and chaperone-mediated autophagy) 
regulate protein degradation by the lysosome, reverse cholesterol transport and NM 
storage. Any defect in the endosomal-lysosomal or lysosome-autophagosomal system 
– e.g. due protein or NM aggregation, due to mutations or SNPs in genes coding for 
proteins important for these systems, or due to a dysbalance of membrane lipids – can 
result in missorting, (further) aggregation of proteins, differential endocytic uptake of 
lipoproteins and changed cholesterol levels in the cell, affecting cellular function and 
viability.
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Thus, either aggregation of NM or proteins and/or a dysbalance of membrane lipids can 
create a vicous cycle of lysosomal dysfunction and increased protein aggregation and/
or a further dysbalance in cellular lipid levels. 
Lastly, systemic regulation of lipoproteins, cholesterol, INS and vitamin D3  are 
associated with PD and might prove valuable targets for future PD therapies. Moreover, 
these factors regulate multiple major cascades in the PD landscape and balancing 
of these factors in the periphery can possibly indirectly improve the viability of DA 
neurons in PD.
C. ER STRESS RESPONSE
The ER has a broad range of functions, including protein folding, lipid biosynthesis 
and Ca2+ storage1237. The balance of synthesis, folding and degradation of proteins is 
perturbed as we age, resulting in the production and accumulation of misfolded 
proteins1238. Aging-linked declines in the expression and activity of ER molecular 
chaperones and folding enzymes compromise proper protein folding and the unfolded 
protein response (UPR)1237. And, as PD incidence is higher among older individuals, with 
most cases older 50 years of age1239, 1240 and PD prevalence rises with age1241, it is possible 
that aging-linked decline of ER function and increase of protein aggregation, resulting 
in ER stress, may play a role in onset of PD pathology.
Section C1 discusses the pathways and proteins that regulate the UPR and section 
C2 discusses the pathways and mechanisms that (when dysregulated) can increase 
protein aggregation and subsequently ER stress. Section C3 shows the interaction 
between ER stress regulation and cholesterol-regulated gene expression and section 
C4 discusses the role of the – in the ER synthesized – male hormone testosterone in PD. 
The functional interactions between the proteins within process C, ‘ER stress response’, 
are shown in Supplementary Figure 2.
C1. Activation of the UPR
Disturbances in normal ER function, e.g. by unfolded or misfolded proteins in the 
ER, cause ER stress, which activates the UPR, a stress response that tries to restore 
normal ER function by degrading misfolded proteins, increasing production of ER 
chaperones that regulate protein folding and halting protein translation. The other 
way around, dysregulation of proteins involved in protein degradation, folding or 
synthesis may result in the accumulation of misfolded proteins that induce ER stress 
and activate the UPR1242, 1243. Misfolded proteins and protein aggregates, e.g. SNCA and 
CTNNB1 aggregates, thus induce ER stress1244-1246 and thereby activate site-1 and site-2 
protease that in turn activate the transmembrane transcription factor ATF61247. ATF6 



















the UPR1248, 1249, i.e. ER stress increases the expression of MCFD2, the cargo receptor for 
ER-to-golgi transport1250 and the selenoprotein SEP15, which both may be involved in 
ER quality control of protein folding312, 1250. Further, also TMX1 is involved in ER quality 
control1251 and binds to MCC387, that in turn binds to CUL2387, DCUN1D1387, SNRPB2387 
and the familial PD proteins VPS35387, UCHL1387 (associated with the ER membrane1252) 
and EIF4G1387. Activation of ATF6 also increases MTOR activity967 that in turn causes 
ER stress by inhibiting autophagy and increasing protein synthesis1253, 1254. Thus, 
MTOR activation increases the amount of misfolded proteins and creates a separate 
reinforcing feedback loop of UPR/ATF6- and MTOR- activation. Nevertheless, mild 
ER stress induces autophagy and inhibits neuronal death939, 1243, whereas prolonged 
ER stress decreases ATF6 activation1255, results in increased SNCA aggregation1245 and 
causes neuronal death due to opening of the mPTP for cytochrome c release1256.
Of note, LRRK2 is associated with the ER in DA neurons1257 and prevents DA 
neurodegeneration by supporting the upregulation of the ATF6-dependent molecular 
chaperone HSPA5 during ER stress1258. HSPA5 (also upregulated by CRH-activation 
of CRHR1, i.e. CRH-induced ER stress1259) activates the UPR and diminishes SNCA 
neurotoxicity in a PD rat model967, 1260.
C1.1 UPR feedback inhibition
The protein phosphatase-1 complex (PP1) dephosphorylates proteins and thereby 
regulates multiple processes in the cell, such as cell division, glycogen metabolism, 
muscle contractility and protein synthesis312. A hallmark of UPR activation is the 
phosphorylation of the translation initiator EIF2A1261 (EIF2 signaling is associated with 
PD165). This attenuates protein synthesis and enables the cell to remove misfolded 
proteins from the ER1262. During ER stress, there is feedback inhibition through PP1-
dependent dephosphorylation of EIF2A312, 1263-1265 (not shown). PP1 thereby reinitiates 
protein synthesis and facilitates the recovery of cell from stress1263. However, 
overactivation of the PP1 complex would shut down the UPR too early and increase 
ER stress. Selective inhibition of the PP1 complex can therefore protect cells from ER 
stress1265.
Two inhibitory subunits of the PP1 (PPP1R12B and PPP1R14C312) were associated with 
PD in the GWASs6, 13. PPP1R12B is part of the myosin phosphatase complex, binds the 
catalytic PP1 subunit PPP1CB1266 and thereby regulates myosin activity312. Further, 
another member of the myosin phosphatase complex PPP1R12A is downregulated in 
the CSF of PD patients224, is activated by PRKG11267 and binds PPP1CB387 and LRRK2742. 
PPP1CA, PPP1CB and PPP1CC are the catalytic subunits of PP1, whereas PPP1CA is the 
physiological LRRK2 phosphatase and is inhibited by the membrane phospholipid 
PA540 and activated by ceramide540. Pathogenic PD mutations in LRRK2 mutations 
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are associated with a decreased phosphorylation state of LRRK21268, implying that 
phosphatase acitivity of PPP1CA is important in PD. PPP1CA also binds to SNCA461, 
EIF2A1269 (not shown), AKT11023 (is inhibited by PPP1CA1023, 1024), ATR1269, AXIN11270, CAV11023 
(not shown) (inhibits PPP1CA1023 (not shown)), CNTN11271 (not shown), CSMD11272, 
CASP91273, DLG21272 (binds NOS11274 (not shown), DSCAM1275 and ATP2B21276), GPATCH21272 
(not shown), GSK3B1277, HSPA81278, MAP1B1272, MAPT1269, PTEN1269 , SIRT7394, TP53859, 
1269, WNK11272 and WWOX1279. PPP1CA expression is increased by GNA12747, regulated 
by vitamin D31094 (not shown) and TP531280 (not shown) and decreased by chronic DA 
depletion509. 
In summary, a disturbance in PP1 activity, e.g. due to dysregulation of PA, ceramide, 
vitamin D3 or DA, affects ER stress regulation and the regulation of multiple proteins in 
the landscape, including the familial PD proteins LRRK2 and SNCA.
Another phosphatase, the PP1-like phosphatase PPM1L, inhibits binding of MAP2K6 
and MAP3K71281 and thereby prevents activation of MAP2K6 by MAP3K71282. MAP2K6 
increases NF-KB complex expression1283-1285 and binds and regulates the expression of 
LRRK21286, but MAP2K6 is also phosphorylated by LRRK2931. Further, MAP3K7 activates 
the AMPK complex1287, is inhibited by TRAF31288 and binds to SMAD51289. SMAD5 is 
activated by BMP71290 and binds to SMAD4859 (binds to ZNF4231291), RUNX31292 and the 
26S proteasome859 (binds FBXO25, that again binds to HSPA8395).
C2. Protein aggregation
Timely detection of misfolded proteins by E3 ubiquitin-protein ligase complexes and 
subsequent degradation by the proteasome prevents protein aggregation and ER stress. 
Section C2.1 discusses shortly proteins that affect protein translation, section C2.2. 
discusses the targeting of proteins to the proteasome by the small protein ubiquitin 
and section C2.3 discusses the proteins in the PD landscape that directly regulate 
proteasome function. Section C2.4 shows the involvement of presenilins and protein 
cleavage and section C2.5 discusses the effects of beta-catenin (CTNNB1) aggregation 
on (DA) neuron function and how its levels are controlled in the cell. 
C2.1 Protein translation
Incorrect protein translation can result in abnormal protein function, mislocalized 
proteins and protein aggregation. The ribosomal DNA transcription factor SIRT7 binds to 
proteins that are involved in the regulation of protein synthesis, e.g. the histone protein 
H1FX394, the RISC complex component SND1394, pre-mRNA splicing factor BAT2394 (binds 
the RNA-binding and alternative splicing regulator RBFOX11293), the 60S ribosomal 
proteins RPL7A394 and RPL38394 and the familial PD protein EIF4G1394 (involved in mRNA 



















and PLOD1 (involved in the formation and stabilization of collagens1295, such as COL2A1 
and COL18A1394) and regulates autophagic (via binding to MTOR, STK11) and cytoskeletal 
(via binding to KIF14, MAP1B, DNM2, ACTN4) processes394. Thus, the PD landscape 
contains multiple proteins that regulate protein transcription and translation. 
C2.2 Ubiquitin
Ubiquitin is a small regulatory protein that, by binding to substate proteins, is able to 
regulate their cellular localization, protein-protein interaction or degradation1296, 1297. E3 
ubiquitin-protein ligase complexes catalyze the ubiquitination of proteins and targets 
them for proteasomal degradation. TRAF3 is an essential constituent of several E3 
ubiquitin-protein ligase complexes312, regulates the NF-KB complex (see above) and 
binds to AGTR1362. Also, TRAF2 is part of the E3 ubiquitinase complex, binds TRAF31298 
and like TRAF3 decreases the expression of the actin polymerization protein1299 
LRRC16A1300. Further, TRAF2 ubiquitin ligase activity is strongly activated by S1P1301, 
TRAF2 mediates SREBF1 activity1302 (not shown) and binds to AMPK1303 and the familial 
PD proteins HTRA2954 and FBXO71304. Upon cellular stress, HTRA2 is released from 
mitochondria and induces apoptosis405 (part of process A) – e.g. by binding to the cell 
cycle and apoptosis regulator CCAR21305 – and inhibits the E3 ubiquitin ligase activity of 
PARK2405. FBXO7 on the other hand, is together with the F-box proteins FBXO25 (binds 
to a complex consisting of PPP1R12A and PPP1R12B395) and FBXO36 part of an ubiquitin-
protein ligase complex312, 1306, 1307. 
Cullin-2 (CUL2) is a core component of E3 ubiquitin-protein ligase complexes312 and 
binds to DCUN1D11308 and NEDD81309. DCUN1D1 activates the E3 ubiquitin-ligase complex 
by recruiting a NEDD8-charged E2 enzyme to the cullin component312. Further, NEDD8 
also binds to SIRT1656, RPL7A1135, HSPA81134, UCHL1846 and binds PARK2 and increases its 
ubiquitinase activity200, 1310 (activates the 26S proteasome1310) and binds and stabilizes 
PINK1200. Moreover, NEDD8 accumulation is observed in LB in DA neurons in the SN of 
PD patients199, 200.
The deubiquitinases UCHL1 and USP9X affect, by their ability to deubiquitinate, 
proteasomal degradation of misfolded proteins43, 1252. Of note, USP9X deubiquitinates 
SNCA and is lower expressed in the SN of PD patients, which may contribute to higher 
levels of monoubiquitinated SNCA43. USP9X thereby determines if SNCA is degraded by 
the proteasome (monoubiquitinated SNCA) or by autophagy (deubiquitinated SNCA)43, 
1311).
Thus, proteasomal targeting of proteins by ubiquitin is highly regulated in the PD 
landscape, either by ubiquitin-protein ligase complexes (composed of among others 
CUL2, DCUN1D1, FBXO7, FBXO25, FBXO36, PARK2 and TRAF3) or deubiquitinases (e.g. 
UCHL1, USP9X).
127

















C2.3 Proteasomal degradation 
Proteasomal function is impaired in the PD SN and results in aggregation of (misfolded) 
proteins45. Degradation of misfolded proteins requires retrograde transport of these 
proteins across the ER membrane and subsequent degradation by the ubiquitin-
proteasome system, which includes the 26S proteasome1312. PSMD11 is a regulatory 
subunit of the 26S proteasome1313. The 26S proteasome is inhibited by AMPK1314, whereas 
aggregated SNCA binds and decreases its activity532, 1315, 1316. The protein BAG6  is part of a 
ubiquitination-complex that prevents aggregation of mislocalized proteins, by targeting 
them for proteasomal degradation1317. Further, BAG6 has a key role in assembly of the 
26S-proteasome complex1318 and cleavage of BAG6 by CASP3 induces apoptosis1319. 
Further, the cGMP-dependent protein kinase PRKG1 (also regulating actin cytoskeleton 
and myosin-mediated trafficking by binding to PPP1R12B1320) increases activity of the 
proteasome and increases proteasome-mediated degradation of misfolded proteins1321. 
Thus, proteasome function is regulated in the PD landscape (via BAG6, PRKG1, PSMD11) 
and defects in this system may result in protein aggregation and neuron death.
C2.4 Presenilins and protein cleavage
Activation of the UPR by ER stress increases the activation of γ-secretase to increase 
proteolytic cleavage of unfolded proteins in the ER1322. The γ-secretase is a protease 
complex (its catalytic core consisting of the presenilin PSEN1 or PSEN2) that cleaves 
single-pass transmembrane proteins within their transmembrane domain. γ-Secretase 
is well known for cleaving of APP1323 (not shown), resulting in amyloid-beta aggregation 
in Alzheimer’s disease1324. In addition to APP, γ-secretase also cleaves and thereby 
decreases CTNNB1 levels in the cell1325-1327, cleaves LDLR1328 (not shown), SDC11328 (not 
shown), LRP1 (is in competition with APP for γ-secretase activity)1329, 1330 and increases 
the expression of IL2RA on the plasma membrane1331 (not shown). AKT1 is necessary 
for γ-secretase activation1332, cholesterol increases γ-secretase activation1333 and RER1 
increases the retention and retrieval of γ-secretase (subunits) in the ER, preventing its 
activity887-889. PARK2 regulates the promoter activity of PSEN1 and PSEN2 and thereby 
increases PSEN1-associated γ-secretase activity and reduces PSEN2-associated 
CASP3 activation1334. The presenilins PSEN1 (activated by ER stress1335) and PSEN2 
also have γ-secretase-independent functions1336, i.e. they decrease INSR expression 
and thereby inhibit INS-signaling1337 and are necessary for protein degradation by the 
lysosome-autophagosomal system (part of process B) by regulating (among others) 
MTOR and LAMP21338. Of note, PSEN1 knockout mice show increased lysosomal SNCA 
aggregation1339.  PSEN1 binds CTNNB11340, MAPT1341, APOE1342, GSK3B1343, HSPA81344 (not 
shown), ENSA1342 (not shown), EIF4G11345, HTRA21346 (not shown) and ATP6V0A11347 (not 
shown) and activates HTRA21348. Furthermore, PSEN2 binds CTNNB11349, ATP6V0A11344 



















shown; and increases activation of CASP3)1351, 1352, decreases expression of PSEN11351 and 
inhibits activation of PLA2G61353 (not shown).
Thus, the presenilins PSEN1 and PSEN2 are important for γ-secretase-dependent and 
-independent cleavage and degradation of proteins. Dysregulation of these presenilins 
or γ-secretase (e.g. due to RER1- and PARK2-dependent regulation or via activation 
by AKT1 and cholesterol) may result in activation of apoptotic processes (via HTRA2, 
TP53, CASP3), dysregulation of the immune response (via SDC1, IL2RA) and of cellular 
cholesterol homeostasis (via LDLR and LRP1) and CTNNB1 and SNCA aggregation. 
C2.5 Beta-catenin aggregation and -dependent transcription
Protein aggregation is not always bad and is sometimes even crucial for cell development, 
i.e. stabilization and subsequent aggregation of cytoplasmic beta-catenin (CTNNB1) in 
ventral midbrain precursor cells increases their differentiation into DA neurons1354. 
Aggregation of CTNNB1 in the cytoplasm causes it to translocate into the nucleus to 
function as a coactivator of transcription factors1355, e.g. CTNNB1 increases expression 
of UCHL11356 and LMX1B1357. This implies that cytoplasmic CTNNB1 aggregation may 
regulate DA neuron development and maintenance (see also section D1.1) and could 
play a role in PD pathology. Nevertheless, cytoplasmic CTNNB1 aggregation also results 
in ER stress and activation of the UPR1246.
CTNNB1 expression and aggregation is decreased by CAV11358 (not shown), COL18A11359-1361, 
PRKG11362, 1363, PTEN1364, WWOX1365 and γ-secretase (see section C2.4). Moreover, in a 
healthy cell, cytoplasmic CTNNB1 is degraded by the beta-catenin destruction complex, 
that consists of, among others, AXIN1 and GSK3B1366. AXIN1 binds CTNNB11366 and 
degrades excessive cytoplasmic CTNNB11367, whereas inhibition of GSK3B stabilizes 
cytoplasmic CTNNB11354. Further, AXIN1 also binds to GAK846 and GSK3B1368, and AXIN1 
inhibits GSK3B-dependent phosphorylation of MAPT (and thus may prevent against 
MAPT hyperphosphorylation and tau aggregation1369). MAPT also binds to SNCA1370, 
LRRK21371 and PARK21372. The wnt pathway inhibits degradation of CTNNB1 by the beta-
catenin destruction complex1373 causing CTNNB1 accumulation – e.g. because WNT3 
is involved in a signaling cascade that stabilizes and increases the expression of 
CTNNB11365, 1374 – and is involved in DA neuroprotection, development and repair1375, 1376. 
Further, under apoptotic-conditions (e.g. Ca2+ influx), the γ-secretase complex promotes 
disassembly of the E-cadherin/catenin-complex and thereby increases the pool of 
cytoplasmic CTNNB1312. 
Other proteins that increase CTNNB1 aggregation or decrease its degradation are the 
deubiquitinase USP9X (binds CTNNB1, close to the AXIN1-binding site, and inhibits 
CTNNB1 degradation)1377, the familial PD protein UCHL1 (binds and stabilizes CTNNB1)1356 
and GNA12 (by decreasing the inhibitory function of cadherins on active CTNNB1740. 
GNA12 also binds and is regulated by AXIN1744). Further, CAV1 binds CTNNB1809 and 
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nuclear CTNNB1 is increased in a mouse CAV1-knockout1358, indicating a role for the 
endocytic/autophagic pathway in maintaining CTNNB1 levels.
Other proteins that bind to CTNNB1 are CACNA1A505, ACTN41378, ARMC81379 (not shown), 
SIRT1645, CDH61380, STK391367, FER1381, PARD31382, UCHL11356 and SNCA461. The latter indicating 
that CTNNB1 and SNCA aggregation may be able to affect each other.
Nuclear translocation of CTNNB1 increases the expression of ACTN41383, BAT21383, 
GJB21383, GNA121383, BMP71357 (not shown), TMEM21384 (not shown), MSX11385, BAMBI1386 (not 
shown), ARL4A1387 (not shown) and UCHL11356. Nuclear CTNNB1 binds to the transcription 
regulators RUNX31388, FOXO11389, MITF1062, SIRT1645, TLE11390 and also to SNCA461 and may 
affect their function. Controlling CTNNB1 levels in the cell may therefore be important 
in DA neuron homeostasis (MSX1), regulation of familial PD proteins (UCHL1, SNCA) 
and multiple (PD associated) transcription regulators (RUNX3, FOXO1, MITF, SIRT1 and 
TLE1).
C3. ER stress- and cholesterol-regulated gene expression
During ER stress ATF6 is cleaved and translocated to the nucleus where it activates 
the transcription of genes involved in the UPR1248, 1249, e.g. HSPA51248 (diminishes SNCA 
neurotoxicity in a rat PD model1260). Further, ATF6 activates NF-KB1391 and is involved in 
astroglia activation and neuronal survival (in a PD mice model)1392.
ER stress not only activates the UPR, but also increases cholesterol uptake by 
increasing SREBF1 activity1393, 1394, as the same site-1 and site-2 proteases that activate 
the transmembrane transcription factor ATF6 also splice and activate SREBF11247, 
1395. Mature, cleaved SREBF1, enters the nucleus and increases the transcription of 
proteins involved in cholesterol metabolism. Of note, a SNP (rs11868035; which was also 
associated with PD via the GWASs12) located in the splice site of SREBF1 is associated 
with gait impairment in PD32. SREBF1 increases transcription of proteins involved in 
lipid and cholesterol regulation, e.g. SCARB1932, LDLR1393, 1396, 1397, ABCA1925 and STAR603, 
604 (not shown) and SREBF1 activation results in activation of the mevalonate pathway 
and synthesis of cholesterol1398. Cholesterol is de-novo synthesized in the ER (in 
small amounts) and transported to the cytoplasm by ABCG11154, 1399. Other proteins that 
regulate the mevalonate pathway are the mitochondrial MCCC1 and ACSL6. MCCC1 is 
a 3-methylcrotonyl-CoA carboxylase (activated via biotinylation by HLCS312) involved 
in the leucine metabolism eventually resulting in the production of HMG-CoA, an 
intermediate of the mevalonate pathway1400. ACSL6 is an acyl-Coa synthase that is 
located in membranes and activates long-chain fatty acids so they can subsequently 
be degraded by β-oxidation in the mitochondria and produce acetyl-CoA312. Acetyl-CoA 




















In addition to ER stress, SREBF1 expression is also regulated by cholesterol1401, 1402, 
increased by LDLR1403 and the tyrosine-protein phosphatase and regulator of the UPR 
PTPN1312, 1404. Moreover, SREBF1 is decreased by vitamin D31104, FOXO1632, PTEN1405, 1406, 
the serine/theronine-protein kinase SIK11004, TP531407, STAT31408, IL1B1409 (not shown) 
and ICAM11410 and binds ATR1411, MED131412 (binds also to CDK191413) and SIRT1647. The 
transcriptional regulator CREM dysregulates cholesterol homeostasis by increasing 
ABCA1 expression1414, decreasing LDLR expression1414 and increasing the expression 
of the SREBF1-inhibiting kinase SIK11414. CREM also decreases expression of HLA-
DRA1415 and TH298 and thereby not only affects cholesterol homeostasis in the cell, but 
also immune function and dopamine production. Next to cholesterol-linked proteins, 
SREBF1 also increases the transcription of SERPINE11416, ULK21011, TP531417, NOS2751 
and AR1418 and decreases the expression of ADH1C1419, a cytoplasmic enzyme involved 
in the production of retinoic acid1420. A mutation in ADH1C is associated with PD 
susceptibility112 and its expression is, in addition to SREBF1, also decreased by RXRA1421 
(not shown) and INS1419 (not shown) and increased by angiotensin II1422 (not shown).
Of note, whereas ER stress increases SREBF1 activity, dysregulation of cholesterol, 
oxLDL, sphingomyelin and SREBF1, and cellular lipid accumulation have been 
associated with ER stress and UPR activation by ATF6523, 778, 1166, 1423-1426.
In conclusion, both ER stress and dysregulation of lipid homeostasis can activate 
ATF6 and SREBF1, and thereby show a complex interaction between ER stress, lipid 
homeostasis and activation of the UPR.
C4. Testosterone metabolism
Overall, in Caucasian populations the incidence rate of PD is 1.5-2.0 times higher among 
men than women1239, 1427, 1428, making the male gender a risk factor for developing sporadic 
PD23, 1239, 1429 and suggesting that sex hormone levels may play a role in PD etiology. Of 
note, in Asian PD patients such a male predominance was not found1239, 1428. Healthy 
Asian males have comparable estradiol levels with healthy non-Asian males, but show 
lower testosterone levels1430, 1431. The higher testosterone levels in Caucasian males may 
make them more susceptible for the effects of a testosterone drop than females. Due 
to their lower testosterone levels, there is no such drop in Asian males, which may 
explain the absence of the male gender as a risk factor in the Asian population. Indeed, 
male PD patients show significantly reduced testosterone levels compared to healthy 
controls1432-1434, and their possible contribution to PD pathogenesis may be illustrated 
by the inverse correlation of testosterone level and apathy in PD patients1432. Further, 
other indicators of testosterone involvement in PD-related mechanisms are; the lower 
testosterone levels by inhibition of mitochondrial complex I in the rotenone-treated 
rat, a model for PD1435, and the increase in SNCA levels accompanying a decrease in 
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TH-positive neurons and fibers in the SN and striatum respectively after castration of 
young male mice1436.
C4.1 Regulation of testosterone and cholesterol
CYP17A1 dysregulation could attribute to the lower testosterone levels seen in male 
PD patients, namely, CYP17A1 is one of the enzymes involved in the conversion of 
pregnenolone and progesterone (both synthesized from cholesterol) to testosterone623, 
1437. CYP17A1 is located on the mitochondrial and ER membrane312 and its expression 
is increased by INS1200, 1201, AR1438, angiotensin II1439, MTOR and the mTORC11440, S1P (via 
activation of SREBF1)737 and decreased by RELA609, AR1441, BMP71442 (not shown) and 
the acid ceramidase ASAH1 (hydrolyzes ceramide into sphingosine)1443. The role of 
ASAH1 can be explained by the inhibiting effect of sphingosine on CYP17A1 expression 
by binding to NR5A1, a nuclear receptor that activates (synergistically with DGKQ312) 
CYP17A1 transcription1444. NR5A1 also binds CTNNB11445, NF-KB1446 (not shown), AR1447 
(not shown), SREBF11448 and DGKQ (539 and increases the expression of SCARB11449 (not 
shown), DGKQ1448 and the mitochondrial cholesterol transporter protein STAR597, 598 (not 
shown). Dysregulation of the sphingosine-S1P balance in the cell can therefore have 
major consequences on (mitochondrial) cholesterol levels, CYP17A1 expression and 
subsequently testosterone levels. See for details on the role of sphingosine and S1P in 
the PD landscape section B1.2.
Dysregulation of more upstream processes of the testosterone synthesis cascade, i.e. 
the cholesterol metabolism, could also affects testosterone levels. For example, the 
transporters STAR and TSPO regulate import of cholesterol into the mitochondria 
for conversion into pregnenolone and subsequently testosterone619, 620, 1450. Indeed, 
inhibition of TSPO results in a decreased testosterone production1450 and testosterone 
itself functions as a feedback inhibition by decreasing the expression of STAR620. 
Furthermore, the cholesterol transporter ABCA1 and also INS increase the quantity of 
testosterone1201, 1451, 1452.
In healthy adult men, free testosterone levels are positively correlated with LDL-, HDL- 
and total cholesterol levels1453. A decreased testosterone level could influence several 
processes in the PD landscape (not shown), as testosterone regulates efflux of LDL- 
and HDL-cholesterol to the blood1454-1456, increases the expression of INS1457, MHC class 
II proteins1458, CAV11459, CASP31460, SYT111461, PSEN11461, SIRT11462, SOD21463 and decreases 
expression of PLAU1464, TGFBR21465 and CRHR11466. 
In summary, dysregulation of the cholesterol metabolism (e.g. due to ER stress) may 
result in lower testosterone levels as seen in PD patients. And, in return, changes in 
testosterone levels can affect cholesterol homeostasis and multiple pathways in the PD 



















C4.2 Androgen receptor (AR) 
In the nucleus, testosterone binds and activates the AR, increasing AR-dependent 
transcription1467. This results in a positive feedback loop, as CYP17A1 expression is 
increased by the AR1438. Regulation of the AR by other pathways and proteins in the PD 
landscape can thus indirectly also affect testosterone levels. In the PD landscape, AR 
expression is increased by SREBF11418 and NF-KB1468 and decreased by SIRT1653, TP531469 
and regulated by MTOR1470, 1471, SLC45A31472 and CTNNB11473, 1474. Moreover, multiple PD 
landscape proteins bind to the AR, i.e. SREBF11475, EFCAB61476, CAV11477 (not shown), 
FOXO11478, PARK71479, AKT11480, GSK3B1481, STAT31482, POU2F11483 (not shown), NF-KB1484, 
SIRT1653, HSPA51138 (not shown), PTEN1485, CASP31486 (not shown), TP531487, GAK1488 and 
STK391489. Most of these physical interactions are often accompanied by an inhibition 
or activation of one or both of the binding partners, i.e. AR is activated by BMP71490 and 
PARK71479, 1491 (by binding and inhibition of EFCAB61476), activates AKT11492 (not shown) 
and activates and is activated by STAT31482. Further, AR is inhibited by SREBF11475, 
FOXO11493, AKT11480, GSK3B1481 and PTEN1485, inhibits and is inhibited by NF-KB1484 and is 
cleaved by CASP31494 (not shown).
AR activation increases the expression of TACC21495, CTNNB11496 (increases nuclear 
CTNNB11497 and CTNNB1-mediated transcription1498), MAOA277, PLAT1499 (not shown), 
CACNA1A1499, HSPA51500 (not shown), IGF11501 (not shown), PTEN1502 and STAT31482. Further, 
AR decreases the expression of ITGA61503, SERPINE11504 (not shown) and SERPINB51505 
(not shown), is required for BAX translocation to mitochondria1506 (not shown) and 
decreases nuclear TP53 accumulation1507.
In summary, the AR is regulated by several major pathways in the PD landscape, is 
regulated by testosterone and by the familial protein PARK7. Moreover, AR itself 
regulates CTNNB1-mediated transcription, ER stress responses (via HSPA5), coagulation 
(via PLAT, SERPINE1), testosterone levels (via CYP17A1), intracellular Ca2+ levels (via 
CACNA1A), INS (via IGF1), immune (via STAT3, ITGA6) and apoptotic (via BAX, TP53) 
pathways. A slight change in testosterone level, as seen in PD patients can therefore 
have a huge effect on the regulation of these pathways.
C5. Concluding remarks
Dysfunction of E3 ubiquitin ligase complexes, the proteasome or processes involved 
in protein translation, modification, cleavage and degradation (by presenilins, the 
proteasome and/or lysosome) result in protein misfolding and/or aggregation that leads 
to ER stress, activation of ATF6 and the subsequent induction of the UPR. ER stress 
activates presenilins, that (either γ-secretase-dependent or –independent) decrease 
protein aggregation, but also regulate activation of apoptotic and immune pathways. 
The site-1 and -2 proteases necessary for ATF6 activation during ER stress, also activate 
SREBF1 and thereby affect the cellular cholesterol homeostasis. In turn, cholesterol, 
and (oxidated) lipids not only affect SREBF1 activation, but also induce ER stress and 
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activation of the UPR via ATF6. This shows that ER stress and cholesterol metabolism 
are highly interconnected, indicating that their dysregulation can lead to ER stress-
induced mitochondrial dysfunction (as discussed in section A2.2.1) and neuron death. 
Moreover, testosterone metabolism is affected by both cholesterol regulation and ER 
(dys)function, i.e. it is synthesized from cholesterol and produced in the ER. Lower 
testosterone levels as seen in male PD patients can result from a disbalance in either 
cholesterol metabolism or ER function and may play a role in PD pathology.
D. NEURON DEATH AND IMMUNE RESPONSE
DA neuron death can occur due to dysregulation of intracellular pathways and 
processes, immune responses targeting DA neurons, or a combination of the two. This 
section discusses pathways that regulate DA neuron determination, neuron survival 
and death (section D1) and pathways that regulate the immune response and immune 
cell activation (section D2). The functional interactions between the proteins within 
process D, ‘neuron death and immune response’, are shown in Supplementary Figures 
2 and 3.
D1. DA neuron determination, survival and death
The following subsections discuss the regulation of a small set of transcription 
factors necessary for differentiation into and maintenance of DA neurons (D1.1), the 
neurotrophic factors brain-derived neurotrophic factor (BDNF) and glial cell line-
derived factor (GDNF) that support the survival of neurons (D1.2) and the pro-apoptotic 
factors (GSK3B, PTEN, TP53 and CASP3) that regulate cellular death (D1.3).
D1.1 Regulation of the “DA signature”
The transcription factors ASCL1, MSX1, LMX1A, LMX1B, NEUROG2, NR4A2, PITX3 and 
SOX2 are implicated in DA neuron development and are sufficient for reprogramming 
of fibroblasts into DA neurons1054, 1508-1510. These transcription factors are therefore 
important in maintaining an expression pattern typically for DA neurons. ASCL1 
increases the expression of TH1511 and CACNA2D31512 and is itself regulated by active 
AKT11513. SNPs in LMX1A and LMX1B may increase PD risk1514. LMX1A increases the 
expression of NR4A21509, SLC6A31515, NEUROG21516 (not shown), SLIT21517 and INS1518. 
LMX1B is required for normal functioning of the lysosomal-autophagosomal system 
and DA neuron survival and is decreased in PD DA neurons193. LMX1B expression is 
increased by CTNNB11357 and decreased by PTEN297. MSX1 increases expression of 
COL2A11067. NEUROG2 expression is increased by PINK11519 (not shown) and PITX31516 (not 
shown), decreased by SIRT11520 (not shown) and is inhibited by GSK3B1521 (not shown). 



















TH1522, LMX1B1522, PITX31522, EIF4EBP21523 and PRKAA21523, regulates oxLDL1524 (not shown) 
and binds to RELA1525 and RCOR11525. NR4A2 expression is increased by HMOX1332 (not 
shown), MC1R1526 (not shown), STAT31527, IL1B1528 (not shown) and TNF1528 (not shown) 
and decreased by oxLDL1529 (not shown), PTEN297 and ASAH1611 (not shown). Mutant 
SNCA increases the degradation of NR4A2, which is dependent on th 26S proteasome 
complex1530 (not shown). SOX2 increases expression of JARID21531, TBX31532, ASCL11532, 1533, 
GSK3B1534, binds1534-1537 and increases expression of CTNNB11538, decreases expression of 
NFKB21532, WNT31532, 1533 and AXIN11533 and phosphorylates TP531539 (not shown). CAV11540 
(not shown), FOXO11541 and CTNNB11542-1544 increase the expression of SOX2. AKT1 binds, 
phosphorylates and stabilizes SOX2, which increases SOX2 expression1545, 1546 (not 
shown). Further, SOX2 binds CCAR21536, EHMT21536, ETV61536, TBX31536, TIAL11536, USP9X1536, 
the nuclear transporter KPNA41536 (not shown) and NR5A11547. CTNNB1 also increases 
expression of MSX11385.
In summary, normal transcriptional activity of ASCL1, MSX1, NEUROG2, NR4A2, PITX3 
and SOX2 is necessary to maintain a dopaminergic phenotype. Multiple proteins 
in the landscape regulate and are regulated by these transcription factors, whose 
dysregulation would affect expression of proteins that are crucial for DA signaling 
and regulation e.g., TH, SLC6A3 and SLC18A2. Interestingly, oxLDL decreases NR4A2 
expression, and AKT1 – which is highly regulated in the PD landscape – regulates both 
ASCL1 and SOX2.
D1.2 Neurotrophic factors
BDNF is an extracellular protein that supports the survival, growth and differentiation 
of neurons1548, 1549. Further, BDNF is associated with cognitive and motor impairment 
in PD128, 131, is decreased in PD SN neurons130 and dysregulated in PD serum131, 132 and 
CSF133. BDNF expression is increased by SIRT11550, 1551 and NF-KB1552 and decreased by 
INS1553, IFNG1554 (not shown), PLAT1555 and SNCA1556, 1557. BDNF activates PLAT1558, NF-
KB1559 (increases NF-KB translocation to the nucleus1560) (not shown), STAT31561 (not 
shown), RAC1 (via PARD3)1562 (not shown), MTOR1563, 1564 (not shown), SIK1 (and increases 
its translocation from the cytoplasm to the nucleus)1565 (not shown) and AKT11566 (not 
shown) and inhibits CASP31567 (not shown). Further, BDNF regulates activity of DRD21568 
(not shown), increases cholesterol synthesis1569 (not shown), decreases INS levels in 
the blood1570 (not shown) and binds clathrin in the cytoplasm1571 (not shown). BDNF 
increases the release of DA1571, 1572 (not shown) but can also decrease the expression of 
TH1573 (not shown). Furthermore, BDNF decreases expression of CXCR41574 and increases 
expression of DA receptors1571, 1575, 1576 (not shown), AR1577 (not shown), PTEN1578 (not 
shown), SOD21579 (not shown) and MBP1580. MBP is the major component of myelin sheats, 
allowing the axon to rapidly propagate action potentials312. Further, MBP binds to PA547, 
HLA-DRA1581 and binds and is phosphorylated by STK391582 and LRRK21583, 1584. Antibodies 
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against MBP are increased in the serum of PD patients110, indicating a dysregulation of 
MBP, affecting signal transduction between cells. Moreover, GLDN is probably involved 
in the formation the nodes of Ranvier312 and CNTNAP2 is localized at juxtaparanodes of 
myelinated axons and mediates interactions between neurons and glia1585, 1586, indicating 
that signaling between DA neurons and glia cells may be disturbed in PD.
Thus, BDNF is regulated by and regulates the immune response (CXCR4, NF-KB, IFNG, 
STAT3), regulates the activity and expression of DA receptors and DA (TH), affects 
signaltransduction (MBP) and regulates lipogenesis (MTOR, SIK1), oxidative stress 
(SOD2) and apoptosis (CASP3).
The neurotrophic factor GDNF promotes survival and differentiation of DA neurons and 
increases their DA uptake1587 and is decreased in neurons of the SN of PD patients130. 
GDNF expression is increased by ITGA81588, NF-KB1552, regulated by CTNNB11589 (not 
shown) and decreased by SNCA1556. GDNF activates STAT31590 (not shown), RAC11591, 1592 
(not shown), AKT11591, 1593, 1594 (not shown) and TH1595 (not shown). Further, GDNF increases 
secretion of DA1596 (not shown) and increases the expression of TH1597, 1598 (not shown), 
SLC6A31598-1600, DRD21572, SPHK1418 (increasing synthesis of S1P418), ITGA61601 and decreases 
the expression of CASP31602 (by decreasing cleavage of pro-CASP31603) (not shown) and 
cytochrome c1602 (not shown). However, chronic upregulation of GDNF decreases TH 
expression1604 (not shown). 
Thus, GDNF regulates DA homeostasis (TH, SLC6A3, DRD2) is regulated by and regulates 
the immune response (NF-KB, ITGA6, ITGA8, S1P) and apoptotic processes (CASP3, 
cytochrome c).
D1.3 Pro-apoptotic proteins
Cellular death is regulated by a variety of proteins, the main proteins that regulate 
apoptotic pathways in the PD landscape, GSK3B (D1.3.1), PTEN (D1.3.2), TP53 (D1.3.3) and 
CASP3 (D1.3.4) are discussed in this section.
D1.3.1 GSK3B
PD-associated polymorphisms alter the transcription and splicing of GSK3B158 and 
affect it functions in the cell. For example, GSK3B is part of the CTNNB1 destruction 
complex (see also section C2.5), regulates cellular energy levels, inhibits mitochondrial 
complex I, which affects mitochondrial function and increases ROS production1605, 1606 
and increases accumulation of SNCA1607. In turn, SNCA can activate GSK3B1606, 1607, which 
may lead to a vicous cycle of GSK3B activation and SNCA aggregation. Further, GSK3B 
is also activated by CRHR11608, IFNG1609, mTORC1971, PTEN1610 and inhibited by PARD31611, 
PTPN11612, PIK3CD628, 1613, AKT11614, PTEN1615, INSR1616, NTF31617, ASAH11618 (not shown), ATR1619 
(not shown), PRKCE1620, TP531280 and HDL-S1P1621. Further, GSK3B binds to SREBF11622, 



















PTPN11612, AXIN11368, NF-KB1627, mTORC1884, STAT31628 and the PD proteins LRRK21629 and 
SNCA1630.
GSK3B increases the phosphorylation of MAP1B1631 (binding to both SNCA1632 and 
PINK11633) and MAPT312 (dephosphorylated by AXIN11369), affecting microtubule binding 
and stabilization. GSK3B activation also increases accumulation of cholesterol1634, 
increases the accumulation and activation of TP531635, 1636 and the activation of CASP31637, 
1638 and STAT31609. Further, GSK3B inhibits SREBF11639, inhibits lysosomal acidification 
and regulates autophagy by regulating mTORC1 activity963, 1640 and regulates NF-KB 
complex activation (in the nucleus)1641-1645 and TP53 expression1646-1648. Therefore, GSK3B 
can play a crucial role in SNCA aggregation, autophagy, cholesterol regulation and 
activation of the apoptotic factors TP53 and CASP3.
D1.3.2 PTEN
The phosphatase and tumor suppressor PTEN is located in the cytoplasm when it 
is nonubiquitinated and located in the nucleus when monoubiquitinated312. PTEN 
knock down in DA neurons is neuroprotective in PD models297. PTEN interacts with 
the familial PD proteins PARK7 and PINK1. (Oxidized) PARK7 binds PTEN1649, decreases 
its expression428 and inhibits its activity1649, whereas PINK1 is bound and regulated by 
PTEN1650, 1651. Further, PINK1 also binds to KIF111633, the familial PD proteins HTRA21652, 
PARK21653, PARK71654 and SNCA1655 and binds and is activated by MARK21000 (MARK2 
increases the expression of the vasopressin transporter1656 SLCO3A11657 (not shown) and 
vasopressin levels are altered in PD1658, 1659). Thus, PTEN can affect multiple familial PD 
proteins via PINK1 regulation. PTEN expression is increased by JARID21660, whereas 
COL18A1 decreases tyrosine phosphorylation of PTEN752. In addition to PINK1 regulation, 
PTEN also regulates STAT3 expression1661, increases the expression of FAM134C1405, 
HAVCR11405, MBP1662 and RAP1A1663 and decreases the expression of PLOD11405, NF-KB1664, 
SREBF11405, 1406, MTOR965, CTNNB11364, ANGPT21665, PITX3297, PLAU1666, CCL51667 and TH297. 
Further, PTEN activates CASP31668, inhibits RAC1852, and binds MAP2K61650, CENPC1650, 
AR1485, PPP1CA1269, CAV1801 and MC1R1070. 
PTEN also decreases FOXO1 phosphorylation1669, increases cytochrome c release410 and 
increases mislocalization of the adaptor protein PARD3850 (not shown; PARD3 binds to 
FRMD4A1670). PTEN is therefore involved in regulation of apoptosis (CASP3, cytochrome 
c), autophagy (MTOR) protein modification (PLOD1), cholesterol homeostasis (SREBF1, 
CAV1), the immune response (STAT3, NF-KB, CCL5, HAVCR1; see also section D2), 
DA metabolism (TH, PITX3), the MAP kinase pathway (MAP2K6) and beta-catenin 
aggregation (CTNNB1).
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TP53 is activated in response to, among others, oxidative stress and DNA damage. 
Phosphorylated (i.e. activated) TP53 levels are increased in the SN of the PD brain251. 
TP53 expression and thus the susceptibility to TP53-dependent apoptosis is increased 
by SREBF11417, GAS21671, the familial PD protein UCHL1 (increases TP53 accumulation)434 
and histon demethylase KDM2B1672 and decreased by the transcriptional repressor 
TBX31673. TP53 is activated by PARK71674 (not shown), GSK3B1636, STK11997, CXCR41675 and 
BAG61676, 1677 and binds MAP1B1678, SERPINB9846 (not shown) and UCHL11679. TP53 increases 
the cleavage of familial PD protein EIF4G11680 (not shown). 
Activated TP53 translocates into the nucleus by binding to KPNA41681, where TP53 
subsequently binds to EHMT21682, KANSL1 1683 (suggested to be involved in PD risk1684), 
ATR1685 (ATR binds to HUS11686, TP53BP11687 and transcription factor E2F11685 and E2F1 
binds to MCPH11688), TP53BP11689 (binds to E2F11690), PRKRIR1691, GSK3B1692, SIRT1650 and 
PARK7436. Inhibition of the deacetylase activity of SIRT1 by CCAR2655 increases acetylated 
TP53 levels and TP53-mediated apoptosis651, whereas oxidized PARK7 binds to the TP53 
DNA-binding region and thereby inhibits TP53-dependent gene transcription1693.
TP53 increases the expression of AGTR11694, COL2A11695, COL18A11696, 1697, ULK21695, MPI713, 
PRKG11698, FRMD4A1699 (not shown), COMT282, CD2001700 and ICAM11701, 1702 and decreases 
the expression of HLA-DQA11703, HLA-B1704, HS3ST11703, WDHD11705, IL2RA1706, HSPA81703 
and SREBF11407, showing involvement in regulation of, among others, DA degradation 
(via COMT), the angiotensin system (via AGTR1), autophagy (via ULK2), the immune 
response (via CD200, HLA-DQA1, HLA-B, IL2RA), protein degradation pathways (via 
HSPA8, PRKG1) and cholesterol regulation (via SREBF1).
D1.3.4 CASP3
CASP3 induces apoptosis and is increased in the SN of PD patients125, 136. CASP3 is activated 
by UCHL1434, ATG7958, PTPN11707 (also activates CASP91707), HTRA2435, 1708 and CASP9433 and 
inhibited by the TGF-beta propeptide BMP71709, JAK21710, SIRT1660, FRMD4A1711, PRKCE1712, 
PARK7436, 1713 and SNCA1714, whereas AGTR1 activation increases CASP3 expression359. 
CASP3 activates the cell death substrate GAS21715, which is associated to the cytoskeleton 
and during apoptosis cleaved by CASP3 causing rearrangements of the cytoskeleton1715. 
The myristoyltransferase NMT2 binds to both CASP3 and TP531716. Myristoylation, the 
transfer of a myristoyl-group, a 14-carbon saturated fatty acid, to a protein, typically 
promotes membrane binding, which is essential for protein localization and function1717. 
During apoptosis CASP3 mediated cleavage of NMT2, results in a relocalization of 
NMT2 from the cytoplasm to the plasma membrane1718 and CASP3-mediated cleavage 
of intracellular proteins enables NMT2 to myristoylate many of these proteins1717, 
resulting in the translocation of these caspase-cleaved and myristoylated proteins to 




















The PD landscape includes the regulation of immune cells, that may become activated 
by the death of DA neurons and/or cause the induction of DA neuron death. More 
specifically, the main immunological cascades in PD in a dendritic cell, astroglia, 
microglia, CD4+ T(helper) cell, CD8+ T(helper) cell, B cell and the DA neuron are 
presented. The next sections discuss the immune cell-specific processes. Yet, note that 
multiple pathways that are described below are not per se limited to immune cells and 
may also fulfill functions in DA neurons. Section D2.1 discusses the immune-related 
pathways and proteins in the PD landscape and section 2.2 discusses the activation of 
the immune cells of the innate and adaptive immune response.
D2.1 Immune-related pathways
STAT3 and the NF-KB-complex both regulate cellular responses to (extracellular) 
stimuli and both regulate activation of immune-related processes. More specifically, 
STAT3 and NF-KB are stress-responsive transcription factors that after activation in 
the cytoplasm bind to, and are transported into the nucleus by nuclear importin alpha 
3 (KPNA4)1720-1722. In the nucleus they regulate transcription together with (among 
others) earlier mentioned transcription regulators SIRT1, PTEN, GSK3B and CTNNB1, the 
transcription factors SREBF1, ATF6, AR, VDR, FOXO1, and MITF and the – in DA neuron 
development implicated – transcription factors ASCL1, MSX1, NEUROG2, NR4A2, PITX3 
and SOX2.
D2.1.1 JAK2/STAT3
The JAK2-STAT3 pathway transduces extracellular signals over the cell membrane into 
the cell by binding of JAK2 to multiple cell surface receptors. JAK2 binds to CXCR41723, 
AGTR1358, the interleukin 5 receptor IL5RA1724 and binds and is inhibited by PTPN11725 
and is activated by FER1726, vitamin D31105, the immune factors IL21727, IL121728, 1729 (not 
shown) and CCL51730 and the receptors CXCR41731, AGTR1356, 357 and the INS receptor 
(INSR)1230. Subsequently, JAK2 increases activation of NF-KB complexes1732 and binds1733 
and activates the transcription factor STAT31734-1736, which is involved in cell growth, 
immune response312, DA neuronal apoptosis1737 and extracellular SNCA-mediated 
neurotoxicity1738. STAT3 binds (in addition to JAK2) also to FOXO1625, RAC11739 (not shown), 
CXCR41723 (is increased by JAK21723), PTPRT1740, PTPN11741 and PRKCE1742 and is activated 
(via JAK2) by FER1726, IL21743 (not shown), IL61744 (not shown), IL101745 (not shown), IFNG1746 
(not shown), CXCL121747 (not shown) and mTORC11748 and inhibited (via JAK2 inhibition) 
by PTPN11725, 1749 and PTPRT1740.
Moreover, STAT3 expression is increased by CCL51750 and decreased by COL18A1752 and 
SIRT1668 and is indirectly affected by CCAR2 that binds and inhibits SIRT1 activity655.
STAT3 increases the proliferation of T cells by preventing apoptosis1751 by limiting their 
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production of IL2 (via upregulation of FOXO11752). Activation of STAT3 results in its nuclear 
translocation where it acts as a transcription activator1720. This translocation of STAT3 
is an active process that requires receptor-mediated endocytosis1753, e.g. dysregulation 
of the clathrin-mediated endocytosis regulator AMPH disrupts co-localization of STAT3 
with endocytic vesicles and subsequent transport to the perinuclear region1753. In the 
nucleus STAT3 binds to ETV61754, SIRT1651, FOXO1625, MTOR1755 (not shown), MITF1063 and 
NF-KB1756-1758. By binding, STAT3 and NF-KB can influence each other’s transcriptional 
activity1758, 1759 or can collaboratively induce gene expression1760. STAT3 also binds to the 
promoter of IFNG1761, IL51762, IL61760 and CCL51763, increases the expression of IL2RA1764, 
AKT11765 (not shown), PLAU1766, SOD21767, PROK21768, CCL51760 (and also CCL5 release1763), 
ITGB21769, 1770 and ICAM11211, 1769, 1771, regulates the expression of HLA-DRB1, HLA-DQA1 and 
HLA-C1772 and decreases the expression of transcription factor SP1101766, MITF1059 and 
SREBF11408.
Thus, STAT3 regulates (or is regulated by) the immune response (via NF-KB, IFNG, 
IL2, IL5, IL6, CCL5, ITGB2, IL2RA, ICAM1, HLA-DRB1, HLA-DQA1, HLA-C), regulates gene 
transcription with multiple other transcription regulators (SIRT1, FOXO1, MITF, NF-
KB, SREBF1), is affected by the ER UPR (via PTPN1) and regulates the AKT1/mTORC1/
SREBF1 pathway (see also 973).
D2.1.2 NF-KB
The cytoplasmic NF-KB complex (consisting of NFKB1, NFKB2, REL, RELA and RELB) 
functions as a transcription factor that rapidly acts upon cell stimulation by extracellular 
stimuli312 and regulates autophagy1773, immune responses, inflammation, cell growth 
and apoptosis312. PD patients show increased NF-KB levels in the nigrostriatal DA 
region201 and in the nuclei of DA neurons225.
The NF-KB-complex is activated by CPNE4507, CUL2507 (not shown), GNA12746, PRKCE1774, 
1775, PIK3CD1776, TRAPPC91777, PARK21778, ZAK1779 and AGTR1360, 361, regulated by TRAF3 
(inhibits NFKB21300, REL1780, RELA1780, RELB1780 and activates NFKB11781) and inhibited 
by PTPN11782, SENP71783 and NPTX2 (inhibits NF-KB through a TP53-PTEN-PI3K-AKT1 
pathway1784, regulates excitatory synapse formation, is highly upregulated in PD and is 
a component of Lewy bodies80). Further, NF-KB binds to CXCR41785, CCAR21132, RPL7A1132, 
CUL21786 (also binds to TMCC31134), USP9X1132 and SND11002, activates PIK3CD1776 and 
NF-KB transport into the nucleus is increased by PARK71787. These NF-KB-regulating 
proteins are involved in a variety of processes, such as signal transduction (GNA12, 
CXCR4, PRKCE, PIK3CD), angiotensin system (AGTR1) protein synthesis (RPL7A, SND1), 
post-translational modification (SENP7), protein ubiquitination and degradation by the 
E3 ubiquitin ligase complex (PARK2, TRAF3, CUL2, USP9X), (apoptotic) transcription 



















protein synthesis, modification and degradation. Dysregulation of these processes may 
result in misfolded proteins in the cytoplasm, resulting in increased ER stress and UPR 
activation.
Further, NF-KB expression is increased by FOXO1629 and MAP2K61284, 1285 and decreased 
by PTEN1664 and the transcription factor POU2F11788 (that also decreases HLA-DRA1789 
and ICAM11790 expression). 
Nuclear NF-KB binds to POU2F11788, 1791, the histon methyltransferase EHMT21792 (that 
also decreases CXCL12 expression1793 and binds to histon modificator RCOR11794), 
GSK3B1627, TP53BP11795, SND11002, TLE11796 (not shown), DDX3X1132, STAT31756-1758 and CCL51797 
(not shown). Further, NF-KB increases the expression of the cytokines CCL51798, 1799, 
CXCL121800, IFNG1801, IL1B1802, IL21803, IL51804, IL61805, 1806, IL101807, IL121108, 1806 and TNF1802, 1806 and 
of ABCG11808, CREM1809, CXCR41810, 1811, HLA-B1812, IL2RA1803, 1813-1816 and ICAM11798, 1817. Further, 
NF-KB decreases the expression of CYP17A1609 and regulates PRF1 expression1818 (not 
shown). Thus, NF-KB regulates histon regulation (via EHMT2, RCOR1), many immune 
related processes (via CXCL12, IFNG, IL1B, IL2, IL5, IL6, IL10, IL12, TNF STAT3, CCL5, HLA-B, 
CXCR4, IL2RA, ICAM1, PRF1), testosterone production (via CYP17A1) and cholesterol 
regulation (via ABCG1).
Also multiple nuclear proteins regulate NF-KB activity, i.e. NF-KB is activated by 
MAP2K61283 and GSK3B1643 and inhibited by CTNNB11819 and by the kinase and DNA 
damage sensor ATR1820 (inhibits GSK3B-mediated NF-KB activation1619) and by a 
complex consisting of the transcriptional corepressor TLE1 and SIRT1652. Moreover, TLE1 
also binds to GSK3B884, the 26S proteasome846 and the transcription factor RUNX31390 
(decreases expression of AKT11821 and increases expression of IFNG1822 (not shown) and 
ITGAL1823 (not shown)).
Thus, NF-KB is regulated by signal transduction, protein synthesizing and modifying 
pathways in the PD landscape, resulting in activation of multiple immune response 
pathways. Increase in NF-KB, as seen in the DA neurons of PD patients, mirrors the 
increased stress and the inflammatory state in DA neurons resulting in cell death.
D2.1.3 Cell adhesion, cell-cell interaction, axon guidance and immune regulation
Many proteins in the PD landscape are involved in cell adhesion, cell-cell interaction 
and axon guidance and are hereby also often involved in regulation of immune cells, 
for immune cells require these same mechanisms for e.g. chemotaxis, co-stimulation 
and activation. Members of the immunoglobulin superfamily are often associated with 
the immune system and include proteins involved in antigen presentation, cytokine 
binding, cell adhesion and co-stimulation. The immunoglobulin-like domains of the 
immunoglobulin superfamily proteins can be classified as variable (IgV), constant (IgC1 
and IgC2) or intermediate (IgI). All PD-GWAS-associated HLA proteins have the IgC1 
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domain312 and can therefore interact with the T cell receptor. Further, AMIGO2, CD200, 
CNTN1, DSCAM, NEO1, NCAM2, NEGR1, PTPRT, ROBO2 and SEMA3E all have one or 
more IgC2 domains312, the same domain that is found primarily in the mammalian T 
cell surface antigens CD2, CD4 and CD80 and the intercellular cell adhesion molecule 
ICAM1312. Furthermore, HAVCR1 and BTNL2 have the IgV domain that is also located on 
the T cell surface antigens CD2 and CD4312. Indicating that all these proteins may have 
a function in the immune system. And, apart from AMIGO2, CNTN1 and NEGR1 (that 
are involved in cell-adhesion and axon guidance1824-1826) all of these proteins indeed 
have a known function in the immune response. For instance, CD200 is involved cell 
adhesion and in the activation of the immune response (see also section D2.2.1). The 
axon guidance receptor DSCAM is involved in neuronal self-avoidance312 and is part 
of the innate immune system in invertebrates1827, 1828. (However, it is unknow if DSCAM 
has a function in the human immune system.) RGMA is expressed by T- and B-cells 
and inhibits migration of these cells by contact- and chemo-repulsion via its receptor 
NEO11829, 1830, activating RHOA1831 (not shown), which regulates the actin cytoskeleton 
in migration, axon guidance and cell adhesion312. NCAM2 is a cell adhesions molecule 
that regulates neurite outgrowth1832, its expression is increased by IL2 and essential for 
survival and differentiation of natural killer cells1833 (not shown). PTPRT is involved 
in cellular adhesion312 and increases dephosphorylation of STAT3 (not shown)1740, 
which is essential in the differentiation of T cells1834. SLIT2, the ligand for ROBO21835, 
1836 has a role in axon guidance and regulates cell migration312, but also inhibits CCL5-
induced1837 and CXCL12-CXCR4-induced1838 leukocyte chemotaxis (not shown). The 
secreted semaphorin SEMA3E (not shown) inhibits the CXCL12 regulated migration of 
thymocytes in the thymus1839. (SEMA6D, the other semaphorin in the GWASs, has no 
immunoglobulin-like domain, but is nevertheless required for late-phase activation of 
T cells, and its expression on the membrane of CD4+ T cells is increased after their 
activation1840.) And lastly, HAVCR1 is expressed on CD4+ T cells and amplifies their 
activation1841, whereas BTNL2 is a negative regulator of T cell proliferation312. As a result, 
expression of IL2 by T cells is increased by HAVCR11842 and decreased by BTNL21843.
Other PD-GWAS-associated proteins involved in cell adhesion, cell-cell interaction 
and/or axon guidance, but without immunoglobulin-like domain, are the integrins 
ITGA2B, ITGA6 and ITGA8, the cadherins CDH6, CDH23 and PCDH8, the cell-surface 
protein NLGN1, the contactin CNTNAP2 and the metalloproteases ADAM12, ADAMTS2 
and ADAMTS14. The integrines ITGA2B (binds COL2A11844, is increased by PRKCE1845 
and SCIN1846), ITGA6 and ITGA8 mediate cell-cell interactions, neurite outgrowth 
and adhesion to the ECM312. The Ca2+-dependent cadherins CDH2, CDH6, CDH23 and 
PCDH8 form adherends junctions for cell-cell interactions. CDH2 binds to GNA12740 
and AMPK1847, and is probably internalized by interaction with PCDH8312. NLGN1 binds 



















formation of excitatory synapses1850. CNTNAP2 regulates the myelination of axons by 
glia cells1851. The metallopeptidase ADAM12 is involved in amyloid-beta neurotoxicity 
and neuronal death1852. PRKCE binds to ADAM121853 and increases, like ANGPT21854, 
expression of ADAM121855 and increases, like COL2A11853, translocation of ADAM12 to 
the cell membrane1856. At the cell membrane ADAM12 binds to TGFBR21857 a growth 
factor receptor that decreases the expression of gap junction protein GJB21858, binds to 
BAG61859 and is inhibited by BAMBI1386. The extracellular pro-collagen N-propeptidases 
ADAMTS2 and ADAMTS14 process procollagens into mature collagens that are able to 
form collagen fibrils and thereby regulate ECM organization312, 1860.
Of all these proteins, only ITGA2B, ITGA6, ADAM12 and ADAMTS2 have explicitly 
been linked to immune regulation. For ITGA2B increases proliferation of T cells1861 
and secretion of IL61862, ITGA6 increases microglia activation1863, ADAM12 regulates 
differentiation of T cells1864 and ADAMTS2 mRNA is increased specifically in monocytes 
and macrophages after glucocoricoid stimulation1865.
Thus, multiple proteins in the landscape regulate cell adhesion and axon guidance and 
many of those proteins, especially when containing an immunoglobulin-like domain, also 
have explicit functions in immune cell regulation. The cell adhesion proteins, without 
an immunoglobulin-like domain (the integrins, cadherins and metalloproteases) are 
only sporadically linked to immune regulation. However, increasing knowledge about 
their protein function may show that they are also involved in adhesion, activation 
and/or migration of immune cells. Overall, dysregulation of these proteins may affect 
immune cell regulation and ofcourse also neuronal axonal and synaptic functioning.
D2.2 Immune cell activation
PD is associated with immune system alterations, such as ratio changes in lymphocyte 
populations1866-1869, immunoglobulin1870 and cytokine levels185, 1871. Moreover, PD patients 
show a lower incidence of infections and cancer, suggesting an (over)active immune 
system1872. PD pathogenesis is associated with multiple interleukines, inflammatory 
factors and cytokines. For example, SNPs in the gene or gene promotor of IL1B183, TNF247-
249, IL6187 and IL8188 are associated with PD. And, IFNG178, 179, CCL5140, 141, CXCL1279, IL1B141, 184, 
185, IL2186 185, IL4179, 185 (not shown), IL6184, IL8141, IL10181 and TNF141, 179, 250 all show increased 
expression levels in PD patients. Further, the receptors (subunits) for IL2, IL5, CCL5 and 
CXCL12, respectively IL2RA, IL5RA, CCR4 and CXCR4 were found in the GWASs.
Upon cytokine activation the expression of intercellular adhesion molecule 1 (ICAM1) 
is increased (by IL1B1873, 1874, IFNG1874, 1875, TNF1874, 1876 that increase binding of NF-
KB to the ICAM1 promotor and by IL2 that increases binding of STAT3 to the ICAM1 
promotor1877). ICAM1 regulates cell-cell interactions, adhesion and proliferation and is 
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expressed on many (immune) cell types, i.e. it is expressed on astroglia176, dendritic 
cells1878, microglia1879, T cells1880-1882, B cells1883, 1884 and vascular endothelial cells1885 and 
subsequently functions as a ligand for the integrin lymphocyte function-associated 
antigen-1 LFA-11886-1889 and thereby attracts immune cells1887, 1889, 1890. LFA-1 is a complex 
of integrin alpha-L (ITGAL) and integrin beta-2 (ITGB2)1891, 1892 that is expressed on 
circulating leukocytes and mediates rolling on ICAM1, which makes leukocytes bind 
to vascular endothelial cells, so they can enter the target tissue1893. The actin anchor 
ACTN4 binds to ICAM11894 and is required for leukocyte extravasation1894. 
In addition to cytokines, ICAM1 expression is also increased by ANGPT21895, TP531701, 
FOXO1641, COL2A11896, familial PD protein PARK71787, JAK2 activation1897, 1898 and by INS 
that increases binding of STAT3 to the ICAM1 promotor1211. Further, ICAM1 expression 
is decreased by HLX1899, BMP71900, POU2F11790, COL18A1752 and IL10 (decreases NF-KB 
binding to the ICAM1 promotor1875). ICAM1 itself increases expression of IL2RA on CD8+ 
T cells1901 (not shown), decreases the expression of SREBF11410 and binds IL2RA1902 and 
ACTN41894. Furthermore, cholesterol1903, 1904, VLDL1905, 7-ketocholesterol1169 (not shown), 
LDL and oxLDL1906 increase expression of ICAM1, showing a role for lipids in activating 
the immune response.
(Sphingo)lipids (e.g. cholesterol, ceramide and sphingomyelin) are important in 
regulation of the immune response, i.e. shingomyelinase and ceramide inhibit IL2 
production1907, ceramide increases expression and secretion of the proinflammatory 
interleukin IL81908, 1909, expression of intercellular adhesion molecule 1 (ICAM1)1910 and 
is involved in the secretion of IL61911. Ceramide and sphingomyelin are themselves 
also regulated by cytokines that are elevated in PD, i.e. IL4 decreases the quantity of 
ceramide1912 (not shown) and IFNG decreases the quantity of sphingomyelin1913 (not 
shown). Lipid rafts on the membrane also regulate clathrin-independent constitutive 
endocytosis of the lipid raft-associated interleukin-2 receptor (IL2R, subunit IL2RA 
in GWASs)1914, recycling of the immune related integrin complex LFA-1 to the plasma 
membrane1915 and LFA-1-mediated adhesion of T cells and primary T cells1916.
Therefore, a proper balance of sphingolipids and cholesterol in the cell is mandatory 
to maintain a normal immune regulation, for their dysregulation directly affects 
the regulation of cytokines and migration of immune cells. Moreover, membrane 
organization is of crucial importance for antigen-presenting cells to capture and present 
antigens, i.e. membrane lipid rafts are involved in regulation of endocytosis, membrane 
trafficking and activation of the immune response781, 782. Discrimination between ‘self’ 
and ‘non-self’ antigens during antigen presentation is one of the key elements of 
the adaptive immune system (see section D2.2.2). The proteins required for antigen 



















HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, were found in the 
PD GWASs, and the HLA gene region has been associated to PD71-73. Whereas MHC class 
I peptides for antigen presentation to CD8+ T cells are derived from 26S-processed 
cytoplasmic proteins, MHC class II peptides for presentation to CD4+ cells are acquired 
via endocytosis of antigens1917. This shows the importance of the proteasome and the 
endosomal system in immune cell activation. For example, disruption of lipid rafts 
inhibits internalization of SNCA by microglia1918 and affects localization of MHC class 
II proteins on the plasma membrane of dendritic and B cells782, 1919, which again affects 
T cell activation1919. 
In summary, activation of the immune response, production of cytokines, immune 
cell migration and regulation of antigen presentation (which requires the endosomal/
lysosomal system (see also section B2) for antigen processing) are regulate by (sphingo)
lipids and are highly associated with PD. The next sections discuss the activation 
of the innate (D2.2.1) and adaptive (D2.2.2) immune response and the involvement of 
coagulation factors in immune regulation (D2.2.3).
D2.2.1 Activation of the innate immune response
The innate immune system is the first line of defense against infection, and consists 
of epithelial barriers, astroglia1920, phagocytes (e.g. microglia, denritic cells) and the 
complement system. Activated astroglia secrete cytokines (e.g. IL6) that regulate both 
innate and adaptive immune responses1920. SNCA stimulates astroglia to produce IL6 
and ICAM11921, and together with the ability of SNCA to activate microglia, this can 
attract microglia to the site of inflammation1922. Indeed, the astroglia cells in the SN 
of PD patients, show increased ICAM1 expression, which is associated with increased 
LFA-1 positive microglia in the SN176. Moreover, activated, ICAM1 and LFA-1 positive, 
microglia are increased in the SN and striatum of PD patients50, 1923 and based on in 
vitro studies contribute to the death of DA neurons1924-1926. Multiple factors such as 
(extracellular) SNCA, NM, S1P and cholesterol activate microglia 1927-1930, whereas 
oxLDL/oxysterols ameliorates microglia activation via the LXR receptor1170, 1930. SNCA-
mediated microglia activation increases the expression of MHC class II proteins, 
leading to CD4+ Th cell proliferation (part of the adaptive immune response) and 
DA neurodegeneration1931. Further, NM-mediated microglia activation is NF-KB-
dependent1927, 1932 and results in the production of pro-inflammatory cytokines1932. The 
interaction of glycoprotein CD200, located on the plasma membrane of a neuron, with 
its receptor CD200R1 (reduced expression in PD patients144) on the microglia holds the 
microglia in a quiescent state1933. In a PD rat model impaired CD200-CD200R1 function 
resulted in an increase in microglia activation and increased degeneration of DA 
neurons1933, 1934. CD200 expression is inversely correlated with expression of ICAM11933 
and CD200 decreases the expression of ITGAL and thus LFA-11935 and thereby controls 
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the regulation and signaling of immune cells. Microglia activation is also increased by 
ITGA61863, IL5 and IL5RA1936, STAP11937 and IFNG178 and inhibited by RCOR1, that thereby 
prevents inflammation-induced death of DA neurons1525. In contrast, RCOR1 also inhibits 
astroglia activation1525, whereas astroglia activation (by ATF6) results in neuronal 
survival in an MPTP mice model1392. This indicates that a delicate balance in microglia 
and astroglia activation and inhibition is necessary for DA neuron survival. Moreover, 
extracellular NM also stimulates the maturation of dendritic cells1938. Dendritic cell 
levels are reduced in blood of PD patients (maybe due to recruitment to inflammatory 
sites) and negatively associated with motor symptom severity1939.
Activated microglia and dendritic cells start secreting the pro-inflammatory factors IL1B, 
IL12 (IL12 is a heterodimeric protein, encoded by IL12A and IL12B312), TNF and CCL51929, 
1940-1942. IL1B increases NF-KB-dependent ICAM1 expression on glial cells1873, increases 
the expression of NR4A21528 (not shown) and CCL51941 and decreases the expression 
of HLA-DRA1943. IL12 secretion by microglia is inhibited by IL10 and astroglia1940 (not 
shown) and its expression is decreased by TRAF31780, 1944 and blockage of Ca2+ influx1108 
(e.g. via CACNA1A and CACNA2D3), but increased by PRKCE1945. In dendritic cells the 
intramembrane-cleaving aspartic protease SPPL2B promotes proteolysis of TNF to 
trigger IL12 production1946. Secreted IL12 increases the expression of IL2RA1947, ITGA61948, 
HLX1949 and CCL51950 and decreases the expression of the CCL5 receptor CCR41951. 
Lastly, the complement protein C9 is located in lewy bodies in PD SN52 and is a subunit 
of the membrane attack complex that forms pores in the plasma membrane of target 
cells312. The plasma protease C1 inhibitor (SERPING1) inhibits the complement system1952 
(not shown).
Thus, the innate immune response is activated in PD pathology and NM- and SNCA-
dependent activation of dendritic cells and microglia results in the presentation of 
SN antigens to the adaptive immune system1938, 1953. This indicates that autoimmune 
responses to DA neuron-specific antigen may play a role in the pathology of PD. Of 
note, whereas cholesterol and oxysterols both increase ICAM1 expression, they have 
opposing effects on microglia activation.
D2.2.2 Activation of the adaptive immune response
The adaptive immune system is unlike the innate immune system highly specific to the 
invading pathogens and is activated when the innate immune system is not sufficient. 
Cytokines secreted by cells of the innate immune system recruit and activate the cells 
of the adaptive immune response, (CD4+ and CD8+) T cells and B cells, to the site of 
inflammation, i.e. IL1B stimulates T and B cell maturation and proliferation1954, IL12 



















of naïve CD8+ T cells1956, whereas TNF activates CD4+ T cells1957, 1958. And lastly, CCL5 is 
a chemoattractant for T cells312 and increases the expression of IL1B1959 and STAT31750.
The next sections will show in more detail the processes involved in migration and 
chemotaxis of T and B cells (D2.2.2.1) and the activation of T (D2.2.2.2) and B cells 
(D2.2.2.3).
D2.2.2.1  Migration and chemotaxis of T and B cells
In addition to ICAM1-mediated attraction of immune cells (see section D2.2), B and T cell 
migration is inhibited via contact repulsion by the repulsion guidance molecule RGMA 
together with its receptor NEO1 1829. They thereby regulate lymphocyte infiltration in 
the tissue and suppress the inflammatory response 1829. Moreover, chemotaxis is also 
regulated by PARD3, CCR4, CXCL12-CXCR4 interaction and S1P, i.e. PARD3 regulates 
polarization and chemotaxis of T cells1960 and CCR4 is a chemoattractant homing 
receptor on circulating T cells312 and microglia1961, for the T cell attractant CCL51750. 
CXCL12 activates RAP2A (not shown), which is essential for B cell migration1962. 
Cholesterol increases the binding of CXCL12 to CXCR41963, which activates CXCR4 
resulting in increased intracellular Ca2+ levels312, activation of the JAK2/STAT3 and 
NF-KB pathways (see sections D2.1.1 and D2.1.2) and an increased expression of LFA-1, 
which increases adhesion of B cells to ICAM11731, 1887, 1964, 1965 (not shown). Interestingly, 
CXCR4 is increased in the nigro-striatal system of PD patients79 and CXCL12 and CXCR4 
are both increased in a mouse model preceding DA neuron loss79. Moreover, CXCR4 
binds the familial PD protein ATP13A2866 and CXCR4 distribution on the cell membrane 
is regulated by the CXCL12-activated1966 RAP1A1967. 
And lastly, S1P is transported out of the cell by SPNS2734, to create a S1P gradient that 
attracts T and B cells1968. S1P is transported by the lipoproteins LDL and HDL1969 (HDL 
is the major S1P carrier1970 and has a 9-fold higher S1P content than LDL1969). HDL-S1P 
inhibits GSK3B1621, activates STAT3 and increases cell migration1971. STAT3 increases the 
expression of the S1P receptor (not shown), creating a positive feedback loop1972. S1P 
activates both STAT3 and NF-KB1973. 
In summary, migration of T and B cells to their target tissue is regulated by ICAM1-LFA1, 
RGMA-NEO1, CCL5-CCR4 and CXCL12-CXCR4 ligand-receptor interactions and S1P 
gradients. Further, cholesterol, oxysterols and lipoproteins regulate the activation and 
expression of ICAM1 and LFA1 and are therefore important in astroglia and microglia 
mediated activation of T and B cells. An increase of these factors in the PD SN indicates 
that T and B cell activation may be increased.
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D2.2.2.2   T cell activation 
In the blood of PD patients, CD4+ T cells subsets1866-1868 and CD4+:CD8+ T cell ratios1867 
are decreased, and may reflect T cell alterations in brain. CD4+ T cell activation by 
peptides presented on MHC Class II proteins1917, results in expression and secretion 
of IL21974, 1975, IL51974, CCL51976 and IFNG1974. IL21977, 1978 activates T cells and is together 
with IL2RA required for T cell proliferation1979. IL5 stimulates differentiation of B 
cells into immunoglobulin secreting cells312 and is involved in microglia activation 
and proliferation1936, 1980. Further, CCL5 and also NEDD9 increase secretion of IL21981, 
1982 and IFNG activates microglia-mediated DA neuron death178. Thus, IL2, IL5, CCL5 
and IFNG are involved in several reinforcing feedback loops of T cell and microglia 
activation and proliferation. T cell activation and proliferation is also amplified by 
the interaction between TIMD4 (expressed on antigen presenting cells) and its ligand 
HAVCR1 (expressed on T cells early after their activation1841, 1983. And, PIK3CD activation 
contributes to T cell development, migration and differentiation312.
MHC Class I proteins (e.g. HLA-B and HLA-C) are located on almost all cells and present 
peptides to the immune system. CD8+ T cells become activated when these peptides 
are not recognized as endogenous and subsequently destroy the antigen presenting 
cell. The nuclear protein RUNX3 regulates development of CD8+ T cells1984 and increases 
CD8+ T cell proliferation1985. (Activated) CD8+ T cells contain TIAL11986 and PRF11987 
(binds cholesterol1988) in their cytotoxic granules which are secreted into the cleft 
between the T-cell and its target cell. LAMP1 regulates PRF1 quantity and localization 
to these granules1989. PRF1 makes pores in the plasma membrane of the target cell1990 
and TIAL1 induces DNA fragmentation1986. Membrane permeabilization by PRF1 makes 
it possible for granozymes and factors like TIAL1 to enter the target cell and induce 
DNA fragmentation and apoptosis1986, 1991. TIAL1 and PRF1 are both regulated by IL2, i.e. 
it decreases TIAL1466 and increases PRF11818 expression. Further, PRF1 expression is 
increased by IL121992, which also increases activation of MTOR in CD8+ T cells1993.
SERPINB9 (not shown) is a factor that protects cells against cytotoxic T cell-mediated 
apoptosis1994 and is upregulated by STAT31766, IL1B1995 and IFNG1996 and binds to TP53846, 
TLE1846 and PLEKHM1846 (PLEKHM1 regulates vesicle acidification1025 and the endocytic 
and autophagic pathway1026).
In the PD landscape, several nuclear proteins regulate T cell proliferation and 
activation, i.e. TCF12 increases differentiation of T cells1997, RAI1 protects against auto-
immune reactions by inhibiting lymphocyte activation1998 and differentiation of T cells 
into Th1 and Th17 subsets1999 and STAT3 activation is essential for the differentiation 
of helper T cells1834, 2000. Further, HLX is involved in the maturation of Th1 cells2001 and 



















interaction, adhesion and proliferation1882) and Th1-specific gene expression2002. DRG2 
overexpression on the other hand, suppresses T cell growth2003.
In summary, proliferation and activation of T cells, especially CD4+ and CD8+ T cells, 
is regulated by multiple proteins in the PD landscape. CD4+ T cells assist in B cell 
activation (see D2.2.2.3) and CD8+ cells destroy their target cell. Dysregulation in the 
activation or functioning of these cells may increase inflammation or autoimmune 
responses that increase DA neuron death.
D2.2.2.3   B cell activation
B cell activation occurs directly via antigen recognition by the B cell receptor (BCR) 
or with the assistance of CD4+ T cells. After antigen recognition the B cell presents 
a peptide of the antigen on MHC Class II proteins, which can be recognized by CD4+ 
T cells to provide costimulation and trigger B cell activation and proliferation. Now, 
the B cells migrate out of the lymphoid follicle (B cell zone) and a part of the activated 
B cells migrate into the germinal center for affinity maturation2004. Circulating B cells 
levels are reduced in the blood of PD patients1866, and activation, differentiation, affinity 
maturation and migration of B cells is regulated by multiple proteins in the PD landscape. 
Activation of naive B cells is inhibited by BANK1, a protein that is highly expressed in 
B cells2005, 2006. After activation of the BCR, BANK1 is phosphorylated and increases the 
mobilization of Ca2+ in B cells2005 (not shown), inhibits AKT1 activation2006 (not shown) 
and binds to STAT32007. Also, the transcriptional regulator RAI1 inhibits B cell activation 
and proliferation, by inhibiting BCR signaling1998. Activation of the BCR increases the 
activation of STAP12008, 2009. PIK3CD is required for BCR signaling and regulates B-cell 
development, proliferation, migration312. Further, the proteins LRRC25, BST1 and 
TCF12 activate and regulate development and growth of B cells2010-2014. Furthermore, 
TCF12 increases B cell differentiation2015, increases the expression of FOXO1627 and 
decreases the expression of gap junction protein GJB22016. FOXO1 deficiency impairs 
B-cell development2017 and is important in regulation of the PI3K-AKT1 axis in B-cell 
development2017, the same axis that is inhibited by BANK1 (see above). 
During co-stimulation the CD4+ T cell secretes the cytokines IL2, IL4 and IL5 that bind 
to their receptors (e.g. IL2RA and IL5RA) on the B cell and trigger B cell activation and 
proliferation2018-2022. CRH decreases the expression of IL2RA2023, but is also bound and 
inactivated by secreted CRHBP312. JAK2 binds to and is activated by the IL5 receptor 
subunit IL5RA1724, 2022. Further, IL5 and IL12 increase the expression of HLX1949, 2024, which 
is low expressed in inactive B (and T) cells, but high in activated lymphocytes2025, is 
involved in differentiation of B cells2026 and regulates IFNG expression1949, 2027.
B cell trafficking and recirculation through lymphoid tissues, which is required for 
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efficient antigen presentation and subsequent activation of B cells, is regulated by 
CXCL12 and CXCR42028. CXCR4 is expressed on B cells and quickly downregulated after 
CXCL12 binding2029. CXCL12 is produced in the cell layers surrounding the germinal 
center and attracts naive and memory B cells, but not germinal center B cells2029. This 
shows that the responsiveness to the chemoattractant CXCL12 is regulated during 
activation of B cells, to increase their trafficking to germinal centers2029. Moreover, 
adherens of B cells to ICAM1 is impaired in NEDD9 knockout B cells, resulting in a 
reduced migration to secondary lymphoid organs2030 for affinity maturation. B cells 
have to interact with antigen presenting cells in germinal centers to survive2004 
and the LFA-1-ICAM1 interaction contributes to B cell selection and promotes their 
survival2031. RUNX3 is expressed in the late stages of B cells development into plasma 
cells2032, 2033 and increases expression of ITGAL resulting in an increased LFA-1 surface 
expression1823, which would therefore be beneficial in B cell selection and survival. 
ZNF385B (associated with PD in three GWASs) is expressed in germinal center B cells 
and binds to TP532034 (not shown). Depending on the ZNF385B isoform, ZNF385B can 
have both pro- and anti-apoptotic actions in the B cell and can therefore affect B cell 
selection2034.
B cell isotope class switching occurs in germinal centers. MTOR deficiency in B cells 
leads to a reduced high-affinity antibody production by decreasing the activity of 
activation-induced (DNA-cytosine) deaminase (AICDA, not shown). This enzyme causes 
DNA mutations and thereby leads to antibody diversity2035 and thus is necessary for 
isotope class switching. TRAF3 increases the expression of AICDA2036 (not shown), but 
also inhibits (together with TRAF2) mature B cell survival and suppresses expression of 
NF-KB1300, 2037. NF-KB binds to the AICDA promotor and is required for its expression2038 
(not shown). This discrepancy with inhibition of NF-KB expression by TRAF3 is 
explained by TRAF3-mediated inhibition of NF-KB inhibitors2039, 2040. Further, to induce 
isotope class switching, AICDA is actively transported into the nucleus of B cells by the 
importin KPNA42041 (not shown).
S1P induces adhesion to ICAM1 and thereby allows B cells and plasma (B) cells to exit 
the germinal centers and re-enter the circulation2042. Circulating B cells not only bind to 
ICAM1 on other cells, but can also express ICAM1 themselves and thereby costimulate 
T cells2043.
In conclusion, the reduced levels of circulating B cells in PD and the regulation of their 
activation, differentiation, affinity maturation and migration by proteins in the PD 
landscape indicate that their regulation is part of the PD pathology. Changes in B cell 
activation by CD4+ T cells or by changes in their selection and maturation may affect 



















D2.2.3 Coagulation factors, lipoproteins and immune cell activation 
Coagulation factors regulate the formation of a platelet and fibrin clot in a damaged 
vessel wall and dysregulation of this process can lead to increased clotting 
(thrombosis) or increased bleeding (hemorrhage). PD patients show a decrease in the 
serum coagulation factors α-2-antiplasmin and factor V66. Factor V deficiency leads 
to reduced clotting and hemorrhage2044, whereas a decrease in α-2-antiplasmin would 
increase plasmin activity2045. The PLG gene encodes the protein plasminogen, that is 
converted into plasmin by the plasminogen activators PLAU and PLAT312. Extracellular 
SNCA regulates the plasmin system by increasing SERPINE1 expression2046 (a serine 
protease inhibitor that mediates diabetic vascular complications and is increased in 
the plasma of patients with diabetes, obesity and hypertension2047-2050). SERPINE1 binds 
and inhibits both PLAU2051-2053 (PLAU increases proteolysis of MMRN12054) and PLAT2045, 
2055. SERPINE1, PLAT and PLAU bind and are internalized by the low-density lipoprotein 
receptor-related protein 1B (LRP1B)2056 and VLDLR binds to plasminogen and PLAU and 
mediates their endocytosis2057. Further, SERPINE1 increases cholesterol in the blood2050 
and plasmin increases degradation of LDL2057, 2058, whereas plasminogen knockout mice 
show decreased HDL-cholesterol levels2059. Furthermore, SERPINE1 expression and 
secretion is increased by VLDL2060, 2061, VLDLR2061, 2062, LDL2061 and OxLDL2061 (enhances 
SERPINE1 expression compared to LDL induced expression2061) and PLAT expression 
is decreased by LDL2063. Thus coagulation factors and lipoproteins regulate each other. 
Knockout of PLAT in a mouse model decreased levels of dopamine, indicating a role for 
the PLAT/plasmin system in regulating dopamine release2064.
In addition to lipoproteins and SNCA, SERPINE1, PLAT and PLAU expression is regulated 
by multiple other proteins in the PD landscape. Namely, SERPINE1 expression is also 
increased by SREBF11416, 2065, ADAM121857 (not shown), BAG61859, BMP7608, 2066, STK11995 (not 
shown), INS639 (not shown), NEDD92067 (not shown) and AGTR1363, and is decreased by 
COL18A12068, PRKG12069 (not shown), FOXO1639, SMAD52070, vitamin D3 (via inhibition of 
NF-KB)1106 and the cytoplasmic serine-threonine kinase WNK12071 (that binds and is 
phosphorylated by STK392072). Further, SERPINE1 expression is increased by mRNA 
stabilization by TP532073 (not shown), SERPINE1 accumulation is decreased by BMP72070 
and SERPINE1 activation inhibited by SIRT1661. Thus, SERPINE1 expression is regulated 
by lipoproteins (VLDL, LDL, oxLDL, LRP1B), the angiotensin system (AGTR1) and by four 
(SREBF1, FOXO1, NF-KB and TP53) of the main transcription regulatory pathways in the 
PD landscape, which therefore can affect SERPINE1-mediated inhibition of PLAU and 
PLAT. Moreover, the secreted latent-transforming growth factor beta-binding protein 1 
(LTBP1) binds the extracellular protein Fibrillin-1 (FBN1)2074, is activated by plasmin2045 
and increases the expression of COL2A12075 and SERPINE12076 and is thus an important 
regulator in the ECM.
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PLAU is inhibited by IL1B2077 and activated by a splice variant of TMPRSS9 (highly 
expressed in CD8+ T cells)2078, whereas PLAT is inhibited by LDL2079 and activated by 
CRH via its receptor CRHR12080. PLAU expression is decreased by COL18A12068, IL122081, 
PTEN1666, mediated by CXCL122082 (not shown) and increased by MAP2K62083 (not shown), 
AGTR1364, STAT31766, NF-KB2084 (not shown), IFNG2085, IL1B2085 and TNF2085 (not shown). 
PLAT expression is decreased by IL1B2086 and increased by vitamin D31098. So, in addition 
to SERPINE1, also PLAU and PLAT are directly regulated by PD landscape proteins, 
affecting plasminogen / plasmin levels. 
Of note, coagulation factors also have a role in immune cell regulation. PLAT activates 
microglia2087, 2088 and PLAU increases the expression of ICAM12089. Moreover, PLG is 
expressed by microglia2090, and plasmin cleaves and degrades both aggregated and 
monomeric forms of SNCA2046 and thereby inhibits the translocation of extracellular 
SNCA into neighboring cells and the activation of microglia and astroglia by 
extracellular SNCA2046. Plasmin also triggers chemotaxis of dendritic cells triggering a 
T cell response2091 and induces the release of IL8 from SDC1 (a cell surface proteoglycan 
that stabilizes the chemoattractant form of IL8 at the cell surface)2092. SERPINE1 (by 
inhibiting plasmin production) stabilizes the chemoattractant function of IL8 by 
stabilizing its binding to SDC12092. Further, PARK7 increases expression of IL81787 and 
PD patients with a GBA mutation have increased IL8 plasma levels compared to PD 
patients without a GBA mutation2093. The latter indicates an involvement of sphingosine, 
which is indeed shown by a S1P-mediated suppression of IL8 secretion by T cells2094 
(not shown). PLAT triggers activation of SPHK1 by binding to its receptor PLAUR2095 
(not shown) and thereby increases the phosphorylation of sphingosine to S1P, a major 
regulator of T- and B-cell traficking2096.
In summary, coagulation factors, regulated by cytokines, lipoproteins and SNCA, 
regulate the chemotaxis of immune cells via IL8- and S1P-regulation and prevent SNCA-
mediated activation of astroglia and microglia. Moreover, coagulation factors regulate 
lipoproteins, sphinglipids and cholesterol and can therefore modify their effects on 
immune cell activation.
D3. Concluding remarks
The viability of DA neurons is maintained by DA neuron specific transcription factors, 
increased by neurotrophic factors and is decreased by activation and upregulation of 
pro-apoptotic proteins. The transcription factors ASCL1, MSX1, NEUROG2, NR4A2, PITX3 
and SOX2 are necessary to maintain a dopaminergic phenotype. The neurotrophic 
factors BDNF and GDNF support the survival of DA neurons by regulating apoptotic 
pathways, whereas GSK3B, PTEN, TP53 and CASP3 increase apoptotic signaling and 



















with the transcription factors STAT3 and NF-KB, immune cell activation. In PD patients, 
cytokines and cytokine receptors are dysregulated and both the innate and adaptive 
immune response are affected. The innate immune response is activated by NM, SNCA 
and cholesterol, and results in the presentation of SN-specific antigens to the adaptive 
immune system that subsequently targets these cells for destruction. Migration, 
maturation, proliferation and activation of T and B cells (cells of the adaptive immune 
system) is regulated by proteins in the PD landscape. Moreover, almost all transcription 
factor pathways in the PD landscape regulate the immune regulator ICAM1, which 
stresses the importance of this protein in (dysfunctional) immune regulation in 
PD. Changed (oxidized) lipoprotein levels affect the immune response, directly, by 
regulating immune cell activation (and ICAM1 expression), or indirectly due to changes 
in membrane lipid composition, affecting (among others) internalization of antigens 
and localization of receptors responsible for chemotaxis or immune cell activation. 
Lastly, coagulation factors (regulated by cytokines, lipoproteins and SNCA) regulate the 
chemotaxis of immune cells, prevent SNCA-induced immune cell activation, but also 
regulate lipoproteins, sphingolipids and cholesterol and thereby mediate their effects 
on the immune response.
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ΔΨm,  mitochondrial transmembrane potential;
Ca2+,  calcium ion;
CSF,  cerebral spinal fluid; 
DA,  dopamine;
eQTL,  expression quantitative trait locus; 
ECM,  extracellular matrix;
ER,  endoplasmic reticulum;
FPD,  amilial Parkinson’s disease; 
GWAS,  genome-wide association study; 
GWASs,  genome-wide association studies;
INS,  insulin;
IPD,  idiopathic Parkinson’s disease; 
K+,  potassium ion;
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LD,  linkage disequilibrium; 
Mg2+,  magnesium ion;
mPTP,  mitochondrial permeability transition pore;
Na+,  sodium ion;
NM,  neuromelanin;
nonsyn, nonsynonymous; 
NS,  not shown;
OR,  odds ratio;
PD,  Parkinson’s disease;
RAS,  renin-angiotensin system;
SN,  substantia nigra; 
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3.1 ABSTRACT
Parkinson’s disease (PD) is characterized by dopaminergic (DA) neuron death in the 
substantia nigra (SN) and subsequent striatal adaptations. Mice treated with the 
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP) are widely used as 
a model for PD. To assess the validity of the MPTP mouse model for PD pathogenesis, 
we here identify the biological processes that are dysregulated in both human PD and 
MPTP-treated mice. Gene enrichment analysis of published differentially expressed 
mRNAs in the SN of PD patients and MPTP-treated mice revealed an enrichment of gene 
categories related to motor dysfunction and neurodegeneration. In the PD striatum, a 
similar enrichment was found, whereas in the striatum of MPTP mice acute processes 
linked to epilepsy were selectively enriched shortly following MPTP treatment. More 
importantly, we integrated the proteins encoded by the differentially expressed 
mRNAs into molecular landscapes showing PD pathogenesis-implicated processes 
only in the SN, including vesicular trafficking, exocytosis, mitochondrial apoptosis 
and DA neuron-specific transcription, but not in the striatum. We conclude that the 
current use of the MPTP mouse as a model for studying the molecular processes in PD 
pathogenesis is more valid for SN than striatal mechanisms in PD. This novel insight 
has important practical implications for future studies using this model to investigate 
PD pathogenesis and evaluate the efficacy of new treatments.
KEYWORDS:  Parkinson’s disease, MPTP mouse model, Genome-wide mRNA expression, 
Molecular landscape
3.2 INTRODUCTION
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxic impurity that may occur 
during the synthesis of the opioid drug desmethylprodine, causes an irreversible 
parkinsonian syndrome in humans almost indistinguishable from Parkinson’s disease 
(PD)1. Therefore, MPTP toxicity in monkeys, rats and mice has been studied to elucidate 
the pathogenic mechanisms implicated in PD. MPTP-treated mice are advantageous 
to explore the molecular background of MPTP toxicity, because lines of genetically 
engineered animals allow high levels of control of the experimental conditions. 
Mice treated with MPTP share specific biological features with PD, including loss of 
dopaminergic (DA) neurons in the substantia nigra (SN) and dopamine depletion in the 
striatum2. However, their pathogenetic backgrounds are different, being a toxic nature 
in a mouse model and a neurodegenerative process in human PD. Moreover, not all PD 
phenomenology is reproduced in MPTP-treated mice3. Therefore, the construct validity 
of the MPTP mouse as a model to study and elucidate the pathogenesis of PD remains 
unclear. 
In order to identify the biological processes that are dysregulated in MPTP toxicity 




postmortem SN and striatum of PD patients, as well as differentially expressed mRNAs 
in the SN and striatum of MPTP-treated mice, were analyzed. Furthermore, based on 
proteins encoded by the mRNAs that were differentially expressed in both PD patients 
and MPTP mice, molecular landscapes of interacting proteins were built for both the 
SN and striatum. These landscapes represent molecular mechanisms that are shared 
between PD and MPTP toxicity. Together, these analyses will help to understand and 
value experimental findings in the MPTP mouse in the light of human PD pathogenesis.
3.3 METHODS
3.3.1 Genome-wide mRNA expression data
Available genome-wide mRNA expression data from multiple previously published 
studies were used to generate a list of differentially expressed transcripts in the 
postmortem SN and striatum of PD patients and MPTP treated mice, studied at various 
time points following MPTP treatment. If raw expression data was available at the 
Gene Expression Omnibus (GEO) site, this data was re-analyzed in GeneSifter (www.
genesifter.com) using robust microarray analysis (RMA). The Benjamini-Hochberg 
method was then used to correct for multiple comparisons, and only mRNAs with a 
fold change (FC) of ≥ 1.2 or ≤-1.2 and a corrected p-value <0.05 were considered to be 
differentially expressed and used for the subsequent gene enrichment analysis, as 
described below. If no raw data was available, our inclusion criteria were:  1) correction 
for multiple testing was performed, with a corrected p-value <0.05 and the correction 
method was explicitly mentioned; and 2) an mRNA expression FC of ≥ 1.2 or ≤-1.2. Only 
protein-coding mRNAs were included in our analyses.
3.3.2 Enrichment analysis
The Ingenuity pathway analysis software package (www.ingenuity.com) was used to 
identify enriched gene categories in the lists of differentially expressed mRNAs in 
the SN and striatum of both human PD patients and MPTP-treated mice, and in the 
lists of overlapping mRNAs that were differentially expressed in the SN or striatum 
of both PD patients and MPTP mice. Ingenuity assigns genes and their corresponding 
mRNAs/proteins to (sub) categories of functional classes, e.g. ‘diseases and disorders’ 
and ‘molecular and cellular functions’. For these analyses, only functional categories 
and pathways with significant enrichment (i.e. Benjamini-Hochberg corrected p < 0.05) 
and containing two or more genes were taken into account.
3.3.3 Molecular landscape building
Subsequently, the mRNAs that were differentially expressed in the SN and striatum 
of both PD patients and MPTP-treated mice were analyzed in more depth. Guided by 
the results of the Ingenuity enrichment analyses, the literature was searched for the 
(putative) function of all the proteins encoded by the mRNAs overlapping between 
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human PD and the MPTP mouse, as well as their functional interactions, using the 
UniProt Protein Knowledge Base (http://www.uniprot.org/uniprot)4 and PubMed (http://
www.ncbi.nlm.nih.gov/sites/entrez). Based on these findings and applying an approach 
similar to the one we used previously to build landscapes based on genome-wide 
association data5,6, we then built two molecular landscapes comprising interacting 
proteins encoded by the overlapping mRNAs in the SN and striatum, respectively. To 
complement these protein interaction cascades, we also added a number of proteins 
that were not encoded by the overlapping differentially expressed mRNAs but that have 
been implicated in PD etiology through other lines of (genetic) evidence. In this respect, 
proteins encoded by familial PD candidate genes were included if they have at least one 
functional interaction with one or more other landscape proteins. Additional proteins 
were included when having at least two interactions with other landscape proteins. 
Serif Drawplus 4.0 (www.serif.com) was used to draw the landscape figures.
3.4 RESULTS
In this study, we analyzed with gene enrichment approaches and systematic literature 
searches published datasets of differentially expressed transcripts in SN and striatum 
of PD patients and MPTP-treated mice that met our criteria for inclusion (see Table 1 
for dataset details).
3.4.1 Enrichment analysis of SN mRNA expression data
Human PD. Ingenuity enrichment analysis of the mRNAs that, compared to healthy 
controls, were differentially expressed in the SN of human PD patients, revealed the 
subcategories that were most significantly enriched within the two main functional 
classes, “diseases and disorders” and “molecular and cellular functions” (Table 2). 
When analyzing all differentially expressed SN mRNAs, the most significantly enriched 
diseases and disorders were predominantly in the movement disorders domain. Similar 
annotations were found for the top-5 enriched categories within the downregulated 
mRNAs, while the enriched annotations within the up-regulated mRNAs were not 
specifically related to (any) neurological function (data not shown). At a more functional 
level (i.e. the ‘molecular and cellular functions’ category), the enriched annotations 
were all related to neuronal and/or synaptic function.
MPTP mouse. Similar Ingenuity analyses revealed the most enriched functional 
categories within the mRNAs that were differentially expressed in the SN of MPTP-
treated mice compared to untreated animals (Table 2). Analyzing mRNA expression 
profiling data at different intervals following MPTP treatment assessed temporal 
aspects of MPTP-induced neurotoxicity. More specifically, mice were injected four times 
within an eight-day period, and subsequently sacrificed for analysis one and seven days 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Z predominantly in movement disorders-
related domains. The enriched molecular 
and cellular functions categories were 
also similar over time, relating mainly to 
cell death, proliferation and development 
(both intervals), as well as to structural 
organization of the cell (short interval 
only). 
Overlap between human PD and MPTP 
mouse. The most significantly enriched 
functional categories within the mRNAs 
that were differentially expressed in 
the SN of both PD patients and MPTP-
treated mice are also shown in Table 2. 
Similar to the human and mouse results 
mentioned above, the enriched diseases 
and disorders encompass movement 
disorders-related domains, while the 
more functional categories related 
to neuronal cell death, microtubule 
dynamics and cellular functions, 
including neurotransmitter synthesis 
and exocytosis, as well as (neuronal) cell 
growth and death.
3.4.2 Molecular landscape of 
shared processes in the SN
Figure 1 shows a molecular landscape 
of interacting proteins encoded by the 
mRNAs that are differentially expressed 
in the SN of both human PD patients 
and MPTP-treated mice. These proteins 
form signaling cascades that are located 
in the SN neuron presynapse, cell body 
or nucleus. The main cascades in the 
presynaptic landscape regulate DA 
synthesis, autophagy, calcium signaling, 
vesicle trafficking and exocytosis 
(Fig. 1A). In the cell body and nucleus, 
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particularly mitochondrial (dys)function and transcriptional regulation through 
histone and nucleosome modification and its reciprocal effect on pre-mRNA splicing 
are present (Fig. 1B). More specifically, NR4A2 and SOX2, two of the five transcription 
factors that are required for a DA neuron-like expression pattern, bind to HDAC1, a 
histone deacetylase that interacts with many proteins in the landscape. Therefore, 
dysregulation of any of these processes affects DA neuron-specific expression and 
reduces the number of neurons with a DA phenotype. In the Supplementary Information, 
the landscape is described in full detail, and the current knowledge about the functions 
of all landscape proteins is summarized. 
3.4.3 Enrichment analysis of striatal mRNA expression data
Human PD. Similar to the SN data described above, the disease/disorder categories 
that are directly related to PD-like movement disorders and motor symptoms were 
significantly enriched within the mRNAs that were found to be differentially expressed 
in the striatum of PD patients (Table 3). Furthermore, the enriched functional categories 
were mainly related to neuronal functions such as (synaptic) transmission, and 
molecular/metal ion transport.
MPTP mouse. Again, the most significantly enriched categories were determined at 
various time points following MPTP treatment. However, the respective study used 
a timing regimen different from the study focusing on the SN mentioned above. At 5 
and 24 hrs after injection, the predominant functional categories were implicated in 
(neuronal) cell death and other acute, MPTP toxicity-related processes, including (dys)
regulation of inflammatory responses and immunity-related cells, and endometriosis. 
At 72 hrs after MPTP injection, the most significantly enriched categories shift towards 
those enriched within the PD patient striatal data, i.e. categories related to PD-like 
motor symptoms and neuronal/synaptic function (Table 3).
Overlap between human PD and mouse MPTP. The most significantly enriched 
categories within the mRNAs that were differentially expressed in the striatum of both 
human PD patients and the MPTP mouse model comprise a combination of the enriched 
‘diseases and disorders’ categories identified in human PD and MPTP-treated mice as 
summarized above, i.e., relating to both movement disorders and epilepsy (Table 3). 
Indeed, the ‘cellular and molecular functions’ categories involved in both neuronal/
synaptic function and neuronal cell growth/death are enriched within the overlapping 
PD patient/MPTP mouse striatal data.
3.4.4 Molecular landscape of shared processes in the striatum
Figure 2 shows a molecular landscape of interacting proteins encoded by the mRNAs 




Figure 1. Molecular landscape of interacting proteins, encoded by the mRNAs that are differentially expressed in 
the SN of both human PD patients and MPTP-treated mice, located primarily in the (pre) synapse and axon of the 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mice. PD as well as MPTP treatment result in the degeneration of nigrostriatal DA 
neurons, which decreases DA release in the striatum and results in diminished 
activation of the DRD2 and DRD3 DA receptors, in turn affecting postsynaptic striatal 
protein expression and calcium signaling. Furthermore, the majority of the proteins in 
this landscape regulate CREB1 - a transcription factor that is essential for DA-dependent 
gene expression in the striatum - either directly via calcium signaling or through 
activation of the ERK1/2 kinases. In the Supplementary Information, the landscape is 
described in full detail, and the current knowledge about the functions of the landscape 
proteins is presented.
Figure 2. Molecular landscape of interacting proteins, encoded by the mRNAs that are differentially expressed in 
the striatum of both human PD patients and MPTP-treated mice located in the post-synapse of a striatal neuron. 
See text and Supplementary Information for details. 
3.5 DISCUSSION
This study aimed to determine the construct validity of the MPTP mouse as a model 
to study human PD pathogenesis. First, the most important dysregulated biological 
processes underlying both human PD and MPTP toxicity were identified by enrichment 
analyses of published genome-wide mRNA expression data from postmortem SN and 
striatum of PD patients and MPTP-treated mice. Second, proteins encoded by the 
mRNAs that were differentially expressed in both PD patients and MPTP-treated mice 
were integrated into molecular landscapes representing the main biological processes 
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that are shared by human PD and mouse MPTP toxicity. Our findings demonstrate that, 
at the level of the SN, MPTP toxicity has substantial relevance for PD pathogenesis. 
This is less obvious for the striatum, in which important temporal effects of MPTP 
toxicity were noted. 
Because categories related to basal ganglia-based motor dysfunction and 
neurodegeneration were enriched in the SN of both PD patients and MPTP-treated 
mice, the effects of MPTP toxicity on gene expression in the mouse SN appear to have 
similar phenotypic consequences as human PD. However, differences exist between PD 
and MPTP toxicity regarding the specific (dysregulated) biological processes involved. 
While in the SN of PD patients, enriched molecular and cellular functions relate to 
neuronal and synaptic functions, functional themes pertaining to cell growth and 
death predominate in the MPTP mouse model. This discrepancy could well reflect the 
differences between the protracted processes of neurodegeneration in PD, as well as 
simultaneous compensatory neuroplastic mechanisms, compared to the acute MPTP 
toxicity in mice. Moreover, the biological processes that overlap between the SN of 
both PD patients and MPTP-treated mice mainly relate to neuronal/synaptic function 
and (neuronal) cell death, while the molecular signaling cascades involved regulate 
DA synthesis and recycling, endocytosis and exocytosis of (DA-containing) synaptic 
vesicles, and cytoskeleton-dependent synaptic remodeling. These biological processes 
have been implicated in the pathogenesis of PD before19-21. Proteins encoded by other 
differentially expressed mRNAs are important players in other processes that have 
been implicated in DA neuronal dysregulation and death, including  cytoplasmic 
and nuclear cascades regulating (vesicular) trafficking22, mitochondrial function and 
apoptosis23, proteosomal degradation (including the degradation of DA neuron-specific 
transcription factors)24, as well as transcriptional, post-transcriptional and translational 
processes such as histone regulation25 and pre-mRNA splicing26.
As opposed to the SN findings, the categories that were most significantly enriched 
within the differentially expressed striatal mRNAs did not unequivocally overlap 
between human PD and mouse MPTP-induced toxicity. In PD, they are related to PD-
associated motor symptoms, but in the MPTP-treated mouse striatum, the enriched 
categories depend on the length of the time period between MPTP treatment and 
transcriptional profiling. Early (i.e., 5 hours) after MPTP injection, the most significantly 
enriched disease categories within the mouse striatal mRNA expression data are not 
related to motor dysfunction, but to epilepsy. Epilepsy is a known acute side-effect 
of MPTP injection in mice27 and is directly linked to the temporary presence of the 
active MPTP metabolite MPP+28. Although observational studies have reported an 
association between epilepsy and PD29, an acute side effect of MPTP is more likely, as 




line with a gradual reduction of MPP+ levels in the mouse brain over time, at 24 hours 
after injection, some of the significantly enriched disease categories point towards 
an inflammatory response, while at 72 hours, they are related to motor dysfunction 
and neurodegeneration. A similar pattern is observed for the molecular and cellular 
functions, where at 5 hours after injection, the enriched functions are mainly related 
to cell growth and death, shifting to cellular organization- and morphology-related 
functions at later time points. Although direct comparison of studies is challenging 
due to different injection regimens, these findings may suggest that in the striatum – 
more clearly than in the SN – the MPTP-induced expression changes and the molecular 
signaling cascades that are affected by these expression changes are not consistent 
but change towards more PD-relevant processes over time. The overlap between PD 
and MPTP-treated mice in biofunctions of striatal mRNAs, encompassing both ‘acute’ 
toxicity-related and ‘chronic’ PD-related categories, is corroborated by the molecular 
landscape. In this landscape, part of the affected biological processes and functions 
appears directly related to diminished DA striatal innervation through postsynaptic 
DA receptors. In addition, there seems to be a strong convergence on the regulation 
of intracellular calcium levels as well as CREB1-related signaling, which have both 
been functionally linked to epilepsy before31. Again, it remains unsure whether these 
signaling cascades are affected by the reduced DA innervation from the presynaptic 
SN neuron, or that they merely reflect an acute ‘side-effect’ of MPTP rather than having 
much direct relevance for PD pathogenesis. The finding of endometriosis-related 
enrichment in mice may be related to the fact that only female mice were used, while 
for the human studies, both male and female subjects were included. However, since 
8 out of the 14 proteins with the annotation ‘endometriosis’ are also present in the 
annotated category ‘dyskinesia’, the ‘endometriosis’ enrichment may be due to either a 
true gender effect, an enrichment of genes involved in movement dysfunction-related 
processes, or both.
Thus, our transcriptome analyses and molecular landscapes indicate that the MPTP 
mouse constitutes a valid model for the chronic molecular and pathological changes 
that occur in the SN of PD patients, and hence of the PD phenotype that is associated 
with these changes. However, this is less obvious for the striatum, because early after 
MPTP injection, enriched categories and functions encompass mainly processes that 
are not directly related to PD. It appears that human PD pathogenesis in the striatum is 
better recapitulated at the molecular level in the MPTP-treated mouse model 72 hours 
post-injection, and perhaps even later. Effects of the level of chronicity of the dosing 
regimen on markers of DA neurotransmission – e.g. TH expression and striatal DA 
levels – and behavioral outcome have been reported before32-34, but specific effects on 
the transcriptome have not been addressed. In this respect, assessing the relationship 
between the temporal expression patterns in human PD patients and their disease 
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duration would be of interest, similar to the analyses that were performed on the 
mouse-MPTP data. Unfortunately, for the reported human expression studies, disease 
duration data were not available for all cases.
In addition to the acutely toxic nature of early MPTP-induced pathology, there may 
be several other explanations for the apparent discrepancy between the striatal 
PD pathogenesis and MPTP toxicity.  First, presynaptic DA denervation may result 
in enriched processes that are different between humans and mice due to species 
specificity. For example, similar degrees of DA degeneration in humans and mice do 
not result in similar phenotypic severity35 and clinical phenotypes differ as mice do 
not show the tremor often seen in patients. Second, chronic compensating processes 
including adaptive neuroplasticity could play an important role in PD, but less in MPTP-
treated mice. In PD, these processes may be linked to the synaptic transmission- and 
molecular transport-related functions that are enriched in striatal mRNAs. The acutely 
toxic nature of MPTP would not allow for such an adaptation. Finally, it should be noted 
that, despite the high degree of overlap, the absolute number of differentially expressed 
mRNAs that overlap between human PD striatum and MPTP mouse striatum is low, 
perhaps prohibiting the detection of statistically relevant enrichment.
The principal differences between the chronological orders of events in PD-linked 
neurodegeneration versus MPTP-induced toxicity are summarized in Figure 3. In PD, 
a number of molecular mechanisms in presynaptic SN neurons – including vesicular 
trafficking and exocytosis, mitochondrial apoptosis, as well as several transcriptional 
and translational processes – cause neuronal / synaptic dysfunction and cell death, 
which is followed by chronic, postsynaptic compensatory mechanisms in the striatum. 
In contrast, MPTP is taken up readily as MPP+ through the DA transporter (DAT) in 
presynaptic SN neuron terminals36, causing toxicity and sequestration of MPP+ 
into synaptic vesicles37. MPP+ also reaches the cell body of presynaptic SN neurons 
through retrograde axonal transport38, which in turn causes neuronal death through 
mitochondrial accumulation and electron transport chain inhibition, inducing neuronal 
apoptosis39. This relatively rapid cell death causes more acute compensatory effects in 
the postsynaptic striatal neurons40.
Together, our findings provide further evidence that the molecular changes in the SN 
of MPTP-treated mice correspond to the observed alterations in the SN of PD patients. 
However, for a proper reflection of the molecular changes occurring during PD 
pathogenesis in the striatum, the time point of studying the changes following MPTP 
treatment is crucial. Further transcriptome studies are needed to determine whether 
waiting longer than 72 hours would indeed provide a better construct validity for 




injection to assess striatal PD pathology in the MPTP mouse model. Such knowledge 
will have important practical implications for the use of the MPTP mouse as a model 
for PD and for PD drug testing.
Figure 3. Proposed fundamental mechanisms underlying the degeneration of dopaminergic neurons in 
Parkinson’s disease and mouse MPTP toxicity. The numbers denote the sequence of events in Parkinson’s 
disease and the MPTP mouse respectively. See text for further details. 
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Parkinson’s disease (PD) as well as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) treatment result in the degeneration of dopaminergic neurons in the substantia 
nigra (SN), leading to a decrease of dopamine (DA) release to the striatum. Below, the 
molecular landscapes of biological processes shared between PD and MPTP treatment 
in the substantia nigra (SN) (Figures 1A and 1B) and striatum (Figure 2) are described 
in full detail, and the current knowledge about the functions and interactions of all 
landscape proteins is presented. In these descriptions, proteins that appear in bold are 
dysregulated in both human PD and the MPTP mouse model. Underlined proteins are 
associated with PD through either expression or genetic data from PD patients, and 
familial PD proteins are double underlined.
1.  DETAILED DESCRIPTION FIGURE 1A
Figure 1A shows a molecular landscape of interacting proteins, encoded by the mRNAs 
that are differentially expressed in the SN of both human PD patients and MPTP-treated 
mice, located primarily in the (pre) synapse and axon of the DA neuron. The biological 
processes depicted in the figure are described below:
1.1 DA synthesis
TH catalyzes the rate-limiting step in DA synthesis, i.e. the conversion of the amino 
acid L-tyrosine into L-3,4-dihydroxyphenylalanine (L-DOPA)1, 2. TH expression is 
increased by the receptor tyrosine-protein kinase RET3 and SLC6A34. TH is activated 
by the adaptor protein YWHAZ5, 6 and the cyclin-dependent kinase CDK57, and DA itself 
inhibits TH activity in a negative feedback loop8, 9. YWHAZ also binds to the kinases 
MARK210, involved in microtubule regulation11, and PDXK12, required for the synthesis of 
pyridoxal-5-phosphate (PLP) from vitamin B611. PLP, in turn, is an essential cofactor for 
the conversion of L-DOPA into DA by dopa decarboxylase13.
1.2 (DA) release
Soluble NSF Attachment Protein Receptor (SNARE) proteins form a complex that is 
required for synaptic vesicle docking and subsequently the release of their contents 
(e.g., DA) into the synaptic cleft11. SNAP25 and VAMP2, core components of the SNARE 
complex, physically interact with each other14 and form a complex together with 
STXBP115, a protein that is also involved in synaptic vesicle fusion and docking11. 
STXBP1 binds to CDK516, a protein involved in cytoskeleton regulation, synapse 
plasticity, exocytosis and endocytosis (see more on CDK5 below). The vesicle fusion 
ATPase NSF increases the dissociation of the SNARE complex (dissociation of SNAP25 
and VAMP2) and thereby enables the vesicle to fuse with the plasma membrane17. NSF 



















The DA – acetylcholine (ACh) balance may be involved in PD pathology21 and ACh 
regulates DA release22. The extracellular protein ACHE hydrolyzes ACh that is released 
into the synaptic cleft11. Although ACHE does not directly interact with other landscape 
proteins, its function may well be linked to PD since its activity is reduced in the cerebral 
cortex and the medial occipital cortex of PD patients23. Moreover, ACHE is inactivated 
by MPTP24 and ACHE deficiency is neuroprotective in the MPTP mouse model25.
1.3 DA reuptake    
In response to an action potential, DA is released from vesicles in the synaptic cleft by 
exocytosis and reuptake of extracellular DA occurs by SLC6A3 to terminate the signal26, 
27. SLC6A3 binds to the familial PD proteins PARK228 and SNCA29, which both enhance 
its activity. PARK2 and RET increase the expression of SLC6A33 , 28, 30, while SNCA 
increases SLC6A3 translocation to the plasma membrane29. In addition to increasing the 
expression of TH, SLC6A3 activates AKT131 and both inhibits the activity32 and decreases 
the expression of CDK533. Cytoplasmic DA (either synthesized by TH or after reuptake 
by SLC6A3) is transported into cytoplasmic vesicles by SLC18A211. These vesicles are 
subsequently translocated via axoplasmic transport to the synapse for exocytosis.
1.4 Recycling of membrane-bound synaptic components    
To further control DA levels in the synaptic cleft, proteins including SLC6A3, DRD2 
and the voltage-dependent calcium channel (VDCC) are endocytosed, transported to 
the endosome and either recycled back to the membrane or degraded. ATP6V0D1 is a 
subunit of the proton V-ATPase and increases the acidity of the endosome11, which is 
required for a normal endosomal function. DRD2 binds to SLC6A334 and increases its 
localization in the plasma membrane35, and activates the transport activity of SLC6A336. 
SNAP25 is also involved in this process, by binding to SLC6A337 and VDCC38, 39. Correct 
regulation of the recycling and degradation of DRD2 and SLC6A3 is essential for normal 
neuronal DA signaling and deregulation of the proteins that regulate their endocytosis 
and/or expression at the plasma membrane can disturb this signaling. The G protein 
GNAI2 regulates the expression of, binds to, and prevents the plasma membrane 
translocation of, DRD240. RGS4 binds to both DRD241 and GNAI242, and increases the 
GTPase activity of GNAI2 (not shown)43. In turn, GNAI2 increases the recruitment of RGS4 
to the plasma membrane (not shown) 44, where it binds – among others – to LPAR141. 
The Rab GTPases RAB4A, RAB6A, RAB11A and RAB14 are also involved in (vesicular) 
recycling and endosomal function; see the section ‘(Vesicle) trafficking and exocytosis’ 
in the detailed description of figure 1b below for their functions within the landscape.
1.5 Cytoskeleton / cytoplasmic cascades
Recycling, trafficking and exocytosis require cytoskeletal regulation. A substantial 
number of landscape proteins control cytoskeleton dynamics, e.g., by regulating RAC1 
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activity. RAC1 is activated by FRAT245, TNK246, FYN47, DLK148, RET49, 50, LPAR151, and 
KIFAP352, and inhibited by CDK553 and CRMP154. Further, RAC1 binds to RBM3955 and 
RAP1GDS156. The latter also binds to KIFAP357 and regulates the GDP/GTP exchange of 
GTP-binding proteins such as RAC158.
RAC1 has multiple functions. First, it increases the expression of CDH259 and activates 
MAPK860, a serine/threonine-protein kinase that is involved in cell proliferation, 
differentiation, migration, transformation and programmed cell death (see also the 
section ‘Mitochondrial function and apoptosis’ in the description of figure 1b for the role 
of MAPK8 in apoptosis)11. MAPK8 binds to MAP3K761, CASP362, mTORC163 and KLC164. 
Apart from RAC1 activation, MAPK8 is also activated by MAGED165, GNAI266, MAP2K467, 
RET49, LPAR168 and DA69, and inhibited by AKT170. MAGED1 also binds to MAP3K771 and 
ATXN1072, and activates CASP365. MAPK8 also activates CASP373, 74 and mTORC163, and 
inhibits AKT175, 76. MAP2K4 is an essential part of the MAP kinases signaling pathway 
and is bound to the phosphatase DUSP1977, AKT170 and MAP3K778, whereas AKT1 
inhibits70 and MAP3K7 activates MAP2K479. Multiple proteins in the landscape regulate 
AKT1. AKT1 binds to NSF and MAP2K4, as mentioned above, as well as to YWHAZ80 and 
MARK281, is activated by SLC6A3 (see above), YWHAZ82, GNAI283, LPAR168, TNK284 and 
CDH285, and inhibited by MAPK8 (see above), RGS486 and DLK187. Second, RAC1 increases 
the polymerization of globular actin (ACTG1)88 to filament actin (F-actin)11. ACTG1 binds 
to CTBP289, MAP3K790 and NDRG191 (see Figure 1b and its description for more ACTG1 
interactions). Moreover, CDH292, GNAI293 (not shown), VSNL194 and the NMDAR95 bind to 
actin, and CDK5 increases actin polymerization53.
1.6	 Microtubule-dependent	trafficking
In addition to RAC1, FYN is a non-receptor tyrosine-protein kinase that is involved in 
cell growth and survival, cell adhesion, cytoskeletal remodeling and axon guidance11. 
FYN is activated by L1CAM96 and is itself an activator of RAC1 (see above), TNK297 and 
CASP398. FYN is cleaved by CASP399, 100and binds to TNK297, GABRG2101 and MAPT102. Like 
FYN, TNK2 is a non-receptor tyrosine-protein kinase and is involved in cell survival, 
proliferation and endocytosis11, whereas GABRG2 is a subunit of the GABA receptor 
and regulates neuronal inhibition11. Moreover, FYN phosphorylates MAPT103, 104, which 
is a susceptibility gene for idiopathic PD105-109 that promotes assembly and stability of 
microtubules11. Microtubule-dependent trafficking is affected in PD and, among others, 
affects axonal transport of autophagosomes that contain damaged mitochondria and 
aggregated proteins, which can lead to SNCA accumulation and synaptic dysfunction110, 
111. In the landscape, MAPT binds to MARK2112, YWHAZ10, KLC1113, CDK5114, STXBP116 
and PPP2R2A115. In addition, MAPT is phosphorylated by CDK5116 and FYN104, whereas 
PPP2R2A dephosphorylates MAPT117. Furthermore, MARK2 phosphorylates both MAPT 
and MAP4 which causes microtubule detachment and disassembly11. CHP1 binds to 



















apparatus with microtubules (not shown)11. Other proteins in the landscape that bind 
microtubules are MAPRE2 (not shown)118, NDRG1 (not shown)119, KLC1 (not shown)11 and 
MAP4 (not shown)120. KLC1 is a kinesin that regulates microtubule-associated transport 
of organelles11 and MAP4 promotes the assembly of microtubules121. In addition, MAPK8 
is known to increase microtubular assembly122, 123.
1.7 Cell adhesion
The proteins L1CAM, FYN, CDH2, CDH8 and RET regulate cell adhesion11. L1CAM 
regulates neuron-neuron adhesion and is found in axon terminals11 and FYN regulates 
synapse formation124. The cadherins CDH2 and CDH8 are calcium-dependent adhesion 
molecules11. CDH2 binds KIFAP3125, NMDAR95 and actin92. Cleavage of RET by caspases 
results in a fragment that functions as a cadherin accessory protein that potentiates 
cadherin-mediated cell aggregation126.
1.8 Autophagy
As indicated above, microtubule-dependent trafficking is necessary for the transport 
of autophagosomes and degradation of their cargo. Autophagy dysregulation is also 
directly implicated in PD via the familial PD proteins127. In the landscape, MAPK8, CDK5 
and AKT1S1 (mTORC1) regulate autophagy, e.g., MAPK8 phosphorylates BCL2, which 
induces dissociation of BCL2 from Beclin-1 and autophagy activation (not shown)128. 
In addition, mTORC1 binds to63, and is activated by, MAPK863, and has been shown 
to inhibit autophagy129, 130. Furthermore, mTORC1 binds to PPP2R2A131, YWHAZ12 and 
RPL5132, whereas YWHAZ and RPL5 also bind to each other12. Lastly, the kinase CDK5 
has been shown to be required for autophagy in multiple PD models133-135. 
1.9 Calcium
Calcium channels regulate neuron excitability and release of neurotransmitters such 
as DA. In PD, nigral DA neurons show a dysregulation of calcium136. In the landscape, 
calcium is transported into the cell by the NMDAR137 and the VDCC138, and transported 
out of the cell by SLC8A1139, 140. The NMDAR binds to CDH295 and the VDCC binds to 
SLC8A139, 141, TSPAN7142, MAP439, MARK239, SLC4A339, CRMP1142, PFKM39, RAB1439 and, as 
already mentioned above, SNAP2538, 39. These proteins have a wide range of functions. 
SLC8A1 rapidly transports Ca2+ out of the cell to prevent overloading of intracellular 
stores139. TSPAN7 is a surface glycoprotein that may have a role in neurite outgrowth143. 
MAP4 and MARK2 regulate microtubular dynamics (see above). SLC4A3 is an anion 
exchanger that exchanges HCO3- for Cl- and thereby regulates the intracellular pH11. 
Another protein in the PD landscape that regulates neuronal pH by transporting HCO3- 
into the cell is SLC4A811. CRMP1 regulates remodeling of the cytoskeleton11. PFKM binds 
to YWHAZ18 and catalyzes the conversion of D-fructose 1,6-phosphate to D-fructose 
1,6-biphosphate11. Binding of D-fructose 1,6-bisphosphate to soluble Fe2+ prevents its 
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conversion to the insoluble Fe3+, an oxidation step that produces oxygen radicals. The 
availability of D-fructose 1,6-biphosphate may therefore affect iron content and oxygen 
radical levels144 in the SN of PD patients. Lastly, RAB14 and SNAP25 are involved in 
intracellular trafficking (see above). Furthermore, VDCC function and thus calcium 
influx is inhibited by CDK5145, 146. LPAR1 increases calcium mobilization in the cytosol147, 
whereas RGS4 and RGS7 both decrease mobilization of calcium148, 149. In addition, RAB4A 
and RAB11A (not shown) increase the intracellular calcium concentration150. Calcium in 
turn activates MAPK8151, FYN96 and VSNL1152, 153, and inhibits NSF154. Moreover, calcium 
increases the expression of NDRG1155 and binds to VSNL1156, CHP1 (not shown)157, CDH211 
and CDH811.
1.10 Familial PD proteins
The familial PD proteins have many interactions with components within the 
landscape. SNCA, the primary component of Lewy bodies in PD DA neurons, binds to 
SLC6A329, TH158, YWHAZ159, MARK2159, MAPK8160, KLC1161, MAP4159, ATP6V0D1159, FYN162, 163, 
STXBP1159, SNAP25164 and VAMP2165. Further, SNCA activates SLC6A329, decreases TH 
expression (not shown)166, inhibits TH158, 167 and MAPK8168, and is inhibited itself by FYN162. 
Interestingly, SNARE (SNAP25 and VAMP2) dysfunction results in mislocalization 
and accumulation of SNCA and could be an important pathomechanism of PD169, 
which emphasizes the importance of the normal functioning of the SNARE complex. 
Furthermore, binding of PARK7 to VAMP2170 and of LRRK2 to NSF171 shows that other 
familial PD proteins also have a direct impact on SNARE complex function. LRRK2 also 
binds to MAP2K4172, GNAI2173 and YWHAZ174, and activates AKT1175. PARK2, UCHL1, EIF4G1 
and PINK1 are four other familial PD proteins that have interactions with proteins in 
the landscape, i.e., PARK2 binds to and is phosphorylated by CDK5176, binds to SLC6A328 
and ACTG1177, inhibits MAPK8178, and increases expression of SLC6A330. UCHL1 binds to 
AKT119, SNCA179, RANBP9180, mTORC1181 and EIF1B72, while EIF4G1 binds to YWHAZ182 and 
MARK2 binds to183, and activates, PINK1183.
2. DETAILED DESCRIPTION FIGURE 1B 
Figure 1B shows a molecular landscape of interacting proteins, encoded by the mRNAs 
that are differentially expressed in the SN of both human PD patients and MPTP-treated 
mice, located primarily in the cell body and axon of the DA neuron. The biological 
processes depicted in the figure are described below:
2.1 Transcriptional and translational regulation
2.1.1  Histone regulation
HDAC1 deacetylates core histones and thereby represses gene transcription11. HDAC1 



















in the landscape of SN mechanisms overlapping between PD and MPTP-treated mice. 
HDAC1 expression is increased by SASH1185 and HDAC1 binds to CDK511, DHX36186, 
CCDC6187, PARK7188, MAPK8189, PAPOLA190, the transcriptional regulators SIRT1191, GTF2I192, 
DDX5193 and NFKBIA194, and the transcription factors SOX2195, NR4A2196, SATB1197 and 
NFKB198. HDAC1 itself activates AKT1199, decreases the expression of BAX200 and binds 
to the promoters of the genes encoding  SLC8A1201 and TH196. The HDAC1-associated 
transcriptional regulators SIRT1, GTF2I, DDX5 and NFKBIA have multiple other 
landscape interactors. Variants in the SIRT1 gene promoter contribute to PD risk202, and 
SIRT1 deacetylates HDAC1 and thereby increases its enzymatic activity (not shown)191. 
Further, SIRT1 binds to USP22203, 204, a histone deubiquitination protein that inhibits SIRT1 
degradation204 and, by removing ubiquitin from H2A and H2B, functions as a coactivator 
of histones11. Furthermore, SIRT1 binds to SATB1205, PAPOLA190, GTF2I206, MAPK8207 and 
the PD-associated208 FOXO1209. SIRT1 inhibits FOXO1 (not shown)210, whereas FOXO1 
increases SIRT1 expression211. Further, MAPK8 increases the degradation of SIRT1212. 
The familial protein PARK7 binds in the cytoplasm to GTF2I and thereby prevents 
its translocation to the nucleus in which GTF2I213 is together with HDAC1 part of the 
deacetylation complex11. In addition to binding to HDAC1, DDX5 binds to NDRG191, 
AKT1214 and YWHAZ182. Expression of NFKB is increased in the PD brain215. NFKBIA 
binds to NFKB and thereby prevents its activation and translocation to the nucleus216. 
NFKBIA degradation is increased by RET217, FYN218 and MAPK8219, and inhibited by 
BCL2220. Increased degradation or inhibition of NFKBIA increases NFKB activation and 
translocation to the nucleus216. NFKBIA binds to ACTG190 and PSMA1221, and activates 
MAPK8222. Further, NFKBIA increases the expression of the transcriptional repressor 
MXD4223 and RGS4, a regulator of G proteins224. Furthermore, NFKBIA decreases the 
expression of the familial PD protein PARK7223 and of adaptor protein YWHAZ225. 
Regulation of the expression by NFKBIA is probably an indirect effect of its inhibitory 
function on the NFKB complex. Like NFKBIA, NFKB binds also to ACTG190, PSMB590, 
PAPOLA90 and DDX190. HDAC1 deacetylates the NFKB subunit RELA and in this way 
inhibits the transcriptional activity of NFKB11.
In addition to binding to NFKBIA and NFKB (see above), ACTG1 also binds to LRRK2173, 
PARK2177, SNCA159 and YWHAZ182. The adaptor protein YWHAZ binds (in addition to the 
proteins mentioned above) to the 60S ribosomal protein RPL10A12, the ATP-dependent 
RNA helicases DDX112 and DDX5182, GIGYF212, AKT180 and FOXO1226. GIGYF2, AKT1 and 
FOXO1 are all associated with PD208, 227, 228 and dysreglation of YWHAZ may interfere with 
their function. On its turn, DDX1 binds to NDRG191 and SNCA229 and acts as a coactivator 
to enhance NFKB-mediated transcriptional activation11.
2.1.2 DA neuron signature
NR4A2 and SOX2 are important transcription factors for establishing and maintaining 
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a DA-neuron-like expression pattern,230 as is also apparent from their requirement for 
reprogramming fibroblasts towards a dopaminergic phenotype231. NR4A2 increases 
the expression of TH232, SLC6A3232, PITX3232, RET233 and SLC18A2232, and decreases the 
expression of SNCA234. In addition to binding to HDAC1, NR4A2 binds to GTF2I235 and 
NFKB236. SATB1 decreases expression of NR4A2237 and increases the expression of 
ACTG1237. The HDAC1-binding SOX2 (see above)195 also binds to YWHAZ238, RANBP9238, 
CTBP2195 and NFIB195, and its expression is increased by AKT1239 and FOXO1240. 
2.1.3 Other transcriptional regulators
PTEN is a phosphatase that dephosphorylates PIP3 to PIP2 and hence inhibits AKT1 
signaling11, 241. RET activates AKT1242 that subsequently translocates to the nucleus11 
and increases the expression of NDRG1243 and SOX2 (see above)239. Furthermore, PTEN 
binds to and activates the familial PD protein PINK1244 and affects the expression of 
multiple proteins in the landscape by increasing the expression of PAPOLA245, GTF2I245, 
MXD4245 and NDRG1246, and decreasing the expression of NR4A2247, MAPK8248 and TH247. 
The expression of PTEN itself is decreased by the 60S ribosomal protein RPL5249 and the 
transcriptional repressor CTBP2250.
2.1.4 Alternative pre-mRNA splicing
The polymerase PAPOLA creates the 3’-poly(A) tail of mRNAs11, is required for 
endoribonucleolytic cleavage at poly(A) sites11 and binds to HDAC1 (see above). YTHDF2 
has also a role in mRNA stability and splicing, by binding to N6-methyladenosine11. 
Of note, multiple other proteins involved in mRNA splicing are dysregulated in both 
human PD and the MPTP mouse model. MAGOH1 and CASC3 are core components of 
the exon junction complex that is deposited at splice junctions on mRNAs, regulating 
mRNA splicing, nuclear export, cellular localization and translation efficiency11. 
MAGOH1 binds to CASC3251, ZC3H11A251, SRSF7251, RBM39251, and SRPK2 (not shown)252. 
RBM39 also binds to SRSF7253 as well as YWHAZ182 and SRPK2254. SRPK2 is required 
for spliceosome complex formation255 and, together with MAGOH1 and RBM39, binds 
to SRSF7252 and MAPT256, and increases the phosphorylation of RBM39 (not shown)252, 
SRSF7 (not shown)252 and MAPT (not shown)256. Phosphorylation of SRPK2 at Thr-492 
by AKT1 promotes its nuclear translocation and enhances its activity11. Like CASC3, 
MAGOH1 and SRPK2, RBM39 and SRSF7 are involved in pre-mRNA splicing257, 258. For 
instance, SRSF7 is involved in mRNA export out of the nucleus259 and is known to 
prevent splicing of exon 10 of MAPT (not shown)260. CLK4 phosphorylates proteins of 
the spliceosome complex11 and regulates the alternative splicing of MAPT261. MAPT 
itself increases the expression of MAPK8262.
Other proteins that also affect alternative splicing and are involved in nucleosome/ 
histone regulation are HNRNPH3, CRMP1, H2AFJ and ANP32B. HNRNPH3 associates 



















histone variant and core component of the nucleosome11 and ANP32B stimulates core 
histones to assemble into a nucleosome11. Nucleosomes define the exon-intron border 
and since pre-mRNA splicing occurs co-transcriptionally, nucleosome organization, 
transcription elongation rate or epigenetic marks can affect pre-mRNA splicing265, 
266. Moreover, histone deacetylation by HDAC1 affects pre-mRNA splicing, resulting in 
local repression of transcription265, 267, 268. HDAC1 is up-regulated in the SN of human PD 
patients and interacts with multiple proteins in the landscape (see also above).
Taken together, the central position of HDAC1 and the occurrence of multiple proteins 
involved in histone regulation and pre-mRNA splicing in the SN landscape suggest that 
dysregulation of nucleosome organization and the splicing machinery are important 
factors in the biological processes that overlap between PD and the MPTP mouse model.
2.2	 (Vesicle)	trafficking	and	exocytosis
In Figure 1A, the involvement of the SNARE complex in (DA) exocytosis is shown, 
however, the SNARE complex also regulates intracellular transport, as is apparent 
from the binding of SNAP25 to both NAPB269 and KLC1270. NAPB is required for vesicular 
transport between the ER and the Golgi apparatus11, and KLC1 is a microtubule-
associated protein that regulates the transport of organelles such as mitochondria. 
Like the SNARE complex, the familial PD protein SNCA may be involved in DA release 
and transport11, but also in ER-to-Golgi vesicle trafficking271, 272. SNCA modulates vesicle 
trafficking by binding to RABAC1 (not shown)273, a protein that regulates the interaction 
between Rab GTPases and the SNARE complex274. Overexpression of SNCA disrupts 
vesicle trafficking and increases accumulation of vesicles in the cytoplasm273. Four Rab 
GTPases (RAB4A, RAB6A, RAB11A and RAB14) are overlapping between PD and the MPTP 
mouse. These proteins are involved in vesicular trafficking between compartments of 
the cell. RAB4A regulates localization of VAMP2 to early endosomes and vesicles275 and 
the membrane-bound form of RAB4A binds to NDRG1276, a protein that is required for 
vesicular recycling11. NDRG1 binds to actin filaments by binding to ACTG191 as well as 
to ACOT7277 and PPP2R2A91, and activates CASP3278. The RAB proteins RAB6A, RAB11A 
and RAB14 are located in the Golgi complex and regulate protein trafficking to other 
organelles and the plasma membrane of the cell. Dysfunctioning of these proteins 
results in defective protein trafficking and membrane fusion, which can result in protein 
aggregation. RAB6A is located at the Golgi279 and regulates vesicular transport from early 
and recycling endosomes to the Golgi (not shown)280 but also transport from the Golgi 
to the ER281. Furthermore, RAB6A affects release of the SNARE (SNAP25 and VAMP2) 
complex, which itself is involved in membrane fusion (see also Figure 1a) by binding 
and activating NSF282. RAB11A is located in recycling endosomes, the Golgi complex 
and on the cytoplasmic side of cytoplasmic vesicles, and regulates transport from the 
Golgi to the endosome283 and from the Golgi to the plasma membrane283. RAB11A binds 
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to the neuronal cell adhesion protein L1CAM284 and therefore is probably involved in 
its trafficking. The RAB protein RAB14 regulates vesicular transport between the Golgi 
and early endosomes, and is involved in CDH2 shedding (not shown)285 and as such 
affects cell-cell adhesion (not shown)285. Lastly, also the ER-shaping protein RTN2286 is 
involved in vesicular ER to Golgi transport287.
Dysregulated (vesicle) trafficking affects exocytosis, receptor trafficking, (membrane) 
recycling and ultimately decreases the viability of the neuron.
2.3 Proteasomal degradation
The proteasome is involved in removal of unwanted, damaged or aggregated proteins288, 
289. PSMA1 and PSMB5 are both part of the 26S proteosomal complex290, bind to each 
other291 and both bind to PARK2292, 293. Moreover, PSMA1 binds to PTEN294 and NFKBIA221, 
whereas PSMB5 binds to the NFKB complex291. Dysregulation of the 26S proteasome 
can heavily affect the PD protein landscape, for it degrades RGS7295, NR4A2296, GRIN1 
(NMDAR)297, NFKBIA298, SNCA299, NFKB300, 301, SIRT1302, HDAC1303, MAPT304, MAP3K7305, 
PTEN306, 307 and SOX2308. Reduced activation of the proteosomal complex could therefore 
increase protein (e.g., SNCA) aggregation, which would affect neuronal functioning.
2.4 Mitochondrial function and apoptosis
Mitochondrial dysfunction is associated with both familial and sporadic PD309. BCL2, 
located in the nuclear membrane and in the mitochondrial outer membrane, is an 
important anti-apoptotic factor that binds to, inhibits and decreases the expression 
of the proapoptotic protein BAX310-313. BAX inhibition is mediated via the inhibition of 
MAPK8 that inhibits the binding of YWHAZ and BAX, and in this way increases the 
translocation of BAX to the mitochondrial membrane314. BCL2 is bound and regulated by 
multiple proteins in the landscape, i.e., SATB1 decreases and NFKBIA increases BCL2 
expression315, 316. MAPK8 also increases BCL2 expression317, but inhibits BCL2 function318, 
319. BCL2 in turn inhibits MAPK8319, decreases expression of NFKBIA320, NDRG1321 and 
PTEN322, increases expression of SNAP25321, and decreases cleavage of SRPK2323. 
BCL2 binds MAPK8324, CASP3325 and PARK2326, and inhibits apoptotic pathways in 
that it, in addition to inhibiting BAX, also inhibits CASP3327 and HTRA2328 and HTRA2 
translocation out of mitochondria329. In the cytoplasm, HTRA2 binds EIF4G1330, PARK2 
(not shown)331, PINK1 (not shown)332 and CDK5332. CDK5 in turn inhibits PARK2176 and 
increases TH expression7. SNCA binds to PARK2333 and, in contrast to CDK5, decreases 
TH expression166, 334.
Other proteins in the landscape that affect mitochondrial function are MRPL15, 
ATP5C1 and RET. The 39S ribosomal protein MRPL15 is located in mitochondria and 
involved in mitochondrial-specific protein expression. Moreover, MRPL15 binds to the 
transcription factor SOX2 (not shown)238 and as such may affect DA-neuron-specific 



















translational regulation’). The ATPase ATP5C1 is part of complex V of the respiratory 
chain that uses the proton gradient across the mitochondrial membrane to produce 
ATP from ADP11. SNCA may also affect the respiratory chain directly by binding to 
ATP5C1159. Lastly, the tyrosine kinase RET increases the expression of TH and SLC6A3 
(Figure 1a), and ameliorates complex I dysfunction in a PD model335.
3. DETAILED DESCRIPTION FIGURE 2
Figure 2 shows a molecular landscape of interacting proteins, encoded by the mRNAs 
that are differentially expressed in the striatum of both human PD patients and MPTP-
treated mice located in the post-synapse of a striatal neuron. The biological processes 
depicted in the figure are described below:
As a result of the dysregulation of the biological processes constituting the molecular 
landscape of the processes shared in the SN (summarized in Figure 1A and B), the 
release of DA to the striatum is decreased. Due to the lower DA release into the synaptic 
cleft, affecting protein expression in the striatal post-synapse, the activation of the DA 
receptors DRD2 and DRD3 is diminished; these receptors are associated with PD336, 337. 
When activated, DRD2 (long variant) and DRD3 increase intracellular calcium338, but they 
also inhibit the function of the NMDA receptor (NMDAR)339 and the VDCC340, 341. The VDCC 
binds to ITSN139, a protein involved in actin reorganization and assembly342, 343. DCLK1 
and ENC1 are also involved in actin regulation, i.e. DCLK1 regulates the distribution of 
actin344 and ENC1 is an actin-binding protein345 that also binds to SNCA161.
DRD2 also binds to calmodulin (CaM)346, 347 and thereby exerts influence on calcium 
signaling in the striatal neuron. Namely, CaM binds to the VDCC142, the NMDAR (not 
shown)348, SNCA349, LRRK2173, TGM2350, KCNQ5351, DIRAS2352 and DCLK1352, and can thereby 
affect multiple proteins in the landscape. Furthermore, CaM regulates KCNQ5353 and 
inhibits calcium flux through the NMDAR into the cell354, 355. In addition, calcium-bound 
CaM activates CREB1356, 357 and CAMK1G358, and regulates TGM2 function (not shown)350. 
CAMK1G also activates CREB1358, and TGM2 activates ERK1/2359 and CREB1360, but also 
binds to CASP3361, decreases the expression of KCNQ5362 and increases the expression 
of LRRK2362. TGM2 is also activated by calcium363, increases the efflux of calcium out 
of the cell364, binds to SNCA365 and increases its aggregation (not shown)365, 366. Calcium 
and CaM therefore affect the activity of ERK1/2 and CREB1 either directly or via the 
activation of TGM2 or CAMK1G. 
Activation of DRD2 by DA also results in the activation of ERK1/2367 and CREB1368. 
ERK1/2 binds to CHGB369 and the familial proteins SNCA370 and PARK7371. Furthermore, 
in addition to DRD2 and TGM2 (see above), S100A10372 and ITSN1373 activate ERK1/2, 
whereas the nuclear membrane protein TMEM176B inhibits ERK1/2 activation374. Of 
note, all these processes converge on CREB1. ERK1/2 activates CREB1375, 376, and CREB1 is 
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activated by CaM, CAMK1G, TGM2 and DRD2 (see above), but also by the NMDAR356, 377 and 
the (L-type) VDCC (not shown)356 due to their ability to increase calcium influx, which 
is necessary for CREB1 activation378, 379. Thus, CREB1 is regulated by the majority of the 
proteins in the striatal landscape, either directly or via ERK1/2 activation. Moreover, DA 
activates both ERK1/2367 and CREB1 (via the DA receptors)368, 380, suggesting that ERK1/2 
and CREB1 activation (via phosphorylation) is reduced in PD or after MPTP treatment 
due to the absence of DA. 
These pathways also play a role in the effect of L-DOPA, the mainstay of treatment in 
PD. L-DOPA administration activates ERK1/2 in the striatum381. DA-induced, CREB1-
dependent transcription in the intact striatum in a PD model382 is further potentiated 
by NMDAR activation377. The secretory granule protein CHGB is one of the proteins of 
which the expression is regulated by CREB1, i.e. CREB1 binds to the CRE element of 
the CHGB gene promoter383. Furthermore, calcium decreases the expression of CHGB384 
and CHGB binds to PARK2263. In addition to ERK1/2 and CREB1, L-DOPA also activates 
DRD2385, DRD3385 and NMDAR385, 386, and increases the expression of DRD3386, CASP3387 
and S100A10388. In a PD rat model, S100A10 is involved in L-DOPA-induced abnormal 
involuntary movements389. The activation of striatal ERK1/2 by L-DOPA also appears 
involved in L-DOPA-induced dyskinesias389, but not the L-DOPA induced CREB1 
activation381, 390, 391. These processes could therefore not only give insights into the PD-
related disease mechanisms in the striatum, but also in the beneficial, and adverse, 
effects of pharmacological treatment.
CREB1 and ERK1/2 are also known for their role in epilepsy. Brain areas prone to 
epileptic seizures show an increased activation of CREB1 and ERK1/2382, and an up 
regulation of CHGB392, CREB1392, ENC1356 and NPTX2392. NPTX2 is thought to play a role 
in long-term plasticity392 and increases apoptosis11. Further, KCNQ5393, the NMDAR394 
and the VDCC395 are associated with epileptic seizures. Therefore, the landscape cannot 
only give insight in treatment outcome, but can also explain the associations seen in 
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4.1 ABSTRACT 
Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic (DA) 
neurons in the substantia nigra (SN) pars compacta, resulting in motor and non-motor 
dysfunction. Physical exercise improves these symptoms in PD patients. To explore 
the molecular mechanisms underlying the beneficial effects of physical exercise, we 
exposed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP)-treated mice to a four-
week physical exercise regimen, and subsequently explored their motor performance 
and the transcriptome of multiple PD-linked brain areas. MPTP reduced the number 
of DA neurons in the SN, whereas physical exercise improved beam walking, rotarod 
performance and motor behavior in the open field. Further, enrichment analyses of 
the RNA-sequencing data revealed that in the MPTP-treated mice physical exercise 
predominantly modulated signaling cascades that are regulated by the upstream 
regulators L-DOPA, RICTOR, CREB1, or bicuculline/dalfampridine, and involved in 
movement disorders, mitochondrial dysfunction and epilepsy. To elucidate the 
molecular pathways underlying these cascades in the various brain areas studied, 
we integrated the proteins encoded by the exercise-induced differentially expressed 
mRNAs for each of the top upstream regulators into a molecular landscape. Most notable 
was the opposite effect of physical exercise compared to previously reported effects of 
L-DOPA on the expression of mRNAs in the SN and the ventromedial striatum that are 
involved in – among other processes – circadian rhythm and signaling involving DA, 
neuropeptides and endocannabinoids. Altogether, our findings suggest that physical 
exercise can indeed improve motor function in PD, may counteract L-DOPA-mediated 
molecular mechanisms and ameliorate non-motor symptoms of PD, some of which 
may be the result of (chronic) L-DOPA use.
KEYWORDS:  Parkinson’s disease, physical exercise, MPTP, L-DOPA, motor function, non-motor 
function, molecular landscape
4.2 INTRODUCTION
Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic (DA) 
neurons in the substantia nigra pars compacta (SNpc). The clinical phenotype 
encompasses motor symptoms – including bradykinesia, rigidity, tremor, gait 
dysfunction and postural instability – and non-motor symptoms such as sleeping 
disturbances, pain, or cognitive deficits that affect executive functions, attention, 
mood and working memory1-3. Levodopa (L-DOPA), a precursor of DA, has been used 
since the 1960s to treat PD motor symptoms and is still considered the gold standard of 
therapy4, 5. In recent years, physical exercise – including intervention strategies such 
as aerobic exercise (e.g. treadmill exercise, cycling or dancing) or strength training 
(e.g. using a modified fitness counts program or progressive resistance exercising) 




bradykinesia11, 12, rigidity13 and tremor11. Physical exercise has also been reported to 
improve less dopamine-dependent symptoms involving postural control such as 
turning performance6 and instability14, as well as cognitive function2, 15, 16 in PD patients. 
Although these beneficial clinical effects of exercise on PD symptoms are evident, the 
underlying molecular mechanisms are not well understood. A better understanding of 
these processes may ultimately lead to a more efficient treatment of these symptoms, 
through directly targeting the underlying pathways.
Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in 
mice results in the loss of nigrostriatal DA neurons, and is widely used to study the 
pathophysiological mechanisms underlying DA neuron degeneration in PD17. Moreover, 
similar to human PD, physical exercise improves motor behavior and reduces cognitive 
impairment in MPTP-treated mice18-21. In this study, we aimed to elucidate the molecular 




Six month old male C57BL/6J mice were housed, five-to-a-cage, with ad libitum access 
to food and water and at a constant 12/12h light/dark cycle (lights on between 07:00 and 
19:00h). Room temperature was controlled at 21°C and rooms were homogenously lighted 
by 60 LUX with controlled humidity. Following arrival, the mice were acclimatized 
to their new housing for one week, after which they were randomly assigned to one 
of four treatment groups: (1) saline-treated; (2) saline-treated with physical exercise; 
(3) MPTP-treated; and (4) MPTP-treated with physical exercise. MPTP-HCl (Sigma-
Aldrich) dissolved in saline was administered via four intraperitoneal injections 
at 2h intervals, amounting to a total administered dose of 70mg/kg (free-base). The 
control mice underwent the same protocol using saline injections. Mice were allowed 
to recover from the injections for two weeks. All animal experiments were approved 
by the Animal Care Committee of the Radboud University Nijmegen Medical Center, 
The Netherlands, and performed according to the guidelines of the Dutch Council for 
Animal Care and the European Communities Council Directive 2010/63/EU.
4.3.2 Physical exercise
Physical exercise was initiated three weeks following MPTP or saline treatment and 
was performed daily. Mice ran 30 minutes twice a day during a training period of 28 
consecutive days in individual, horizontal lanes on a 5-lane treadmill (Panlab Harvard 
Apparatus) at a speed of 20cm/s. Automated short air puffs were used to stimulate the 
mice to keep running when drifting too far to the back of the lane. Mice assigned to the 
groups without physical exercise were placed in the same experimental room, adjacent 
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to the treadmill, in their housing cage.
4.3.3 Behavioral testing
Behavioral testing commenced one week before the physical exercise regimen started 
(week 0), and was repeated each week during the exercise regimen (weeks 1-4): beam 
walk on the first, rotarod on the third and open field on the fifth day of each week, in 
each case performed between 08:00 and 13:00h. Prior to all behavioral tests, the animals 
of all four treatment groups were habituated to the experimental room for one hour. 
Mice from different treatment groups were tested concurrently on the rotarod and in 
the open field.
Open field
The mice were placed in a white plexiglass box (50x50x40cm) and video recorded from 
above for 30 minutes using Ethovision XT 7.0 software (Noldus Information Technology 
B.V., Wageningen, The Netherlands). Afterwards, the parameters ‘total walking distance’, 
‘total movement time’, ‘mean velocity’ and ‘mean angular velocity’ were calculated by 
the software.
Rotarod
Mice were placed on the rotarod apparatus (IITC Inc.) with a rod diameter of 32 mm 
and an increasing speed of 4 to 38 rpm in 300s. Five mice were tested simultaneously 
on the rotarod and their latency to fall was measured. On each testing day, each mouse 
performed one pre-trial and three trials, each with a maximum duration of 300s and 
with a minimum of one hour of rest between the trials. The pre-trial enabled the mice 
to habituate (again) to the rotarod and was not included in the results. For each testing 
day, the latency times of the three trials were averaged per mouse.
Beam walk
The mice were placed on a white plasticized iron rod (full length 80cm, diameter 10mm) 
suspended at 40cm height and were trained to cross the beam to their home cage. 
Training of the mice occurred on the first day. During the training the distance to cross 
was increased each time they successfully reached their cage, until they were able to 
reach their home cage over the full length of the beam. For testing, the time it took for 
the mouse to cross the full beam to reach their home cage was measured each week in 
three trials, with at least one hour of rest between the trials. For each testing day, the 
times of the three trials were averaged per mouse.
4.3.4 Immunohistochemistry
Twenty-four hours following their last exercise training, mice were sacrificed by 
cervical dislocation and brains were dissected and fixated in 4% paraformaldehyde 




sucrose for twenty-four hours. After cryosectioning, DAB staining was performed on 
20µm thick coronal slices, placed on gelatinized glass slides. For this, the sections 
were washed with PBS (3x10min), non-specific sites blocked with blocking buffer 
(2.5% normal donkey serum, 2.5% normal goat serum, 1% BSA, 1% glycine, 0.1% lysine 
and 0.4% Triton X-100 in PBS) for 30 minutes and incubated with rabbit anti-tyrosine 
hydroxylase (TH, 1:1000; Pel-Freez Biologicals #P40101-0; Lot.No.: 19335) for 16 hours 
at 4°C. This was followed by one hour incubations with biotinylated goat-anti-rabbit 
(1:200; Jackson Immuno Research; 711-065-152; Lot.No.:117858) and avidin-biotin-
peroxidase complex (A and B 1:800; Vectastain Elite ABC kit, PK-6100 Standard), with 
PBS washing steps in between. To visualize antibody binding, the sections with SNpc 
and ventral tegmental area (VTA) areas were incubated for 30 minutes, and those with 
dorsolateral striatum (DL) and ventromedial striatum (VM) areas were incubated for 
20 minutes, in a DAB/H2O2-solution potentiated by ammonium-nickel-sulphate. The 
sections were subsequently dehydrated and cover-slipped. For each mouse, every sixth 
section throughout the different brain areas was included in the counting procedure 
and for optimal comparison between groups, sections of different treatment groups 
were stained concurrently.
Images were captured by a Leica DM6000B microscope. TH-positive (TH+) cells were 
counted in the sections of the SNpc (-2.54 to -3.88mm to Bregma22) and VTA (-2.92 to 
-3.88mm to Bregma22), using a 20x magnification. The number of TH+ cells in each 
section (both the left and right side) were counted by a blinded assessor, and averaged 
over the total number of sections per animal. DA fiber density was estimated in the 
DL (1.18 to -0.10mm to Bregma22) and VM (1.54 to 0.62mm to Bregma22) by quantifying 
the optic density (OD) with FIJI23, using a 5x magnification. In both areas, the OD per 
section was determined by averaging the OD of ten separate areas within the striatal 
matrix (i.e. in-between the striosomes). Subsequently, the OD in the DL and VM was 
normalized by subtracting the OD of respectively the corpus callosum (CC) and anterior 
commissure (AC) in the same section, and all sections were averaged per animal.
4.3.5 RNA isolation and sample preparation
Twenty-four hours following the last physical exercise training, brains of 8-10 mice 
per group – that were sacrificed by cervical dislocation – were dissected, immediately 
frozen on dry ice and stored at −80°C until further preparation. Specific brain areas, 
i.e. prefrontal cortex (PFC), DL, VM, VTA, SN, pedunculopontine nucleus (PPN), were 
then cryo-punched based on the stereotaxic atlas of the mouse brain22 from 200µm 
thick coronal slices, using punch needles with a diameter of 0.5 and 0.75mm (see 
Supplementary Figure 1 for the estimated punching locations per area). All specimens 
were kept at -20°C during processing. For RNA isolation, punched samples were 
homogenized with a TissueLyser (Retsch GmbH) in 800µL TRIzol reagent and RNA 
isolation was performed according to the manufacturer’s instructions (Invitrogen). Total 
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RNA concentration was determined with a NanodropTM ND-1000 spectrophotometer 
(Thermo Fisher Scientific Inc.) and RNA quality was visually assessed by 1% agarose gel 
electrophoresis. Genomic DNA was removed by treatment with DNase I in the presence 
of RNAsin (Thermo Fisher) in 5x FSB buffer and RNAse-free water. Subsequently, total 
RNA samples were stored at -80°C until further use. For each treatment group and brain 
area, RNA samples of six mice were pooled for RNAseq analysis.
4.3.6 RNA sequencing and data processing
All RNA samples were subjected to RNA sequencing (RNAseq; HudsonAlpha Genomic 
Services Lab, Huntsville, AL). In short, total RNA concentration was estimated by 
Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA, USA) and RNA integrity by using the 
Agilent 2100 Bioanalyzer (Applied Biosystems, Carlsbad, CA, USA). RNAseq libraries 
were formed from approximately 500ng total RNA of each pooled sample, followed by 
poly(A)-enrichment. RNAseq was performed using paired end sequencing on Illumina 
HiSeqH2000 (Illumina, San Diego, CA, USA), at 50 base pairs, generating over 25 million 
paired reads per sample. Raw RNAseq FASTQ files were demultiplexed by bcl2fastq 
conversion software v1.8.3 (Illumina, Inc., San Diego, CA, USA) using default settings.
RNAseq  data was analyzed using GeneSifter software (VizX Labs, Seattle, WA). RNAseq 
reads were mapped to the Mus musculus reference genome build 37.2 and for this, 
the reads were trimmed by 15 base pairs at the 5-prime end. Subsequently, transcript 
abundance was calculated by estimating the reads per kilobase of exon per million 
mapped reads (RPKM) and normalization to the number of mapped reads was used 
for comparison of two mRNA sets. A t-test was used for pairwise comparison and a 
Likelihood Ratio Test to adjust for distribution probability.
4.3.7 qPCR validation
The RNAseq results were validated by comparing expression levels of at least eight 
mRNAs/genes per area with their expression as established by qPCR. These genes were 
chosen randomly, although there was one requirement, namely that genes from all 
three comparisons of interest, i.e. the comparisons to assess the effect of MPTP (group 
3 vs. group 1), physical exercise (group 2 vs. group 1) and physical exercise in the MPTP-
model of PD (group 4 vs. group 3), should be included. RNA from the same samples 
used for the RNAseq pools was reverse-transcribed to cDNA with random primers using 
the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific, #K1632 Lot 
No: 00167909) according to the manufacturer’s protocol. Three-step qPCR (95°C for 10 
min, followed by 45 three-step-cycles of 95°C for 5 sec, 65°C for 10 sec, and 72°C for 20 
sec and the generation of melting curves from 70°C to 95°C; Rotor-Gene 6000 Series, 
Corbett Life Science Pty. Ltd.) was performed using the 2x SensiFAST SYBR No-ROX 
mix (Bioline Lot No: SF582-313209) and primers designed with NCBI Primer-Blast (www.




Netherlands) (For a complete overview of used primers see Supplementary Table 1). 
The housekeeping genes ACTB and YWHAZ were used as reference for normalization of 
gene expression. Based on the qPCR results, the minimum requirements to be included 
in the enrichment analysis – regarding fold change (FC) cut-off, maximum likelihood 
ratio value and minimal RPKM value – were adjusted so that at least 90% of the gene 
expression changes could be validated by qPCR. As there was insufficient remaining 
RNA available to perform the complete qPCR validation for the PPN RNAseq data, the 
same cut-off values were used as for the other brain areas. 
4.3.8 Overlap of MPTP- and exercise-regulated genes
To determine the direct effect of exercise on MPTP-regulated genes we looked at the 
overlap between the genes regulated by MPTP (group 3 vs. group 1) and the genes 
regulated by exercise in the MPTP model (group 4 vs. group 3). To quantify this overlap 
we used the hypergeometric distribution test:
 
and determined the chance of observing exactly x overlapping genes from a total of 
n differentially expressed genes by exercise in the MPTP-model, with a total of M 
genes that were differentially expressed by MPTP and a total of N genes detected with 
RNAseq. The number of unique genes detected with RNAseq in each brain area (N ), 
consists of genes detected in both comparisons (group 3 vs. group 1 and group 4 vs. 
group 3), irrespective of their FC or expression p-value. Of note, for all comparisons only 
protein-coding genes were considered.
4.3.9 Enrichment analysis and building of molecular landscapes
The Ingenuity pathway analysis software package (www.ingenuity.com) was used 
to identify enriched gene categories in the lists of differentially expressed protein-
coding mRNAs in each of the brain areas. Again, we focused on the three main 
comparisons of interest (see above) – i.e. the comparisons that assess the effect of 
MPTP, physical exercise and physical exercise in the MPTP-model of PD – in the six 
brain areas. Ingenuity assigns genes or rather their corresponding mRNAs/proteins to 
functional (sub)-categories, i.e. ‘canonical pathways’ and ‘biofunctions’, with the latter 
including ‘diseases and disorders’ and ‘molecular and cellular functions’. In addition, 
Ingenuity generates a list of ‘upstream regulators’, i.e. proteins or compounds that 
regulate multiple proteins/mRNAs from the input list. When possible, the program 
also calculates a z-score that is based on the expression changes of the input mRNAs 
and that is a measure for the directionality of the upstream regulator, canonical 
pathway or biofunction. A z-score <-2 or >2 is considered significant. For all analyses, 
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only functional categories and upstream regulators with significant enrichment (i.e. 
Benjamini-Hochberg corrected p<0.05) and containing at least two genes were taken 
into account.
Proteins/mRNAs regulated by the top upstream regulators were analyzed in more 
depth to identify their relation to physical exercise-induced processes in the MPTP-
model of PD (i.e. the comparison of group 4 with group 3). Guided by the results of the 
Ingenuity enrichment analyses, an extensive literature search was performed for the 
(putative) roles of all the proteins encoded by the differentially expressed mRNAs 
as well as their functional interactions, using the UniProt Protein Knowledge Base 
(http://www.uniprot.org) and PubMed (http://www.ncbi.nlm.nih.gov/pubmed). Based 
on these findings and applying an approach similar to the one we used previously for 
genome-wide association and expression data24-26, we then built molecular landscapes 
containing interacting proteins encoded by the mRNAs that are differentially expressed 
by physical exercise and are known to be regulated by the top regulators for each 
brain area. To complement these protein interaction cascades, we added a number of 
proteins that were not encoded by the differentially expressed mRNAs but that have 
been implicated in PD etiology through other lines of (genetic) evidence. In this respect, 
proteins encoded by familial PD candidate genes were included if they have at least one 
functional interaction with one or more other landscape proteins. Additional proteins 
were included when having at least two interactions with other landscape proteins.
4.3.10 Statistics
Statistical comparisons of values between multiple treatment groups were carried out 
using a two-way ANOVA. For behavioral test data, with data at multiple time points, a 
linear mixed model was applied using SPSS (IBM, version 23), with ‘week’, ‘physical 
exercise’ and ‘MPTP’ as fixed factors to calculate the main effects of the training period, 
physical exercise, and the interaction between physical exercise and MPTP. The main 
effect of MPTP in the behavioral tests was assessed using a pair-wise comparison of 
saline-treated and MPTP-treated mice before the start of the exercise regimen. For 
pair-wise comparison, an F-test was used to determine if the distributions of the 
compared two groups have the same variance. Based on the F-test, a Student’s t-test for 
equal or unequal variance was then used to evaluate the significance of the expression 
differences. For all comparisons, data are represented as mean with the standard error 
of the mean (SEM), and a p-value <0.05 was considered statistically significant.
The p-values calculated with the hypergeometric distribution test were adjusted for 
multiple testing using the Bonferroni correction.
4.4 RESULTS
In this study, we assessed the effects of physical exercise in the MPTP-treated mouse 





At baseline, i.e. following recovery from MPTP treatment but before the exercise regimen 
started, MPTP-treated mice showed in the open field an increased total walking distance 
(p<0.01), total movement time (p<0.005) and mean velocity (p<0.005), and a decreased 
mean angular velocity (p<0.005) compared to saline-treated control mice. In contrast, 
their performance on rotarod and beam walk tests were not significantly different from 
controls (Figure 1).
Figure 1. Effect of MPTP. Results of the behavioral tests in week 0 (set as the baseline for the effect of physical 
exercise see Figure 2). No effect of MPTP was shown for the beam walk (A) or rotarod (B) tests, but MPTP 
significantly affects the parameters in the open field (C-F). **P<0.01; ***P<0.005, mean+SEM, n=28 for controls 
(saline-treated) and n=23 for MPTP-treated mice.
In Figure 2, the effects of physical exercise during the course of the training period 
relative to baseline are shown for each of the four treatment groups. The beam walk 
task showed a clear training effect over time in all groups (main effect of ‘week’ p<0.001), 
and the test performance was improved by physical exercise in both the MPTP-treated 
and saline-treated mice, without significant differences between the groups (main 
effect of physical exercise p<0.05) and no significant interaction between physical 
exercise and MPTP-treatment (Figure 2A). Rotarod performance was also significantly 
improved by physical exercise (p<0.01), but no improvement over time or interaction 
with MPTP-treatment was found (Figure 2B). Of the tested parameters in the open 
field (total walking distance, total movement time, mean velocity, and mean angular 
velocity), the mean angular velocity was increased (p<0.001), and the total movement 
time showed a decreasing trend (p=0.051) for all treatment groups over time during the 
exercise regimen (i.e. main effect of ‘week’). There was no significant (main) effect of 
physical exercise on any of the four tested open field parameters, only a trend towards a 
higher ‘mean velocity’ (p=0.082). However, for all four open field parameters, significant 
217
4
EFFECTS OF PHYSICAL EXERCISE IN THE MPTP MOUSE MODEL
interactions between physical exercise and MPTP-treatment were found (p<0.05). 
Physical exercise increased the walking distance and mean velocity of saline-treated 
mice, but not of MPTP-treated mice. Moreover, physical exercise increased the total 
movement time of saline-treated mice and decreased that of MPTP-treated mice. This 
opposite effect was also observed for mean angular velocity, i.e. a decrease by physical 
Figure 2. Effect of physical exercise and interaction with MPTP compared to the baseline (week 0); results of the 
behavioral tests in week 0-4. Measurements in week 1-4 were normalized to week 0 (100%). Dark orange arrows 
indicate the main effect of physical exercise (A-B) and light orange arrows show the effect of the interaction 
between physical exercise and MPTP treatment (C-F). mean±SEM. n=14 for both CNR and CR, n=10 for MNR and 





exercise in saline-treated mice and an increase in MPTP-treated mice (Figure 2C-F).
4.4.2 TH depletion in the SNpc and striatum following MPTP treatment
The number of DA neurons in the SNpc and VTA of each treatment group, as well 
as an estimate of DA fiber density in striatal target areas (DL and VM, respectively) 
was determined by immunohistochemistry for TH – the rate-limiting enzyme in DA 
synthesis. These measures were primarily taken to confirm and estimate the degree 
of neuronal loss due to MPTP treatment, but they may also provide some insight into 
whether exercise could affect these structural changes. MPTP significantly reduced 
the number of TH+ cells in the SNpc (p<0.005), but not in the VTA. Pairwise comparison 
between the treatment groups revealed that the number of TH+ cells in the SNpc of 
MPTP-treated mice without and with physical exercise was reduced by 29% and 20%, 
respectively, compared to the saline-treated group without exercise (both p<0.05; Figure 
3). There was no significant effect of physical exercise on the number of TH+ cells in 
either the SNpc or the VTA, and no interaction between MPTP and physical exercise.
In Supplementary Figure 2, the relative OD of TH+ fibers in the DL, the primary striatal 
target area of the SNpc, is shown. The OD of TH+ fibers was reduced by MPTP (p<0.05), 
without a main effect of physical exercise or an interaction between MPTP and physical 
exercise. Pairwise comparison showed that MPTP decreased the density of TH+ fibers 
in MPTP-treated mice without exercise by 33% (p<0.005) compared to saline-treated 
mice without physical exercise. There was a trend towards an increased TH+ OD by 
physical exercise in MPTP-treated mice, but this increase was not significant.
Supplementary Figure 3 shows the OD of TH+ fibers in the VM, the primary striatal 
target area of the VTA. Although all treatment groups (physical exercise, MPTP and 
MPTP + physical exercise) showed a reduced OD of TH+ fibers, no significant effects of 
MPTP, physical exercise or their interaction were found.
4.4.3 qPCR validation of the RNAseq data
The RNAseq data were obtained from pooled samples and in order to validate these data, 
the mRNA expression levels in each of the investigated brain areas were determined 
in individual samples by qPCR. The results of the qPCR experiments (Supplementary 
Figure 4) led us to adopt the following requirements for the inclusion of differentially 
expressed protein-coding mRNAs in the subsequent analyses: FC >1.2, likelihood ratio 
<0.05, RPKM >5.
4.4.4	 A	direct	effect	of	physical	exercise	on	MPTP-regulated	genes
The overlap between the protein-coding mRNAs that are differentially expressed due to 
MPTP alone and due to exercise in MPTP-treated mice is represented in Supplementary 
Figure 5. In all brain areas the probability of this overlap was calculated by using the 
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hypergeometric distribution test, which showed that for all areas, the overlap is greater 
than would be expected based on random gene selection (p<0.05). Further, in all areas 
82-99% of the overlapping mRNAs are regulated in opposite directions by MPTP and 
exercise. Enrichment analyses of mRNAs that overlap but are regulated in opposite 
directions are summarized in Supplementary Table 2. The VTA and PFC show the most 
Figure 3. TH+ neurons in the SNpc and VTA. The upper panel shows a representative picture for each of the 
four treatment groups and the lower panel shows the average number of TH+ neurons in the SNpc and the VTA 
per treatment group. *P<0.05, mean+SEM, n=5 for CNR and MR and n=4 for CR and MNR for both brain areas. 
CNR, control not running; CR, control running; MNR, MPTP-treated but not running; MR, MPTP-treated and 




significant results, and are also the brain areas with the biggest absolute and relative 
overlap (i.e. the overlap in number and proportion of mRNAs). The analysis of the VTA 
displays a downregulation of the top regulator ‘inosine’, whereas the PFC and to a lesser 
extent also the DL show an increase in effect of dalfampridine and bicuculline.
4.4.5 Enriched regulators, pathways and biofunctions in the RNAseq data
Enrichment analysis of the differentially expressed mRNAs was performed for each of 
the brain area examined to investigate the effects of MPTP (i.e. comparing the MPTP-
treated group without exercise to the saline-treated group without exercise), physical 
exercise (i.e. comparing saline-treated mice with exercise to saline-treated mice without 
exercise), and the effects of physical exercise in MPTP-treated mice (i.e. comparing the 
MPTP-treated mice with exercise to MPTP-treated mice without exercise). In Tables 
1-3, a short overview of the main effects – the top regulator(s), canonical pathway(s) 
and biofunction(s) – of MPTP, physical exercise and physical exercise in MPTP-treated 
mice is provided for each brain area separately. A more elaborate overview of these 
enrichment analyses per brain area can be found in Supplementary Tables 3-8.
In all brain areas examined, MPTP treatment affected a set of mRNAs that is involved 
in epilepsy, which is reflected by the presence of the epilepsy-regulating transcription 
factor CREB1, the convulsants bicuculline and dalfampridine, and the biofunction 
‘epilepsy’. Other regulators and related functional themes enriched within the mRNAs 
affected by MPTP are RICTOR and its regulation of ribosomal and mitochondrial 
proteins, as well as L-DOPA and DA receptor signaling (Table 1).
Furthermore, in the various brain areas examined, physical exercise affected sets of 
mRNAs that are regulated by the upstream regulators CREB1, RICTOR, L-DOPA and 
dexamethasone. These regulators overlap to some extent with the upstream regulators 
for the MPTP-regulated mRNAs as mentioned above. However, the top canonical 
pathways and biofunctions due to physical exercise are not epilepsy-related, but rather 
associated with ‘mitochondrial dysfunction’ and ‘movement disorder’ (Table 2).
The top regulators of the mRNAs differentially expressed due to physical exercise in 
MPTP-treated mice are L-DOPA, RICTOR, bicuculline/dalfampridine, and CREB1. The 
top canonical pathways and biofunctions enriched in exercised MPTP-treated mice 
are ‘mitochondrial dysfunction’ and ‘protein synthesis’ in the VTA and DL, ‘G-protein 
signaling’, ‘movement disorder’, ‘seizures and cytoskeleton dynamics’ in the VM and 
are related to (cell) death in the PFC (Table 3). 
Of note, the predicted direction of effect of the top regulators RICTOR and L-DOPA is 
changed in the VTA, DL and VM of exercised MPTP-treated mice compared to exercised 
saline-treated mice. More specifically, the predicted direction of effect of RICTOR is 
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(strongly) decreased in the VTA and DL after exercise in saline-treated mice, but is 
strongly increased and has no significant predicted direction in the VTA and DL of 
exercised MPTP-treated mice, respectively. Further, L-DOPA shows a strongly decreased 
predicted direction of effect in the VM of exercised MPTP-treated mice, whereas this 
direction of effect was absent after exercise alone.  
Table 1. Main effects of MPTP (MPTP-treated mice without physical exercise vs. saline-treated mice without physical exercise) 
per brain area. For each of the effects, the corresponding z-score, a predicted direction of the effect, is displayed as increased 
(z-score ≥ 2; Ʌ), no significantly predicted direction (=) or decreased (z-score ≤ -2; V). “N/A”: no significantly enriched canonical 
pathways or biofunctions for a brain area (p≥0.05).
Brain area Regulator(s) Canonical pathway(s) Biofunction(s)























PFC bicuculline/dalfampridine V N/A N/A




Table 2. Main effects of physical exercise (saline-treated mice with physical exercise vs. saline-treated mice without physical 
exercise) per brain area. For each of the effects, the corresponding z-score, a predicted direction of the effect, is displayed as 
increased (z-score ≥ 2; Ʌ), no significantly predicted direction (=), decreased (z-score ≤ -2; V) or very much decreased (z-score ≤ -6; 
VV). “N/A”: no significantly enriched canonical pathways or biofunctions for a brain area (p≥0.05).
Brain area Regulator(s) Canonical pathway(s) Biofunction(s)








Protein synthesis = Seizures V





VM L-DOPA = N/A N/A








Table 3. Main effects of physical exercise in MPTP-treated mice (MPTP-treated mice with physical exercise vs. MPTP-treated 
mice without physical exercise) per brain area. For each of the effects, the corresponding z-score, a predicted direction of the 
effect, is displayed as very much increased (z-score ≥ 6; ɅɅ), increased (z-score ≥ 2; Ʌ), no significantly predicted direction (=), 
decreased (z-score ≤ -2; V) or very much decreased (z-score ≤ -6; VV). “N/A”: no significantly enriched canonical pathways or 
biofunctions for a brain area (p≥0.05).
Brain area Regulator(s) Canonical pathway(s) Biofunction(s)
SN L-DOPA = N/A N/A




























4.4.6 The main molecular pathways regulated by physical exercise 
To elucidate the main molecular pathways regulated by physical exercise in MPTP-
treated mice, the mRNA sets regulated by the top upstream regulators L-DOPA (in the 
SN and VM, Supplementary Tables 9 and 10), RICTOR (in the DL and VTA, Supplementary 
Tables 11 and 12), bicuculline/dalfampridine (in the PFC, Supplementary Table 13) and 
CREB1 (in the PPN, Supplementary Table 14) were studied in greater detail and used to 
build molecular landscapes for each top upstream regulator in the various brain areas. 
Here, we provide a short description of each of these molecular landscapes. In the 
Supplementary Information, all landscapes are described in full detail.
The molecular landscapes of interacting proteins encoded by the L-DOPA-regulated 
mRNAs that are differentially expressed in the SN and the VM due to physical exercise 
in MPTP-treated mice, are shown in Figures 4 and 5, respectively. In the SN landscape, 
G-coupled receptor signaling (involving the proteins ARRB2 and GRP39), glucose 
uptake and signaling (SLC2A1), DA signaling (PPP1R1B) and reactive oxygen species 
(ROS) regulation (HSPB6, FTL, ROMO1) converge on the activation of ERK1/2 (ACKR1, 
EDNRB, GPR39, IER3, TP53), apoptotic pathways (CASP3, TP53), CREB1, and circadian 
clock regulation (PER1, DBP, CIART) (Figure 4). In the VM landscape, the main molecular 
Figure 4. Landscape of proteins encoded by the mRNAs regulated by physical exercise and the upstream 
regulator L-DOPA in the SN. mRNAs differentially expressed in the SN due to physical exercise in MPTP-treated 
mice are shown in gray. Blue proteins are additional genes/proteins that are associated with PD through 
genetic and/or expression studies, whereas white proteins have no known link with PD. The direction of effect 
of physical exercise (measured) and L-DOPA (from literature) on the expression of these mRNAs is depicted 
through coloured borders. L-DOPA-activated proteins are shown with purple writing for the protein name, and 
familial PD proteins are shown with a blue border.
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pathways are (interneuron-mediated) DA release (involving the proteins CHAT, DOC2B, 
SYN1 and TH) and signaling (DRD2, PPP1R1B), cannabinoid signaling (CNR1, FAAH) 
and neuropeptide signaling (PDYN, PENK, TAC1) that subsequently regulate/activate 
ERK1/2, CREB1 and CCND1 signaling. The latter is a cell cycle regulator that may also be 
involved in synaptic plasticity and learning27 (Figure 5). Of note, almost all proteins in 
this landscape are regulated by physical exercise and L-DOPA in opposite directions. 
Figure 5. Landscape of proteins encoded by the mRNAs regulated by physical exercise and the upstream 
regulator L-DOPA in the VM. mRNAs differentially expressed in the VM due to physical exercise in MPTP-
treated mice are shown in gray. Blue proteins are additional genes/proteins that are associated with PD through 
genetic and/or expression studies, whereas white proteins have no known link with PD. The direction of effect 
of physical exercise (measured) and L-DOPA (from literature) on the expression of these mRNAs is depicted 
through coloured borders. L-DOPA-activated proteins are shown with purple writing for the protein name, and 
familial PD proteins are shown with a blue border. 
The RICTOR-regulated mRNAs that are differentially expressed in the DL and VTA due 
to physical exercise in the MPTP-treated mice encode proteins that are specifically 
involved in three cellular systems: the complex I-V of the electron transport chain, the 
40S and 60S ribosomal subunits, and the proteasome (see Supplementary Tables 11 and 
12). These are complexes that regulate cellular energy, protein translation and protein 
degradation, respectively (Supplementary Figures 6 and 7). Of note, physical exercise 
and RICTOR have an opposite effect on the expression of all differentially expressed 
mRNAs in the mitochondrial electron transport chain in the DL, whereas physical 
exercise and RICTOR exert the same direction of effect (i.e. a decreasing effect) on the 




In the PFC, 8 out of 9 mRNAs differentially expressed due to physical exercise in 
MPTP-treated mice and regulated by bicuculline/dalfampridine have been linked to 
epilepsy (Supplementary Table 13). Immediate-early gene activation is one of the main 
processes regulated by these mRNAs e.g. via the early response genes/proteins FOS, 
FOSB and NR4A1, which in turn are regulated by insulin and low density lipoprotein. 
In Supplementary Figure 8, an overview of the interactions of the proteins encoded by 
these mRNAs and their regulation by bicuculline/dalfampridine and physical exercise 
is shown in a molecular landscape.
In the PPN, the proteins encoded by the mRNAs that were differentially expressed due 
to physical exercise in MPTP-treated mice and regulated by CREB1 have only a limited 
number of interactions in the built landscape (Supplementary Figure 9). Nevertheless, 
a few functional themes such as vascular remodeling, neuropeptide signaling, lipid 
metabolism, epilepsy/immediate early gene regulation and calcium signaling were 
identified, with CREB1 as their central regulator (Supplementary Table 14).
4.5 DISCUSSION
This study aimed to explore the molecular mechanisms underlying the beneficial 
effects of physical exercise on motor functioning in the MPTP-treated mouse model 
of PD. After validation of the model, through demonstrating significant nigral neuronal 
loss following MPTP treatment, the effects of a four-week physical exercise regimen on 
motor performance, and the accompanying molecular changes in multiple brain areas 
were assessed using behavioral tests and RNAseq analysis, respectively. The behavioral 
tests showed that physical exercise improved beam walk and rotarod performance in 
both MPTP-treated and control mice, but had a different and often opposite effect on the 
four tested open field parameters in these groups. Our RNAseq findings demonstrated 
that physical exercise in MPTP-treated mice mainly affects the expression of mRNAs 
involved in L-DOPA-mediated pathways in the SN and VM that regulate DA signaling, 
RICTOR-mediated pathways in the VTA and DL involved in energy metabolism and 
cellular stress28, 29, and bicuculline/dalfampridine-mediated pathways in the PFC and 
CREB1-mediated pathways in the PPN that are both a measure of neuronal activity30, 
31. To further elucidate the specific molecular mechanisms underlying the effects of 
physical exercise in MPTP-treated mice, the differentially expressed mRNAs regulated 
by these top regulators were integrated into molecular landscapes, depicting the main 
biological processes and signaling cascades affected.
Our animal model was validated by demonstrating a significant nigral DA neuronal loss 
following MPTP treatment. The observed moderate neuronal loss in the midbrain due 
to MPTP-treatment, i.e. a 29% reduction of TH-positive neurons in the SNpc without a 
statistical significant loss in the VTA, is in keeping with earlier studies using a similar 
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MPTP treatment regimen in 5-month old mice showing 33% loss in the SNpc and no 
significant loss in the VTA32. Other studies, in 8-10 week old mice, reported a neuronal 
loss of more than 50% in the SNpc7, 33, 34. Differences in level of neurodegeneration35 
and molecular effects26 due to MPTP toxicity may be explained by age of the mice, 
MPTP dosing, and the duration between MPTP injection and sacrifice. We did not find 
a significant effect of physical exercise on the number of surviving DA neurons, but 
noted a trend towards an increased number of TH-positive neurons in the SNpc and 
an increased TH-positive fiber density in the DL and VM in MPTP-treated mice with 
physical exercise compared to MPTP-treated mice without exercise. From previous 
studies, it remains unclear whether physical exercise can protect against cellular loss 
in the MPTP mouse model. Preservation of SNpc neurons by physical exercise has been 
described before34, 36, but the findings were inconsistent7, 21. 
Regarding motor function, MPTP treatment alone resulted in an increased activity in 
the open field, as reported before32, 35, 37-39, but did not affect the performance on beam 
walk and rotarod. The effects of exercise on the motor performance included an 
improvement on the beam walk and rotarod in both saline and MPTP-treated groups. 
However, the effects of physical exercise on the open field parameters in saline-treated 
mice was either absent or opposite in MPTP-treated animals. These findings suggest 
that some effects of physical exercise may be dependent on the ‘disease-state’ (i.e. 
saline- or MPTP-treated). It could be argued, however, that the lack of effect of physical 
exercise in MPTP-treated mice on total walking distance and mean velocity (Figure 
2) may be due to their MPTP-induced hyperactivity (Figure 1) that could have limited 
a further increase in motor performance due to physical exercise. Furthermore, the 
opposite effect of exercise on total movement time and mean angular velocity in MPTP-
treated mice (Figure 2) compared to the effect of MPTP alone (Figure 1) suggests that 
physical exercise counteracts the effect of MPTP. 
The RNAseq analysis showed that the level of overlap between MPTP-regulated genes 
and physical exercise-regulated genes differed between the brain areas studied and 
was particularly high in the PFC and VTA. These data suggest that in the PFC and VTA, 
physical exercise influences the processes affected by MPTP more directly than in the 
other areas in which more indirect mechanisms may prevail. Nevertheless, in all brain 
areas examined, the majority of overlapping genes (82-99%) were regulated in opposite 
directions by physical exercise compared to MPTP, suggesting counteracting effects 
of physical exercise on MPTP-regulated mechanisms. For example, the enrichment 
analysis of the overlapping genes in the PFC and DL (see Supplementary Table 2) shows 
a predicted activation of the top regulators dalfampridine, bicuculline and CREB1 – 




The roles of the PD-related brain areas examined in this study can be summarized in a 
simplified basal ganglia circuitry model, wherein PPN, SN and DL are mainly involved 
in motor control, and the VTA, VM and PFC contribute particularly to the regulation of 
(complex) behavior and cognition (Figure 6)40-45. The top regulators – and to a lesser 
extent also the canonical pathways and biofunctions – regulated by physical exercise in 
the cognition-associated brain areas of MPTP-treated mice, showed highly significant 
predicted directions of effect, whereas these effects were less prominent in the motor-
related areas. This implicates that, although physical exercise is able to improve motor 
function (as supported by the behavioral tests), it may also have strong effects on 
cognition and behavior. This is interesting from a therapeutic point of view, because 
non-motor symptoms in PD patients – including cognitive impairment, depression, 
pain and sleep disorders – are usually less responsive to dopamine replacement 
therapy and therefore treatment options are limited46-48.
Figure 6. Overview of the brain areas analyzed, and the top upstream regulators and processes per area. The 
brain areas are shown in a simplified model of the basal ganglia circuitry. Green, red and gray triangles depict 
positive (>2), negative (<-2) or non-significant z-scores respectively from the enrichment analyses of the physical 
exercise-regulated mRNAs in MPTP-treated mice. DL, dorsolateral striatum; GPe, globus pallidus external; GPi, 
globus pallidus internal; PFC, prefrontal cortex; PPN, pedunculopontine nucleus; SNpc, substantia nigra pars 
compacta; SNr, substantia nigra reticularis; STN, subthalamic nucleus; VM, ventromedial striatum; VTA, ventral 
tegmental area.
Almost five decades after its introduction4, the DA precursor L-DOPA is still the gold 
standard for symptomatic treatment to alleviate the motor symptoms of PD5. It should 
be noted, however, that chronic high-dose L-DOPA use is associated with complications 
such as dyskinesias49-51. Moreover, the effects of L-DOPA on non-motor symptoms in 
PD are even less predictable and L-DOPA use may even lead to deterioration of these 
symptoms, e.g. impaired reversal learning or motor sequence learning deficits52-59. It 
has been suggested that these adverse cognitive effects of L-DOPA may be due to a 
higher L-DOPA demand in the motor systems compared to cognitive areas, resulting in 
227
4
EFFECTS OF PHYSICAL EXERCISE IN THE MPTP MOUSE MODEL
a relative L-DOPA overdose in cognitive areas60-62. Therefore, novel ‘add-on’ treatments 
that can enable low-dose L-DOPA use and/or reduce the adverse effects of (long-term) 
L-DOPA use are desirable. In this respect, our study suggests that physical exercise 
is an attractive add-on treatment for PD, and that exercise combined with L-DOPA 
treatment may be more beneficial than treatment of PD patients with L-DOPA alone9, 63. 
Other findings that support this hypothesis include the reports indicating that physical 
exercise not only improves the motor symptoms of PD patients8, 9, but also L-DOPA-
induced dyskinesias in PD patients64 and animal models65, and cognitive function in 
PD patients2, 15, 16.
Considering the above, it is worth noting that our landscapes revealed that physical 
exercise and L-DOPA regulate similar pathways in the SN and VM – often in an opposite 
direction – and that most of these pathways have been linked to sleeping problems (SN) 
and cognitive and/or motor dysfunctioning (VM) in PD. For example, the expression of 
clock proteins was affected by physical exercise and L-DOPA in the SN, a brain region 
known to be involved in the regulation of REM sleep66, 67 and causing circadian rhythm 
irregularities when damaged by MPTP68, 69. Further, the use of L-DOPA can disturb REM 
sleep70 and result in a delayed sleep onset in PD patients, which suggests an uncoupling 
of sleep and circadian regulation71. On the other hand, physical exercise can improve 
circadian rhythm regulation72-74 and may therefore serve as a complementary therapy 
to strengthen circadian function in PD, as suggested earlier75.
In the VM, both physical exercise and L-DOPA regulate DA, neuropeptide and 
endocannabinoid signaling, but in opposite directions. L-DOPA treatment results in 
sustained DA signaling in the striatum and can disrupt DA and (endo)cannabinoid 
receptor crosstalk76, 77. In contrast, physical exercise may rebalance DA signaling after 
sustained L-DOPA treatment (by reducing PPP1R1B activation)65, attenuates depression-
like behavior by decreasing the expression of neuropeptides78 and activates the 
endocannabinoid system79-81. In turn, the endocannabinoid system modulates synaptic 
(DA) transmission in the striatum of PD patients82-84, restores homeostasis following 
DA depletion85, 86 and exerts beneficial effects on cognition, mood and nociception80. 
Therefore, physical exercise seems to exert a positive effect on the regulation of 
DA, neuropeptide and endocannabinoid signaling. Moreover, these three signaling 
pathways are not only associated with L-DOPA-induced dyskinesia87-92, a process that is 
mainly due to dysregulation in the DL, but are also involved in regulating VM-associated 
cognitive functions and behaviors78, 93-98, supporting the notion that the anatomical and 
neurophysiological boundaries of the striatal domains regulating control of movement 
(DL) and (more) cognition-related processes (VM) may functionally overlap99, 100.
In summary, the molecular pathways that are regulated in the SN and VM by both 




Interestingly, the overall effects of physical exercise on these pathways seem to 
particularly improve the motor and behavioral clinical phenotype, whereas (chronic) 
L-DOPA-treatment can also cause adverse effects. Moreover, to our knowledge, physical 
exercise exerts – although it may counteract some L-DOPA-regulated pathways – no 
adverse effects on PD patients. To confirm the positive effects of physical exercise on 
cognitive function, future physical exercise studies in PD animal models and patients 
should include cognitive tests, e.g. reversal learning tasks. Furthermore, these studies 
should aim at further elucidating the molecular pathways underlying physical exercise 
in relation to (chronic) L-DOPA treatment in animal models.
Taken together, our findings provide further evidence that physical exercise improves 
motor function in PD, while it also affects the regulation of non-motor brain areas of 
MPTP-treated mice. We found that physical exercise and L-DOPA exert opposite effects 
on molecular pathways in several PD-associated brain areas, including those involved 
in sleeping and cognitive function. Overall, the present study suggests that physical 
exercise has therapeutic potential, not only to improve motor function but it may also 
improve non-motor symptoms of PD – and perhaps even alleviate detrimental effects 
associated with (chronic) L-DOPA use.
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Supplementary Figure 1. Punching locations per brain area. For each brain area – PFC (A), DL (B), VM (C), SN (D), 
VTA (E) and PPN (F) – the punching locations are visualized in a cross section adapted from the Paxinos mouse 
brain atlas1. Punching locations with a punching needle of 0.5mm are shown with red circles, and blue circles 



















Supplementary Figure 2. Optical density of fibers in the DL. The upper panel shows a representative picture for 
each of the four treatment groups and the lower panel shows the optic density in the DL per treatment group. 
*P<0.05, means ± SEM, n=5 for CNR and MR and n=4 for CR and MNR. CC, corpus callosum; DL, dorsolateral 
striatum.
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Supplementary Figure 3. Optical density of fibers in the VM. The upper panel shows a representative picture 
for each of the four treatment groups and the lower panel shows the optic density in the VM per treatment 




















Supplementary Figure 4 (part 1/3). Validation of the RNAseq data using qPCR.
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Supplementary Figure 4 (part 3/3). Validation of the RNAseq data using qPCR. The fold change of each mRNA in 
the RNAseq dataset and the brain area (PFC, DL, VM, SN, VTA) are shown above each graph, with the expression 
levels as measured by qPCR shown underneath. Expression levels are normalized to ACTB and YWHAZ and 
shown in arbitrary units (AU). Mean+SEM. The p-values are indicated in each graph (Student’s T-test). 
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Supplementary Figure 5. The effect of physical exercise on MPTP-mediated genes. Per brain area the number of 
differentially expressed genes due to MPTP alone (in blue) or due to exercise in MPTP-treated mice (in gray), and 
their overlap are shown. The chance of observing this overlap is calculated with the hypergeometric distribution 
test and shown next to the overlapping area. Below the blue and gray circles, the total number of unique genes 
detected by RNAseq for each brain area is shown and also the number and percentage of overlapping genes that 


















4 Supplementary Figure 6. mRNAs differentially expressed in the DL due to physical exercise in MPTP-treated 
mice and regulated by RICTOR. The expression of the purple mRNAs is decreased by both physical exercise and 
RICTOR. The expression of orange mRNAs is increased by physical exercise and decreased by RICTOR.
243
















4Supplementary Figure 7. mRNAs differentially expressed in the VTA due to physical exercise in MPTP-treated 




















Supplementary Figure 8. mRNAs differentially expressed in the PFC due to physical exercise in MPTP-
treated mice and regulated by Bicuculline/Dalfampridine. mRNAs differentially expressed in the PFC due to 
physical exercise in MPTP-treated mice are shown in gray. Blue proteins are additional genes/proteins that are 
associated with PD through genetic and/or expression studies, whereas white proteins have no known link with 
PD. The direction of effect of physical exercise (measured) and Bicuculline/Dalfampridine (from literature) on 
the expression of these mRNAs is depicted through coloured borders. Bicuculline-regulated proteins are shown 
with purple writing for the protein name, and familial PD proteins are shown with a blue border.
245

















Supplementary Figure 9. mRNAs differentially expressed in the PPN due to physical exercise in MPTP-treated 
mice and regulated by CREB1. mRNAs differentially expressed in the PPN due to physical exercise in MPTP-
treated mice are shown in gray. Blue proteins are additional genes/proteins that are associated with PD through 
genetic and/or expression studies, whereas white proteins have no known link with PD. The direction of effect of 
physical exercise (measured) on the expression of these mRNAs is depicted through orange (increase) or purple 



















Supplementary Table 1. Primers used for validation of the RNAseq data by qPCR.



































































Supplementary Table 1. (continued)






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 9. Differentially expressed mRNAs in the SN due to physical exercise in MPTP-treated mice, and regulated 
by L-DOPA. Proteins encoded by the genes are bold when located in the molecular landscape (Figure 4) and single-underlined 
when associated to PD via ‘corroborating evidence’, i.e. when the gene/protein is genetically associated to PD or differentially 
expressed in the SN of PD patients compared to controls.




ACKR1 -1.24 Increased -
ACTA2 -1.27 Decreased -
ALYREF 1.26 Increased -
ARRB2 -1.23 Decreased -
C14ORF166 1.21 Decreased -
CASKIN2 -1.20 Increased -
CDC42EP2 -1.23 Decreased CDC42EP2 mRNA is increased in the SN of PD patients compared to controls2.
CDC42EP3 1.29 Increased -
CIART -1.34 Increased -
CLN6 -1.31 Decreased -
DBP -1.20 Increased -
DGKB 1.31 Increased DGKB mRNA is decreased in the SN of PD patients compared to controls2.
DPP7 -1.20 Decreased -
DUSP6 -1.22 Increased -
EDNRB 1.21 Decreased -
FCRLS -1.26 Decreased -
FKBP5 -1.29 Increased -
FTL -1.24 Decreased FTL mRNA is decreased in the SN of PD patients compared to controls3. FTL 
protein is increased in the SN of PD patients compared to controls4, 5.
GDF1 -1.21 Increased GDF1 mRNA is decreased in the SN of PD patients compared to controls6.
GPR39 -1.26 Increased -
HSPB6 -1.24 Decreased HSPB6 protein is increased in the SN of PD patients compared to controls4.
HVCN1 -1.22 Decreased -
IER3 -1.22 Increased -
INO80E -1.38 Increased -
MFSD2A -1.34 Increased -
MRPL33 1.36 Increased -
PDGFA -1.22 Decreased -
PER1 -1.24 Increased -
PPP1R1B -1.21 Increased PPP1R1B protein is decreased by 66% in the SNpr, and 79% in the SNpc of PD 
patients compared to controls7.
PVALB -1.21 Decreased PVALB mRNA is increased in the SN of PD patients compared to controls8. 
PVALB protein is increased in a subgroup of PD DA SN neurons9.
REEP3 1.21 Decreased -
ROMO1 -1.29 Increased -
SHC1 -1.24 Decreased -
SLC2A1 -1.22 Increased -
TAC1 -1.31 Increased TAC1 mRNA is decreased in the SN of PD patients compared to controls8.
TP53 -1.24 Increased Ser15-phosphorylated TP53 is increased in the PD SN (p<0.001)10.
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Supplementary Table 10. Differentially expressed mRNAs in the VM due to physical exercise in MPTP-treated mice, and regulated 
by L-DOPA. Proteins encoded by the genes are bold when located in the molecular landscape (Figure 5) and single-underlined 
when associated to PD via ‘corroborating evidence’, i.e. when the gene/protein is genetically associated to PD or differentially 
expressed in the striatum of PD patients compared to controls.




ACY1 -1.2 Increased -
AMIGO2 -1.46 Increased -
APBA2 1.28 Decreased -
ARC 1.25 Increased ARC mRNA is decreased in the striatum of PD patients compared to controls8.
ARPP21 -1.2 Increased ARPP21 is decreased in the striatum of PD patients compared to controls11.
C14orf37 1.28 Decreased -
C18orf21 -1.47 Increased -
C4A/C4B -1.32 Decreased -
CACNA2D3 -1.23 Increased (VDCC) CACNA2D3 mRNA is decreased in the striatum of PD patients 
compared to controls12.
CAMK1G -1.49 Increased CAMK1G mRNA is increased in the striatum of PD patients compared to 
controls13.
CBR3 -1.37 Increased CBR3 protein is increased in the striatum of PD patients compared to 
controls8.
CCND1 1.2 Decreased -
CDC42EP3 -1.29 Increased -
CHAT -1.58 Increased -
CHRNA4 1.92 Decreased PD patients have a higher frequency of intron3+182 Del 22 bp (p=0.015)14.
CLIC6 -1.27 Increased CLIC6 mRNA is increased in the striatum of PD patients compared to controls8.
CLN6 1.31 Decreased -
CNIH3 2.8 Decreased -
CNR1 1.49 Decreased The presence of two CNR1 alleles with >16 AAT trinucleotide repeats in PD 
patients, is associated with a reduced prevalence of depression (p=0.003)15. 
CNR1 mRNA is increased in the striatum of PD patients compared to controls13.
CRTAC1 1.79 Decreased -
CRYM -1.41 Increased CRYM protein is increased in the striatum of PD patients compared to 
controls8.
CTNNBIP1 1.31 Decreased -
CYLD -1.24 Increased -
DDIT4L -1.27 Increased -
DGKB -1.2 Increased -
DGKI -1.27 Increased -
DLGAP1 1.73 Decreased -
DLK1 -1.54 Increased -
DOC2B -1.3 Increased -
DUSP6 1.24 Increased -
ECEL1 -1.41 Increased -
ERLIN1 -1.24 Increased -
FAAH 2.15 Decreased The synonymous rs324419 SNP and also the haplotype of rs324419 and 
rs2295633 (both SNPs are located in the FAAH gene) are both associated with 
musculoskeletal pain in PD patients p=0.006 and p=0.012 respectively16.
FAM126A -1.25 Decreased -
FAM184b -1.28 Increased -
FAM81A 2.1 Decreased -
FDPS 1.47 Increased -
FNDC9 -1.3 Increased -
FOXP1 -1.21 Increased -
GABRA3 1.43 Decreased GABRA3 mRNA is increased in the striatum of PD patients compared to 
controls8.
GABRG2 1.24 Decreased GABRG2 mRNA is increased in the striatum of PD patients compared to 
controls13.
GFAP 1.22 Decreased GFAP mRNA and protein is increased in the striatum of PD patients compared 
to controls8.
GNAS 1.55 Decreased -
GNG7 -1.22 Increased -




















Supplementary Table 10. (continued)




GPD2 1.24 Decreased GPD2 mRNA is increased in the striatum of PD patients compared to controls8.
GUCY1A3 -1.33 Increased -
HAPLN4 3.14 Decreased -
HBEGF -1.24 Increased -
HLA-A -1.24 Decreased -
HTR1B -1.32 Increased -
IDO1 -1.35 Increased -
KCNA5 -1.28 Increased -
KCNA6 1.65 Decreased KCNA6 mRNA is increased in the striatum of PD patients compared to 
controls8.
KCNC4 4.15 Decreased -
KCNE5 -1.32 Decreased -
KLF6 1.59 Decreased -
LMNA 1.23 Decreased -
LPPR1 -1.28 Increased -
LRRTM3 -1.26 Increased -
LYPD1 -1.22 Increased -
LZTS3 -1.2 Increased -
MAPK11 2.9 Decreased -
MBP 1.22 Increased MBP mRNA is decreased in the striatum of PD patients compared to controls12. 
MBP protein is decreased in the striatum of PD patients compared to controls8.
MEF2C 1.29 Decreased MEF2C mRNA is increased in the striatum of PD patients compared to 
controls8.
MPP6 -1.33 Increased -
MSMO1 1.24 Increased MSMO1 mRNA is increased in the striatum of PD patients compared to 
controls13.
MTURN 1.26 Decreased -
MYO1B -1.29 Increased -
NAV1 1.31 Decreased -
NPTX2 1.27 Increased NPTX2 mRNA is decreased in the striatum of PD patients compared to 
controls12.
NUAK1 1.24 Decreased -
PARM1 1.53 Decreased -
PDYN -1.49 Increased PDYN mRNA is increased in the striatum of PD patients compared to controls8.
PDZD2 -1.32 Increased -
PENK -1.2 Increased PENK mRNA is increased in the striatum of PD patients compared to controls8.
PGM2L1 1.37 Decreased PGM2L1 mRNA is increased in the striatum of PD patients compared to 
controls13.
PLEKHA2 1.35 Decreased -
PPM1L 1.68 Decreased -
PPP1R1B -1.2 Increased PPP1R1B protein is decreased by 45% in the striatum of PD patients compared 
to controls7.
PPP1R2 -1.24 Increased -
PRICKLE1 1.55 Decreased -
PTPRD 1.26 Decreased -
PVALB 4.27 Decreased -
RAP1GAP -1.2 Increased -
RAPGEFL1 1.24 Decreased -
REM2 -1.23 Increased -
RIMS1 1.52 Decreased -
ROBO2 1.22 Decreased -
SATB1 2.73 Decreased -
SCN4B -1.2 Increased SCN4B protein is increased in the striatum of PD patients compared to 
controls8.
SCUBE3 -1.25 Increased -
SH3GL2 1.3 Decreased SH3GL2 mRNA is increased in the striatum of PD patients compared to 
controls13.
SLC10A4 -1.56 Increased -
SLC24A2 1.61 Decreased -
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Supplementary Table 10. (continued)




SLC2A6 1.68 Decreased -
SLC6A7 1.94 Decreased -
SMUG1 1.21 Increased -
SNCB 1.84 Decreased SNCB mRNA is decreased in the striatum of PD patients compared to 
controls17.
SOBP 1.83 Decreased -
STRN -1.27 Increased -
STXBP1 1.2 Decreased STXBP1 mRNA is decreased in the striatum of PD patients compared to 
controls17.
SYN1 1.3 Decreased SYN1 mRNA is decreased in the striatum of PD patients compared to 
controls17. SYN1 protein is increased in the striatum of PD patients compared 
to controls8.
SYNDIG1L -1.27 Increased -
TAC1 -1.23 Increased TAC1 mRNA is increased8, 13, or decreased11 in the striatum of PD patients 
compared to controls.
TCF4 1.25 Decreased -
TCIRG1 1.34 Decreased -
TH -1.33 Increased TH mRNA and protein is decreased in the terminals of nigro-striatal DA 
neurons of PD patients18, 19.
TLE1 -1.21 Increased -
TMEM141 1.55 Decreased -
TRPC3 -1.49 Increased -
UNC13C -1.37 Increased -
VAMP1 1.59 Decreased (SNARE)
VAT1L -1.32 Increased VAT1L mRNA is increased in the striatum of PD patients compared to 
controls13. VAT1L protein is increased in the striatum of PD patients compared 
to controls8.
WDR17 -1.23 Increased WDR17 mRNA is increased in the striatum of PD patients compared to 
controls13.
WNT7B 2.27 Decreased -
ZCCHC12 -1.23 Increased -



















Supplementary Table 11. Differentially expressed mRNAs in the DL due to physical exercise in MPTP-treated mice, and regulated 
by RICTOR. If the proteins that are encoded by these mRNAs are a subunit of a bigger protein complex, then the name of the 
protein complex is shown in the column ‘part of’.




ATP5E 1.39 Decreased Mitochondrial complex V
ATP5H 1.28 Decreased Mitochondrial complex V
ATP5L 1.54 Decreased Mitochondrial complex V
COX6B1 1.36 Decreased Mitochondrial complex IV
COX7C 1.21 Decreased Mitochondrial complex IV
NDUFA1 1.33 Decreased Mitochondrial complex I
NDUFA11 1.24 Decreased Mitochondrial complex I
NDUFA7 1.25 Decreased Mitochondrial complex I
NDUFA9 1.23 Decreased Mitochondrial complex I
NDUFB4 1.56 Decreased Mitochondrial complex I
NDUFB9 1.22 Decreased Mitochondrial complex I
NDUFS5 1.36 Decreased Mitochondrial complex I
NDUFV3 1.22 Decreased Mitochondrial complex I
PSMA2 1.23 Decreased 20S proteasome subunit α
PSMB6 -1.3 Decreased 20S proteasome subunit β
PSME1 1.28 Decreased Proteasome activator complex
RPL10 -1.34 Decreased 60S ribosome subunit
RPL17 1.26 Decreased 60S ribosome subunit
RPL28 -1.61 Decreased 60S ribosome subunit
RPL29 -1.37 Decreased 60S ribosome subunit
RPL7A -1.21 Decreased 60S ribosome subunit
RPL9 -1.34 Decreased 60S ribosome subunit
RPS15 -1.22 Decreased 40S ribosome subunit
RPS24 -1.25 Decreased 40S ribosome subunit
RPS26 1.23 Decreased 40S ribosome subunit
RPS27A 1.31 Decreased 40S ribosome subunit
RPS29 1.79 Decreased 40S ribosome subunit
SDHB 1.24 Decreased Mitochondrial complex II
SGK1 -1.46 Decreased -
UQCRQ 1.2 Decreased Mitochondrial complex III
VCAM1 1.25 Increased -
Supplementary Table 12. Differentially expressed mRNAs in the VTA due to physical exercise in MPTP-treated mice, and 
regulated by RICTOR. If the proteins that are encoded by these mRNAs are a subunit of a bigger protein complex, then the name 
of the protein complex is shown in the column ‘part of’.




ATP5E -1.64 Decreased Mitochondrial complex V
ATP5F1 -1.29 Decreased Mitochondrial complex V
ATP5G1 -1.42 Decreased Mitochondrial complex V
ATP5G2 -1.28 Decreased Mitochondrial complex V
ATP5H -1.25 Decreased Mitochondrial complex V
ATP5J -1.25 Decreased Mitochondrial complex V
ATP5J2 -1.29 Decreased Mitochondrial complex V
COX17 -1.35 Decreased Mitochondrial complex IV
COX5A -1.28 Decreased Mitochondrial complex IV
COX5B -1.33 Decreased Mitochondrial complex IV
COX6B1 -1.47 Decreased Mitochondrial complex IV
COX6C -1.45 Decreased Mitochondrial complex IV
COX7A2 -1.22 Decreased Mitochondrial complex IV
COX7B -1.25 Decreased Mitochondrial complex IV
COX7C -1.25 Decreased Mitochondrial complex IV
MRPL13 -1.3 Decreased 39S ribosome subunit (mitochondrial)
NDUFA1 -1.58 Decreased Mitochondrial complex I
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Supplementary Table 12. (continued)




NDUFA2 -1.24 Decreased Mitochondrial complex I
NDUFA3 -1.33 Decreased Mitochondrial complex I
NDUFA4 -1.32 Decreased Mitochondrial complex IV
NDUFA7 -1.37 Decreased Mitochondrial complex I
NDUFA9 -1.22 Decreased Mitochondrial complex I
NDUFB10 -1.22 Decreased Mitochondrial complex I
NDUFB2 -1.32 Decreased Mitochondrial complex I
NDUFB4 -1.22 Decreased Mitochondrial complex I
NDUFB5 -1.36 Decreased Mitochondrial complex I
NDUFB6 -1.25 Decreased Mitochondrial complex I
NDUFB7 -1.22 Decreased Mitochondrial complex I
NDUFB8 -1.23 Decreased Mitochondrial complex I
NDUFB9 -1.28 Decreased Mitochondrial complex I
NDUFC1 1.23 Decreased Mitochondrial complex I
NDUFS4 -1.26 Decreased Mitochondrial complex I
NDUFS5 -1.31 Decreased Mitochondrial complex I
NDUFS6 -1.42 Decreased Mitochondrial complex I
NDUFV2 -1.21 Decreased Mitochondrial complex I
NDUFV3 -1.22 Decreased Mitochondrial complex I
POMP -1.37 Decreased Proteasome
PPA2 -1.24 Decreased -
PSMA4 -1.24 Decreased 20S proteasome subunit α
PSMA5 -1.32 Decreased 20S proteasome subunit α
PSMA6 -1.3 Decreased 20S proteasome subunit α
PSMB1 -1.27 Decreased 20S proteasome subunit β
PSMB2 -1.31 Decreased 20S proteasome subunit β
PSMB3 -1.35 Decreased 20S proteasome subunit β
PSMB5 -1.23 Decreased 20S proteasome subunit β
PSMB7 -1.24 Decreased 20S proteasome subunit β
PSME1 -1.2 Decreased Proteasome activator complex
RPL11 -1.38 Decreased 60S ribosome subunit
RPL12 -1.35 Decreased 60S ribosome subunit
RPL17 -1.5 Decreased 60S ribosome subunit
RPL21 -1.2 Decreased 60S ribosome subunit
RPL23A -1.3 Decreased 60S ribosome subunit
RPL26 -1.41 Decreased 60S ribosome subunit
RPL29 -1.29 Decreased 60S ribosome subunit
RPL30 -1.43 Decreased 60S ribosome subunit
RPL34 -1.44 Decreased 60S ribosome subunit
RPL35A -1.35 Decreased 60S ribosome subunit
RPL38 -1.69 Decreased 60S ribosome subunit
RPL41 -1.26 Decreased 60S ribosome subunit
RPLP1 -1.25 Decreased 60S ribosome subunit
RPLP2 -1.52 Decreased 60S ribosome subunit
RPS10 -1.2 Decreased 40S ribosome subunit
RPS15 -1.32 Decreased 40S ribosome subunit
RPS18 -1.25 Decreased 40S ribosome subunit
RPS29 -1.49 Decreased 40S ribosome subunit
RPS3A1 -1.2 Decreased 40S ribosome subunit
RPS4Y1 -1.36 Decreased 40S ribosome subunit
SDHB -1.22 Decreased Mitochondrial complex II
SGK1 -1.62 Decreased -
SHFM1 -1.43 Decreased 26S proteasome
UBA52 -1.33 Decreased 60S ribosome subunit
UQCR10 -1.21 Decreased Mitochondrial complex III
UQCRB -1.23 Decreased Mitochondrial complex III
UQCRHL -1.36 Decreased Mitochondrial complex III



















Supplementary Table 13. Differentially expressed mRNAs in the PFC due to physical exercise in MPTP-treated mice, and 
regulated by Bicuculline and Dalfampridine. For each gene/mRNA their association to epilepsy and/or seizures is shown in the 
column ‘Association to epilepsy / seizures’.





ACTA2 -1.58 Decreased [1] The R179H mutation in ACTA2 results in neonatal stroke and progressive 
leukoencephalopathy21.
ARC 1.68 Increased Immediate early gene, increased in epilepsy (6.2x)22.
BTG2 1.57 Increased -
DUSP1 1.38 Increased Increased in epilepsy (3.4x)22.
FOS 2.26 Increased Immediate early gene, increased in epilepsy (4.2x)22.
FOSB 1.24 Increased Immediate early gene, increased in epilepsy (3.0x)22.
GADD45G 1.23 Increased Increased in epilepsy (2.0x)22.
NPAS4 1.85 Increased Npas4 inhibits seizures in pilocarpine-induced epileptic rats23.
NR4A1 1.24 Increased Immediate early gene24, increased in epilepsy (4.7x)22.
Supplementary Table 14. Differentially expressed mRNAs in the PPN due to physical exercise in MPTP-treated mice, and 
regulated by CREB1. For each gene/mRNA the cellular process in which they exert an effect is described in the column ‘Involved 
in’.




CALCB -2.10 Increased Vascular remodeling
CALN1 1.23 Decreased Calcium signaling
CARTPT 1.47 Increased Neuropeptide signaling
EBP -1.24 Increased Cholesterol/lipid signaling
FAM65B -1.27 Increased Cytoskeleton rearrangement
FASN 1.21 Increased Cholesterol/lipid signaling
JUN 1.22 Regulated Immediate early gene; Increased in epilepsy (1.6x)22.
LMO1 -1.49 Decreased Transcription regulator
MVK 1.27 Increased Cholesterol/lipid signaling
NAB2 -1.27 Increased Transcription regulator
NOS1 1.52 Regulated Nitric oxide signaling
NR4A1 1.27 Increased Immediate early gene24; Increased in epilepsy (4.7x)22.
NRGN -1.23 Decreased Calcium signaling
NRP1 -1.22 Decreased Vascular remodeling; Calcium signaling
PENK -1.26 Increased Neuropeptide signaling
SGK1 -1.54 Increased Vascular remodeling
SV2C 1.35 Increased Increased in epilepsy (2.1x)22.
TAC1 -1.36 Increased Neuropeptide signaling; Vascular remodeling; Increased in epilepsy (1.8x)22.
TINF2 1.32 Increased Telomere regulation
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Ingenuity analysis of the mRNA sequencing (RNAseq) data of the MPTP-treated mice 
with physical exercise compared to MPTP-treated mice without physical exercise 
revealed the top regulator in each of the PD-related brain areas. In the SN and the 
VM, L-DOPA is the top regulator, whereas RICTOR is the top regulator in the DL and 
VTA, Bicuculline/Dalfampridine are the top regulators in the PFC, and CREB1 is the 
top regulator in the PPN. For each brain area a molecular landscape was built that 
represents the interactions between the proteins encoded by the mRNAs regulated 
by the top regulator and physical exercise. Figure 4 and Figure 5 show the molecular 
landscapes of the SN and VM, respectively, and the landscapes for the DL, VTA, PFC and 
PPN are shown in Supplementary Figure 6-9. Below, a description of the interactions 
that are represented in the molecular landscape figures is given. 
All names of proteins derived from the mRNAs that were differentially expressed in 
the RNAseq due to physical exercise are shown in bold and proteins that are associated 
with PD (via genetic evidence, or differentially expressed in PD patients compared 
to controls) are (also) single-underlined. For a complete overview of all proteins in 
the landscapes (and the corroborating evidence for their associations with PD), see 
Supplementary Tables 9-14. In the molecular landscape descriptions below, the gene 
name abbreviations refer to both the gene and the protein. Furthermore, the terms 
‘activates’ and ‘inhibits’ indicate effects on protein function (e.g. by (de)phosphorylation) 
by another protein, while ‘increases the expression of’ or ‘decreases the expression of’ 
denote effects on the abundance of a protein (directly or indirectly) induced by another 
protein. 
Not all proteins encoded by mRNAs from the RNAseq were placed in the landscape, 
either because there were no connections with other landscape proteins or due to 
lack of annotation, or both. However, this does not necessarily mean that they are not 
involved in physical exercise-mediated effects. Interactions in the landscape that are 
(for practical reasons) not shown in the figures are indicated with ‘(not shown)’ in the 
text.
Overall, in order to interpret protein-protein interactions in the landscape, two 
generalizations have been made. First, when a knock-out of protein A in a cell or animal 
model increases the expression of protein B, we assume that endogenous expression of 
protein A leads to the opposite effect and decreases the expression of protein B. Second, 
we assumed that all identified protein interactions (in any organism and/or cell type) 
can be extrapolated to the interactions in human (DA) neurons, even when the specific 
interactions have not been studied in these specific substrates.
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1.    MOLECULAR LANDSCAPE OF THE SN
In Figure 4 the physical exercise-mediated changes in expression in the SN are 
shown in combination with the L-DOPA-mediated expression of the same proteins. In 
Supplementary Table 9 an overview of the regulatory effects of physical exercise and 
L-DOPA in the SN is given. First, in the description below, the interactions and pathways 
of these proteins in the landscape are discussed (independent of their regulation by 
physical exercise or L-DOPA). And, secondly, the last paragraph of this section discusses 
the differential effects of physical exercise and L-DOPA on these pathways.
The central themes in the landscapes that represent the protein interactions associated 
with the changes in expression due to physical exercise in the SN are G-coupled receptor 
signaling, the regulation of cell survival (including ERK1/2 signaling, ROS regulation, 
glucose uptake and signaling and CREB1 signaling), as well as circadian clock proteins. 
Here we describe concisely the proteins involved in each theme, and their interactions.
1.1   G-coupled receptor signaling and cytoskeleton regulation
ARRB2 mediates the signaling by G-protein coupled receptors and is e.g. activated by 
the G-coupled receptor GRP3925. ARRB2 binds phosphorylated AKT1 (total and Ser473-
phosphorylated AKT1 are lower in the PD brain, but are increased in glia cells in the SN 
of PD patients26) and facilitates the inactivation of AKT127, and binds to the cytoskeleton 
protein ACTA228, to the familial PD29-33 proteins VPS3528 and PARK234, to the nuclear 
export adapter ALYREF28 (binds also to AKT135), and to the small GTPase CDC4236 that 
is known to control actin polymerization and thereby e.g. affects cell morphology and 
endocytosis. ACTA2 also binds the familial PD37-41 proteins LRRK242 and PARK243, and 
binds TP5344. TP53, in turn, increases ACTA2 expression45, 46. LRRK2 and CDC42EP3 
bind47, while CDC42EP3 and CDC42EP2 both bind CDC4248, 49, thereby regulating 
assembly of actin filaments20. Furthermore, both CDC42EP2 and CDC42EP3 both bind to 
the familial PD50-54 protein SNCA55.
1.2   The regulation of cell survival
The ERK1/2 pathway is activated by a wide array of stimuli, including growth 
factors, cytokines and ligands for G protein-coupled receptors, and regulates neuron 
proliferation, survival and apoptosis. In the molecular landscape represented here, 
ERK1/2 is activated by PPP1R1B56, ACKR157, EDNRB58 (also binds to PARK259), IER360 and 
SHC161, 62. ERK1/2 also binds to and is regulated by TP5363-65, and binds to and is inhibited 
by DUSP666-69. Moreover, ERK1/2 expression is increased by GPR3970. These proteins are 
also known to affect pathways involved in cell death, i.e. IER3, TP53 and SHC1 activate 
CASP371-74 and thereby induce apoptosis. CASP3 expression is increased in the SN of PD 
patients75, 76. Moreover, IER3 inhibits the activation and expression of AKT177, and TP53 



















PARK7 activates TP5381. Further, TP53 increases the expression of DUSP682, FKBP583, 
84, PDGFA85 and IER386-88. SHC1 is also important for the cellular response to oxidative 
stress20 and functions downstream of TP53 to induce apoptosis20. While reactive oxygen 
species (ROS) are necessary for normal cell functioning89, 90, high levels are toxic and 
induce cell death89, 91, 92. The mitochondrial protein ROMO1 increases the production of 
ROS93. The ferritin light chain protein FTL, on the other hand, reduces the formation of 
ROS by regulating iron homeostasis94 and also the heat shock protein HSPB6 decreases 
the production of ROS95. HSPB6 binds SNCA96, increases calcium levels97, activates 
AKT195, and inhibits CASP3 signaling95. Cytoplasmic calcium levels are decreased by 
PVALB98, that is increased in a subgroup of PD DA SN neurons9.
ERK1/2 activation, in turn, increases the expression of the glucose transporter 
SLC2A199. Glucose influx is necessary for maintenance of cellular energy levels and cell 
survival, and PD patients show increased metabolic rates of glucose in the SN100. The 
glucose transporter SLC2A1 regulates the influx of glucose into the cell and inhibits 
the activation of CASP3101. SLC2A1 expression is also increased by AKT1102-104 and the 
familial PD105-107 protein PINK1108, but decreased by TP53109-111. Further, the growth factor 
complex PDGF (composed of PDGFA and PDGFB) activates SLC2A1112 thus increases the 
uptake of glucose113. The neuropeptide TAC1 inhibits glucose uptake114, 115 and thereby also 
increases extracellular (blood) glucose levels115, 116. Moreover, glucose activates ERK1/2117, 
118 and CDC42119, 120, increases the expression of the anti-apoptotic proteins PARK2121, 
PINK1121 and SHC1122 and decreases the expression of TP53123, 124 and ACTA2125. Thus, the 
maintenance of sufficiently high cellular glucose levels prevents ROS formation and 
activation of apoptotic signaling cascades.
Lastly, ERK1/2 also decreases the expression of FKBP5126 (part of the steroid receptor 
complex20 and binds AKT1127) and activates SHC1128, IER3129 and CREB1130-132. CREB1 is a 
transcription factor that binds to cAMP response elements on the DNA and thereby 
regulates gene transcription of e.g. TH (not shown)133, 134. The earlier mentioned PPP1R1B 
(DARPP-32) integrates the signals in response to extracellular DA and glutamate135, 136 
and activates CREB1 (in response to DRD2 activation)137, 138, increases the expression 
of LRRK2139, SNCA139 and CREB1140 and increases mobilization of calcium141. CREB1 is 
also activated by glucose142, calcium143 and AKT1144-147, binds TP53148-150 and binds to the 
nuclear exporter adapter ALYREF151 that transports spliced mRNAs from the nucleus to 
the cytoplasm. CREB1 increases the expression of MFSD2A152 and IER3152 and regulates 
the expression of the circadian clock proteins PER1 and CIART (see below).
1.3 Circadian clock proteins
Multiple studies have reported a dysregulation of the circadian clock in PD patients and 
e.g. sleep-wake disturbances and increased daytime sleepiness are widely studied153-159. 
Also degeneration of DA neurons in the SN of MPTP-treated mice cause circadian rhythm 
irregularities160. In the SN landscape, the proteins CIART (not shown), DBP and PER1 
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are involved in circadian clock regulation. CREB1 increases the expression of PER1152, 
161, 162 and is necessary for expression of CIART162. Calcium increases the expression of 
both PER1163 and DBP163, and TP53 (a regulator of the circadian clock164) increases the 
expression of DBP46, whereas DBP and PER1 increases each other’s expression165. Thus, 
multiple proteins involved in regulation of the circadian rhythm are regulated in the SN 
landscape, suggesting that physical exercise might affect the (dysregulated) circadian 
clock function in PD.
1.4 Regulation by physical exercise vs. L-DOPA
Physical exercise and L-DOPA have an opposite effect on the regulation of proteins 
involved in glucose homeostasis (SLC2A1), ERK1/2 activation (ACKR1, EDNRB, GPR39, 
IER3, TP53), the DARPP-32 pathway (PPP1R1B) and circadian clock-regulating proteins 
(PER1, DBP, CIART). Namely, physical exercise downregulates the expression of SLC2A1, 
PPP1R1B and clock proteins, while (chronic) L-DOPA administration results in increased 
SLC2A1 expression and (over)activation of the neuron by L-DOPA-mediated activation 
of ERK1/256, 166, PPP1R1B167 and CREB1168 and the subsequent activation of clock proteins. 
Further, in addition to the proteins differentially expressed due to physical exercise, 
L-DOPA activates166 and increases the expression of CASP3166, 169.
2. MOLECULAR LANDSCAPE OF THE VM
In Figure 5 the physical exercise-mediated changes in expression in the VM are 
shown, in combination with the L-DOPA-mediated expression of these same proteins. 
Supplementary Table 10 gives an overview of the regulatory effects of physical 
exercise and L-DOPA. The central themes in the landscapes that represent the protein 
interactions associated with the changes in expression due to physical exercise in 
the VM are (interneuron mediated) DA release, cannabinoid signaling, neuropeptide 
signaling, calcium mobilization and subsequent activation of PPP1R1B, ERK1/2, CREB1 
and CCND1 signaling. Here we describe concisely the proteins involved in each theme, 
and their interactions. First, in the description below, the interactions and pathways 
of these proteins in the landscape are discussed (independent of their regulation by 
physical exercise or L-DOPA). Secondly, the last paragraph of this section discusses the 
differential effects of physical exercise and L-DOPA on these pathways. 
2.1 DA- and interneuron-mediated MSN activation
Medium spiny neurons (MSNs) are GABAergic inhibitory cells and represent the 
majority of cells present in the striatum. There are two primary MSNs subtypes, the DRD1 
and DRD2 expressing MSNs, representing the direct and indirect pathway respectively. 
MSNs of the direct pathway project to the globus pallidus internal segment (GPi) and 



















to the external segment of the globus pallidus (GPe), to the subthalamic nucleus and 
subsequently to the GPi and SNr. Outputs of the direct and indirect pathway, respectively, 
cause an excitation and inhibition of the upper motor neurons in the cortex170, 171.
DA release in the striatum is not only dependent on SN neuron activation, but also 
depends on the activity of cholinergic interneurons. Cholinergic interneurons integrate 
synaptic signaling in the striatum and mediate DA-dependent striatal plasticity of 
MSNs172-175. Through the activation of both muscarinic and nicotinic cholinergic receptors 
on DA terminals and the co-release of glutamate, activated cholinergic interneurons 
trigger striatal DA release176-183. Of note, in PD and in dystonia, a reduced release of DA 
in the striatum leads to an increased acetylcholine (ACh) release by interneurons184, 
whereas DA-dependent pauses in the tonic firing of cholinergic interneurons are 
hypothesized to function as a learning mechanism in reward- and motor-related 
learning185-187. Further, the differentially expressed potassium channels (KCNA5, KCNA6, 
KCNC4, KCNE5) may regulate DA release and presynaptic DRD2 function188, or may 
regulate the firing patterns of cholinergic interneurons via hyperpolarization-activated 
potassium currents189, 190 or may be involved in depolarization of MSNs after activation 
of muscarinic ACh receptors191-194.
Thus, the interplay between striatal ACh and DA release, by respectively cholinergic 
interneurons and DA neurons, is important for learning and plasticity of MSNs. 
Another factor involved in memory and learning is the transcription factor MEF2C, 
that suppresses the number of excitatory synapses on neurons20. MEF2C increases 
the expression of KCNA5195, and MEF2C itself is activated by MAPK11196, 197 and MEF2C 
expression is increased by HLA-A198 and BDNF199, 200 (not shown; BDNF is associated 
with (cognitive impairment in) PD201-203).
In the VM landscape, the choline O-acetyltransferase CHAT, necessary for ACh synthesis 
in cholinergic synapses, is decreased by physical exercise. Moreover, activation of the 
neuronal acetylcholine receptor subunit CHRNA4 by ACh leads to opening of an ion 
channel, influx of calcium and depolarization that facilitates activation of the SNARE 
complex and neurotransmitter (e.g. DA) release204, 205. Depolarization through calcium 
influx is also mediated by the voltage-dependent calcium channel (VDCC)20, that binds 
to RIMS1206, 207 and UNC13C208 and is inhibited by REM2209. The SNARE complex binds 
STXBP1210, 211 and RIMS1206 and SNARE assembly is inhibited by calmodulin (CaM)212. 
STXBP1 regulates synaptic vesicle docking and fusion and binds also to CaM213, DOC2B214 
(DOC2B expression is increased by CaM215), APBA2216, 217 and familial PD protein SNCA218.
Cytoplasmic vesicles are recycled and are again filled with DA for release into the 
synaptic cleft. Removal of SYN1 from the cytoplasmic side of cytoplasmic vesicles 
mobilizes the vesicles for neurotransmitter release20. SYN1 binds SH3GL2219, LRRK2220, 
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PARK2221, SNCA222 and CaM213, 223. SNCA decreases the expression of SYN1224, whereas 
CaM binds the synaptic vesicle membrane protein VAT1L213 and induces the release of 
SYN1 from cytoplasmic vesicles20. SH3GL2 regulates synaptic vesicle endocytosis and 
binds in addition to SYN1 also to DRD2225, PARK2226, LRRK2227 and CaM213. DA for release 
into the synaptic cleft is either synthesized in the DA neuron, or is taken up by the DA 
transporter SLC6A3 (that is associated with PD228-230) from the extracellular matrix231. 
TH is the rate-limiting enzyme in DA synthesis and binds SNCA232. TH is activated by 
calcium233, 234 and inhibited by SNCA232, 235 and DRD2236. Further, the TH expression is 
increased by the neuropeptide TAC1237 and the SNCA-homologue SNCB238. SNCB also 
binds to SNCA238, AKT1239 and inhibits CASP3 activation240. Cytoplasmic DA is transported 
into the cytoplasmic vesicles by the DA transporter SLC18A2241 (that is associated with 
PD242, 243) so it can be released. The protein MYO1B is a motor protein involved in among 
others vesicular transport and binds to LRRK242. CDC42EP3 is another protein involved 
in cytoskeleton regulation and binds to SNCA55 and LRRK247. 
In summary, DA release in the striatum is regulated by controlling reuptake, storage 
and synthesis of DA and thereby controlling the availability of DA ready for release. 
However, it should be noted that the proteins involved in vesicle fusion and release of 
neurotransmitter are not only involved in DA release in the synaptic cleft, but may also 
mediate e.g. ACh, GABA or glutamate release. 
DA released in the synaptic cleft activates the DRD1 and DRD2 receptors present on 
MSNs244. The PD-associated DRD2245, 246 binds to DRD1247 and also to the chloride ion 
channel CLIC6248. In turn, DA receptor activation results in increased cytosolic calcium 
concentration249, 250. Cytoplasmic calcium levels are also increased by TAC1251-253, VDCC254 
(binds to AMIGO2255), TRPC3256-258 and decreased by SLC24A220, 259, HTR1B260 and PVALB98, 
261, 262. Calcium increases the expression of ARC263 and CCND1264, 265 and activates FAAH266, 
PPP1R1B267, ERK1/2268, 269 and CaM270, 271. CaM is a calcium sensor and transduces the 
calcium signal and thereby increases the expression of LRRTM3215, binds and decreases 
the expression of TCF4272, 273 (TCF4 also binds to TLE1274 and PARK2275), binds TRPC3276, 
CCND1277, STRN278, MYO1B279, 280, MAPK11281 (binds also to MBP282), ARPP21283, MBP284, 285 
(MBP expression is increased by BDNF (not shown)286) and RAP1GAP213. Moreover, CaM 
activates CAMK1G287 that in turn activates CREB120, 287. Calcium mobilization therefore 
increases the main signaling cascades in the VM landscape; PPP1R1B, ERK1/2, CREB1 
and CCND1 signaling.
2.2 Main signaling cascades
Increased phosphorylation (and thus activation) of PPP1R1B and ERK1/2 in striatal 
neurons after chronic L-DOPA treatment is associated with L-DOPA-induced 
dyskinesias56, 288, 289. PPP1R1B is also known as dopamine- and cAMP-regulated neuronal 



















291 and regulates AKT1 activation138, 292.
ERK1/2 are protein kinases that are signal transducers for e.g. growth factors, cytokines 
and G protein-coupled receptors. In addition to activation by PPP1R1B, ERK1/2 are 
activated by HBEGF293-295 (regulates the survival of midbrain dopaminergic neurons296), 
DLK1 297, 298, GNAS299-301, DGKI302, HTR1B303 and the endogenous cannabinoid receptor 
CNR1304-307 (see also below), and are inhibited by DUSP667, 69, 308, 309 and RAP1GAP310. ERK1/2 
increase the expression of neuropeptide TAC1311 and activate CREB1131, 132.
The transcription factor CREB1 is, in addition to CAMK1G, PPP1R1B and ERK1/2 (see 
above), also activated by glucose142, 312 (that decreases the expression of CBR3313), 
potassium314, AKT1144-146, 315 and GNAS316. Subsequently, CREB1 regulates the expression 
of GABRG222, decreases the expression of DLK1317 (also decreased by KLF6318), PGM2L1152, 
PTPRD152, MYO1B152 and CRYM152 and increases the expression of ARC162, NPTX2152, 
ECEL1152, BDNF (not shown)143, 152, 319, KCNC4152, HLA-A152 (not shown, HLA-A binds MBP320 
and GNAS321, and its expression is decreased by ERK1/2 (not shown)322) and of the 
neuropeptides TAC122, 152, PENK152, 323 and PDYN324, 325.
All three, PPP1R1B, ERK1/2 and CREB1, increase the expression of the cell cycle regulator 
CCND1 152, 292, 326-328. CCND1 may be involved in synaptic plasticity and learning329 and its 
expression is increased by BDNF330, WNT7B331, AKT1332-334, glucose335, calcium264, 265 and 
TCF4336, 337 and decreased by RAP1GAP310, PARK2338, ZEB2339 (ZEB2 inhibits AKT1)340 and 
CTNNBIP1336. Nuclear translocation of CCND1 is activated by AKT1341 and calcium264 
and inhibited by KLF6342. CCND1 decreases the expression of STXBP1343 and increases 
the expression of CTNNBIP1344. Further, CCND1 binds KLF6342, LMNA345 (AKT1 activates 
LMNA 346) and MAPK11347. Thus, CCND1 is regulated by all the main signaling cascades 
in the landscape (PPP1R1B, ERK1/2, CREB1) and may affect synaptic plasticity.
2.3 Endogenous cannabinoid signaling
Following DA depletion, the endocannabinoid system in the basal ganglia rearranges 
to restore homeostasis348, 349. The cannabinoid receptor CNR1 is abundant within 
the basal ganglia350, can repress the release of glutamate and GABA (e.g. by cortical 
synapses, not shown)351, 352 and interacts with DA transmission in the striatum353, 354, i.e. 
CNR1 forms heterodimers with DA receptors354 and CNR1 activation increases DRD2 
expression355. Further, indirect pathway signaling (via DRD2-positive MSNs) is rescued 
by endocannabinoid signaling and improves motor dysfunction in PD models356, 
357. Paradoxically, both CNR1 agonist and antagonists alleviate L-DOPA-induced 
dyskinesia in PD models358. This contradiction may be explained by the differential 
coupling of CNR1 to G proteins, either due to interaction with DA receptors353, or by 
the functional selectivity of the different agonists and antagonists for G proteins and 
CNR1 subpopulations358. Moreover, DRD2 activation modulates coupling of different G 
proteins to CNR1359 (not shown). CNR1 expression is increased by DA360, glucose361 and 
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BDNF362 (and CNR1 increases BDNF expression355, 363). CNR1 binds and decreases the 
expression of RAP1GAP364 and binds and inhibits VDCC208, 365, 366. Further, CNR1 decreases 
the expression of the neuropeptides PDYN367 and PENK367, regulates the  activation of 
ERK1/2304-306, 368, 369 and increases DA release370, 371.
The two most abundant endocannabinoids, 2-arachidonoylglycerol (2-AG) and 
anandamide, bind and activate CNR1372-374 and 2-AG also increases the expression of 
CNR1375. 2-AG and anandamide inhibit FAAH (not shown)376, whereas FAAH in turn 
increases the hydrolysis and breakdown of both endocannabinoids366, 377. GABRG2 and 
GABRA3 form a GABA receptor complex378, 379 and are activated by 2-AG379. Further, DA 
decreases the expression of GABRG2360.
In summary, the endocannabinoid system interacts with and compensates for defects 
in the DA system and may therefore have a therapeutic potential in the treatment of PD.
2.4 Neuropeptides
PD and L-DOPA-induced dyskinesia are associated with abnormal expression of 
striatal precursor peptides, i.e. PENK, PDYN and TAC1 derived peptides are increased 
in the globus pallidus and their production is DA-state dependent380-382. Neuropeptides 
are small peptides used for communication between neurons. As shown above, CREB1 
increases the expression of the neuropeptides PENK, PDYN and TAC1. PENK decreases 
the excretion of K+ (potassium)383, whereas K+ increases the expression of PENK384. 
PENK expression is increased  by DA385, 386 and BDNF387 and decreased by DRD2388. 
PDYN decreases degeneration of DA neurons in the rat midbrain389. PDYN expression is 
increased by glucose390, DRD1391 and TAC1392. TAC1 expression is increased by BDNF393, 394 
(not shown), DA360, DRD2388 and ERK1/2311. In turn, TAC1 activates ERK1/2395, 396 (not shown), 
increases plasma glucose levels (by decreasing its uptake in cells)114-116, increases 
intracellular calcium251-253, binds CaM397 (not shown) and increases the expression 
of TH237 and GFAP398 (not shown; GFAP is a marker for astrocytes and its expression 
is increased by BDNF399 (not shown) and decreased by glucose313 (not shown)). The 
mitochondrial GPD2 binds PARK243, and when activated, increases the release of ROS 
from the mitochondria400. Calcium binds and activates GPD220, whereas glucose inhibits 
GPD2 activation401 and may therefore regulate ROS levels in the cell.
In summary, the regulation of neuropeptides is DA-state dependent and may affect 
neuron communication and functioning in the striatum and globus pallidus.
2.5 Regulation by physical exercise vs L-DOPA
The main signaling themes of the landscape encompass ACh interneuron functioning, 
potassium signaling, vesicle release, cannabinoid and neuropeptide signaling, calcium 
mobilization and subsequent activation of PPP1R1B, ERK1/2, CREB1 and CCND1 signaling. 



















almost all proteins in this landscape, i.e. physical exercise increases the expression of 
vesicle release proteins (STXBP1, RIMS1, SNARE, APBA2), CCND1 and proteins involved 
in cannabinoid signaling (FAAH, CNR1) and decreases the expression of PPP1R1B, 
neuropeptides (PDYN, PENK, TAC1) or proteins involved in ERK1/2 regulation (HTR1B, 
DGKI, HBEGF, DLK1, RAP1GAP). L-DOPA exerts an opposite effect on the expression of all 
these proteins compared to the effect of physical exercise and also activates PPP1R1B167, 
CREB1168, ERK1/256, 166, DRD1 and DRD2402, and activates and increases the expression of 
CASP3166, 169. Of note, L-DOPA disrupts the crosstalk of an CNR1-DRD2 complex403 and 
an CNR1 agonist reduces L-DOPA-induced motor dysfunction in a PD rat model404, 405. 
Further, L-DOPA-induced dyskinesia is associated with increased neuropeptide levels in 
the striatum and globus pallidus381, 382, 406-408. Furthermore, ablation of striatal cholinergic 
interneurons attenuates L-DOPA-induced dyskinesia in mice409, 410. Of interest, whereas 
physical exercise decreases the ACh synthase CHAT and increase the expression of the 
ACh receptor subunit CHRNA4, L-DOPA causes the exact opposite. 
In summary, physical exercise has been shown to have an opposite effect on the 
regulation of proteins that are regulated by L-DOPA and associated with L-DOPA-induced 
dyskinesia. Physical exercise may therefore have therapeutic value in attenuating the 
side effects of chronic L-DOPA use.
3. MOLECULAR LANDSCAPE OF THE DL
In Supplementary Figure 6 the physical exercise-mediated changes in expression in 
the DL are shown in combination with the RICTOR-mediated expression of the same 
proteins. 
The proteins regulated by both physical exercise and RICTOR are part of complex I-V of 
the electron transport chain in the mitochondria, the 40S and 60S ribosomal subunits, 
or the proteasome. Supplementary Table 11 shows the localization of each of the 
proteins in these complexes and also provides an overview of the regulatory effects of 
physical exercise and RICTOR.
3.1 Regulation by physical exercise vs. RICTOR
RICTOR decreases the expression of all proteins in the landscape, and thereby regulates 
cellular energy levels, protein translation and degradation. In contrast to RICTOR, 
physical exercise increases the expression of all proteins in the landscape located in 
the electron transport chain, and also increases the expression of the proteins that are 
part of the ribosome or proteasome.
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4. MOLECULAR LANDSCAPE OF THE VTA
In Supplementary Figure 7 the physical exercise-mediated changes in expression in 
the VTA are shown in combination with the RICTOR-mediated expression of the same 
proteins. 
The proteins regulated by both physical exercise and RICTOR are part of complex I-V of 
the electron transport chain in the mitochondria, the 40S and 60S ribosomal subunits, 
or the proteasome. Supplementary Table 12 shows the localization of each of the 
proteins in these complexes and also provides an overview of the regulatory effects of 
physical exercise and RICTOR.
4.1 Regulation by physical exercise vs. RICTOR
Physical exercise and RICTOR both decrease the expression of all mRNAs in the 
landscape of the VTA. Therefore, physical exercise and RICTOR exert the same 
direction of effect on the functioning of the electron transport chain, the ribosome 
and the proteasome. This is in contrast to the opposite regulation of mRNAs in the 
ribosome, proteasome and especially the electron transport chain by physical exercise 
and RICTOR in the DL (see above).
5. MOLECULAR LANDSCAPE OF THE PFC
In Supplementary Figure 8 the physical exercise-mediated changes in expression 
in the PFC are shown in combination with the Bicuculline/Dalfampridine-mediated 
expression of the same proteins. The drugs Bicuculline and Dalfampridine induce 
epileptic seizures, and eight out of nine of the mRNAs regulated by physical exercise 
and these convulsants are associated with epilepsy or seizures (Supplementary Table 
13).
The main theme in the PFC landscape is immediate early gene activation, namely 
three out of nine proteins in the landscape – FOS, FOSB and NR4A1 – are encoded 
by immediate early genes. FOS and FOSB decrease each other’s expression411 and 
NR4A1 inhibits activation of FOSB412. The activation of these immediate early genes is 
regulated by insulin and low density lipoprotein (LDL). Impaired insulin homeostasis is 
associated with PD413 and oxidized LDL is increased in the plasma of (L-DOPA-treated) 
PD patients414. Oxidized LDL regulates the expression of FOS415, 416, and increases the 
expression of FOSB417 and NR4A1417, 418 and both insulin and LDL increase the expression 
of DUSP1419-421 and activate the PI3K complex337, 422 in the cytoplasm. The PI3K complex 
activates NR4A1423 and ERK1/2424-426 and increases the expression of FOS411, 427, 428. 
Oxidized LDL activates the ERK1/2 pathway429 that is also activated by insulin (via PI3K 



















both SNCA and PARK2 inhibit ERK1/2 activation433, 434 and SNCA also binds to ERK1/2433. 
Furthermore, ERK1/2 is activated by the NMDA receptor (NMDAR)435, 436 that also 
increases the expression of FOS411 and ARC437 and is involved in DUSP1 regulation438 (not 
shown). The phosphatase DUSP1 binds to ERK1/2439 and inhibits ERK1/2 activation440, 
441. In turn ERK1/2 activates DUSP1442, 443 and FOS 444, 445, regulates BTG2446, and also 
increases the expression of FOS447, 448, FOSB449 and regulates the expression of DUSP1450. 
Insulin expression/secretion is regulated by PARK2451, increased by BTG2452 and 
decreased by NPAS4453 and NR4A1454. The actin protein ACTA2 binds to the familial 
PD proteins LRRK242 and PARK243. Insulin increases the level of intracellular glucose, 
which is mediated by PI3K113, 455, 456. In turn, glucose decreases the expression of ACTA2125, 
increases the expression of PARK2121 and NPAS4453, activates PI3K457, 458 and activates 
ERK1/2117, 118.
Thus, immediate early gene activation and the epilepsy-related signaling are the main 
pathways in the PFC regulated by both physical exercise and Bicuculline/Dalfampridine. 
Further, (oxidized) LDL, insulin, glucose and the ERK1/2 and PI3K pathways seem 
important for the regulation of these proteins.
5.1 Regulation by physical exercise vs. Bicuculline/Dalfampridine
Physical exercise and Bicuculline/Dalfampridine exert the same direction of effect 
on all mRNAs in the PFC landscape, i.e. they decrease the expression of ACTA2 and 
increase the expression of the other eight proteins. Bicuculline/Dalfampridine 
treatment and physical exercise may therefore (partially) have the same effects on 
the molecular pathways in the PFC. The mRNAs coding for NMDAR and ERK1/2 did 
not show a differential expression due to physical exercise, but are both regulated by 
Bicuculline459, 460.
6. MOLECULAR LANDSCAPE OF THE PPN
In Supplementary Figure 9 the physical exercise-mediated changes in expression in 
the PPN are shown in combination with the CREB1-mediated expression of the same 
proteins. These proteins show very limited interactions in the landscape, but a few 
themes could be distinguished such as vascular remodeling / angiogenesis (CALCB, 
NRP1, SGK1, TAC1), neuropeptide signaling (CARTPT, PENK, TAC1), lipid metabolism 
(EBP, FASN, MVK), epilepsy/immediate early response (JUN, NR4A1, SV2C, TAC1) and 
calcium singaling (CALN1, NRGN, NRP1, Calmodulin (CaM)) (see also Supplementary 
Table 14).
Central in the landscape is the transcription factor CREB1 that regulates the expression 
of JUN461, 462 and NOS1463, increases the expression of NR4A1152, 464, FASN465, MVK162, 
EBP152, TINF2152, FAM65B152, SGK1152, CARTPT152, CALCB466, SVC2C152, NAB2162, PENK152 and 
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TAC1152 and decreases the expression of CALN1152 (binds calcium20), LMO1152, NRGN152 and 
NRP1152. Further, CREB1 binds to JUN467, SGK1468 and is activated by SGK1468, NOS1469 and 
CaM411. The proteins of these CREB1-regulated mRNAs show only a small number of 
interactions with each other. The immediate early response proteins JUN and NR4A1 
bind470 and JUN inhibits NR4A1 activation470. Further, JUN regulates the expression 
of LMO1471, increases the expression of PENK472 and SGK1473 and mediates alternative 
splicing of PARK2474. NR4A1 regulates the expression of FASN475 and is activated by 
TAC1476. Further, CALCB increases the expression of CARTPT477. Furthermore, NOS1 
binds to the calcium binding CaM478, 479 that is binding to the calcium binding NRGN480, 
481. NOS1 is activated by CaM479, 482, NRP1483 (binds calcium20) and SNCA484, and NOS1 
expression is decreased by PARK2485. Lastly, insulin increases the expression of JUN486, 
NR4A1475 and FASN487 and activates SGK1488 and CREB1489 and may therefore be a 
modulating factor of the landscape.
6.1 Regulation by physical exercise vs. CREB1
Physical exercise increases the expression of mRNAs related to epilepsy/immediate 
early response, and decreases the mRNAs involved in neuropeptide signaling. However, 
whereas some of these proteins are increased by CREB1, others are decreased by CREB1 
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ACh,  acetylcholine;
CC,  corpus callosum;
CNR,  control (saline) not running; 
CR,  control (saline) running; 
DA,  dopamine;
DL,  dorsolateral striatum;
FW,  forward strand;
GPe,  globus pallidus external;
GPi,  globus pallidus internal;
L-DOPA, levodopa;
MNR,  MPTP but not running; 
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MSNs,  medium spiny neurons; 
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PFC,  prefrontal cortex;
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RV,  reverse strand;
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VDCC,  voltage-dependent calcium channel;
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VTA,  ventral tegmental area

5
Integrated molecular landscape of 
amyotrophic lateral sclerosis provides 
insights into disease etiology
Cornelius J.H.M. Klemann1, Jasper E. Visser1,2,3, Ludo van den Bosch4, Gerard J.M. 
Martens1#, Geert Poelmans1,5#
1Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Radboud Institute for 
Molecular Life Sciences (RIMLS), Radboud University, Nijmegen, The Netherlands
2Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 
Nijmegen, The Netherlands
3Department of Neurology, Amphia Hospital, Breda, The Netherlands
4Department of Neurosciences, Laboratory of Neurobiology, Experimental Neurology, KU Leuven and VIB, Vesalius 
Research Center, Leuven, Belgium
5Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
# equal contribution
Brain Pathology (2016) [Epub ahead of print]
doi: 10.1111/bpa.12485
5.1 ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a severe, progressive and ultimately fatal motor 
neuron disease caused by a combination of genetic and environmental factors, but its 
underlying mechanisms are largely unknown. In order to gain insight into the etiology 
of ALS, we here conducted genetic network and literature analyses of the top-ranked 
findings from six genome-wide association studies of sporadic ALS (involving 3589 
cases and 8577 controls) as well as genes implicated in ALS etiology through other 
evidence, including familial ALS candidate gene association studies. We integrated 
these findings into a molecular landscape of ALS that allowed the identification of 
three main processes that interact with each other and are crucial to maintain axonal 
functionality, especially of the long axons of motor neurons, i.e. (1) Rho-GTPase signaling; 
(2) signaling involving the three regulatory molecules estradiol, folate and methionine; 
and (3) ribonucleoprotein granule functioning and axonal transport. Interestingly, 
estradiol signaling is functionally involved in all three cascades and as such an 
important mediator of the molecular ALS landscape. Furthermore, epidemiological 
findings together with an analysis of possible gender effects in our own cohort of 
sporadic ALS patients indicated that estradiol may be a protective factor, especially 
for bulbar-onset ALS. Taken together, our molecular landscape of ALS suggests that 
abnormalities within three interconnected molecular processes involved in the 
functioning and maintenance of motor neuron axons are important in the etiology of 
ALS. Moreover, estradiol appears to be an important modulator of the ALS landscape, 
providing important clues for the development of novel disease-modifying treatments.
KEYWORDS:  Amyotrophic lateral sclerosis, Molecular Landscape, Etiology, Estradiol, RNP 
granule, Axon maintenance, GWAS
5.2 INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the 
gradual degeneration of upper motor neurons in the cerebral motor cortex, and lower 
motor neurons in the brainstem and spinal cord. The subsequent muscle weakness and 
atrophy leads to death from respiratory failure, usually within two to five years after 
the first symptoms arise1-4. ALS has a worldwide incidence of 1-3 per 100,000 person-
years, a mean age of onset between 50 and 65 years2, 5-7, and a male to female ratio of 
approximately 2:1REF8, 9. Based on the neuroanatomical substrate from which the initial 
symptoms originate, ALS can be categorized as of either bulbar- or spinal-onset, which 
are characterized by initial speech/swallowing problems or limb-related symptoms 
respectively2.
Previous ALS research has mainly focused on glutamate toxicity, or deficits in protein 




and RNA processing10, 11 as underlying disease-causing mechanisms. The familial ALS 
genes that cause the disorder when mutated often served as a starting point for these 
studies. Thus far, at least twelve familial genes causing ALS have been unequivocally 
identified (C9ORF72, CCNF, CHCHD10, FUS, OPTN, PFN1, SOD1, SQSTM1, TARDBP, TBK1, 
UBQLN2, VCP), whereas mutations in a number of other genes (e.g. ALS2, ANG, ATXN2, 
CHMP2B, HNRNPA1, HNRNPA2B1, NEFH, VAPB) have also been associated with ALS12, 13. 
Approximately 10% of the ALS cases are classified as ‘familial’, i.e. following a Mendelian 
inheritance pattern. However, this classification is no longer so clear because mutations 
in ‘familial’ genes also explain up to 11% of the sporadic, non-inherited cases of ALS11, 
12. Nevertheless, ALS is still considered to be mainly a sporadic disease that, together 
with environmental and lifestyle risk factors14, 15, is associated with a large number of 
common genetic variants (typically single nucleotide polymorphisms or SNPs), each 
with a slightly increased disease risk16, 17. In recent years, genome-wide association 
studies (GWASs) of ALS have identified many of these SNPs for sporadic ALS18-27.
In this study, we have integrated the most significant findings from six published 
GWASs of sporadic ALS, through genetic network and elaborate literature analyses, 
into a molecular landscape that also includes proteins encoded by familial genes 
and therefore covers both familial and sporadic ALS-linked signaling cascades. The 
constructed landscape reveals the involvement of deficits in the functioning and 
maintenance of motor neuron axons as well as estradiol signaling in ALS etiology, and 
provides important clues for new ALS treatments.
5.2 METHODS
5.2.1 ALS GWAS gene selection
ALS candidate genes were selected based on GWAS SNPs and their corresponding 
p-values. All GWASs of sporadic ALS published to date were considered. Criteria for 
study inclusion were a publicly available independent GWAS discovery sample, with 
(at least) all SNPs associated at p<0.0001. From the GWASs for which these data were 
available, SNPs were selected that were associated with ALS at p<0.0001 to compile a 
list of associated genes. The selected genes either contained a SNP that was located 
within an exonic, intronic or untranslated region of the gene, or were found within 100 
kilobases (kb) downstream or upstream of the SNP. The latter was based on the fact that 
the vast majority of expression quantitative trait loci (eQTL) for a given gene are located 
within 100 kb downstream and/or upstream of a gene28-30 and because trait-associated 
SNPs are more likely to be eQTL31. The chosen statistical cut-off for association 
(p<0.0001) has been employed to designate ‘suggestive’ evidence of association 
before32-34. Subsequently, the literature was searched for additional (genetic) evidence 
linking the proteins encoded by the selected GWAS candidate genes to ALS. 
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5.2.2 Genetic network enrichment analysis
To identify enriched protein networks in the ALS GWAS candidate genes, a network 
analysis using the Ingenuity Pathway Analysis (IPA) software package (http://www.
ingenuity.com) was performed, using default parameters. For each network, the 
Ingenuity software generates an enrichment score, i.e. the negative logarithm of the 
right-tailed Fisher’s exact test result.
5.2.3 Molecular landscape building
Guided by the results of the network enrichment analysis, the literature was 
extensively searched for the (putative) functions of all proteins encoded by the ALS 
GWAS candidate genes using the Uniprot Protein Knowledgebase (UniProtKB) (http://
www.uniprot.org/uniprot)35 and PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez). 
Further, the literature was searched for interactions between the ALS GWAS candidate 
gene-encoded proteins and additional ALS candidate genes implicated in the disease 
through other (genetic) evidence, as well as genes/proteins and metabolites that have 
no known link with ALS, but have extensive functional connections with other proteins 
in the landscape.
5.2.4 Analysis of data from a cohort of sporadic ALS patients
We used epidemiological data from a cohort of sporadic ALS patients that were diagnosed 
and followed at the Department of Neurology, University Hospital Gasthuisberg (KU 
Leuven, Belgium) until death to analyze possible gender effects, linked to the relative 
abundance of estradiol in pre-menopausal women. In this respect, the male:female 
ratios before and after the start of the menopause (corresponding to 51 years of age 
on average in Western European women36-39) were compared for the disease-related 
variables ‘age at first symptoms’ and ‘age at death’ for the whole cohort of ALS patients 
and separately for the cases with spinal and bulbar onset. For these comparisons, a 
Chi-square test was used and p-values <0.05 were considered statistically significant. 
Further, possible gender effects on the mean disease duration – the mean time in 
years from age at first symptoms to age at death – before and after the menopause was 
assessed for all ALS patients and separately for the cases with spinal and bulbar onset. 
A Student’s t-test was used and p-values <0.05 were considered statistically significant.
5.3 RESULTS
5.3.1 Selected ALS GWAS genes and genetic network enrichment analysis
Six of the eleven published ALS GWASs met our inclusion criteria (Supplementary Table 
1) and were used to compile a list of 197 unique ALS candidate genes (Supplementary 
Table 2). The most significantly enriched genetic network (p<1.00E-43; Supplementary 




5.3.2 The molecular landscape of ALS
Guided by the most significantly enriched genetic network and extensive literature 
searches, we built a molecular landscape that contains interacting proteins encoded 
by 121 of the 197 GWAS genes (61%; Supplementary Table 2), 92 proteins (and protein 
complexes) implicated in ALS etiology through (familial) candidate gene, mRNA/protein 
expression and/or functional studies (Supplementary Table 3), and 12 proteins that 
have not been directly linked to ALS (yet) but have extensive functional interactions 
within the landscape (Supplementary Table 3).
Supplementary Figures 2 and 3 show all relevant protein interactions that constitute 
the landscape. In the Supplementary Information, a detailed description of the evidence 
linking all the proteins in the ALS landscape is provided, together with the respective 
references. The description here will be restricted to the overview of the ALS landscape 
as shown in Figure 1, depicting the main biological processes and signaling cascades 
in the landscape. Three interconnected main signaling cascades are present in the 
molecular ALS landscape: (1) regulation of Rho-GTPase signaling, (2) signaling involving 
three regulatory molecules (estradiol, folate and methionine) and their metabolites, and 
(3) ribonucleoprotein (RNP) granule functioning and axonal transport. These signaling 
cascades will be briefly discussed below.
Figure 1. Overview of the molecular landscape of ALS. The different pathways and signaling cascades of the 
molecular landscape are shown in a healthy motor neuron (left) and a defective motor neuron from an ALS 
patient (right). Red crosses indicate the dysregulation of pathways and cascades that may result in motor 
neuron destabilization and death. See text for details. 
The first cascade involves signaling through the Rho-GTPases (CDC42, RAC1 and 
RHOA), and controls cytoskeletal dynamics and neurite outgrowth, and is regulated by 
growth factors (e.g. EGF, NGF and VEGF), axonal guidance factors (e.g. CXCL12, netrin) 
and familial ALS proteins (e.g. SOD1 and TARDBP). In addition, the Rho-GTPase RAC1 
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is part of the NADPH oxidase complex that produces reactive oxygen species (ROS) 
and regulates neurite outgrowth. Therefore, dysregulated or deficient Rho-GTPase 
signaling affects cytoskeletal dynamics and neurite outgrowth of motor neurons and 
may increase ROS-mediated oxidative stress. Of note, two very recent genetic studies 
have identified novel ALS genes, C21ORF2 and NEK1 40, 41. The proteins encoded by these 
genes both fit within our ALS landscape, i.e. C21orf2 is a direct functional interactor of 
the NEK1 kinase and a regulator of the cytoskeleton. Moreover, NEK1 is also involved 
in regulating cytoskeletal dynamics, binds the kinesin-II motor complex and is a 
downstream target of the estradiol receptor ESR1.
Second, the folate and methionine cycles, linked with each other through vitamin B12, 
are implicated in ALS through multiple metabolites (e.g. carnitine, homocysteine and 
S-adenylmethionine) and affect estradiol metabolite levels and estradiol-mediated 
transcription (e.g. through transcriptional regulation by the methyltransferase 
MLL). The levels of folate and estradiol metabolites are regulated by the multidrug 
resistance transporters ABCB1 and ABCG2. Tetrahydrofolate (THF), the active form of 
folate, upregulates ABCG2 expression in the cell membrane and downregulates this 
transporter in intracellular organelles, which makes its localized expression dependent 
on THF availability. Furthermore, folate metabolites are involved in the synthesis of 
co-activators of the NMDA glutamate receptor, whereas polyglutamation – the binding 
of multiple glutamate groups – of folate metabolites affects their kinetics in the cell. 
Riluzole, the only FDA-approved drug to treat ALS, is an antiglutamatergic compound 
that reduces glutamate-induced excitotoxicity by inhibiting the NDMA receptor and 
increasing the expression of astrocytic glutamate transporters. However, riluzole itself 
is also transported by ABCB1 and ABCG2, and it increases the expression of ABCG2. 
Hence, riluzole not only affects and regulates glutamatergic signaling, but also the 
intracellular levels of estradiol and folate (metabolites). Estradiol metabolites have 
different affinities for ESR1 and their regulation (e.g. through efflux and conversion) 
affects ESR1-dependent transcription and activation. Taken together, a complex 
interaction exists between folate, methionine and estradiol metabolites, associated 
with glutamate-induced excitotoxicity and effects of riluzole.
Third, most of the proteins encoded by genetically linked ALS genes appear to be 
involved in RNA processing and transport. These proteins are located in RNPs, which 
are complexes of mRNAs and RNA-binding proteins. RNPs regulate the processing, 
transport and immediate local translation of their constituent mRNAs, enabling the 
neuron to quickly react to environmental cues and/or damage in the axon and/or distant 
synapse. Motor neurons have exceptionally long axons and therefore rely heavily on the 
RNP system to locally regulate protein expression far away from the cell body. Cellular 




until future demand. The formation and aggregation of these stress RNPs, or stress 
granules, are increased in ALS motor neurons. Moreover, mutations in e.g. the familial 
ALS genes FUS and TARDBP result in increased stress granule formation and affect 
(local) mRNA translation. The RNP system does also rely on the above-mentioned Rho-
GTPase signaling, which is required for cytoskeletal maintenance and neuronal (out)
growth. RNPs are transported via this ‘cytoskeletal framework’ to their site of action in/
along the axon. Therefore, deficient Rho-GTPase signaling also negatively affects the 
axonal transport and function of RNPs.
Of note, estradiol and ESR1 control axonal (out)growth by regulating Rho-GTPases and 
their expression, physically interact with RNPs and familial ALS proteins, and affect 
the regulation of glutamate-induced excitotoxicity and the NADPH oxidase complex. 
Moreover, estradiol and ESR1 interact with and/or regulate (the expression of) multiple 
other proteins in the landscape. Therefore, estradiol-related signaling appears to be 
an important modulator within the ALS landscape, through regulating axonal function 
and maintenance and hence motor neuron function and survival.
5.3.3 Analysis of data from a cohort of sporadic ALS patients
Our molecular landscape of ALS pointed towards an important regulatory role of 
estradiol in the etiology of the disease. Therefore, we used epidemiological data of 
a cohort of sporadic ALS patients to analyze possible gender effects – linked to the 
relative abundance of estradiol in pre-menopausal women – on the age at onset, disease 
duration and age at death of bulbar- and spinal-onset ALS patients. An overview of the 
cohort of sporadic ALS patients is shown in Supplementary Table 4. The male:female 
ratio of all ALS patients is significantly lower after the start of the menopause – 
indicating a relatively increased number of affected females – for the disease-related 
variable ‘age at first symptoms’ (P=0.016; Figure 2). Further, the mean duration of 
Figure 2. Analysis of data from a cohort of sporadic ALS patients for possible gender effects on the prevalence, 
onset and disease duration of (bulbar- and spinal-onset) ALS. The male:female ratio for the disease-related 
variable ‘age at first symptoms’ (left), the ‘mean duration of disease’ (middle) and ´age at death´ (right) was 
compared for all ALS cases, and separately for the cases with spinal or bulbar onset, before and after the start 
of the menopause (corresponding to 51 years of age in Western European women). A Chi-square test was used 
for the analyses of ‘age at first symptoms’ and ‘age at death’, and the Student’s t-test was used for the analysis 
of ‘mean duration of disease’. P-values are indicated above the bars and considered significant when p<0.05.
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disease is longer in younger ALS patients (all <51 versus all ≥51 years old; p=5.3E-06), 
and in spinal-onset versus bulbar-onset ALS patients (p=6.5E-11), but is independent 
of gender for both. However, when analyzing bulbar- and spinal-onset separately, 
postmenopausal women with bulbar-onset ALS have a longer mean duration of disease 
compared to male bulbar-onset ALS patients (p=0.029). Furthermore, the parameter ‘age 
at death’ showed that the male:female ratio of all patients and especially that of bulbar-
onset ALS patients is reduced (from a ratio of 3:1 to 1:1) after the start of the menopause 
(p=0.011 and p=0.022, respectively).
5.4 DISCUSSION
In this study, we integrated available ALS data into a molecular landscape that reveals 
the main biological processes that are affected in ALS, i.e. Rho-GTPase signaling, 
signaling involving estradiol, folate and methionine, and RNP granule functioning and 
axonal transport, that may contribute to motor neuron dysfunction and, ultimately, 
death. The molecular ALS landscape represents processes and cascades that may be 
affected in both the monogenic, familial and the more prevalent polygenic, sporadic 
forms of ALS. In this respect, the landscape includes processes and signaling cascades 
reported to be involved in familial ALS such as oxidative stress and RNA processing, 
as well as processes of ‘classical’ ALS theories such as glutamate toxicity. However, 
the landscape also comprises processes that have been less well studied before – e.g. 
growth- and guidance factor signaling and cytoskeletal dynamics – and also sheds 
further light on the functional relationships between the various ALS-linked processes. 
Interestingly, estradiol signaling is functionally involved in all main processes and as 
such an important modulator of the ALS landscape.
It is important to note that the molecular landscape is not intended to imply a fixed 
‘sequence of events’ that eventually leads to motor neuron death in all patients, i.e. 
a number of biological processes that occur in a temporally and/or spatially distinct 
order. Instead, we propose that deficits in any of the main landscape processes, either 
by themselves or in combination with others, can cause motor neurons to die. Of note, 
the familial proteins are often involved in more than one of these main processes and/
or of crucial importance to these processes. Consequently, mutations in the familial 
ALS genes have a functionally ‘high impact’ in the landscape and directly lead to 
ALS, whereas in sporadic ALS patients multiple functionally ‘lower-impact’ genetic 
variations are required to develop the disease. For example, mutations in the familial 
gene SOD1 result in oxidative stress42, affect Rho-GTPase signaling43 and impair axonal 
transport of the enzyme choline acetyltransferase44 that synthesizes acetylcholine, 
the main and essential neurotransmitter at the neuromuscular synapse45. Thus, 
both familial mutations and sporadic variations may result in disorganization of the 




Within our ALS landscape, Rho-GTPases are important regulators of neuronal 
development and survival as well as cytoskeleton dynamics46, and as such they are 
crucial for axonal maintenance, regeneration and transport. This view is supported by 
reported defects in the regulation of motor neuron axonal regeneration of motor neurons 
in ALS patients47, 48 and ALS mouse models49, 50. In addition, regulation of neurofilaments 
– the major building blocks of the cytoskeleton and crucial for axonal regeneration51 – 
is affected in ALS patients52 and in ALS mouse models53, 54, and multiple studies have 
shown defects in axonal transport55-58 and dysregulation of motor proteins59-61 in motor 
neurons of ALS patients. 
Of note, axonal regeneration is dependent on DNA methylation, which is regulated 
by the landscape’s methionine and folate cycles and enhanced by folic acid (folate) 
supplementation62-64. Because the DNA methylation cascade regulates – through MLL 
activation – the transcriptional activity of the estradiol receptor ESR165, these findings 
together imply that methionine, folate and estradiol are important modulators of ALS 
pathogenesis.
The vitamin B12-linked folate and methionine cycles are also implicated in ALS 
through multiple previous studies. For example, homocysteine is increased in 
the plasma and CSF of ALS patients66-68, whereas carnitine69 and methionine70 are 
decreased in the plasma of ALS patients. Furthermore, folic acid supplementation is 
neuroprotective71, S-adenosylmethionine delays disease onset72 and carnitine decreases 
disease progression and increases survival73 in a mouse model for ALS. Carnitine 
supplementation may also be beneficial in ALS patients74 and methyl-vitamin B12 may 
delay the motor symptoms of ALS67, 75, 76. Nevertheless, the benefits of supplementing 
these metabolites may not be universal, as ALS patients may have different nutritional 
deficiencies. For example, hyperhomocysteinemia has been noted in rats on a low 
methionine diet77, as well as in human vegetarians and vegans along with decreased 
vitamin B12 and increased folate levels compared to controls on an omnivorous diet78. 
Another environmental factor that affects these pathways is endurance exercise, 
associated with increased homocysteine plasma levels79, 80 together with low vitamin 
B12 and folate levels79, 81, 82. Vigorous physical activity may therefore – at least partially 
– affect pathways that are part of ALS etiology, and it is tempting to speculate that 
this may be the link between a highly active lifestyle and/or high level of physical 
fitness (e.g. athletes, blue-collar workers) and increased ALS incidence14, 83-87. Therefore, 
it is worthwhile to further investigate whether individuals on a specific diet, with or 
without an active lifestyle, have an increased risk to develop ALS due to dysregulation 
of their folate and methionine cycles.
Another important factor in the ALS landscape is estradiol signaling that functionally 
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integrates, regulates and is regulated by key landscape processes. Estradiol mediates 
cytoskeleton dynamics through interacting with Rho-GTPases and the NADPH oxidase 
complex, and as such may protect motor neurons against degeneration. This apparent 
critical role of estradiol and related signaling in ALS etiology is corroborated by several 
lines of evidence. First, epidemiological studies have demonstrated that men have 
an approximately three times higher risk to develop ALS before the age of 50 years 
than women88, a gender difference that gradually decreases with increasing age38. Our 
epidemiological analysis of a large cohort of sporadic ALS patients confirms these 
findings and suggests that premenopausal women are – to a certain extent – protected 
against ALS. Further, for bulbar-onset – but not spinal-onset – ALS, the mean duration 
of disease is longer in postmenopausal women than in men, and also the male:female 
ratio for the age at death is drastically decreased after the menopause. This indicates 
that estradiol may exert a protective effect especially for bulbar-onset ALS and that 
the effect on the disease duration may be due to residual estradiol slowing disease 
progression. To our knowledge, this is the first study that shows an association between 
estradiol and the primary neuroanatomical substrate (spinal versus bulbar) from which 
the initial ALS symptoms originate. 
The involvement of estradiol signaling in ALS pathogenesis is also in line with 
functional studies in ALS animal models showing that estradiol delays disease onset 
and progression, and increases survival89-91. Moreover, estradiol protects cultured spinal 
motor neurons against excitotoxicity and rescues these neurons from degenerating 
and dying92-95. Taken together, these findings imply that estradiol and estradiol-related 
signaling have an important modulatory role in motor neuron function and survival.
In this respect, it is of note that gender differences can also be observed at the genetic 
level, i.e. SNPs in the gene encoding the ESR1 co-activator PPARGC1A are associated 
with age of ALS onset and survival in males specifically96. Moreover, genetic variations 
in MTHFR 97, 98 – which encodes an important enzyme in the folate cycle – and in 
the promoter region of the growth factor VEGFA99 have been associated with ALS in 
women. These notions imply that the presumed hormonal neuroprotective advantage 
of women could be counteracted by genetic variations in, for example, the folate cycle 
and/or VEGF signaling.
Currently, the antiglutamatergic drug riluzole is the only FDA-approved drug to treat 
ALS and extends the life expectancy of ALS patients by approximately 2-3 months100. 
Multiple other antiglutamatergic compounds have been tested in clinical trials – either 
by themselves or in combination with riluzole – but were unsuccessful101-107. These 
findings imply that the beneficial function of riluzole may not be limited to regulating 




is regulated by transporters that also control folate and estradiol metabolite levels in 
the cell108-110, which may therefore be an additional mechanism through which riluzole 
conveys neuroprotection in ALS. It is tempting to speculate that such a multi-modal 
effect of riluzole explains its effectiveness in ALS, while other antiglutamatergic 
compounds fail.
In conclusion, our integrated molecular landscape of ALS highlights the involvement 
of processes that lead to deficient axonal functioning of motor neurons (i.e. axonal 
transport, local translation, regeneration and outgrowth) and points toward estradiol-
related signaling as an important mediator of ALS pathological mechanisms. 
Consequently, the landscape not only yields in-depth insights into the etiology of ALS 
but also provides new clues for the development of disease-modifying ALS treatments.
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Supplementary Figure 1. Top enriched Ingenuity genetic network. Shown is the network with the highest score 
(P=1.00E-43) and containing the highest number of proteins (23), as obtained by a network enrichment analysis 






































Supplementary Figure 2. Molecular landscape of ALS (1/2). The landscape is visualized in a motor neuron and 




















Supplementary Figure 3. Molecular landscape of ALS (2/2). The landscape is visualized in a motor neuron and an 
astrocyte, and it especially shows regulation of estradiol metabolites and the effects of the folic acid and methionine 
cycles on estradiol signaling.
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Supplementary Table 4. Overview of ALS patient cohort
Spinal onset Bulbar onset Total
Male patients 341 114 455
Female patients 171 121 292
Mean age at first symptoms (years) 58.9 62.12 59.89
Mean age at death (years) 62.25 64.57 62.98























1.  RHO-GTPase SIGNALING 316
1.1 Guidance factors 316




1.3 Intracellular signaling 320
1.3.1 Adaptor proteins 320
1.3.2 ERK1/2 signaling 321
1.3.3 Regulation of neurite outgrowth 322
1.3.3.1 Rho-GTPase-associated kinases 322
1.3.3.2 Amyloid-beta precursor protein APP 323
2.  ESTRADIOL SIGNALING 324
2.1 NADPH-oxidase 325
2.2 Folate cycle and methionine cycle 325
2.2.1 Regulation of estradiol and cholesterol metabolites and riluzole 327
2.2.1.1 Estradiol and cholesterol metabolites 327
2.2.1.2 FA, glutamate toxicity and riluzole 328
2.3 Interaction between NF-KB, ESR1 and MLL-complex 330
3.  RNP GRANULES, INTERMEDIATE FILAMENTS AND AXONAL TRANSPORT 332
3.1 Assembly and function of RNP- and stress granules 333
3.2 Stress granule clearance 334
3.3 Intermediate filaments and RNP granules 335
3.4 Axonal transport by motor complexes 336





















In this supplementary section, the protein interactions and regulatory processes 
in the molecular landscape of amyotrophic lateral sclerosis (ALS) are described and 
divided into three themes: (1) Rho-GTPase signaling, (2) estradiol signaling, and (3) 
ribonucleoprotein particle (RNP) granules and intermediate filament functioning. 
These themes overlap functionally and are all involved in neurite outgrowth.
In the description of the ALS landscape, names of proteins derived from the genome-
wide association studies (GWASs) are in bold, single-underlined proteins are genetically 
associated with ALS, dotted underlined genes encode proteins that are differentially 
expressed in ALS or functionally linked to ALS, and double underlined genes are 
genetically associated with ALS and encode a protein that is differentially expressed 
in or functionally linked to ALS. The gene name abbreviations refer to both the gene 
and the protein. Furthermore, the terms ‘activates’ and ‘inhibits’ are used to indicate 
the activation/inhibition of a protein (e.g. by (de)phosphorylation) by another protein. 
To describe a difference in abundance of a protein (directly or indirectly) induced by 
another protein, the terms ‘increases the expression of’ or ‘decreases the expression of’ 
are used. Finally, interactions in the ALS landscape that are not shown in the figures are 
indicated as ‘(not shown)’ in the text.
Supplementary Figures 2 and 3 show all relevant protein interactions in the ALS landscape; 
the metabolites within the landscape are mostly presented in Supplementary Figure 3. 
Supplementary Table 2 presents all GWAS gene-encoded proteins in the landscape and 
the corroborating evidence for their associations with ALS, and in Supplementary Table 
3 all other landscape proteins and the corroborating evidence for their associations 
with ALS are listed.                                                                                                                                                     
Not all GWAS gene-encoded proteins were placed in the landscape, either because 
they do not interact with any of the landscape proteins or due to lack of annotation, 
or both. However, this does not necessarily mean that they are not involved in ALS 
pathophysiology. For example, the genes coding for arylsulfatase G (ARSG ), alpha-protein 
kinase 1 (ALPK1) and protein FAM189A1 (FAM189A1) contain (multiple) nonsynonymous 
single nucleotide polymorphisms (SNPs) that are associated with ALS and alter the 
amino acid sequence of these proteins. However, the functions of these proteins 
and their interactions with other proteins are essentially unknown and therefore 
these proteins could not be linked to processes or pathways in the ALS landscape. 
Nevertheless, future research may link these proteins to ALS pathophysiology and the 
processes and pathways in the current ALS landscape.



















or animal model increases the expression of protein B, we presume that endogenous 
expression of protein A leads to the opposite effect and decreases the expression of 
protein B. Second, we assume that the protein interactions and regulatory processes 
observed in various organisms and/or cell types can be extrapolated to events occurring 
in human cells.
1.  RHO-GTPase SIGNALING
Central in the ALS landscape is the regulation of the GTP-hydrolyzing (Rho-GTPase) 
proteins RAC1, CDC42 and RHOA, important mediators of neuronal functioning, 
including neurite outgrowth and apoptosis. The following findings indicate that the 
regulation of Rho-GTPase signalling and neurite outgrowth is indeed involved in 
the pathogenesis of ALS. First, (motor) neuronal cytoplasmic inclusions containing 
clusters of the familial ALS protein TARDBP have been found in the vast majority of 
familial and sporadic ALS patients157, 158 and TARDBP activates the three GTPases RAC1, 
CDC42 and RHOA159. Second, the familial ALS, and cytoskeleton regulating protein 
profiling-1 (PFN1) binds to CDC42160 and RHOA161. Third, RAC1 is bound, and regulated by 
the familial proteins SOD1102 and ALS2127, 162-164 that also bind to each other165 and regulate 
neurite outgrowth127, 164, 166.
In the next sections, the regulation of the three Rho-GTPases by guidance factors (section 
1.1) and growth factors (section 1.2), and their link with ALS is described, followed 
by a description of the regulation of adaptor proteins and signalling cascades in the 
cytoplasm eventually leading to GTPase activation and regulation of the cytoskeleton 
(section 1.3).
1.1 Guidance factors
Netrin axonal guidance ‘cues’ bind to the netrin receptor DCC which activates CDC42167 
and RAC1168 and (eventually) results in neurite attraction towards the netrin guidance 
cues169, 170. DCC-mediated RAC1 activation occurs through activation of the cytoplasmic 
guanine-nucleotide exchange factor DOCK1171, 172. DCC also binds and interacts with 
the netrin receptor UNC5C, which regulates axon guidance173, 174 as well and is required 
for spinal motor neuron development175. In spinal motor neurons, DCC also binds and 
interacts with ROBO1 – a receptor for the SLIT family of axonal guidance cues that 
mediates neurite repulsion away from SLIT cues176. Upon binding to SLIT molecules, 
ROBO1 binds and interacts with the peripheral membrane protein SRGAP3163 and 
DOCK1177. SRGAP3 inhibits both CDC42 and RAC1163, whereas DOCK1 activates RAC1172. 
Further, PIP4K2A is a cytoplasmic kinase that binds to RAC1 and RHOA178, is activated 
by CDC42 as well as RAC1 and RHOA (not shown)178, 179 and catalyzes the formation of 
phosphatidylinositol 4,5-bisphosphate (PIP2)180 that negatively regulates netrin/DCC-
dependent neurite outgrowth of motor neurons (not shown)181. On the other hand, 
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DAB1-dependent signalling increases DCC expression182 (not shown). The RHOA-ROCK1 
signaling cascade, that is involved in neurite outgrowth inhibition, is activated and 
initiated through binding of RGMA, a repulsive axonal guidance membrane protein, to 
its receptor NEO1183-186. The cell surface receptor SEMA6A is another repulsive axonal 
guidance protein and its inhibitory function on axonal growth can be attenuated by 
NGF187-189.
The extracellular chemoattractant CXCL12 induces neurite outgrowth190, 191 and binding 
of CXCL12 to its membrane receptor CXCR4 activates DOCK1172; CXCR4 is neuroprotective 
in motor neurons derived from the SOD1-G93A transgenic mouse model of ALS65. 
Furthermore, CXCL12-CXCR4 signaling is inhibited by ADRBK2, a cytoplasmic kinase 
and negative regulator of cell growth192, 193. CXCL12 also increases the binding of adhesion 
membrane glycoprotein ICAM1 to its receptor ITGAL194, 195 (not shown). ICAM1 binds 
TUBA4A196, activates RAC1197 (not shown) and RHOA198 (not shown), and upregulates 
of the expression of interferon gamma (IFNG)199, 200, an extracellular cytokine and 
sporadic ALS biomarker93 that regulates the apoptosis of motor neurons201. In addition, 
ICAM1 competes with ESM1 for binding to ITGAL202 (not shown) and is inhibited by the 
motor neuron survival-promoting angiogenin (ANG)92. Conversely, IFNG induces the 
formation of the ICAM1-ITGAL complex through increasing the expression of ITGAL203 
and decreasing ESM1 expression204. Further, IFNG can induce a neuronal (auto)immune 
response through increasing the expression of HLA class II membrane proteins HLA-
DQA1, HLA-DQB1 and HLA-DRA205, and HLA class I membrane protein HCP5206. Thus, the 
GTPases RAC1, CDC42 and RHOA are regulated via netrin, SLIT and RGMA signalling, 
but also by the more immune related proteins CXCL12, ICAM1 and IFNG.
1.2 Growth factors
The main growth factors in the ALS landscape are epidermal growth factor (EGF), nerve 
growth factor (NGF), and vascular endothelial growth factor (VEGF). In the next three 
paragraphs we describe how these growth factors regulate multiple (intracellular) 
cascades through activation of their receptors on the cell membrane, and how they are 
regulated themselves in the ALS landscape. 
1.2.1 EGF
EGF binds to the EGF receptor (EGFR) and thereby stimulates the growth of cells and 
neurite outgrowth in motor neurons207. EGF increases the expression of the transporter 
ABCG2208 (see also section 2.2.1) and decreases the expression of the estradiol 
receptor ESR1209 (not shown). When bound/activated by EGF, EGFR binds to the Rho 
guanine nucleotide exchanged factors RAPGEF1210, 211 and ARHGEF7211 and activates 
the adapter protein GRB2183 (not shown, see also section 1.3.1), the kinases ERK1/2209, 212, 



















activation213, 215-218 – and RAC1 itself219 (not shown). In turn, RAC1 inhibits EGFR220 (not 
shown). In addition, EGFR binds to the adenylate kinase AK4221 (not shown), the serine 
carboxypeptidase CPVL221 (not shown), the RNA-binding protein MATR3222, the ESR1 
coactivator PPARGC1A223 (not shown), the kinase TBK1221, the tubulin protein TUBA4A223, 
and the TGF-beta receptor subunit TGFBR2224 (that is increased by EGF225, decreased 
by estradiol226 and itself regulates the expression of the autophagy regulator WDFY3 
that increases the removal of aggregated SOD1 proteins in mutant SOD1 mice227 and 
binds to the autophagy receptor SQSTM1228, 229). Further, EGFR increases the expression 
of MTHFR230, ABCG2231, E2F3232 (not shown), and the hnRNP proteins HNRNPA1233, 234 
and HNRNPA2B1233. The ALS-associated protein ATXN2 functionally interacts with 
TARDBP51, binds to EGFR235, is involved in trafficking of EGFR and is a negative regulator 
of EGFR internalization235.
The isoforms of pro-neuregulin-1 (NRG1) regulate neurite outgrowth and differentiation, 
induce the expression of the acetylcholine (ACh)-receptor, and may therefore play a 
role in motor neuron regulation183, 236-238. Moreover, NRG1 binds to the EGFR211, 239 and 
thereby inhibits EGF binding to the EGFR211. Nevertheless, NRG1 activates RAC1 via 
transactivation of EGFR, and independently of the tyrosine kinase receptor ERBB4219, 
240, which is activated by NRG1183, 241-243. After binding NRG1, ERBB4 is internalized and 
promotes (neuronal) cell migration and reorganization of the actin cytoskeleton183.
1.2.2 NGF 
NGF is a ligand for its high-affinity receptors NTRK1 and NTRK2, and important for 
neuronal proliferation and survival by activating these receptors183. The extracellular 
proprotein convertase PCSK6 produces NGF244, and binding of NGF to NTRK1 promotes 
cell survival and differentiation by activating RAC1163. The GDP-dissociation stimulator 
protein TIAM1 mediates NGF-induced NTRK1 and NTRK2 signaling and subsequent 
neurite outgrowth245.
The NGF-NTRK1 complex binds and activates TRPV1246, a non-selective cation channel 
that regulates apoptosis247 and increases the release of the neuropeptide NPS248. Further, 
NTRK1 binds to the microtubule motor protein KIF14249, the RNA-binding protein 
MATR3249, the kinase PLK1249, the ALS-associated proteins ATXN2249, SQSTM1250, 251 (not 
shown), TARDBP249, UBQLN2249 (binds and modulates TARDBP levels252), VAPB249, PFN1249, 
VCP249 and TBK1249, the RAC1-activator ARHGEF7249, the transporter ABCB1249, RAD23B249, 
but also to enzymes involved in the methionine cyle (MTR249, CBS249, MARS249, MAT249 
and AHCY249; see also section 2.2) and to the hnRNP proteins HNRNPA2B1249 (not shown) 
and HNRNPA1249.
Activation of NTRK2 results in the phosphorylation and inhibition of the potassium 
channel KCNJ3253 (that also binds to and is activated by DRD2254, 255 and upregulated 
by AR256; not shown). In addition, binding and activation of NTRK2 by NGF257 results 
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in the activation of ERK1/2258 and binding of NTRK2 to TIAM1259. TIAM1 is activated by 
NTRK2259 and NRG1260, and subsequently binds RAC1 and stimulates RAC1 activation259, 
261-263. Further, the familial ALS protein SQSTM1 binds to NTRK2251, whereas ALS2 
increases the endocytosis of NTRK2264 (not shown) and activates PAK1164 (not shown).
Thus, NGF signaling is linked to major processes in the ALS landscape, namely to RAC1 
signaling, neurite outgrowth, the methionine cycle by binding most of its regulating 
enzymes (see Figure 2), and the regulation of mRNA and RNP granules (see also section 
3) by binding to multiple familial ALS and RNA-binding proteins.
1.2.3 VEGF
VEGF is originally described as an angiogenic factor, but has more recently also been 
shown to be involved in neurogenesis, nerve repair, neuronal survival, protection and 
growth265, 266. VEGF protects against hypoxia-induced motor neuron degeneration in 
mice267 and delays disease onset and prolongs survival in a rat model of ALS268. The 
VEGF family consists of five proteins that are encoded by the genes VEGFA, VEGFB, 
VEGFC, VEGFD and PGF183 (which are in the figures depicted together as VEGF) that bind 
and activate the VEGF receptors FLT1, KDR and FLT4269. The interactions and effects on 
protein expression and activation within the ALS landscape are described below for 
each VEGF family member and receptor.
VEGFA was genetically associated to ALS154 and binds and activates the VEGF receptors 
FLT1270-272 and KDR273-276 and increases the expression of PPARGC1A277 (not shown), 
HSD17B1278 (not shown), TEK279, NRF1280 (not shown), NRG1281, FLT4282 (not shown), 
CXCR4283-285 and KMT2A (the core subunit of the MLL-complex)281, and decreases the 
expression of CASP3286 (not shown) and EPO287. Further, VEGFA increases the activation 
of NF-KB288, 289 (not shown), the kinase PAK1290, the Rho-GTPases RHOA291 (not shown), 
and activates and increases the expression of the Rho-GTPases RAC1292-295 (not shown) 
and CDC42295, 296 (not shown). In turn, VEGFA expression is increased by RAC1297, 298, 
PAK1299 (not shown), AR300 (not shown), NF-KB301, 302, NRG1299, 303 (not shown), IFNG304, 
EGF305, 306, EGFR307-309, TBK1310, homocysteine311, PPARGC1A312, estradiol301, 313-315 and ESR1316-
318, and regulated by NGF319, 320 (not shown), TEK321 (not shown) and TGFBR2322, 323 (not 
shown). Lastly, VEGFA binds to HABP2324 that increases the cleavage of VEGFA324. 
VEGFB binds and activates FLT1325, 326, activates ERK1/2327, 328 (not shown) and NF-KB327 
(not shown) and decreases the expression of CASP9326 (not shown). NRG1 decreases the 
expression of VEGFB329, but increases the expression of VEGFC via NF-KB330. 
VEGFC binds, activates and increases the expression of KDR274, 331-333 and FLT4333-336. 
Further, VEGFC activates ERK1/2337, increases the expression of CXCR4338, and increases 
the synthesis of hyaluronic acid (HA)339. VEGFC expression is increased by EPO340, 
BMI1341, EGF342, IFNG343, and decreased by ESR1344. 



















expression is decreased by ERBB4350.
PGF binds and activates FLT1272, 351-354, activates ERK1/2355, 356, inhibits CASP3357 and 
increases the expression of FLT1354 and CXCR4358. 
FLT1 binds and inhibits KDR354, 359, 360, binds CRK361, activates RAC1362 (not shown) and 
ERK1/2356, 363 (not shown). The soluble isoforms of FLT1 are secreted and sequester VEGF 
to block its access to the VEGF receptors on the cell membrane, and thereby regulate 
VEGF signaling360. Further, FLT1 increases the expression of G3BP1362, MAT2A (isoform 
of MAT, see also section 2.2)362, and decreases the expression of the homocysteine 
producing enzyme AHCY362. FLT1 expression is increased by ERK1/2364 and cholesterol365.
KDR binds ERK1/2366, and the adaptor proteins SHC1367, 368 (not shown) and GRB2367 (see 
also 1.3.1). KDR activates ERK1/2369 and mediates the activation of RAC1370 (not shown) 
RHOA370 (not shown) and SHC1371 (not shown). Further, KDR activation is inhibited 
by DRD2372 and DA increases (via DRD2 activation) the endocytosis of KDR373. On the 
other hand, SEMA6A increases the activation of KDR374, and also EPO increases KDR 
activation by increasing the expression of VEGF375. KDR expression is increased by 
estradiol376-378, TGFBR2323, SEMA6A374 and NF-KB379, and decreased by IFNG380.   
FLT4 binds to the adaptor proteins SHC1381 (not shown) and GRB2381 (not shown), and to 
KDR382 (not shown). FLT4 expression is increased by IFNG383 (not shown).
In summary, VEGF signalling regulates, and is regulated by (among others) Rho-
GTPase signalling (through RAC1, CDC42, RHOA), estradiol signalling (through estradiol, 
HSD17B1, PPARGC1A), other growth factors (EGF, NGF), the methionine cycle (through 
AHCY, homocysteine, MAT) and HA signalling (through HA and HABP2). Thus, VEGF 
signalling interacts with multiple major ALS landscape processes and may in this way 
exert neuroprotective effects on motor neurons.
1.3 Intracellular signaling
The above-described signaling cascades that regulate the GTPases RAC1, CDC42 
and RHOA require cytoplasmic adaptor proteins (section 1.3.1) and activate ERK1/2 
signaling (section 1.3.2). Activation of these pathways eventually leads to the activation 
of the Rho-GTPases and subsequently the activation of the major downstream effector 
proteins ROCK1 and LIMK1 that regulate neurite outgrowth (section 1.3.3).
1.3.1 Adaptor proteins
Adaptor proteins such as SHC1, GRB2, CRK and YWHAB regulate the signal transduction 
processes of receptor-ligand complexes in the cytoplasm.
The adaptor protein SHC1 inhibits RAC1 and in this way mediates ALS-like motor 
neuronal death129 (not shown), and increases the expression of SQSTM1384 (not shown) 
that also binds to and interacts with the familial ALS proteins TARDBP385, 386, SOD1142, 
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OPTN387 and TBK1388. Following activation, SHC1 binds to GRB2, another adaptor 
protein183, 389, 390. SHC1 as well as GRB2 bind to and are activated by (NRG1-activated) 
ERBB4391-394, are recruited to, and bound and activated by the NTRK1-NGF complex249, 
395-398, and bind to the phosphatase DUSP15399 and the membrane protein TEK400-402 
(not shown). TEK activates SHC1403, increases the expression of IFNG404 and regulates 
a number of processes, including cell survival and proliferation, reorganization of 
the actin cytoskeleton183 and neurite outgrowth405. SHC1 is also activated by ALK406, a 
neuronal receptor tyrosine kinase that is on its turn activated through binding to the 
extracellular growth factor midkine (MDK)407, and promotes neuronal cell growth and 
neurite outgrowth408, 409. Further, GRB2 binds to MATR3410 and to the RAC1-activators 
ARHGEF7411 (not shown) and DOCK1412, 413 (not shown). ARHGEF7 is a guanine nucleotide 
exchange factor and binds to the kinase PAK1412, 414, 415 and also binds and subsequently 
increases the activation of CDC42416-418 and RAC1417, 419, 420. ARHGEF7 expression is 
increased by AR421 (that also decreases expression of PLK1422 (not shown), and binds 
to SQSTM1423 (not shown)) and is decreased by ESR1424. Like ARHGEF7, DOCK1 is a 
guanine nucleotide exchange factor that binds to RAC1425, 426 (not shown) and activates 
RAC1 by increasing the exchange of bound GDP for free GTP172, 183, 427, 428. The adaptor 
proteins SHC1 and GRB2 bind and interact with the guanine nucleotide exchange factor 
RAPGEF1429-432, which in turn activates both CDC42433 and RAC1433, 434, and increases 
neurite outgrowth435, 436.
The adaptor protein CRK binds to EGFR211, 437 (not shown), DAB1438, 439, GRB2440, 441 (not 
shown), SHC1442, ERBB4392, FLT1361, PPP1CA443 (not shown), AR444 (not shown), ABAT399 
(not shown), ATXN1445 (that binds also to RAPGEF1446) and YWHAB447 (not shown), binds 
to and activates RAPGEF1429, 432, 448-450 and DOCK1413, 441, 451, and activates RAC1452, 453 (not 
shown). Further, CXCL12 binding to its receptor CXCR4 activates CRK454 (not shown) 
and CRK itself regulates the binding of DAB1 to DOCK1438. Lastly, the adapter protein 
YWHAB forms functional complexes with the PAK4 kinase455 and the cytoplasmic 
proteins ALS2455, 456, VCP457, EPB41L3456, 458 (a cytoskeleton adaptor that is involved in 
axoglial junction maintenance459 and binds to AP3B1460 and endosomal sorting protein 
CHMP2B461 that also binds to RAC1461; not shown), DDIT4L462, GFAP463, the adaptor protein 
SHC1464 and the Rho GTPase activators TIAM1263 and ARHGEF7465, 466. 
1.3.2 ERK1/2 signaling
Aggregates of abnormally phosphorylated ERK1/2 have been found in spinal motor 
neurons of ALS patients79, which indicates that ERK1/2-related signaling – that regulates 
many processes including neurite outgrowth467 and (motor) neuronal survival468 – is 
involved in ALS pathogenesis. ERK1/2 bind to the ALS-associated proteins VCP457 and 
SQSTM1469, 470. Further, the ERK1/2 cascade is activated by EGF, NGF and VEGF signaling 



















(DISC1 functionally interacts with the dopamine receptor DRD2476, 477, binds to MATR3478, 
and increases neurite outgrowth by increasing the expression of cell-cell adhesion 
protein CDH2479 that is involved neurite outgrowth480 and axonal guidance481), ESR1482, 
folic acid (FA)483 (not shown), NRG1219 (not shown), DRD2484 (not shown) and the familial 
ALS protein ANG485. Further, ERK1/2 is (positively or negatively) regulated by ICAM1486, 
487 and inhibited by the microtubule-associated protein MTUS1488 and the GTPase 
CHN2219. Further, ERK1/2 expression is increased by TNFSF11489, that also increases 
the expression of IFNG490 and ICAM1491, and interacts with ESR1 (see section 2.3). 
ERK1/2 binds to VCP457, PRPH492 (not shown) and VAPB492, and interacts with SOD1492. 
In addition, ERK1/2 interacts with ROCK1 (see section 1.3.3.1), increases the expression 
of PPARGC1A493 and RAC1494, decreases the expression of ESR1495, 496, and increases the 
activity of nuclear NF-KB212, 497 (not shown). Thus, ERK1/2 is an important effector protein 
in multiple neurite outgrowth- and axonal guidance-regulating cascades, and thereby 
regulates RAC1, ESR1 and NF-KB function, i.e. main cascades in the ALS landscape.
Hyaluronic acid (HA) is increased in serum, skin and urine of ALS patients498, 499. 
Through binding HA activates the extracellular protein HABP2183 that in turn activates 
RHOA500 (not shown) and inhibits ERK1/2 activity501. HA also activates RAC1502, 503, ESR1504, 
NF-KB505, ROCK1506 and EGFR507, inhibits CASP3508, binds to APP509, and increases the 
expression of RHOA506 and ABCB1510. Further, HA production/synthesis is increased by 
EGF511 and NRG1512. Furthermore, the HA-synthesizing enzyme513 HAS2 is activated512 
and its expression increased by ERK1/2514, and regulated by NF-KB515, 516. HAS2 itself 
regulates the distribution of CDH2 in the plasma membrane517. Thus, HA and ERK1/2 
signaling interact, and like ERK1/2 HA regulates the RAC1, ESR1 and NF-KB signaling 
cascades.
1.3.3 Regulation of neurite outgrowth
Multiple proteins in the ALS landscape regulate neurite outgrowth and guidance, e.g. 
the neurite outgrowth inhibitor SHROOM3 reduces neurite outgrowth518, 519, whereas 
the contactin CNTN5 (not shown) increases neurite outgrowth520 and the cadherin 
membrane protein CDH13 regulates neuronal cell growth and guidance180, 521 and 
activates both CDC42 and RAC1522. The regulation of neurite outgrowth by Rho-GTPase 
associated kinases and by amyloid beta will be discussed below (sections 1.3.3.1 and 
1.3.3.2, respectively).
1.3.3.1		Rho-GTPase-associated	kinases
Activation of the GTPases RHOA, CDC42 and RAC1, via guidance cues, growth factors 
or other signalling pathways, eventually leads to the activation of the NADPH-
oxidase complex (see also section 2.1) and the kinases ROCK1 and LIMK1, essential for 
cytoskeleton regulation and neurite outgrowth183, 523-526.
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ROCK1 is a Rho-associated protein kinase that inhibits neurite outgrowth526, whereas 
LIMK1 is a serine/threonine-protein kinase downstream of ROCK1 stabilizing the actin 
cytoskeleton and stimulating neurite outgrowth183, 527. ROCK1 is regulated by RHOA 
that binds to (not shown) and regulates the activity of ROCK1528-532. Further, ROCK1 
expression is regulated by estradiol533 (not shown) and decreased by EPO534 (not shown). 
In addition, ROCK1 inhibits familial ALS protein PFN1535 that through binding actin 
filaments, affects the structure of the cytoskeleton183. PFN1 also binds to RHOA161 and 
CDC42160 (also mentioned above) and the ALS-related proteins DAO536 and SMN1/2537. 
ROCK1 binds to CASP3538 (not shown), NTRK1249 (not shown) and HNRNPA1539, and is 
also bound by RND3540. RND3 stimulates neurite outgrowth541, 542 and inhibits ROCK1-
mediated apoptosis540. Moreover, ROCK1 phosphorylates and hence activates ERK1/2543, 
544 and is itself inhibited by ERK1/2545. LIMK1 is activated by ROCK1163, 530, 546, and binds 
to and is activated by the serine/threonin-protein kinases PAK1 and PAK4547-549 that are 
both activated by CDC42550, 551 (not shown) and RAC1164, 550, 551. In addition, PAK1 and ESR1 
bind to552 and activate each other553, 554. Furthermore, PAK1 binds the serine/threonine 
kinase receptor TGFBR2555 (increased in expression by DRD2556 (not shown)), and 
binds557 (not shown) and regulates the activation of PLK1558, which in turn is located in 
a complex with C9ORF72559 and regulates activation of RHOA560. LIMK1 expression is 
increased by TNFSF11561 and by mutant SOD1562. Further, LIMK1 is bound by NRG1563 and 
degraded through polyubiquitination by the E3 ubiquitin-protein ligase RNF6564 that by 
regulating local LIMK1 levels in axonal growth cones regulates neurite outgrowth564. 
Thus, there is a complex interaction between the Rho-GTPases and the kinases PAK1, 
PAK4, ROCK1 and LIMK1 to regulate cytoskeleton dynamics and neurite outgrowth.
1.3.3.2 Amyloid-beta precursor protein APP
The cell surface receptor APP regulates neurite outgrowth and the formation of 
axons183. APP accumulates in spinal motor neurons of ALS patients47, is increased in 
the CSF of ALS patients compared to controls48, and its inhibition or ablation (APP-
KO mice cross-bred with mutant SOD1 mice) delayed disease onset and improved 
motor function and motor neuron survival of the mutant SOD1 mice49, 50. APP can be 
bound by the extracellular proteoglycan GPC6, which inhibits APP-induced neurite 
outgrowth565. In addition, APP binds to C1orf112566, TGFBR2566, the anti-apoptotic ER-
anchored autophagy receptor FAM134B566, 567 (not shown), the familial ALS protein 
TBK1566, the mitochondrial AK4566 (not shown), the contactin and regulator of axonal 
guidance and growth CNTN4568-572 and CNDP1566, an extracellular enzyme that degrades 
the dipeptide carnosine (not shown) which itself has been shown to be neuroprotective 
in SOD1 mutation-dependent ALS573. Moreover, the cytoplasmic aminopeptidase DNPEP 
cleaves APP574, and both APP575 and the extracellular hormone erythropoietin (EPO)576, 
577 are involved in decreasing the expression of CXCR4. APP increases the expression of 



















of IFNG579, 580 and binds DISC1581.
RAC1 increases the expression of the APP-binding protein APBB1582, an adapter protein 
forming a transcription complex with APP that translocates to the nucleus upon DNA 
damage to induce apoptosis180, 183. DAB1 binds and modulates the degradation and 
clearance of both APP and APBB1583. In turn, APP retains DAB1 in the cytoplasm and 
thereby antagonizes reelin-induced neurite outgrowth inhibition that depends on 
DAB1584, 585. APBB1 binds to ATXN1445, FMN2586 and MCPH1587, whereas APBB1, FMN2 
and MCPH1 are all three involved in (neuronal) DNA damage repair and apoptosis588-591. 
Moreover, FMN2 binds to TGFBR2592 and regulates growth cone stabilization, and axon 
guidance and outgrowth593.
Motor neurons in which APP has accumulated display increased immunoreactivity of 
the cleaved pro-apoptotic caspase CASP347, i.e. APP activates CASP3594 that subsequently 
triggers a cascade of caspases involved in the execution of (neuronal) apoptosis183. 
CASP3 is cleaved and thereby activated by the caspase CASP9183 (that binds to SQSTM1595; 
not shown) and the cytoplasmic proteins GNLY596 and NLRP1597, and is inhibited by 
the cytoplasmic kinase PLK1598. PLK1 binds to the APP-regulating/associated protein 
PIN1599, 600 and stabilizes PIN1 by inhibiting its ubiquitination601. MIS18A also binds to 
and functionally interacts with PIN1602. Lastly, CASP3-mediated cleavage of the familial 
ALS protein TARDBP attenuates its toxicity 603. Therefore, dysregulation of APP and 
subsequent APP accumulation as seen in motor neurons of ALS patients may interfere 
with neurite outgrowth and eventually lead to motor neuron death.
2.  ESTRADIOL SIGNALING
The female sex hormone estradiol is neuroprotective for motor neurons in cell and 
animal models604-610. Estradiol binds to and activates its receptor ESR1183 and (activated) 
ESR1 is involved in many molecular signaling cascades in the landscape. First, ESR1 
binds and regulates the adaptor proteins SHC1611 and GRB2612, and activates ERK1/2613, 
which itself is involved in downregulating ESR1 expression495, 496. Further, CXCL12 
binding to CXCR4 increases ESR1 activity614 and estradiol-bound/activated ESR1 is 
neuroprotective through inhibiting the translocation of APP to the nucleus by binding 
APBB1615. Furthermore, activated ESR1 increases the activity of CDC42 and RAC1 but 
decreases the activity of RHOA and in this way regulates neurite outgrowth616. Thus, 
estradiol signaling is involved in the pathways discussed in the previous section on 
Rho-GTPase signaling.
In the sections below, we describe the processes that are directly linked to, and are 
themselves also directly affected by, ESR1 signaling. First, we discuss the interaction 
between estradiol signaling and the NADPH-oxidase, of which RAC1 is a subunit617 
(section 2.1). Second, the effects of the folate and methionine cycles on ESR1 signaling 
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and glutamate toxicity are described (section 2.2). Third, the nuclear interactions 
between ESR1 and among others the NF-KB-complex and MLL-complex are discussed 
(section 2.3).
2.1 NADPH-oxidase
The NADPH-oxidase is an enzyme complex that generates reactive oxygen species 
(ROS) and thereby converts NADPH to NADP+183, and is overactivated in spinal motor 
neurons from ALS patients and in a mouse model of ALS100. Inactivation of the NADPH-
oxidase in an ALS mouse model delays neurodegeneration and extends the survival 
time of the mice100. The Rho-GTPases RAC1, CDC42 and RHOA increase the activation 
of the NADPH-oxidase complex618-621. Further, NADPH-oxidase subunit RAC1617 increases 
the assembly, activation618, 619, 622, 623 and stabilization of the NADPH-oxidase complex624. 
ALS2 and SOD1 bind to and regulate RAC1 (see above). Mutations in SOD1 disrupt RAC1-
mediated regulation of the NADPH-oxidase complex102, i.e. SOD1 mutations keep RAC1 in 
a GTP-bound state, resulting in elevated NADPH-oxidase activity and ROS production102. 
ALS2 suppresses mutant SOD1 toxicity by binding to mutant SOD1, but not wild-type 
SOD1165 and also decreases activation of RAC1 which increased by mutant SOD1625. The 
NADPH complex is inhibited by AMPK626, 627 (not shown) and activated by the RAC1-
activating protein TIAM1628. Of note, whereas RAC1 increases neurite outgrowth163, 629, 630, 
NADPH-oxidase activity negatively regulates NGF-NTRK1-induced neurite outgrowth631. 
Further, the physiological levels of ROS produced by NADPH-oxidase are necessary to 
maintain a dynamic cytoskeleton524. Furthermore, NADPH-oxidase is located in growth 
cones and its inhibition reduces F-actin content and neurite outgrowth525. Thus, there 
is a complex interaction between RAC1 and the NAPDH-oxidase complex regulating 
neurite outgrowth and cellular ROS levels.
Estradiol signaling interacts with and modulates the activation of both RAC1 and the 
NADPH-oxidase, i.e. estradiol, via the activation of ESR1, decreases the expression of 
RAC1 protein and mRNA632 (not shown), and decreases the activation of the NADPH-
oxidase complex632, 633. Nevertheless, estradiol increases neurite outgrowth by activating 
RAC1 and CDC42 and inhibiting RHOA616 (RHOA inhibits the activity of ESR1634). In 
turn, RAC1 regulates the activity of ESR1, i.e. RAC1 has been reported to inhibit ESR1 
transcriptional activity634, but also to increases the activity of ESR1635. In addition, RAC1 
binds to and activates PAK1554, which in turn forms a mutual activation complex with 
ESR1552-554. Therefore, estradiol and ESR1 mediate neurite outgrowth by regulating RAC1 
and NADPH-oxidase.
2.2 Folate cycle and methionine cyle
We next describe the regulation of the folate (FA) cycle and methionine (MET) cycle, 



















neuroprotective636, and the FA metabolite 5-methyl-tetrahydrofolate (5-MTHF) is 
decreased in an ALS mouse model637. Methyl vitamin B12 (Met.Vit.B12) increases 
survival time of ALS patients638-640, MET is lower in the plasma of ALS patients641, 
carnitine (CAR) is lower in plasma of ALS patients642 and carnitine supplementation 
decreases disease progression and increases survival in an ALS mouse model643 and 
in ALS patients644, S-adenosylmethionine (SAM) supplementation delays the onset 
of disease in an ALS mouse model645 and homocysteine (HCY) is increased in ALS 
patient’s plasma and CSF639, 646, 647. First we discuss the regulation of these metabolites in 
the landscape, followed by their interaction with estradiol metabolites (section 2.2.1.1), 
glutamate toxicity and the effect of riluzole (2.2.1.2).
FA is an essential vitamin that mainly enters the body through food intake and is 
converted into dihydrofolate (DHF) and subsequently to tetrahydrofolate (THF) by 
DHFR, a cytoplasmic enzyme that also requires and converts NADPH into NADP+183, 648. 
Further, FA has a direct inhibitory effect on DHFR, to prevent intracellular FA levels 
from becoming too low649 (not shown). In addition, the FA metabolite 5,10-methylene-
tetrahydrofolate (5,10-MTHF) is converted into DHF by the cytoplasmic enzyme TYMS183 
(that is inhibited by APBB1650) and to 5-MTHF by MTHFR, a cytoplasmic enzyme that, 
like DHFR,  also requires and converts NADPH into NADP+183. Both DHFR and MTHFR 
are genetically linked to ALS, i.e. a deletion in the gene encoding DHFR is associated 
with bulbar onset ALS69, and polymorphisms in the MTHFR gene are associated with 
spinal and bulbar onset of ALS in female patients99. Activation of ESR1 increases the 
expression of the FA cycle enzymes, DHFR651 and TYMS652, which may therefore also 
play a role in gender-specific risk for developing ALS as has been observed for MTHFR99. 
Nuclear export of DHFR mRNA is regulated by the with ALS associated88 GLE1653 (not 
shown), a protein that shuttles between the nucleus and the cytoplasm to regulate 
mRNA export and translation, and stress granules (dis)assembly654, 655.
The FA cycle is linked to the methionine cycle through MTR, a cytoplasmic enzyme 
that uses vitamin B12 (Vit.B12) as its cofactor, and converts 5-MTHF and HCY into THF 
and MET, respectively183. In addition, MET is converted into SAM by the cytoplasmic 
enzyme MAT183 (of which three isoforms exist; MAT1A, MAT2A and MAT2B) that binds to 
NTRK1249, AMPK455 (not shown), APP566 and the familial ALS protein FUS656, and decreases 
the expression of SOD1657.  SAM is converted into S-adenosylhomocysteine (SAH) by the 
methyltransferases GAMT and MLL, i.e. GAMT transfers the methyl group of SAM to 
guanidinoacetate, creating SAH and creatine, and MLL uses SAM as a methyl donor to 
regulate histon methylation and as such gene transcription183, 658. SAH is converted into 
HCY by AHCY183, to ‘close’ the ‘methionine’ cycle. AHCY binds to NTRK1249, the adaptor 
protein GRB2410 and the familial ALS protein FUS656.
HCY, which is increased in plasma and CSF of ALS patients (see above), can – in 
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addition to its conversion into MET – also be metabolized to cystathione (the precursor 
for cysteine, CYS) by the enzyme CBS, allowing the elimination of the neurotoxic HCY183, 
659. Further, the methionyl-tRNA synthetase MARS can charge a tRNA with MET for 
translation183. MARS binds to EGFR223, NTRK1249, ESR1660, AMPK455 (not shown), NF-
KB661 (not shown) and GRB2410. MET can – apart from being converted into SAM, or 
used for translation – be metabolized to carnitine (CAR)662. CAR is neuroprotective663 
and has strong antioxidant properties, i.e. it inhibits the NADPH-oxidase complex664, 
665. CAR is transported out of (neuronal) cells by the transporter SLC22A16183 and into 
mitochondria by the transporter SLC25A20 (that binds to ESR1666, and is activated and 
increased by the ESR1 coactivator PPARGC1A667, 668; not shown) where it is involved in the 
mitochondrial fatty acid-oxidation pathway183. The metabolite SAM is also transported 
into mitochondria by SLC25A26183, 669 where it acts as a methyl donor and hence 
regulates mRNA and protein function. Mutations in SLC25A26 lead to a deficiency of 
intra-mitochondrial methylation, which affects RNA stability, and protein modification 
and translation670. Furthermore, SAM inhibits the activity and decreases the expression 
of RAC1671, and has an inhibitory effect on MTHFR672, reflecting its participation in the 
regulation of the FA cycle. In turn, FA protects motor neurons against increased HCY 
and apoptosis in a mutant SOD1 mouse model636.
Thus, multiple metabolites of the FA and MET cycles are associated with ALS and 
their dysregulation affects RAC1 and NADPH-oxidase regulation, but also increases 
mitochondrial dysfunction and oxidative stress. Of note, also the NGF and EGF growth 
factor pathways heavily interact with MET cycle enzymes, showing the interactions of 
these enzymes with major pathways in the landscape.
2.2.1 Regulation of estradiol and cholesterol metabolites and riluzole
This section will elaborate on the interactions of landscape metabolites with the ABC 
transporters ABCB1 and ABCG2, in particular the transport of estrone 3-sulfate (E3S), 
cholesterol (CH) and riluzole by these transporters. We already described that ABCG2 
transports FA and that its expression is regulated by FA (previous section).
2.2.1.1 Estradiol and cholesterol metabolites
E3S is the most prominent estrogen in postmenopausal women and men, and a 
long-lived estradiol derivative and as such acts as a reservoir that when necessary 
can be converted into the more active estradiol673-675. E3S is converted into estrone 
and subsequently into estradiol which is regulated by the enzyme estradiol 17-beta-
dehydrogenase (HSD17B, that has multiple isoforms e.g. HSD17B1 and HSD17B2). HSD17B 
catalyzes the conversion of estradiol and NAD(P)+ into estrone and NAD(P)H and vice 
versa183, i.e. HSD17B1 favors the conversion of estrogen into estradiol, whereas HSD17B2 




















The membrane transporters ABCB1 and ABCG2 regulate the uptake and secretion of 
E3S and glucuronidated estradiol (E2G), but not that of free estrogens680-685. ABCG2 
expression is increased by TEK686, and decreased by APP687 and ALDH1A2688 (a 
cytoplasmic dehydrogenase that decreases CDC42 expression689 (not shown) and its 
expression is increased by estradiol690). Further, ABCB1 decreases the expression of 
ABCG2691 and BTNL2692 (that decreases the expression of IFNG692). Of note, activated 
ESR1 increases the expression of both ABCB1693, 694 and ABCG2695,696. The sulfotransferase 
CHST10 (located in the membrane of the Golgi apparatus) adds a sulfate group to E2G and 
thereby reduces the activity of estradiol by diminishing its binding affinity for ESR1697. 
Moreover, CHST10 also downregulates estrogen levels, i.e. sulfation of glucuronidated 
steroids facilitates their export and elimination from the body697. Thus, CHST10 and 
the transporters ABCB1 and ABCG2 regulate estradiol signaling by modulating estradiol 
metabolite activity and export from the cell.
The ABCB1 transporter also transports CH into motor neurons698, 699. CH is converted 
into 27-hydroxycholesterol (27-OH-CH) by the mitochondrial membrane-located 
enzyme CYP27A1700 that is associated with ALS67. 27-OH-CH is also associated with 
ALS701 and directly competes with estradiol to bind ESR1702 within the nucleus, which 
has a negative effect on the transcriptional activity of ESR1. Moreover, 27-OH-CH is the 
natural ligand of LXRB (encoded by NR1H2), a transcription factor that is upregulated 
by IFNG203 and involved in regulating motor neuron death and survival703, 704. 27-OH-
CH is further metabolized through 7alpha-hydroxylization of 27-OH-CH by the enzyme 
CYP7B1705, 706, whose expression is increased by ESR1707.
2.2.1.2 FA, glutamate toxicity and riluzole
Depending on its location, ABCG2 transports FA out of the motor neuron or into 
intracellular organelles such as mitochondria. Low intracellular FA levels decrease 
expression of ABCG2 in the cell membrane and increase ABCG2 expression in 
mitochondrial membranes683, 708-710. In this way, the remaining intracellular FA is 
transported into mitochondria, and can still be used for serine-glycine metabolism, i.e. 
glycine is synthesized from serine by simultaneous conversion of THF to 5,10-MTHF 
– by cytoplasmic or mitochondrial serine hydroxymethyltransferase (SHMT) – and 
glycine is also cleaved by simultaneous conversion of THF into 5,10-MTHF183, 711-714. 
Glycine is an inhibitory neurotransmitter that is decreased in the spinal cord of ALS 
patients715, whereas serine is increased716, 717. Moreover, glycine is a major component of 
collagen, and both are markedly decreased in the skin of ALS patients718. Intriguingly, 
the familial ALS protein DAO regulates the degradation of serine717 and glycine719, and 
dysregulation of this system or mutations in the DAO gene increase glutamate toxicity 
and motor neuron death, since serine and glycine are the endogenous co-agonists of 
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the N-methyl D-aspartate receptor (NMDAR), the receptor for glutamate716, 717, 720-722. Thus, 
regulation of FA levels in the cell is important for the regulation of serine and glycine 
levels, to prevent glutamate toxicity and motor neuron death. 
NMDA is another agonist of the NMDAR and decreased via oxidation by DDO183, 723, 
reducing potential glutamate toxicity in the synapse. The glial glutamate transporter 
EAAT2 (SLC1A2) removes excessive glutamate from the synapse to prevent an 
overstimulation of NMDAR on the postsynapse723. HNRNPA2B1 decreases SLC1A2 
expression724 (not shown) and mutant SOD1 and mutant TARDBP inhibit the activity 
and decrease the expression of SLC1A2 725-727. Editing of SLC1A2 pre-mRNA is increased 
in the spinal cord and motor cortex of ALS patients132. Thus, in addition to NMDAR 
agonists (glycine, serine, NMDA), also dysregulation of glutamate transporters is 
associated with ALS and contributes to glutamate toxicity. Of note, folylpolyglutamate 
synthase (FPGS) catalyzes polyglutamation of folates (FA, DHF, THF)728 and thereby 
increases the clearance of glutamate, but is also important for FA homeostasis by 
affecting the kinetics of the polyglutamated folates729(not shown). The lipase LIPH 
binds to FPGS592(not shown) and catalyzes the production of 2-acyl lysophosphatidic 
acid (LPA) that increases cell proliferation and regulates neurite retraction730-732.
The anti-glutamatergic ALS drug riluzole – currently the only FDA-approved drug to 
treat ALS – inhibits activation of NMDAR complexes733, 734, decreases the release of 
glutamate727, 735, 736 and activates and increases the expression of glutamate transporters 
(e.g. SLC1A2)737-739. Further, riluzole may exert its anti-glutamatergic effects by inhibiting 
sodium channel activation and subsequent glutamate release in the synapse740, 741. 
Riluzole binds to and likely inhibits the sodium channel SCN8A742, 743 that is involved in 
the regulation of voltage-dependent sodium ion permeability of excitable membranes183 
and regulates neurite outgrowth744. RBFOX1, an RNA-binding protein regulating 
alternative splicing745, binds to the RNA-binding protein ATXN1445 and the familial ALS 
protein ATXN2445 (ATXN1 and ATXN2 also bind to each other445) and regulates alternative 
splicing of the gene coding for SCN8A746. Of interest, riluzole is transported out of the 
motor neuron by both ABCB1 and ABCG2, and increases the expression of ABCG2, which 
implies that riluzole decreases its own intraneuronal concentration when given over a 
longer period of time747-749.
In summary, the regulation of the membrane transporters ABCB1 and ABCG2 by e.g. 
riluzole, FA and ESR1, but also by the growth factor receptors NTRK1 and EGFR (see 
section 1.2) may affect ABCB1- and ABCG2-mediated transport of E3S, (sulfated) E2G, FA, 
27-OH-CH and riluzole (see also sections above) and may affect the viability of motor 
neurons. Since trials with other anti-glutamatergic drugs have been unsuccessful678, 750-



















system, but may also be the result of its regulation of ABCB1 and ABCG2.
Of note, NADPH-oxidase, the estrone-estradiol converting enzyme HSD17B and the FA 
cycle enzymes DHFR and MTHFR all require NADPH for their activation. Hyperactivation 
of the NADPH-oxidase complex  as found in spinal motor neurons from ALS patients and 
in a mouse model of ALS (see section 2.1) has a negative effect on NADPH availability 
and hence may affect the conversion and metabolism of FA and estradiol. Moreover, 
high NADP+ levels may favour the reverse reaction of HSD17B, i.e. the conversion of 
estradiol into the lesser active estrone.
2.3 Interaction between NF-KB, ESR1 and MLL-complex
NF-KB, ESR1 and the MLL-complex are the main transcriptional regulators in the ALS 
landscape. In this section, we describe their activation by proteins in the landscape, 
their interactions with each other and with other transcriptional regulators, and the 
subsequent effects on transcription and cellular function.
NF-KB is upregulated in the spinal cords of ALS patients107, 756 and regulates motor 
neuron survival757, 758. In the cytoplasm, NF-KB is activated by HA (see above), the 
cytoplasmic proteins AP4B1759, ADRBK2760, ERK1/2 (see above), RAC1761, 762, RHOA763, 
ROCK1544, 764, TNFSF11765 and the familial ALS proteins TARDBP107, SQSTM1766, 767, VCP768 
and TBK1769, 770, and inhibited by the familial ALS protein OPTN771, 772 (OPTN and TBK1 
bind and regulate each other’s activation773-777). In addition, NF-KB binds to the familial 
ALS proteins DAO778, C9ORF72778, FUS779, MATR3661 and TBK1661, the membrane protein 
KCTD12661 and the NF-KB-associated cofactor UXT780. Following activation, NF-KB 
translocates to the nucleus where it functions as a transcription factor. AMPK – which 
itself is bound to and inhibited by NT5C1A43, 781 – inhibits translocation of NF-KB to 
the nucleus626. In the nucleus, NF-KB is bound to and retained by ANKRD33782, and is 
activated by the transcription factor ZFP64759 and by the kinase UHMK1759. Subsequently, 
NF-KB increases the expression of the ABC transporter ABCB1783, the methionine cycle 
enzymes MAT784, 785 and CBS786, and binds and increases the expression of PLK1787 (not 
shown), ATXN1778, 788 and the transcription factor E2F3789, 790. E2F3 also binds to the MLL-
complex791 and regulates the expression of BMI1792 (that is also increased by PLK1793 
(not shown)), PIN1794 (not shown), the FA cycle enzyme DHFR795 and the transcription 
regulator UXT796 (not shown). UXT binds ESR1797 and AR797, and together with its 
binding partner ALS2 activates NF-KB798. Further, UXT forms a functional complex 
with the mitochondrial protein LRPPRC that regulates mitochondrial aggregation and 
apoptosis799. LRPPRC800, the mitochondrial membrane protein COX10801 and SOD1802 – 
that, when mutated like in familial ALS, aggregates and accumulates in mitochondria183 
– activate cytochrome-c oxidase (COX), the main enzyme involved in  mitochondrial 
electron transport that has a decreased activity in spinal motor neurons from ALS 
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Thus, NF-KB activation and function is regulated by multiple familial ALS proteins 
(TARDBP, VCP, OPTN, DAO, FUS, ALS2), Rho-GTPases and the transcriptional regulator 
UXT that also regulates mitochondrial function. 
In addition to these processes, NF-KB and ESR1 bind to and activate each other803-806. ESR1 
also binds to the familial ALS proteins PFN1807, FUS808, VCP660 and TBK1809, the hnRNP 
proteins HNRNPA1660, 808 and HNRNPA2B1808 (see also section 3) and TOP2A808, and binds 
to and regulates ERBB4424, 810, 811 (not shown). Estradiol potentiates NGF-induced neurite 
outgrowth812 and estradiol-activated ESR1 upregulates the expression of the nuclear 
landscape proteins BMI1792, E2F3813, FOXF2814, GATA3815 and the transcription factor 
NRF1816, 817 that positively regulates neurite outgrowth818, 819, upregulates the expression of 
mitochondrial COX820 and decreases the expression of ESM1821 and autophagy receptor 
SQSTM1424. TNFSF11 decreases the expression of ESR1822 and increases the expression 
of SIGMAR1561, a familial ALS protein that regulates mitochondrial function823. ESR1 
increases the expression of TNFSF11824, UHMK1424, DCHS1815, SOD1825, GFAP826 and the 
acetylcholine-synthesizing enzyme choline acetyltransferase CHAT827. CHAT is specific 
for motor neurons (for more on CHAT regulation, see section 3.4) and its expression is 
also increased by the transcription factor SATB2828 that regulates neurite outgrowth 
by increasing the expression of the differentiation factor NEUROD6829 (that stimulates 
mitochondrial mass, preceding axonal growth, to provide the necessary energy for 
cytoskeleton dynamics830), and decreasing the expression of netrin receptor DCC831 and 
BHLHE22832 (that forms a transcription repressor complex regulating the expression of 
genes that are important for guidance of motor neuron axons833). 
The cell cycle regulating protein CACUL1 binds ESR1 and regulates its activity666. 
Estradiol-induced transcription is mediated by transcriptional activator and stress 
granule-associated protein TDRD3834 (see section 3.2). Further, ESR1 is bound to and 
activated by the ESR1 coactivator PPARGC1A835, and its expression is increased by 
PPARGC1A835. PPARGC1A mRNA levels are decreased in ALS patients compared to 
controls117, and polymorphisms in the promoter region of the PPARGC1A gene are 
associated with an earlier age of onset in male ALS patients only118. In addition to its 
association with ESR1, PPARGC1A836 binds to NRF1837, EGFR223, AMPK838, 839, NF-KB840, 841 
(not shown), LRPPRC842, MED17843 and the MLL-complex844. PPARGC1A inhibits CASP3845 
and increases the expression of AMPK846, DIO2847 (an iodothyronine deiodinase183) 
and NRF1837, and activates and increases the expression of SLC25A20667, 668. Further, 
PPARGC1A expression is increased by IFNG848 (not shown), AMPK849-851, ERK1/2493 and 
the MLL-complex852, 853. The transcriptional repressor ZNF746 binds ZAK854, inhibits the 



















The MLL-complex methylates histone H3 lysine 4 (H3K4) (not shown) to activate gene 
transcription183. Activation of the MLL-complex is driven by the methionine cycle (see 
section 2.2). The MLL-complex binds the RNA- and DNA-binding protein MATR3857, 858, 
and binds to and interacts with the nuclear transcription regulators BMI1859 and E2F3791, 
860 that are also upregulated by ESR1 (see above). The DNA topoisomerase TOP2A binds to 
BMI1861 and nuclear ERK1/2862 (not shown), and downregulates the expression of MLL863. 
BMI1 binds to TARDBP658, ATXN2658 (not shown) and GATA3864, a transcription factor 
that decreases the expression of IFNG865 and AGPAT5866, and regulates the expression 
of HSD17B867. Further, GATA3 and EPO decrease each other’s expression868, 869, whereas 
GATA3 and NF-KB870-872, but also GATA3 and ESR1318, 873, and NF-KB and BMI1874, 875 increase 
each other’s expression. Furthermore, ESR1 and the MLL-complex increase each other’s 
transcriptional activity876 and both bind to the transcriptional mediator MED17877, 878. 
Moreover, the nuclear receptor ESRRB may be an important modulator of this ESR1-
MLL-interaction by binding to the MLL-complex879, PPARGC1A880, the mediator complex 
proteins MED17879 and MED13L879 – that regulate transcription of RNA polymerase II-
dependent genes183 – and inhibiting the transcriptional activity of ESR1 in the nucleus881 
(not shown).
In addition, SMAD1 binds to the MLL-complex882, SKIL883 and ESR1884, 885, and is bound 
and regulated by ZNF423886. SKIL positively regulates axonal growth887 and enhances 
the transcriptional activity of ESR1888. Moreover, SKIL upregulates the expression of 
DCHS1889, a membrane protein and member of the cadherin protein family that regulates 
neuronal cell adhesion183 and neuronal migration890. ESR1 is bound and modulated by 
the transcription initiation factor GTF2B891, which itself binds to and interacts with the 
transcription factor FOXF2892.
In summary, in the ALS landscape NF-KB, ESR1 and the MLL-complex as well as the 
ESR1 coactivator PPARGC1A interact with each other to regulate gene transcription and 
cellular processes, such as neurite outgrowth.
3.   RNP GRANULES, INTERMEDIATE FILAMENTS AND AXONAL TRANSPORT
Motor neurons have long axons, i.e. upper motor neurons project from the motor cortex 
to the spinal cord, from where the lower motor neurons project to the muscles. Axonal 
transport over long distances is challenging and makes these neurons especially 
vulnerable for defects in axonal transport. To maintain their axons and distant synapses, 
motor neurons transport proteins to the required location, but are also able to quickly 
synthesize the necessary proteins locally in the axon or synapse. For this purpose, 
the cells transport translationally silent mRNA to the proper location in so-called 
ribonucleoprotein particle (RNP) granules. RNP granules are clusters of mRNA-binding 
proteins that regulate mRNA transport and translation, and initiate protein synthesis 
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upon various stimuli, such as injury, guidance cues and growth factors893-896. In the next 
sections the ALS landscape proteins involved in assembly, function (section 3.1) and 
clearance (section 3.2) of RNP granules will be discussed, followed by a description of 
the regulation of intermediate filaments that are important for axonal transport and 
neurite outgrowth (section 3.3). In section 3.4 the axonal transport of motor neuron-
specific CHAT and the transport of RNP granules by motor complexes will be discussed.
3.1 Assembly and function of RNP- and stress granules
RNA-binding and -regulating proteins (e.g. HNRNPA1, HNRNPA2B1, TARDBP, FUS, 
YWHAB, ATXN2, PFN1, SMN1/2, MATR3) bind to RNA and form complexes, RNP 
granules, that can be classified into various types, e.g. transport RNP granules, stress 
granules and processing bodies (P-bodies). Transport RNP granules regulate mRNA 
transport and local mRNA metabolism and translation, e.g. in axon terminals, whereas 
cellular stress modifies the RNP granules and gives rise to either stress granules 
– that represses translation of mRNAs and holds mRNAs dormant until needed at a 
later time point – or to P-bodies in which the mRNA is degraded897. Mutations in FUS 
and TARDBP trap themselves and their mRNA targets (see below) in stress granules, 
resulting in pathological inclusions and subsequent impairment of RNA processing, 
axonal migration, protein synthesis by RNP granules in axon terminals and neurite 
outgrowth897-904. The RNA-binding protein MATR3 is associated to ALS97, 98, binds to the 
familial ALS proteins FUS858 and TARDBP905, 906 and localizes to P-bodies and possibly also 
to stress granules907. C9ORF72 localizes to P-bodies and is recruited to stress granules 
during cellular stress908. Further, stress granule assembly is mediated by C9ORF72908 
and by the stress granule assembly protein G3BP1909, 910. Hexanucleotide expansions 
upstream of C9ORF72 dysregulates its expression and leads to spontaneous stress 
granule formation908. TARDBP is also required for stress granule assembly by activating 
and increasing the expression of G3BP182, 911. Further, G3BP1 is inhibited by RAC1-
mediated inhibition of RHOA912. G3BP1 expression is increased by NRG1913 and FLT1362, 
and G3BP1 binds to ATXN2 (a mediator of RNP assembly)914, TARDBP905 (not shown), 
VCP457, NF-KB915, BMI1658 (not shown), AMPK559 (not shown), HNRNPA1916, 917, PIN1918 (not 
shown), APP566, GRB2410 (not shown), NTRK1249 and ESR1808. Thus, key proteins in the 
ALS landscape, such as familial ALS proteins, but also the Rho-GTPases (RAC1, CDC42, 
RHOA) and ESR1 bind to and regulate the assembly of stress granules that are important 
for RNA processing, local protein synthesis in the axons and neurite outgrowth. 
The heterogeneous nuclear ribonucleoproteins (hnRNP) HNRNPA1 and HNRNPA2B1 
regulate the packaging of pre-mRNA into RNP granules, their export from the nucleus 
and subsequent processing and translation183. Upon binding and activation of CXCR4 
by CXCL12, HNRNPA2B1 is transported from the nucleus to the cytoplasm919. Pathogenic 



















decreased in the spinal cord motor neurons of ALS patients89. HNRNPA1 and HNRNPA2B1 
physically interact917, and HNRNPA1 binds to APP566 (that also binds to the pre-mRNA 
regulating CLK3566, 920), ESR1660, 808, FUS917, GRB2410, ICAM1196, LRPPRC916, 921, MATR3 858, 916, 
NTRK1249, PFN1917, RBMS1592, RNF14922, ROCK1539, TARDBP89, 539, 906, 916, UBR2539, UBQLN2923, 
UPF3A (that is a regulator of nonsense-mediated mRNA924 and binds EXOSC10925, 
that also binds to TARDBP926 and the neuronal membrane protein HIATL1926) and 
VCP457. Further, HNRNPA1 decreases homodimerization of RNF14, and the interaction 
between RNF14 and AR922, and increases the degradation of FUS, but not mutant FUS927. 
Furthermore, HNRNPA1 expression is decreased by APP928 and SKIL889, and increased 
by EGFR233, 234.
HNRNPA2B1 binds to GRB2410 (not shown), ICAM1196 (not shown) and TARDBP906, 929, is 
located in a complex with C9ORF72559 and binds to subunits of the MLL-complex930, 
931 (not shown) and, as previously mentioned, NTRK1249 (not shown) and ESR1808. 
HNRNPA2B1 increases expression of IFNG932, 933 and ABCB1724, and regulates expression 
of CPVL724 (not shown) and PPARGC1A724 (not shown).
Of interest, both HNRNPA1 and HNRNPA2B1 bind to the ‘survival motor neuron’ genes 
SMN1 and SMN2 – together designated as SMN1/2 – and function as splicing silencers, 
resulting in the skipping of exon 7934-937. Overexpression of HNRNPA1 abrogates exon 
7 inclusion in the mRNA936, whereas reducing HNRNPA1 levels results in splicing of 
exon 7 and a non-functional SMN1/2 protein934. SMN1/2 binds to the transcription factor 
SP110854, inhibits RHOA938 and binds to and is regulated by coilin (COIL)939. COIL binds to 
ATXN1940 (ATXN1 degradation is increased by SQSTM1941), binds to and interacts with the 
enzyme CYB5R2 445, and is downregulated  by the MLL-complex942 (not shown). SMN1/2 
bind to PFN1938, BMI1658 (not shown), GRB2410, SNRPG937, 943 (binds also to DDIT4L944) and 
the MLL-complex945.
Thus, the hnRNP proteins HNRNPA1 and HNRNPA2B1 control the regulation of (pre-)
mRNA processing by RNP granules, and bind to and interact with multiple familial 
ALS proteins, but also the MLL-complex and ESR1, and regulate estradiol signaling by 
modulating ABCB1, PPARGC1A and ESR1 signaling.
3.2 Stress granule clearance
The scaffolding protein TDRD3 localizes to stress granules by binding dimethylarginine-
containing proteins, binds to FUS and is involved in the disassembly of stress granules183, 
946, 947.
The familial ALS protein VCP increases the clearance of stress granules and as such 
prevents the aggregation of stress granules948. VCP binds to the other familial ALS 
proteins ALS2457, VAPB949, PFN1950, OPTN951 (OPTN also binds to SOD1952 and its expression 
is regulated by FUS953 (not shown)) and FUS656 (that also binds to PFN1656). Further, VCP 
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binds to NTRK1 (see section 1.2.2), NF-KB457, ATXN1954, DIO2955, PLK1457, COIL457, AMPK457, 
956 (that also binds to VAPB957), ERK1/2457, YWHAB457, CASP9457 and RAD23B958 (that is in a 
complex together with UBQLN2959 (not shown), binds SQSTM1960 and its phosphorylation 
is increased by PLK1961) and activates NF-KB768.
Thus, VCP has interactions with multiple proteins involved in RNP-granule functioning 
and prevents pathogenic aggregation of stress granules.
3.3	 Intermediate	filaments	and	RNP	granules
Intermediate filaments, e.g. peripherin (PRPH) and neurofilaments (NEFL, NEFM, NEFH), 
are the ‘building blocks’ of the cytoskeleton and important for neurite outgrowth and 
maintenance of axons962-966. The Lewy body-like inclusions, as found in the motor neurons 
of ALS patients, contain PRPH124, 967, 968, mutations in PRPH are associated with ALS122-126 
and overexpression of PRPH results in defective axonal transport of neurofilaments969. 
Furthermore, the RNP-granule associated proteins SOD1, TARDBP and YWHAB stabilize 
NEFL mRNA through interaction with its 3’UTR970-972 (not shown) and TARDBP increases 
the transport of NEFL mRNA to the distal axon903 (not shown). Mutations in SOD1 and 
TARDBP result in neurofilament aggregates in motor neurons727, 973-975, reduced levels 
of neurofilaments and reduced axonal length976. NEFL mRNA and protein is increased 
in the spinal cord977 and serum and CSF103, 978 of ALS patients, respectively. NEFL binds 
to the cytoplasmic protein phosphatase PPP1CA979 (not shown) that on its turn binds 
to and interacts with the membrane proteins TMEM132C and TMEM132D980, and the 
endosomal sorting protein CHMP2B461, and binds to the membrane protein CSMD1980 
that is involved in neuronal growth cone stabilization981, 982. PTPRD also stabilizes 
growth cones and increases neurite outgrowth982, 983, and its expression is regulated by 
estradiol984 (not shown).
Further, the ALS-associated autophagy receptor SQSTM1 binds NEFM559 (not shown). 
Phosphorylated neurofilament NEFH is increased in the CSF of ALS patients103 and the 
ESR1 co-activator PPARGC1A increases the expression of NEFH mRNA985 (not shown), 
whereas ERK1/2986 and PIN1987 increase phosphorylation of NEFH protein (not shown). 
Thus, a defect in the regulation of RNP and stress granules – either due to upstream 
dysregulation or direct mutations in RNP-granule or intermediate-filament genes 
– cause stress granules to aggregate, resulting in defective local translation of 
intermediate filaments and subsequent (further) weakening of the axon, reduced 
outgrowth and motor neuron death. Proteins that require axonal transport to the 
synapse – e.g. CHAT988 – are therefore unable to exert their function (see section 3.4 
for more on CHAT regulation). Interestingly, estradiol is neuroprotective and increases 
neurite outgrowth via ESR1989, resulting in the inhibition of RHOA and activation of the 
GTPases RAC1 and CDC42616, which is the same pathway that inhibits stress granule 



















Of note, also the intermediate filament GFAP is dysregulated in ALS patients, i.e. GFAP 
is increased in the CSF of ALS patients86, and acetylated and fragmented GFAP levels 
are increased in the spinal cords of ALS patients84, 85. However, GFAP is specifically 
expressed in, and a marker for, mature astrocytes183. Astrocytes interact with motor 
neurons, support their functioning and can affect motor neuron fate, i.e. degenerating 
motor neurons in ALS patients are surrounded by astrogliosis which is toxic to motor 
neurons990, 991. GFAP binds NEFL992 (not shown), APP566 (not shown), RAD23B960 and 
YWHAB463 (not shown). Further, GFAP is phosphorylated and thus inhibited by ROCK1993, 
994 (not shown), and GFAP expression is increased by ESR1826, B4GALT6471, NRXN1995 
(not shown; regulates neurite outgrowth996, 997), TGFBR2998 and TRPV1999, regulated by 
NF-KB1000 (not shown), and decreased by SOD11001, AR1002 (not shown) and carnitine1003. 
Furthermore, GFAP regulates the localization of TARDBP1004 and is cleaved by CASP31005 
(not shown). Thus, GFAP is regulated by ALS landscape genes, that as such may affect 
astrogliosis. ALS pathology is therefore not limited to motor neurons and at least part 
of the ALS landscape processes may take place in astrocytes or affect the functioning 
of astrocytes. 
3.4 Axonal transport by motor complexes 
To transport their cargo, axons require a functional microtubule network for motor 
proteins such as KIF14, Kinesin-II, KIFAP3 and STAU1. Multiple proteins in the ALS 
landscape regulate microtubules, i.e. the non-selective calcium permeant cation 
channel TRPV1 regulates stabilization of presynaptic microtubules and also regulates 
growth cone morphology, increases synaptic growth and regulates axonal guidance 
by activating the RHOA/ROCK1 pathway1006-1008. Further, microtubule dynamics is 
regulated by the microtubule organizing protein CEP44 that binds to TBK11009, BEND7778 
and SPERT944 (that also binds to PIN1778) and the cytoplasmic enzyme AGBL4 that 
modulates microtubules and is thereby critical for neuronal survival1010. Furthermore, 
the microtubule-associated proteins MTUS1 and MTUS2 regulate microtubule stability 
and elongation1011, 1012 (MTUS2 also binds to AMPK778 and PIN1778; not shown). Lastly, 
TUBA4A is a major constituent of microtubules and mutations in the TUBA4A gene 
are associated with ALS147, 148. TUBA4A binds to the RNA-trafficking protein STAU11013, 
therefore, cytoskeletal defects through mutated TUBA4A may in this way affect axonal 
transport and local translation of RNA (see below).
CHAT synthesizes acetylcholine, the main and essential neurotransmitter at the 
neuromuscular synapse between motor neurons and skeletal muscle cells1014-1016. 
CHAT is produced in the cell body of the neuron and transported to the synapse28, 
and therefore relies on axonal transport to exert its function. In mutant SOD1 mice, 
axonal transport of CHAT is impaired and defects in axonal transport precede disease 
symptoms28, 1017. Of note, CHAT expression is lower in spinal motor neurons of ALS 
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patients29, 30 and increased via the NGF pathway by NGF1018, 1019, NTRK11020 and NTRK21020, 
and by estradiol1021 and ESR1827. APP increases the activation of CHAT (not shown) and 
the binding affinity of CHAT for the familial ALS protein VCP1022.
Mutant SOD1 increases the sequestration of KIFAP3, a kinesin-associated protein that 
binds the Kinesin-II motor complex, and regulates microtubule-dependent transport 
of cargo proteins such as CHAT28. A polymorphism in the KIFAP3 gene is associated 
with ALS and is thought to modify the ALS phenotype10, 27. In addition to CHAT, KIFAP3 
binds to RBFOX1445, DISC1478, AR1023 (not shown), NTRK1249 and CDH21024, and increases 
the activity of the Rho-GTPases RAC1, CDC42 and RHOA216 (not shown) and NADPH-
oxidase1025. KIF14 is another microtubule motor protein in the landscape and binds 
to NTRK1249. Of interest, the Kinesin-II motor complex is involved in microtubule-
dependent transport of cargo proteins such as CHAT, regulates the transport of RNP 
granules in the axons of neuronal cells1026 and is required for neurite outgrowth1027. 
KIF3A, an RNP granule-associated subunit of the Kinesin-II motor complex, binds to 
the kinase NEK11028. NEK1 is involved in microtubule dynamics1029, binds to the ALS-
associated58 and cytoskeleton-regulating1030 C21ORF2858 and its expression is increased 
by ESR1424. Further, KIF3A also binds to RNA-binding protein UHMK1 that regulates 
neurite outgrowth and is localized to RNP granules1031. Furthermore, the kinase activity 
of UHMK1 stimulates protein translation and thereby enhances local axonal protein 
translation of e.g. actin1031. In addition, the RNA-trafficking and tubulin-binding protein 
STAU1 is also part of RNP granules and essential for the transport and local translation 
of mRNA1032, 1033. STAU1 binds to the hnRNP proteins HNRNPA11013 and  HNRNPA2B11013, the 
familial ALS protein TARDBP903, APP566 (not shown), LRPPRC1013 (not shown), PPP1CA882, 
1034, MATR31013, NTRK1249 (not shown), ESR1808, and the Rho-GTPases CDC421033 and RAC11033.
Thus, CHAT, the enzyme that is essential for motor neuron function, is regulated by the 
NGF and EGF growth factor pathways and by estradiol signaling. Further, both CHAT and 
RNP granules require a properly functioning cytoskeleton machinery to be transported 
from the cell body to the axon terminal, and defects or dysregulation of motor proteins 
(e.g. Kinesin-II, KIFAP3 or STAU1) or of proteins regulating the cytoskeleton (e.g. 
TUBA4A) may affect their translocation and functioning.
4. CONCLUDING REMARKS
The ALS landscape converges on the regulation of Rho-GTPase signaling, and axonal 
outgrowth and maintenance. These processes are stimulated by guidance cues 
and growth factors (section 1) and mediated by estradiol-dependent signaling that 
interacts with the FA cycle, MET cycle and NADPH-oxidase activity (section 2). Under 
normal conditions, the factors mentioned in section 1 and 2 provide the necessary 



















cargo through the axon to their target location and to allow the regulation of neurite 
outgrowth, axon maintenance or synaptic function (section 3). The familial ALS proteins 
directly regulate crucial pathways within the landscape, such as the regulation of 
growth factor pathways, Rho-GTPases and RNP granules. Consequently, the mutations 
in the familial genes directly lead to (familial) ALS, whereas in individual sporadic 
ALS patients multiple functionally ‘lower-impact’ genetic variations are involved in 
the development of the disease. Nevertheless, disorganization of the cytoskeleton, 
reduced neurite outgrowth and axon maintenance, caused by or causing RNP granule 
dysfunction, results in a defective synapse and motor neuron death in both familial and 
sporadic ALS. Furthermore, estradiol signaling is neuroprotective by regulating neurite 
outgrowth, and the activation of Rho-GTPases and the NADPH-oxidase complex as 
well as by mediating stress granule assembly and regulating CHAT expression. Hence, 
estradiol is a crucial modulator of ALS pathology.
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ALS,  amyotrophic lateral sclerosis;
fALS,  familial amyotrophic lateral sclerosis;
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GWAS,  genome-wide association study; 
GWASs, genome-wide association studies;
IPS-MNs,  induced pluripotent stem cell-derived motor neurons;
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NS,  not shown;
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SMNs,  spinal motor neurons;
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Parkinson’s disease (PD) is caused by a complex interplay of genetic and environmental 
factors, and characterized by the degeneration of dopaminergic neurons in the 
substantia nigra (SN), resulting in motor and cognitive dysfunction. At present, there 
are no disease-modifying therapies for PD. To develop therapies that slow or even 
halt the progression of PD, knowledge about the dysregulated molecular pathways 
underlying the disease is essential. Currently, multiple candidate genes for familial 
PD – encompassing only 5-10% of the patients – have been identified, which provide 
general insights into the underlying pathogenesis of PD. For the other 90-95% of 
PD patients who have the so-called ‘sporadic variant’ of the disease, the underlying 
pathogenic mechanisms have barely been elucidated. However, the completion of the 
human genome project in 20011, 2 enabled researchers to perform genome-wide studies. 
Genome-wide association studies (GWASs) have yielded (putative) genetic risk factors 
for sporadic PD, but it has proven difficult to functionally couple the proteins encoded 
by these GWAS candidate genes to PD etiology, e.g. because they show a broad variety of 
functions and do not belong to a single pathway or biological process. Moreover, detailed 
insights into the interactions between the various GWAS- and familial candidate gene-
associated processes are essentially lacking. Therefore, through building molecular 
landscapes, I focused in this thesis on the integration of all available GWAS data and 
other (genetic) PD data in order to further clarify the molecular mechanisms underlying 
PD. 
In this General Discussion, I will describe how the molecular landscape building 
approach that I used (1) differs from systems biology and bioinformatics approaches, 
such as protein network analysis tools, gene ontology (GO) term analysis, and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and (2) which biases may 
be encountered or prevented when applying this approach (section 6.1). This is followed 
by a discussion of the unique features of the PD landscape (chapter 2) compared to the 
amyotrophic lateral sclerosis (ALS) landscape (chapter 5) (section 6.2) and a section on 
the putative druggable targets that were identified within these landscapes (section 
6.3). Subsequently, I will discuss the differences in the interpretation of GWAS data and 
genome-wide expression data, and to what extent the genes/proteins and functional 
themes that are enriched within these two sets of data overlap (section 6.4). Then, I will 
determine the overlap between human PD brain expression data and expression data 
from the brains of MPTP-treated mice and exercised MPTP-treated mice, as follow-ups 
of chapters 3 and 4, respectively (section 6.5). Lastly, I will discuss how the molecular 
landscapes may contribute to personalized medicine (section 6.6) and will offer 
suggestions for future research directions (section 6.7). An overview of the sections in 





6.1 THE MOLECULAR LANDSCAPE BUILDING APPROACH
Systems biology, which could be defined as the computational and mathematical 
modeling of complex biological systems, is fundamentally different from the landscape 
building approach that underlies many of the studies in this thesis. Still, systems 
biology and the landscape building approach both aim to develop a model to describe 
a complex biological system based on as much relevant, unbiased information as 
possible, such as genomic, transcriptomic, proteomic, metabolomic and lipidomic 





data, and the determination of the interactions between the individual components 
of the system (e.g. protein-protein interactions). However, while all interactions 
in ‘networks’ generated through systems biology approaches are mathematically 
quantifiable, the landscape building approach determines important ‘hubs’ or ‘nodes’ 
within the landscape on the basis of their biological relevance and not solely based 
on quantitative evidence (e.g. how quantifiably ‘connected’ or ‘central’ a hub is in 
the network). A seeming advantage of a network generated through systems biology 
is that it can also be interpreted without a priori biological knowledge, i.e. by only 
considering the most statistically significant outcomes (e.g. for the connectivity or 
centrality of a protein within the network). However, this has an important caveat in 
that, without biological knowledge, the interpretation and application of the findings 
are only based on statistical thresholds which may potentially be misleading2. For 
instance, a potential research bias – i.e. disease-associated proteins are generally 
studied in more detail than proteins with an unknown disease link and/or biological 
function – can have major repercussions for the interpretation of the results3-5. A few 
examples of these frequently studied, disease-associated proteins are tumor protein 
p53 (TP53), breast cancer 1 (BRCA1), interleukin-6 (IL-6), amyloid beta precursor protein 
(APP) and – for PD – alpha-synuclein (SNCA). For each of these proteins, thousands of 
interactions have been identified, leading them to be present as important regulators 
in virtually all computational analyses that are performed. Consequently, this may give 
the impression that these proteins are central in the regulation of a given disease, but 
in reality, they are overrepresented, and 1) mask the functional involvement of other, 
less well-documented, proteins in the analysis, and 2) create a circular reasoning for 
the diseases in which these proteins are already known and validated contributors. The 
latter would for example result in (not very innovative) interpretations such as “TP53 
is central in cancer formation”, “APP is crucial for the development of Alzheimer’s 
disease”, or “SNCA is important in PD”. Thus, the well-documented proteins may be less 
involved in the disease than initially suggested by statistical analyses. Therefore, the 
qualitative aspects of a generated network – for example the involvement of generic vs. 
(more) disease-specific biological processes, the biological relevance of proteins for the 
system, and the degree of documentation of (i.e. literature about) the included proteins 
– are at least as important as the quantitative aspects (connectivity, centrality) to 
understand the biological system under investigation.
Freely available online bioinformatics-based tools can be used to generate protein 
interaction networks and analyze the enrichment of certain functional themes and 
processes within a set of proteins. Here, I will shortly discuss what the limitations 
of these tools are and how the landscape building approach is different from the 
bioinformatics-based generation of protein interaction networks. First, the landscape 




as STRING6, GeneMania7 or IMP8 by manually curating all experimental evidence for 
the interactions in the landscape, but without assigning a confidence score or weight 
to these interactions. It should be noted that the number of interactions listed in 
these tools varies greatly depending on the databases they use, and/or are strictly 
separated per organism which makes it difficult to get a comprehensive overview of 
all possible interactions. Further, the score/weight they assign to these interactions 
is also dependent on these databases and on the algorithm they apply, and may not 
necessarily have any biological meaning due to a research bias (as discussed above). 
Nevertheless, these protein network generation tools have improved significantly in 
recent years (due to increasing content in the annotation/interaction-databases they 
use) and are useful tools to uncover protein-protein interactions. Second, in addition 
to protein-protein interactions, the landscape building approach adds interactions 
with/between molecules that are not proteins e.g. metabolites, endogenous chemicals, 
ions and lipids. Third, through the landscape building approach, protein complexes are 
identified whereas the protein networks generated through bioinformatics tools only 
contain bilateral interactions. The latter means that proteins that do not physically 
interact with each other but that are located in and regulate the same protein complex 
are not recognized as interacting proteins and hence, important information is missed. 
Lastly, candidate proteins that have the same function – e.g. the transport of calcium 
ions over the cell membrane – or belong to the same metabolic pathway – e.g. the folate 
cycle – are not necessarily functionally interacting with each other. Therefore, such 
proteins are not picked up by protein network generation tools, but are nonetheless 
relevant to understand the biological processes that are regulated by a set of candidate 
proteins and therefore included in the landscape building method.
This enrichment or overlap of functions, pathways and processes within a set of genes/
proteins can also be assessed by using GO terms9, 10 and/or KEGG pathways11, 12. GO 
terms are assigned to genes to provide a classification system for the cellular location, 
function, and involvement in biological processes of the proteins they encode. In the 
KEGG pathway database, proteins are assigned to a collection of pathways of various 
functions and (perturbed) biological systems within the cell. However, enrichment 
analyses on the basis of these GO terms/KEGG pathways should be used cautiously 
because the functional annotations these analyses use are often inconsistent, 
incomplete, too general, or sometimes incorrect13-17. Manually reviewing the functions 
and processes in which a protein is involved – as is done in the landscape building 
approach – is therefore necessary to achieve a more accurate, detailed and correct 
picture of the disease-underlying pathways/signaling cascades and processes on the 
basis of current knowledge. However, a functional annotation bias due to the use of 
(high-throughput) experimental assays that can only detect the abundant proteins18, or 




throughput screening that identifies the involvement of proteins in tumor formation 
marks hundreds of proteins with the annotation ‘cancer’, while many of them are 
also involved in multiple other functions and diseases that are not annotated in this 
screening. But again, as with the protein network generation tools, the more complete 
these annotation databases become, the more useful they will be to identify enriched 
processes.
In summary, the landscape building approach focuses on the biological significance 
of the proteins and processes involved, and limits the effects of a potential research 
bias on the interpretation of the identified interactions. The landscapes enable us to 
interpret the functional/biological relevance of large, disease-linked gene/protein 
sets, provide an overview of the interconnectivity of multiple known and less known 
functional themes, and are hypothesis generating. That said, a functional annotation 
bias still seems unavoidable and only additional studies to get a more complete picture 
of all functions of these genes/proteins can decrease this bias.
A further aspect to consider is the personal bias of the researcher building the 
molecular landscape, as this researcher needs to decide e.g. which data sets can be 
used, which interactions have been sufficiently validated by experimental evidence, 
how the interactions are visualized within the landscape, which additional proteins are 
relevant for the molecular landscape, which functional themes and biological processes 
have biological relevance for the disease studied and, eventually, which hypotheses 
can be made based on the landscape. This personal bias can be minimized by 1) being 
as comprehensive as possible, i.e. including all known interactions, functions and 
themes from multiple data sets, and 2) staying hypothesis-free as long as possible to 
avoid a ‘confirmation bias’, i.e. only the evidence supporting the hypothesis is accepted 
and other evidence is dismissed. Finally, the hypotheses drawn from the landscape, 
and the important functional themes and key biological processes within the 
landscape should be tested/validated, which can be accomplished through a genetic, 
epidemiological and/or functional validation. For example, for the PD landscape (see 
chapter 2) we genetically validated the main landscape-derived hypothesis that ‘lipids 
are important in the etiology of PD’ by finding a shared genetic risk between lipid 
traits and PD. Moreover, for the ALS landscape (see chapter 5) we found corroborating 
epidemiological evidence in a cohort of ALS patients for our hypothesis that ‘estradiol 
signaling is involved in the etiology of ALS’. However, these types of validation should 
be followed by a functional validation in which modulation of a landscape-derived 
pathway or process is demonstrated to directly affect PD symptoms and/or disease 
progression in a cell/animal model for PD or in PD patients, and as such provides the 




6.1.1  Improving the molecular landscape building approach 
Newer genetic studies often use bigger patient populations, better genotyping arrays 
and have a higher statistical power for detecting true genetic susceptibility variants. 
Therefore, more recent GWASs may yield more reliable results than older studies. In 
our landscape building method, we select our candidate genes based on set selection 
criteria – as described in the General Introduction – that are the same for all included 
GWASs. Therefore, we do not take into account the differences in power and reliability 
between these GWASs. In general this would mean that older, statistically less powered 
GWASs have a higher false positive rate than more recent GWASs. Using selection 
criteria that take into account these differences between GWASs would reduce the false 
positive rate and improve candidate gene selection.
The following two methods may improve candidate gene selection:
1) Data-driven p-value threshold (DDPT). The p-value threshold used for inclusion 
of SNPs is chosen in such a way that there is a false positive ratio of (for 
example) 0.25, that is calculated as:
This means that when one million (1.00E06) independent SNPs (i.e. SNPs in low 
linkage disequilibrium (LD)) have been genotyped in a GWAS, and an inclusion 
p-value of p<1.00E-04 is used, the expected number of SNPs with a p<1.00E-04 
is 100 (i.e. 1.00E06 / 1.00E04). To obtain a false positive ratio of 0.25, this would 
mean that in the GWAS 400 SNPs should be found with a p<1.00E-04. When 
less SNPs are discovered with a p<1.00E-04, the p-value threshold has to be 
set to a lower threshold, and to a higher threshold when more SNPs are found. 
The resulting list of SNPs could then be used for candidate gene selection. In 
this way, rather than selecting SNPs/genes based on a single, pre-determined 
p-value cut-off, candidate SNPs/genes would be chosen based on the same 
false positive ratio, which (1) is independent of the size of the investigated 
patient population and, linked to this, the statistical power of the study and (2) 
can correspond to different p-value thresholds for different GWASs. 
2) Individual SNP-weighted p-value (ISWP). The number of SNPs in a gene can 
vary and depends on the gene size and on the genetic variation in each gene. 
Moreover, in our landscape building method, we also select candidate genes 
based on SNPs that are not located in a gene itself but in the 100 kb upstream 
and downstream regions from each gene that likely contain expression 
quantitative trait loci (eQTL), SNPs that influence gene expression ‘from a 




p-value-SNP in (the vicinity of) a large gene with many SNPs is therefore 
higher than in a small gene with only a few SNPs. Based on the results of a 
given GWAS, an ISWP can be calculated that takes into account the number of 
SNPs in a gene, with or without the SNPs in the 100 kb upstream/downstream 
regions from this gene, using this formula (for n SNPs):
A disadvantage of the ISWP is that it does not account for high LD between SNPs – 
which is by definition the case for imputed SNPs – and that all SNPs are assumed to 
be of equal functional importance. For example, when a high LD block in (the vicinity 
of) a gene contains a functional SNP with a low p-value, and another LD block in (the 
vicinity of) the same gene has no such SNPs, the latter LD block ‘dilutes’ the signal 
of the functional SNP, which could lead to the gene not being selected. Nevertheless, 
when a locus with multiple genes is associated to a disease, the ISWP-method makes 
it possible to indicate which gene in this locus is most likely to ‘explain’ the signal in 
the locus – i.e. the gene with the lowest ISWP – and can therefore be used as additional 
evidence for selecting a candidate gene. Of note, whereas the ISWP-method requires 
the summary statistics – i.e. the associated p-values for all genotyped SNPs – of a 
GWAS, the DDPT-method can already be applied to published GWAS data for which e.g. 
only the SNPs with a p<1.00E-04 are available.
6.2 HOW UNIQUE IS THE PATHOGENESIS OF PD? 
The landscape building approach ideally results in a molecular landscape that 
encompasses pathways, biological processes and molecules that are disease specific, 
and as such, the landscape provides a unique molecular ‘signature’. In this section, I will 
discuss to what extent the landscape building approach can distinguish between two 
neurodegenerative diseases and result in two landscapes containing unique molecular 
mechanisms (i.e. the landscapes for PD and ALS that are presented in chapters 2 
and 5, respectively). Moreover, I will determine how these unique mechanisms are 
linked to disease-specific cellular and neuroanatomical substrates, i.e. what causes 
the degeneration of especially DA neurons in PD and motor neurons in ALS? First, I 
will describe the generic pathways, followed by the immune processes, and the main 
biological processes in the PD and ALS landscapes. Subsequently, I will discuss which 
of these pathways and processes can be linked to the specificity for DA- and motor 
neurons in PD and ALS, respectively.
Generic pathways – i.e. pathways that are common across cell types and hence not 
unique to a certain cell type – are often involved in a wide variety of (important) cellular 




each landscape, i.e. common proteins such as the Rho-GTPases (RAC1, CDC42, RHOA) 
seem to particularly regulate vesicular transport, and endo- and exocytosis, in the PD 
landscape, whereas in the ALS landscape, their function is more related to growth 
factor signaling and neuronal outgrowth. This discrepancy is due to a different set 
of proteins that regulates the generic pathway in each landscape. For example, RAC1 
is regulated by the familial PD proteins PARK2 and LRRK2, and by the familial ALS 
proteins SOD1, ALS2 and TARDBP. These five regulatory proteins have completely 
different functions. Moreover, the PD and ALS landscapes reveal that the components 
of the generic pathways seldom contain disease-linked genetic variations (i.e. SNPs) 
or more damaging mutations in these late-onset neurological diseases. In this respect, 
I assume that true genetic defects in generic proteins would manifest much earlier in 
life (e.g. such as HPRT mutations in Lesch-Nyhan disease) and would therefore have 
led to either a different disease or to a reduced viability resulting in premature death.
Thus, in our landscapes of (late-onset) neurodegenerative diseases, the generic 
pathways are often involved through a disease-specific set of proteins that regulates 
the pathway (e.g. through activation or inhibition) rather than through direct genetic 
variations/mutations in the genes constituting the generic pathway itself. In this way, 
not all processes regulated/modulated by the generic pathway are dysfunctional, and/
or can be easily compensated for by other proteins/regulators in the cell.
The immune response is involved in both PD and ALS (see chapters 2 and 5, 
respectively), because when neuronal cells degenerate and die – which is the case in 
both diseases – they need to be cleaned up. However, an association of immune-related 
genes (and hence proteins) with the disease implies that the immune processes are 
not just a symptom, but may be causative for or (at least) contribute to the disease. 
Whereas multiple immune-related genes/proteins have been genetically linked to 
PD (e.g. C9, CD200, CXCR4, HLA-genes, IL1B, IL2RA, IL5RA, IL6, PRF1, TIMD4, TNF), the 
genetic basis for the involvement of the immune response in ALS is limited to only a 
few genes/proteins (CXCL12 and the HLA-genes). Therefore, the immune response in 
PD may be an etiological factor, whereas in ALS it may be more likely that it is largely a 
secondary reaction to dying neurons. In this respect, the general scientific consensus is 
that the immune response in PD may be causative rather than responsive to the dying 
neurons20-22, while in ALS it is unclear if the immune reaction is protective, contributes 
to the disease, or is initially protective and becomes neurotoxic over time23-25. Therefore, 
targeting the immune system as a treatment strategy may yield better results in PD 
than ALS to (positively) modulate a truly causative disease mechanism.
The main biological themes/processes in the PD landscape (lipid regulation and 
oxidative stress) are different from the main themes/processes in the ALS landscape 




within these themes overlap between the two landscapes (e.g. cholesterol and the Rho-
GTPases are present in both) but overall, the specific themes/processes provide a unique 
signature per landscape. Moreover, the landscapes show the involvement of specific 
cell organelles that have a remarkable mechanistic overlap with the main themes 
in each landscape. For example, compared to the ALS landscape the involvement of 
mitochondria is more pronounced and widely documented in PD26, 27, and overlaps 
with oxidative stress pathways. Further, the lysosomes, the endocytic pathway and 
the endoplasmic reticulum are firmly represented in the PD landscape, whereas 
these organelles are barely present in the ALS landscape in which especially the 
ribonucleoprotein particle (RNP) granules have a central role. Interestingly, it appears 
that the – to some extent – disease-specific organelles are also the locations where 
the majority of processes involved in the landscape-specific main themes/processes 
occur, which provides a specific ‘compartmentalization’ of the landscapes within the 
neuronal cell.
In summary, we found that (1) generic pathways function in a slightly different context 
and are regulated by a different set of proteins in the PD versus ALS landscapes, (2) a 
dysregulated immune response is probably more of an etiological factor in PD than 
ALS, and (3) the main biological themes/processes within each landscape take place in 
distinct organelles. 
A further question arising from our landscapes is which of the landscape pathways 
and processes are (most) disease-specific and (best) explain the substrate specificity of 
PD and ALS? The generic pathways do not provide this specificity because by default, 
they are present in virtually every cell type. In addition, the pathways of the immune 
response do not provide this specificity as they regulate the function of immune 
cells and not specifically DA neurons or motor neurons. Nevertheless, autoimmune 
processes towards neuron-specific antigens (e.g. neuromelanin generated by and 
accumulating in DA neurons) may explain a part of the substrate specificity. However, 
the strongest proof for the specific involvement of DA or motor neurons can be found 
in the cell-specific processes that are associated with the main biological processes in 
each landscape. DA neurons rely heavily on the regulation of reactive oxygen species 
that are produced in high amounts during to the production of DA, which also results 
in (and requires) the production, processing and storage of neuromelanin. A deficit 
in any of these processes, or related processes such as lipid homeostasis and SNCA 
regulation – that all heavily interact with neuromelanin processing and the regulation 
of reactive oxygen species – makes that the DA neurons are particularly sensitive. In 
PD, DA neurons in brain areas other than the SN are to a lesser extent subjected to 
neurodegeneration28, indicating that SN DA neurons have specific characteristics that 




the DA transporter29-32 and proteins involved in vesicle-mediated transport33 in these 
neurons. As a result, SN DA neurons have the capacity to store more DA32 than other DA 
neuron populations, which makes them even more sensitive to defects in mechanisms 
that protect them from cytosolic DA oxidation34 and defects in related processes such 
as iron, neuromelanin and lipid regulation35, 36.
The specificity for motor neurons in ALS may be explained by their very long axons 
(sometimes up to one meter), which makes that motor neurons, much more than other 
neurons, depend on axonal transport and local translation of proteins. Sensitivity 
to defects in these processes is in accordance with the main processes in the ALS 
landscape, such as axonal maintenance and RNP granule regulation.
In conclusion, the landscape building approach allowed for the identification of 
molecular pathways that are specific to PD and ALS. Moreover, some of these pathways 
are substrate specific and closely related to the main biological processes operating 
in the landscapes and hence provide an explanation why especially these specific 
types of cells degenerate. Of note, neurological diseases are often not as homogeneous 
as they are initially presented, e.g. late-stage PD patients often experience dementia 
and depression37, 38. It would therefore be interesting to find out to which degree the 
molecular landscapes of e.g. Alzheimer’s disease and depression overlap with the 
processes, pathways and cell types in the PD and ALS landscapes. Ultimately, the 
availability of the complete landscapes of all neurological diseases would enable us 
to see their common pathways/processes, and understand why some of the diseases 
show clinical comorbidity and/or overlapping traits.
6.3 DID WE UNCOVER NEW POTENTIAL DRUGGABLE TARGETS?
As discussed above, the PD and ALS landscapes provide disease- and substrate-specific 
pathways and processes, and therefore offer opportunities for the identification and 
further development of novel druggable targets. New hypotheses can be generated based 
on the landscapes, and when these hypotheses turn out to be correct, e.g. ‘lipids are 
important in PD’, we can hypothesize that the proteins involved in e.g. lipid regulation 
are important players in PD pathogenesis and pathophysiology, and therefore represent 
potential druggable targets. The next step would then be to validate these targets in 
preclinical models, and assess if they are specific and can be – at least to some extent 
– specifically targeted by modulating drugs. Subsequently, these drugs should be tested 
in clinical trials to explore their effects. Below, I will elaborate on some of the possible 
druggable targets that we identified in the PD and ALS landscapes, and discuss how 
these proteins function within the landscape and what makes them potential targets. 
Note that these potential druggable targets do not have to be relevant for the entire 
patient population, but may be patient specific, depending on the pathways that are 




6.3.1 Druggable targets in the PD landscape
The molecular landscape of PD harbors four main biological themes, i.e. oxidative stress 
response, endosomal-lysosomal functioning, endoplasmic reticulum stress response, 
and immune response activation (see chapter 2). The main proteins per theme are 
summarized in Figure 2 A-D (a complete description of all proteins functioning in each 
theme can be found in chapter 2) and the most interesting putative druggable targets 
for each of the four themes (A-D) are discussed below:
A) Heme oxygenase 1 (HMOX1) represents a potential druggable target because 
it is involved in lipid regulation (the main overarching theme in the PD 
landscape), regulates DA-specific pathways and is protective in multiple 
cellular PD models39-42. HMOX1 is highly expressed in the periphery of Lewy 
bodies43, increased in PD serum44, regulated by DA45 and degrades cytotoxic 
heme46, and may therefore prevent oxidation of HDL and LDL, the initial heme 
scavengers in the circulation47. Further, HMOX1 regulates iron metabolism, 
reactive oxygen species formation, oxygen supply and mitochondrial function 
in the cell46-48.
B) The propeptide PSAP, the four saposins (A-D), the LDL receptor LRP1 and the 
PSAP receptor GPR37 are potential druggable targets because they control lipid 
synthesis, are associated with DA-specific processes and regulate DA neuron 
survival. That is, PSAP is neuroprotective for DA neurons49, 50 and exerts its 
effect by binding to LRP1 or GPR37 that both internalize PSAP upon binding51, 52. 
GPR37 binds to and regulates the expression of the DA transporter, is associated 
with juvenile PD, and a substrate of PARK253, 54 and hence strongly linked with 
PD. Further, uptake of PSAP results in its processing into four saposins (A-D) 
that regulate the ceramide/spingosine synthesis cascade (composed of SMPD1, 
GBA and ASAH1), but also SNCA aggregation, the immune response, apoptosis 
and membrane lipid composition55-60.
C) Sterol regulatory element-binding protein 1 (SREBF1) is a putative druggable 
target, because it regulates lipid homeostasis, has an effect on ER stress61 
and mitophagy62, and is associated with gait impairment in PD63. Through 
maintaining lipid homeostasis, SREBF1 is able to prevent cellular stress, 
but also the initiation of SNCA amyloid fibrils (the main component of Lewy 
bodies in PD)64 and immune responses towards extracellular lipid and/or SNCA 
aggregation. SREBF1 is generic but the selective vulnerability of DA neurons 
to defects in lipid homeostasis may explain its specificity for these neurons. 
Nevertheless, SREBF1 targeting may also result in oncogenic growth65, which 
possibly makes SREBF1 not specific enough for PD.
D) The angiotensin II receptor AGTR1, SERPINE1 and plasmin regulate the delicate 




potential druggable targets. Namely, loss of AGTR1 correlates with DA neuron 
death and CASP3 activation66, and the DA and angiotensin II systems are 
known to counter-regulate each other67, 68. AGTR1 regulates intracellular 
cholesterol esterification69 and increases the expression of SERPINE170, which 
in turn increases the risk for thrombosis and atherosclerosis71. The latter may 
occur due to a SERPINE1-mediated reduced splicing of plasminogen (PLG) into 
the active protease plasmin72 that degrades blood plasma proteins to prevent 
atherosclerosis, but also degrades (aggregated) SNCA72 and LDL (which 
increases extracellular lipid accumulation)73, 74. The (auto)immune response 
can be triggered by plasmin75, SNCA76, 77, lipids78 and oxidized lipoproteins79, 
which shows that the regulation of these factors may be crucial in PD. 
However, the specific targeting of AGTR1, SERPINE1 and plasmin may prove 
difficult because they also regulate e.g. hypertension, thrombosis, wound-
healing and atherosclerosis80-83.
Figure 2. Putative druggable targets within each of the main themes (A-D) of the PD landscape are indicated 
with green stars. For each theme, the main processes are depicted, a full description of these processes can be 
found in chapter 2. AP, autophagosome; CYT, cytoplasm; ECM, extracellular matrix; ER, endoplasmic reticulum; 




The potential druggable mentioned above are all associated with core processes 
within the PD landscape and are directly or indirectly linked to substrate-specific 
processes such as the regulation of DA, reactive oxygen species and/or neuromelanin, 
which closely interact with SNCA, lipids and iron. In addition, an adjusted lipid diet 
in combination with targeting one or more of these druggable targets, may have the 
potential to alter the course and/or severity of PD.
6.3.2 Druggable targets in the ALS landscape
The ALS landscape points to an important modulatory role for estradiol, Rho-GTPases 
and RNP granules. The protective role of estradiol in women suggests that treatment 
with this steroid may be beneficial and can have protective effects. However, especially 
in males such a treatment will result in side effects. It is tempting to speculate that the 
beneficial effects of riluzole – the only FDA-approved life-prolonging ALS medication 
– are not only due to its effect on reducing glutamate toxicity – which was the initial 
reason for trialing this drug in ALS – but also to its  effect (increase) on ABCG2 
expression84. ABCG2 transports estradiol metabolites, folate and riluzole in and out of 
the cell84-87. ABCG2 is therefore a potential druggable target, not only because it interacts 
with riluzole, but also because it directly affects estradiol signaling.
The Rho-GTPases are probably too generic to serve as specific targets, but targeting 
them indirectly through activation of the NGF receptors – which are functional ‘hubs’ 
with multiple connections in the landscape – may prove beneficial. Of note, gambogic 
amide is a neuroprotective NGF receptor agonist that triggers neurite outgrowth, 
and strongly prevents glutamate-induced neuronal death88, and may therefore be a 
potential drug to treat ALS. Other potential druggable targets within the ALS landscape 
are proteins that regulate RNP granule processing, e.g. the proteins TDRD3 and G3BP1, 
and most of the familial ALS proteins (see chapter 5). 
6.4  INTERPRETATION OF GENOME-WIDE GENETIC AND EXPRESSION DATA
Genetic risk factors are the first dominos that set the causal mechanisms of the 
disease in motion by changing expression levels and/or by changing e.g. the activity, 
localization, folding or posttranslational modification of the encoded proteins. Even a 
subtle change in one gene and its encoded protein may result in a cascade of multiple 
other differentially expressed, (in)activated or abnormally localized proteins within the 
cell. The subsequent molecular changes may happen either directly – e.g. when the 
affected protein is a transcription factor or kinase and directly affects the expression 
and activation of other proteins – or indirectly, e.g. when compensatory mechanisms 
are put in place to counteract these changes and maintain homeostasis. In combination 
with the effects of aging and environmental risk factors, all these interactions represent 
the underlying biological processes that result in the pathological changes leading to 




alterations such as protein modification/(in)activation, binding affinity or cellular 
location are not included. Thus, overall, I do not expect a complete overlap between 
genetic and expression data, but do expect that some genetically associated proteins 
are also differentially expressed.
6.4.1 Overlap between genetic and expression data
The PD landscape (chapter 2) was based on genetic data, and expression data was solely 
used as corroborating evidence for the involvement of the GWAS candidate proteins 
and the additional proteins in the landscape. A total of 451 proteins were linked to PD 
through GWASs of which 158 (35%) were also found to be differentially expressed in 
the SN, striatum, CSF and/or blood of PD patients versus healthy controls in at least 
one study, and 60 proteins (13%) in at least two studies (Table 1). In addition to other 
signaling cascades, these 60 proteins are involved in vesicular transport (e.g. AMPH, 
NAPB, NSF, SNCA), sphingosine regulation (ASAH1), angiotensin regulation (AGTR1), 
cytoskeletal organization (RUFY3, MAPT) and the immune response (CXCR4, CD200, 
SDC1, SEMA6D) and as such represent some of the most prominent biological processes 
in the PD landscape. Of note, mRNAs encoding the vesicular transport-associated 
proteins AMPH, NAPB, NSF and SNCA are all consistently downregulated in the SN 
of PD patients. This could mean that (1) the turnover of these mRNAs is increased, 
(2) vesicular transport is greatly reduced in PD DA neurons and/or (3) that only the 
DA neurons with low vesicular transport survived. The latter implies a selective 
vulnerability of DA neurons with a high vesicular transport and/or SNCA expression, 
and is in accordance with the substrate specificity of SN DA neurons (see section 6.2).
Enrichment analysis of the complete set of GWAS candidate proteins compared to the 
smaller sets of 158 and 60 GWAS proteins that are also differentially expressed in PD 
patients reveals similar biological themes/processes among the three groups (Table 
2). The most enriched canonical pathways are immune-related, and the enriched 
‘disease and disorders’ categories are mainly cancer-/cell proliferation-related, but 
show also enrichment for ‘diabetes mellitus’ and ‘movement disorders’ in the group 
of 60 overlapping proteins. The enrichment for diabetes mellitus may be associated 
with the health problems that accelerate diabetes, such as dyslipidemia and high 
blood pressure89, processes that, together with insulin signaling – the major pathway 
dysregulated in diabetes mellitus90 – are present in the PD landscape. In contrast to 
the analysis of all GWAS candidate genes/proteins, the analyses of the differentially 
expressed genes/proteins show that the cancer-related themes are more specifically 
related to skin cancer and melanoma. Melanoma is a type of skin cancer that develops 
from the pigment-containing skin cells which represents an interesting functional 
overlap with the degenerating, pigment-containing DA neurons in the SN. Lastly, the 




related functions in the category ‘molecular and cellular functions’, whereas the 
differently expressed GWAS candidate genes also show enrichment for synaptic 
transmission. The latter process is expected to be reduced when DA release (and 
therefore synaptic transmission) is decreased.
In summary, the observed overlap of genes/proteins associated with PD through GWASs 
and expression studies represents the most enriched processes from the total set of 
GWAS candidate genes, in particular vesicular transport and neurotransmission. These 
are processes that are expected to be decreased when DA release is reduced. However, to 
understand the pathological effects of all genetic risk factors and accomplish complete 
translatability of these factors to the underlying biological processes, additional studies 
are required that – in addition to expression changes – also map the proteins that are 
e.g. differentially phosphorylated, methylated, glycosylated or located within the cell.
6.4.2 Analysis of expression data
The analysis of PD patient expression data can help to – at least partially – elucidate the 
biological processes underlying the disease and are a reflection of the combination of 
genetic factors (i.e. the underlying causal molecular mechanisms) and environmental 
risk factors that lead to the disease. Therefore, analysis of expression data may provide 
additional information on top of the causal themes and processes derived from genetic 
studies. When we examine all the mRNAs/proteins that are differentially expressed in 
the SN, striatum, CSF or blood of PD patients (and not only those that overlap with GWAS 
candidate genes), other enriched themes/processes emerge (Table 3). The differentially 
expressed mRNAs/proteins in the SN are in particular related to mitochondrial 
dysfunction, disorders of the basal ganglia and movement disorders, which are ‘classic 
PD themes’. In the striatum, we see similar enrichments in the category ‘disease and 
disorders’, whereas the enriched ‘molecular and cellular functions’ mainly relate to 
neurotransmission, which is in line with the reduced DA release in the striatum (see 
above). The CSF and blood analyses show enriched themes that are completely different 
from those from the SN and striatum analyses. Of note, in the CSF analysis, the ‘liver 
X receptor (LXR)/retinoic X receptor (RXR)’ pathway is enriched, in combination with 
‘atherosclerosis signaling’, ‘clathrin-mediated endocytosis signaling’ and the enriched 
functions ‘efflux of cholesterol’ and ‘concentration of lipid’, which are all related to 
cholesterol and cholesterol signaling. In the blood of PD patients, the enriched canonical 
pathways and diseases and disorders are lined to immune regulation, and the enriched 
molecular and cellular functions are associated with cell death.
In summary, whereas the enriched functional categories from the analyses of the 
SN and striatum expression data are closely related to classic PD-linked processes/




show enrichment for cholesterol and lipid regulation, the immune response and cell 
death, themes that are highly similar to the processes in the PD landscape. Therefore, 
these findings corroborate the findings from the PD landscape and indicate that lipid 
signaling is involved in PD.
6.5 THE EFFECTS OF MPTP AND PHYSICAL EXERCISE
In chapter 3, we established that, based on expression data, the MPTP-treated mouse 
accurately represents the underlying biological processes in human PD and therefore 
can be regarded as an adequate model for human PD. We also hypothesized that this 
validity of the MPTP mouse model may improve when a longer interval between 
MPTP treatment and tests is used. In chapter 4, we used this mouse model to explore 
how physical exercise affects the molecular pathways underlying MPTP toxicity 
and modulates the clinical outcome. We assume that these molecular pathways can 
be translated to the human situation. Here, I will discuss – as a follow-up of chapter 
3 – the validity of the MPTP-treated mouse as a model for PD at a later time point, 
i.e. seven weeks after MPTP treatment (section 6.5.1). Further, to assess if physical 
exercise-mediated pathways may indeed regulate mechanisms underlying human 
PD pathophysiology, I will compare – as a follow-up of chapter 4 – the mRNAs that 
are induced by physical exercise in MPTP-treated mice with mRNAs from human PD 
expression data (section 6.5.2).
6.5.1  The validity of the MPTP model revisited
In chapter 3, we concluded that the MPTP mouse model is probably more valid for 
studying the SN-linked than the striatal mechanisms in PD. We noted that further 
transcriptome studies are needed to determine if waiting longer than 72 hours after 
MPTP injection would provide a better construct validity for human PD in the striatum. 
The MPTP-treated mice (without physical exercise; chapter 4) were sacrificed seven 
weeks after MPTP treatment and can therefore serve to study the effects of MPTP at 
a (much) later time point, as proposed in chapter 3. Here I compare the enrichment 
analysis of the differentially expressed mRNAs in the mouse SN and striatum seven 
weeks after MPTP-treatment to the human PD and MPTP-treated mouse mRNA 
expression analyses of chapter 3 (Tables 4 and 5).
Compared to the earlier time points, the enriched upstream regulators in the ‘seven-
week SN’ are not only more epilepsy- (i.e. CREB1) but also more dopamine- (i.e. L-DOPA) 
related. CREB1 is predicted to be increased, which – when epileptic processes are 
considered to reflect neuronal activity91, 92 – may point to an increased activation of the 
remaining neurons to compensate for the loss of DA neurons. The category ‘diseases 
and disorders’ is enriched for ‘movement disorders’, ‘dyskinesia’, and ‘seizures’, the 




functional annotations were predominantly cell death-related at the earlier time points, 
but are associated with neurotransmission and learning/cognition seven weeks after 
MPTP treatment, suggesting more chronic and perhaps adaptive processes following the 
death of a large portion of SN cells. These processes are also more similar to ‘transport 
of vesicles’, the main function that was found to be enriched in the SN expression data 
of human PD and that is related to neurotransmission and/or cell activity (see above).
In the striatum, seven weeks after MPTP treatment, the enriched annotations are 
mainly epilepsy-related for ‘disease and disorders’. Further, the most enriched upstream 
regulators (Dalfampridine, Bicuculline, CREB1) are epilepsy-related and, together with 
the upstream regulator L-DOPA, are predicted to be decreased in activity (not shown). 
Again, when epileptic processes reflect neuronal activity91, 92, the activation of the 
striatum is decreased, in accordance with a decreased activation of L-DOPA-mediated 
pathways and DA innervations as seen in human PD. As in the SN, cell death-related 
processes are enriched in the striatal expression data of the early time points, but 
absent seven weeks after MPTP treatment.
Overall, it seems that seven weeks after MPTP treatment (1) the SN may have to 
‘work harder’, probably to compensate for neuronal loss (as indicated by an increased 
activation state), and (2) the striatum appears less active, probably due to a decrease in 
DA innervations. Moreover, especially because acute effects of MPTP, such as cell death, 
are not present anymore seven weeks after MPTP treatment, the seven-week MPTP 
model provides an even better construct validity for human PD and better mimics the 
slow deterioration seen in PD. Yet, one still has to wonder whether at this time point, the 
SN of the MPTP-treated mice is progressively degenerating while the striatum has to 
adapt continuously to a decreased DA release (as in human PD), or (maybe more likely) 
whether the SN is functioning less well and has reached a status quo and delivers a 
less-than-normal but continuous amount of DA to the striatum.
6.5.2		 How	would	physical	exercise	affect	human	PD?
Physical exercise improves the motor function of PD patients93, 94 and in my animal 
study (counter)regulates mRNAs that contribute to MPTP toxicity, which provides a 
direct ‘knock-on’ effect of physical exercise on the PD model (chapter 4). It would be 
of interest to see if physical exercise also may have the potential to regulate mRNAs 
that contribute to the pathophysiology of human PD, and as such function as a ‘disease 
modifier’. To this end, I compared per brain region (SN, DL, VM) the mRNAs that were 
differentially expressed by physical exercise in the MPTP mice (from chapter 4) with 
the differentially expressed mRNAs in human PD95-112. This comparison shows that the 
number of overlapping mRNAs is larger in the SN (112 mRNAs) and VM (99 mRNAs) 




the MPTP model (chapter 4) – physical exercise may especially have a direct effect 
on disease-related processes in the SN and VM of humans with PD. An enrichment 
analysis was performed on these overlapping mRNAs to assess which processes and 
themes are regulated by physical exercise as well as in human PD (Table 6).
The 112 overlapping mRNAs in the SN show enrichment for ‘Parkinson’s disease’ and 
have microRNA-124-3p as top upstream regulator (and this microRNA is predicted to 
be increased in activity (not shown)). MicroRNA-124-3p is a regulator of apoptosis and 
autophagy, and prevents DA neuron loss113, 114, and may therefore also be a potential 
target to treat PD. In the VM, the 99 mRNAs that overlap with human PD show L-DOPA 
as the top upstream regulator (which is predicted to be decreased in activity) but also 
show enrichment for movement disorder- and epilepsy-related diseases, and enriched 
molecular and cellular functions associated with synaptic transmission and behavior. 
Therefore, this analysis of VM-mRNAs that overlap with human PD shows enrichment 
for similar themes as the analysis of the total set of mRNAs regulated by physical 
exercised in the VM of MPTP-treated mice (see chapter 4). Lastly, in the DL enrichment 
analysis, epilepsy-related annotations predominate, which may indicate that physical 
exercise results in activation91, 92 of the DL and in this way may compensate for the 
reduced basal DA release in the striatum. However, the total number of overlapping and 
epilepsy-related proteins is too low to draw a firm conclusion.
Overall, these analyses show that the effects of physical exercise as seen in the MPTP-
treated mouse may well be translated to human PD, and may provide a direct ‘knock-on’ 
effect on molecular mechanisms of human PD that are markedly related to DA neuron 
loss and L-DOPA signaling. 
6.6 MOLECULAR LANDSCAPES AND THE DEVELOPMENT OF 
PERSONALIZED MEDICINE
The medication for PD is still based on symptomatic treatment – e.g. L-DOPA – and is 
hence not directed at the core underlying disease mechanisms in order to slow down 
the progression or even cure PD. Moreover, the diversity in clinical (sub)phenotypes of 
PD suggests that the underlying molecular mechanisms may vary between individual 
PD patients, which implies that future disease modifying treatments should be tailored 
to the individual patient. Therefore, the development of more personalized medicine 
approaches for PD patients demands (increased) insight into the various subphenotypes 
of PD, both at a clinical level and a molecular level. 
Large population-based analyses such as GWASs are necessary to uncover the 
genetic risk factors/variants and understand which pathways and biological themes/
processes are involved in PD. By integrating all genetic risk factors/variants from 




origins), the molecular landscape reflects the genetic variation spectrum of the disease. 
However, although PD is the end result in all cases, the (sub)phenotype of PD may vary 
greatly, and be dependent on a certain genetic predestination that is present, or more 
pronounced, within a specific population. In this respect, populations with a different 
genetic background – e.g. different ethnic groups – may not only have a different risk 
to develop PD, but may also have other genetic risk factors and affected pathways that 
lead to PD. Overall, three situations may occur:
1)  genetic risk factors/variants overlap between populations, resulting in the 
same affected proteins and pathways, 
2)  different populations have genetic risk factors/variants in different 
proteins that are still functioning in the same pathways, or
3)  genetic risk factors/variants within the genes/proteins from one or more 
pathways are more prominent in one population than another.
To some extent, all three scenarios may occur but the limited overlap between the 
observed top results from the various PD or ALS GWASs indicates that the overlap of 
genetic risk factors/variants between populations is limited. Large genetic studies 
that gain power by including multiple populations (e.g. meta- and mega-analyses) 
may therefore find the most generic disease-associated pathways that are shared by 
different populations, but miss the population-specific signals.
An individual sporadic PD patient may carry multiple common genetic variants – 
typically SNPs – that together with environmental risk factors and aging result in the 
onset of PD. These variants may be located within genes encoding proteins from one 
specific pathway or from multiple pathways, and in both instances, this will result in 
PD. Therefore, not all pathways within the landscape have to be affected for a patient to 
develop PD. Of course, when PD is caused by different combinations of (dysregulated) 
pathways, this also requires different treatment strategies rather than a ‘one-size-fits-
all’ treatment. Ideally, the landscape can be used as a template on which the individual 
patient data is ‘mapped’ to divide the patients into different PD subcategories based 
on which patient-specific PD-associated molecular pathways are (genetically) 
affected. Subsequently, the treatment strategy could then be personalized with 
(disease-modifying) medication/therapy that specifically targets pathways affected in 
(subgroups of) individual patients (Figure 3).
Subcategorization of PD patients, not only on the basis of the molecular pathways that 
are (predicted to be) dysregulated, but also based on their (secondary) symptoms – 
e.g. the development of L-DOPA-induced dyskinesia and/or non-motor PD symptoms 




personalize the treatment for each patient. Furthermore, a consistent link between the 
affected molecular pathway(s) and certain clinical symptoms may point to a genetic 
predisposition for these symptoms, and can again be used to improve PD treatment. For 
example, patients with a genetic predisposition to develop L-DOPA-induced dyskinesia 
could benefit (i.e. more than other PD patients) from starting with physical exercise 
therapy already early after disease onset, in order to minimize the side effects of 
chronic L-DOPA usage115, 116.
Thus, although population-based research is initially necessary to map which 
processes are involved in PD, patients should subsequently be individually examined 
to determine which disease-associated pathways are affected. In this way, pathway-
specific and personalized PD treatments can be developed, which increases treatment 
effectiveness and reduces side effects.
6.7 FUTURE DIRECTIONS
In this thesis, the landscape building approach was used to elucidate the molecular 
mechanisms underlying PD and ALS. In addition, the effect of physical exercise on the 
molecular mechanisms underlying PD was examined in a mouse model. The challenge 
Figure 3. Subcategorization of PD patients by ‘mapping’ their individual data on the PD landscape, allowing 
personalized treatment based on the affected molecular pathways in each individual patient instead of a ‘one 




for the coming years will be to continuously update these molecular landscapes, and 
to (further) validate and use the landscapes to identify and further develop druggable 
targets in order to improve the treatment of patients. Moreover, the landscape building 
approach can be used to provide additional, in-depth insights into the effects of current 
therapeutic treatments at the molecular level, information that can then be used to 
improve these treatments and/or to develop better ones.
PD can be caused by a wide variety of genetic and environmental risk factors, and 
is characterized by a complex and diverse clinical picture. This diversity requires a 
treatment that can be tailored to the symptoms of each individual patient. In order to 
achieve such personalized medicine for PD patients, we first have to establish if we 
can (sub)categorize the patients based on their affected PD-related pathways. For 
this, a large number of PD patients should be screened individually to see if we can 
divide them into subgroups based on their genetic variants, affected proteins and/or 
pathways, in combination with their diagnosis, disease progression and/or clinical 
symptoms. Once we have reached this categorization of PD patients, we can start 
developing treatments (based on the putative druggable targets from the landscape) 
that are specifically targeting the affected pathways for each category, and accomplish 
a more accurate and effective PD treatment. 
In addition to the data from the ‘core’ genetic and expression studies, we have used 
a broad array of other studies on a multitude of topics – including protein-protein 
interactions, druggable targets, environmental risk factors and enzymatic reactions – 
to construct the landscapes. Many of these individual studies did not have a direct 
link with a certain disease but investigated for example the function, intracellular 
location or interactions of one or more proteins. For the landscape building approach, 
particularly these studies provide a wealth of information and enable us to ‘connect 
the dots’ and generate a comprehensive picture of all disease-linked interactions. In 
this respect, the results of these fundamental, ‘basic science’, studies – that are not 
focused on unraveling a disease mechanism or developing a treatment – are critical 
for building a molecular landscape and elucidate the disease-related and -specific 
molecular pathways. Fundamental research is necessary to acquire and maintain a 
broad knowledge base in all kinds of research fields, whereas more applied research 
focuses on known disease processes and proteins and is therefore largely dependent 
on the fundamental research efforts to provide revolutionary new insights and to 
further advance the research field. The problem of applied research and the strength of 
fundamental research is clearly illustrated by a quote in a book by Robbert Dijkgraaf: 
“What is the shortest way from A to B if you do not know what B is or where it is?”. 
Large international research consortia that work towards a common goal – directed 




impact and/or practical use – are necessary. However, in order to let these consortia 
succeed, we should continue to cherish (and finance) research that does not have 
a direct practical use (yet) and of which the societal impact is only apparent to the 
researcher in question. Only when research in the fields of biology and neurology stays 
fundamental and thereby safeguards a continuous stream of knowledge on a multitude 
of new biological concepts, we will find the answers to major research questions. This 
will also be the only way in which methods such as the landscape building approach 
can be successful and result in the generation of new ideas, hypotheses and eventually 




Table 1. PD candidate genes/proteins associated with human PD through both GWASs and genome-wide expression studies. 
Only the genes that are differentially expressed in at least two different (protein and mRNA) expression studies of either the 
SN95-110, 117-119, striatum98, 100, 103, 104, 110-112, CSF120-125 or blood126-135 of PD patients are shown. Genes in bold are also located in the PD 
landscape (chapter 2). mRNAs were only included when their adjusted expression p-value was <0.05 and the corresponding fold 
change was ≥1.5 or ≤-1.5, or when the fold change was ≥2 or ≤-2. Proteins were only included when their adjusted expression 
p-value was <0.05 and the corresponding fold change was ≥1.2 or ≤-1.2, or when the fold change was ≥1.5 or ≤-1.5. SN, substantia 
nigra; STR, striatum; CSF, cerebral spinal fluid; BLD, blood.
Rank Gene SN STR CSF BLD # Rank Gene SN STR CSF BLD #
1 NSF 7 1 0 0 8 31 MAP1B 2 0 0 0 2
2 SNCA 6 0 0 0 6 32 MRPL3 2 0 0 0 2
3 AGTR1 5 0 0 0 5 33 MVB12B 2 0 0 0 2
4 NPTX2 4 1 0 0 5 34 SLC24A3 2 0 0 0 2
5 ROBO2 4 0 1 0 5 35 ACTN4 2 0 0 0 2
6 RUFY3 4 0 0 1 5 36 CALN1 2 0 0 0 2
7 ASAH1 1 1 1 2 5 37 CNKSR3 2 0 0 0 2
8 PCDH8 4 0 0 0 4 38 LMBR1 2 0 0 0 2
9 AMPH 3 1 0 0 4 39 SLC2A13 2 0 0 0 2
10 SCN2A 3 1 0 0 4 40 SYT17 2 0 0 0 2
11 MAPT 3 0 1 0 4 41 TMEM200C 2 0 0 0 2
12 SLCO3A1 3 0 0 1 4 42 GCH1 2 0 0 0 2
13 ADAMTS2 3 0 0 1 4 43 FPR3 1 1 0 0 2
14 NAPB 2 2 0 0 4 44 HAVCR1 1 1 0 0 2
15 CXCR4 1 2 0 1 4 45 ITGA8 1 1 0 0 2
16 ATP2B2 3 0 0 0 3 46 RFX4 1 1 0 0 2
17 FGF12 3 0 0 0 3 47 SUSD3 1 1 0 0 2
18 SDC1 3 0 0 0 3 48 COL18A1 1 0 1 0 2
19 SEMA6D 2 0 1 0 3 49 COL2A1 1 0 1 0 2
20 MBP 1 2 0 0 3 50 CDK19 1 0 0 1 2
21 CD200 1 1 1 0 3 51 GLRA3 1 0 0 1 2
22 CACNA2D3 1 1 1 0 3 52 PLEKHM1 1 0 0 1 2
23 NEGR1 1 1 1 0 3 53 PPP1R12B 1 0 0 1 2
24 DLG2 1 1 0 1 3 54 SCIN 0 2 0 0 2
25 CNTNAP2 1 0 0 2 3 55 SLC38A1 0 2 0 0 2
26 CNTN1 0 2 1 0 3 56 BANK1 0 1 1 0 2
27 GLDN 0 1 1 1 3 57 WNK1 0 1 0 1 2
28 ARHGAP33 2 0 0 0 2 58 FBN1 0 0 1 1 2
29 ATP6V0A1 2 0 0 0 2 59 SAMD4A 0 0 0 2 2
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Parkinson’s disease (PD) is the second most common neurodegenerative disease, after 
Alzheimer’s disease, affecting 1-2% of people over 60 years of age. PD is characterized by 
the death of dopaminergic (DA) neurons in the substantia nigra (SN) that is located in 
the midbrain. Degeneration of these neurons in PD reduces the DA input to the striatum 
and results in motor symptoms such as tremor, bradykinesia, rigidity and postural 
instability. Although we have known for decades that DA neurons in the SN degenerate 
in PD, we still do not know why exactly these neurons are prone to degenerate in PD 
patients and which molecular pathways are responsible for this degenerative process. 
Due to this limited knowledge of the disease mechanisms underlying PD, it has thus far 
been impossible to develop disease-modifying treatments. While current treatments – 
e.g. L-DOPA administration or physical exercise – can improve the motor symptoms of 
PD, they do not stop or slow down disease progression. In this thesis, I aimed to further 
elucidate the molecular pathways underlying PD and the effects of physical exercise on 
PD. By doing so, I wanted to increase our knowledge of disease etiology and provide new 
insights into how physical exercise can alleviate PD symptoms, and thereby move the 
field forward towards the development of disease-modifying treatments.
In chapter 1, a general introduction to PD is provided by presenting a historical 
overview of the advancing insights into the clinical description and pathophysiology 
of PD through the years. This is followed by an outline of the genetic and environmental 
factors that are known to be involved in the etiology of PD. Lastly, the landscape building 
approach – the method used throughout this thesis to interpret large data sets – is 
explained.
In chapter 2, the landscape building approach was used to build a molecular landscape 
of PD, based on genome-wide association study (GWAS) data and other genes/proteins 
implicated in PD through e.g. familial candidate gene associations and functional 
studies. In this PD landscape, we identified four main biological processes that 
interact with each other and regulate DA neuron function and death, i.e. oxidative 
stress response, endosomal-lysosomal functioning, endoplasmic reticulum stress 
response, and immune response activation. Lipids and lipoproteins are functionally 
involved in all four processes and we therefore hypothesized that lipids are involved 
in PD pathogenesis. Subsequently, this hypothesis was confirmed by showing a shared 
genetic risk between lipid/lipoprotein traits and PD.
In chapter 3, we validated at a molecular level the use of mice treated with the neurotoxin 
1-methyl-4-pheynl-1,2,3,6-tetrahydropyridine (MPTP) as a model of PD. We compared 
the genome-wide mRNA expression data of the SN and striatum from MPTP-treated 









trafficking, exocytosis, mitochondrial apoptosis and DA neuron-specific transcription 
– that were dysregulated in both the mouse model and PD patients. It was concluded 
that the MPTP-mouse represents a valid model to study PD, especially when studying 
the SN. In addition, we suggested that the construct validity of the MPTP-model may 
improve when the mice are used at a later time point following MPTP treatment.
In chapter 4, a treadmill device was used to physically exercise MPTP-treated mice, in 
order to study the effects of physical exercise on this PD-model. First, we confirmed 
that MPTP treatment reduces the number of DA neurons in the SN and DA fibers in 
the striatum. Second, we showed that physical exercise is able to improve the motor 
function of MPTP-treated mice. And third, we performed RNA sequencing of six PD-
associated brain areas to study the effects of physical exercise on the transcriptome. 
We found that physical exercise particularly regulates CREB1- and bicuculine/
dalfampridine-mediated pathways in the prefrontal cortex and pedunculopontine 
nucleus, RICTOR-mediated pathways in the ventral tegmental area and dorsolateral 
striatum, and L-DOPA-mediated pathways in the SN and ventromedial striatum. Of 
note, physical exercise and L-DOPA generally exerted an opposite direction of effect 
on the expression of the mRNAs in the L-DOPA-mediated pathways. This indicated 
that physical exercise may counteract certain L-DOPA-mediated pathways, including 
those involved in sleep and cognitive function. Although L-DOPA administration 
greatly improves PD motor symptoms, chronic and/or high-dose L-DOPA use has been 
associated with L-DOPA-induced dyskinesia and may also negatively affect cognitive 
function. On the other hand, moderate physical exercise has no known detrimental 
effects, and has been shown to improve both motor and cognitive functions. Therefore, 
we speculated that physical exercise not only improves motor function, but may also 
alleviate some of the adverse effects associated with (chronic) L-DOPA use.
In chapter 5, we built a molecular landscape of amyotrophic lateral sclerosis (ALS) to 
provide insights into the molecular pathways underlying ALS etiology. In addition, we 
wanted to assess if the landscape building approach can be used to identify which 
underlying molecular pathways are unique to PD and ALS. We integrated the available 
GWAS data of sporadic ALS patients with other genes/proteins implicated in ALS 
etiology through other evidence, including familial ALS candidate gene association 
studies. We identified three main processes that interact and are crucial to maintain 
axonal functionality of motor neurons (the pathological substrate of ALS), i.e. (1) Rho-
GTPase signaling, (2) signaling involving estradiol, folate and methionine, and (3) 
ribonucleoprotein granule functioning and axonal transport. Estradiol is functionally 
involved in all three processes, and epidemiological findings together with our analysis 
of possible gender effects in a cohort of ALS patients indicated that estradiol may be 








the mechanisms underlying motor neuron degeneration in ALS, and that estradiol is 
an important modulator of these pathological mechanisms. Moreover, we saw that the 
landscape building approach resulted in different, unique mollecular pathways for ALS, 
compared to the PD landscape in chapter 2.
In chapter 6, the landscape building approach is discussed and the main findings of 
this thesis are put in a broader context. I have compared the PD and ALS landscapes, 
discussed the use of the landscape building approach in the identification of disease-
specific pathways and processes, and explored the putative druggable targets within 
the landscapes. I also explained the differences in interpretation of genetic and 
expression data, and analyzed the genes/proteins that overlap between the genetic 
and expression data sets. Further, by using our expression data of the MPTP-treated 
mice (chapter 4), I discussed if the hypothesis posed in chapter 3 (i.e. the construct 
validity of the MPTP model may improve when used at a later time point following 
MPTP treatment) still holds. Moreover, I explored if physical exercise not only has an 
effect on mRNAs that contribute to MPTP toxicity (chapter 4), but also has the potential 
to regulate mRNAs that contribute to the pathophysiology of PD. Lastly, I discussed how 
the landscape building approach can be used to achieve personalized medicine and I 
provided suggestions for future research.
Taken together, the research described in this thesis yields in-depth insights into 
the molecular mechanisms underlying PD and ALS, and as such contributes to 
our understanding of the etiology of these diseases and the future development 
of disease-modifying treatments. Moreover, our results provide knowledge of the 
molecular pathways underlying the beneficial effects of physical exercise on PD, and 











De ziekte van Parkinson komt voor bij 1-2% van de mensen boven 60 jaar en is daarmee, 
na de ziekte van Alzheimer, de meest voorkomende neurodegeneratieve ziekte. De 
ziekte van Parkinson wordt gekenmerkt door het doodgaan van dopaminerge (DA) 
neuronen in de substantia nigra (SN), een hersengebied dat zich in de middenhersenen 
bevindt. De degeneratie van deze neuronen vermindert de DA signalen naar het 
striatum en veroorzaakt daardoor motorische symptomen, zoals onvrijwillige trillingen 
(tremor), trage bewegingen (bradykinesie), stijfheid en posturale instabiliteit. Hoewel 
we al tientallen jaren weten dat in Parkinson patiënten DA neuronen in de SN dood 
gaan, weten we nog steeds niet precies waarom juist deze neuronen degenereren 
en welke moleculaire mechanismen verantwoordelijk zijn voor dit degeneratieve 
proces. Vanwege deze beperkte kennis van de mechanismen die ten grondslag 
liggen aan de ziekte van Parkinson is het tot nu toe onmogelijk geweest om een 
behandeling te ontwikkelen die de ziekte daadwerkelijk verandert. Hoewel de huidige 
behandelingen – bijv. L-DOPA toediening of lichaamsbeweging – de motorische 
symptomen van Parkinson kunnen verbeteren, wordt de progressie van de ziekte niet 
gestopt of vertraagd. In dit proefschrift heb ik mij gericht op het ontrafelen van de 
moleculaire mechanismen die onderliggend zijn aan de ziekte van Parkinson, en de 
mechanismen die betrokken zijn bij de effecten van lichaamsbeweging op een model 
voor Parkinson. Met dit onderzoek wilde ik onze kennis over de etiologie van Parkinson 
vergroten en nieuwe inzichten verschaffen in de werking van lichaamsbeweging op 
symptoomverlichting bij de ziekte Parkinson, om daarmee het onderzoeksveld een 
stap dichter bij de ontwikkeling van ziektemodificerende behandelingen te brengen.
In hoofdstuk 1 is een algemene inleiding op de ziekte van Parkinson gegeven 
waarin een historisch overzicht van de voortschrijdende inzichten in de klinische 
beschrijving en de pathofysiologie van de ziekte van Parkinson is beschreven. Daarna 
volgt een overzicht van de genetische- en omgevingsfactoren waarvan bekend is dat ze 
betrokken zijn bij het ontstaan van Parkinson. Tenslotte, is de methode uitgelegd die in 
dit proefschrift is gebruikt om grote datasets te interpreteren en te verwerken tot een 
zogenaamd moleculair landschap.
In hoofdstuk 2 werd de landschap-bouwmethode gebruikt om een moleculair landschap 
voor de ziekte van Parkinson te maken, uitgaande van genen / eiwitten die betrokken 
zijn bij Parkinson op grond van genoomwijde associatiestudies (GWASs), familiale 
kandidaat-genassociaties en functionele studies. In het moleculaire landschap van de 
ziekte van Parkinson konden we vier belangrijke biologische processen identificeren 
die met elkaar interageren en DA neuronfunctie en -dood reguleren, namelijk 
oxidatieve stressreactie, endosomaal-lysosomaal functioneren, endoplasmatisch 










zijn functioneel betrokken bij alle vier processen en daarop baseerden we de hypothese 
dat lipiden betrokken zijn bij de pathogenese van Parkinson. Vervolgens werd deze 
hypothese bevestigd doordat aangetoond kon worden dat er een gedeeld genetisch 
risico is op zowel lipide- / lipoproteïne-eigenschappen als de ziekte van Parkinson.
In hoofdstuk 3 hebben we het gebruik van muizen behandeld met de neurotoxine 
1-methyl-4-pheynl-1,2,3,6-tetrahydropyridine (MPTP), als een model voor de ziekte 
van Parkinson, op moleculair niveau gevalideerd. We vergeleken de genoomwijde 
mRNA expressie in de SN en het striatum van MPTP-behandelde muizen met die 
van parkinsonpatiënten, en vonden processen – bijv. vesiculair transport, exocytose, 
mitochondriale apoptose en DA neuron-specifieke transcriptie – die werden ontregeld 
in zowel het muismodel als in de parkinsonpatiënten. We concludeerden dat de MPTP-
behandelde muis een valide model is voor parkinsononderzoek, vooral met betrekking 
tot het bestuderen van de SN. Bovendien stelden we dat de constructvaliditeit van het 
MPTP-model mogelijk kan verbeteren wanneer de muizen worden gebruikt op een later 
tijdstip na MPTP-behandeling dan dat nu veelal gebruikelijk is.
In hoofdstuk 4 werd een loopband gebruikt om de effecten van lichaamsbeweging op 
MPTP-behandelde muizen te bestuderen. Eerst bevestigden we dat de behandeling met 
MPTP het aantal DA neuronen in de SN en de DA vezels in het striatum vermindert. 
Vervolgens hebben we aangetoond dat lichaamsbeweging de motorische functie van 
MPTP-behandelde muizen kan verbeteren. En als laatste hebben we een RNA sequentie-
analyse uitgevoerd om het effect van lichaamsbeweging op het transcriptoom 
van zes Parkinson-geassocieerde hersengebieden te bestuderen. We vonden dat 
lichaamsbeweging in het bijzonder CREB1- en bicuculine / dalfampridine-gereguleerde 
processen in de prefrontale cortex en pedunculopontinekern, RICTOR-gereguleerde 
processen in het ventrale tegmentale gebied en dorsolaterale striatum, en L-DOPA-
gereguleerde processen in de SN en het ventromedial striatum beïnvloedt. Van belang 
was de vinding dat lichaamsbeweging en L-DOPA over het algemeen een tegengestelde 
invloed hebben op de expressie van de mRNA’s in de door L-DOPA gereguleerde 
processen. Dit wijst erop dat lichaamsbeweging bepaalde L-DOPA-gereguleerde 
processen kan tegengaan, met inbegrip van processen die betrokken zijn bij slaap en 
cognitieve functie. Hoewel toediening van L-DOPA de motorische symptomen bij de 
ziekte van Parkinson sterk verbetert, wordt chronisch gebruik en / of gebruik van een 
hoge dosis L-DOPA geassocieerd met L-DOPA-geïnduceerde dyskinesie, en zou het 
mogelijk ook een nadelig effect hebben op cognitieve functie. Matige lichaamsbeweging 
heeft daarentegen geen bekende nadelige effecten en verbetert zowel motorische 
als cognitieve functies. Daarom speculeerden wij dat lichaamsbeweging niet alleen 
de motorische functies verbetert, maar mogelijk ook enkele van de bijwerkingen 











In hoofdstuk 5 bouwden we een moleculair landschap voor amyotrofe laterale sclerose 
(ALS) om inzicht te krijgen in de moleculaire mechanismen onderliggend aan de 
etiologie van ALS. Daarnaast wilden we bepalen of de methode voor het bouwen 
van landschappen gebruikt kan worden om unieke moleculaire mechanismen te 
identificeren onderliggend aan de degeneratie van neuronen in ofwel Parkinson of 
ALS. We integreerden de beschikbare GWAS-gegevens van sporadische ALS-patiënten 
met andere genen / eiwitten die geassocieerd zijn met de etiologie van ALS via andere 
bewijzen, met inbegrip van familiale ALS kandidaat-gen associatiestudies. We konden 
drie hoofdprocessen identificeren die interageren en cruciaal zijn voor de functionaliteit 
van axonen van motorneuronen (het pathologische substraat van ALS), namelijk (1) 
Rho-GTPase signalering, (2) signalering met estradiol, folaat en methionine, en (3) 
het functioneren van ribonucleoproteïne deeltjes en axonaal transport. Estradiol is 
functioneel betrokken bij alle drie processen, en epidemiologische bevindingen, samen 
met onze analyse van mogelijke geslachtseffecten in een cohort van ALS patiënten, 
duiden er op dat estradiol beschermend kan zijn. Kortom, we concludeerden dat het 
landschap diepgaande inzichten biedt in de mechanismen die ten grondslag liggen aan 
de degeneratie van motorneuronen in ALS en dat estradiol een belangrijke modulator 
van deze pathologische mechanismen is. Bovendien zagen we dat de methode voor 
het bouwen van  moleculaire landschappen resulteerde in andere, unieke moleculaire 
mechanismen in vergelijk met het Parkinson landschap in hoofdstuk 2.
In hoofdstuk 6 worden de belangrijkste bevindingen van dit proefschrift in een bredere 
context geplaatst. Ik heb de landschappen van Parkinson en ALS vergeleken, het 
gebruik van de landschap-bouwmethode voor de identificatie van ziektespecifieke 
mechanismen en processen bediscussieerd, en de mogelijke doelen binnen de 
landschappen onderzocht die in aanmerking kunnen komen voor verder onderzoek 
naar de ontwikkeling van geneesmiddelen. Ik heb ook de verschillen in interpretatie 
van genetische- en expressiedata besproken, en de genen / eiwitten die overlappen 
tussen de genetische- en expressiedatasets geanalyseerd. Door gebruik te maken 
van onze expressiegegevens van de MPTP-behandelde muizen (hoofdstuk 4), heb 
ik tevens bediscussieerd of de in hoofdstuk 3 gestelde hypothese (namelijk dat de 
constructvaliditeit van het MPTP-model kan verbeteren bij gebruik op een later 
tijdstip na de MPTP behandeling) nog steeds geldig is. Verder ben ik nagegaan of 
lichaamsbeweging niet alleen gevolgen heeft voor mRNA’s die bijdragen aan MPTP 
toxiciteit (hoofdstuk 4), maar ook het potentieel heeft om mRNA’s die bijdragen 
aan de pathofysiologie van Parkinson te beïnvloeden. Tenslotte besprak ik hoe de 
landschap-bouwmethode gebruikt kan worden om gepersonaliseerde geneeskunde te 
bewerkstelligen en heb ik suggesties verstrekt voor toekomstig onderzoek.










diepgaand inzicht levert in de moleculaire mechanismen die betrokken zijn bij 
de ziekte van Parkinson en ALS, en als zodanig bijdraagt  aan ons begrip van het 
ontstaan van deze ziekten en de toekomstige ontwikkeling van ziektemodificerende 
behandelingen. Daarnaast verschaffen onze resultaten kennis over de moleculaire 
processen die ten grondslag liggen aan de gunstige effecten van lichaamsbeweging op 
de ziekte van Parkinson, en is verder vastgesteld dat de landschap-bouwmethode een 












Promoveren doe je alleen, maar wel met de steun en inzet van anderen, welke ik dan 
ook uitdrukkelijke dank verschuldigd ben. 
Allereerst wil ik graag mijn promotoren en co-promotoren bedanken. Gerard, bedankt 
voor de mogelijkheid om te kunnen promoveren op jouw afdeling en voor de leerzame 
(en vaak uitvoerige) wetenschappelijke discussies waarvoor ik op elk moment van 
de dag kon binnenlopen. Ik waardeer het enorm dat je altijd de tijd nam om van 
inzicht te wisselen, ook al gaf je klokje (dat strategisch een paar minuten voorliep) 
al lang aan dat je naar een volgende afspraak moest. Bas bedankt voor de inspiratie, 
al was het op afstand. Het was altijd goed om mijzelf te realiseren dat alle datasets 
en muizenmodellen uiteindelijk in het teken staan van de verbetering van de zorg 
en behandeling van parkinsonpatiënten. Jasper, jouw kritische kijk op onderzoek 
heeft mij een betere wetenschapper gemaakt. Bedankt voor je steun en alle leuke 
discussies en gesprekken, die lang niet allemaal onderzoeksgebonden waren. Geert, 
door jou heeft mijn promotieonderzoek een duidelijke wending gekregen richting de 
moleculaire landschappen. Bedankt voor je hulp en optimisme als het onderzoek soms 
eindeloos leek te duren. Helaas werd dat optimisme (al dan niet terecht) ook nogal 
fanatiek doorgevoerd naar de prestaties van vooral de Belgische wielrenners in de 
voorjaarsklassiekers of de grote ronden…
Verder wil ik alle collega’s en studenten – maar met name Nick, Eric, Sharon, Jolien 
en Helena – waar ik door de jaren heen op de afdeling Moleculaire Dierfysiologie 
naast en samen mee heb mogen werken, bedanken voor jullie gezelligheid en hulp op 
het lab (tenminste, als ik het dan toch eindelijk eens in mijn hoofd had gehaald om 
daadwerkelijk gebruik te gaan maken van mijn labtafel…).
De basis voor dit proefschrift ligt – hoe kan het ook anders – bij mij familie. Pa en ma, 
ik heb bewondering voor de manier waarop jullie mij altijd onvoorwaardelijk steunen, 
altijd een luisterend oor zijn, en mij altijd hebben gestimuleerd om mijn eigen keuzes 
te maken. Zonder jullie was mij dit nooit gelukt. Eline en Bart, ik ben erg blij dat ik ook 
met mijn zus en broer over alles in het leven (promoveren en al het andere) kan praten, 
samen kan sporten, kan borrelen of een (dance)feestje kan vieren. Een betere zus en 
broer kan ik mij niet wensen!
Een mens wordt gevormd door de mensen om hem heen, en naast familie zijn dit 
vanzelfsprekend alle vrienden uit Oisterwijk en Nijmegen die er voor zorgen dat het 
leven meer is dan alleen studeren en werken. Allemaal bedankt voor jullie vriendschap, 
en de gezelligheid op terrassen, feestjes, in studentenkamers, collegezalen, woonkamers, 










de afgelopen jaren. Dat we dit nog lang mogen blijven doen! Voor de gezelligheid in 
de keuken (en daarbuiten) wil ik met name Luuk, Loek en Nan bedanken. Als ware 
keukenprinsen weten zij waar een promovendus naar verlangt na (of tijdens) een lange 
werkweek. Mannen bedankt!
Dat promotiefeestjes een grote impact kunnen hebben op je leven is mij volstrekt 
duidelijk. Dat gezegd hebbende, zal zelfs mijn eigen feest niet het promotiefeest van 
Tom Rouwette kunnen overtreffen, het feest waar ik Nienke ontmoette. Nienke, je 













Cornelius Jacobus Hendricus Maria Klemann (roepnaam: Koen) werd geboren op 28 
januari 1986 in Tilburg en groeide op in het Brabantse Oisterwijk. Na het behalen van 
zijn VWO diploma in 2004 (Durendael, Oisterwijk) met het profiel Natuur & Techniek 
is hij begonnen met de studie Natuurwetenschappen aan de Radboud Universiteit in 
Nijmegen. Na vier jaar is Koen alsnog van studie veranderd en heeft in 2011 cum laude 
de master van Moleculaire Levenswetenschappen behaald. Tijdens zijn studie liep 
Koen twee onderzoeksstages. Zijn eerste onderzoeksstage was op de afdeling Cellulaire 
Dierfysiologie (Prof. Eric Roubos) onder begeleiding van Dr. Tom Rouwette. Hier deed 
hij onderzoek naar de dynamische veranderingen in het brein na acute pijnstress. Dit 
onderzoek, samen met een scriptie op de afdeling Cellulaire Dierfysiologie resulteerden 
in zijn eerste twee wetenschappelijke publicaties. Zijn eindstage liep Koen onder 
begeleiding van Dr. Leonie Waanders bij Philips in Eindhoven, waar hij onderzoek 
deed naar de optimalisatie van een biomarker assay voor prostaatkanker. Ondanks 
dit uitstapje naar het bedrijfsleven lonkte de academische wereld en startte Koen 
eind 2011 zijn promotieonderzoek aan de afdeling Moleculaire Dierfysiologie (Prof. 
Gerard Martens) op de Radboud Universiteit resulterend in dit proefschrift. Sinds april 
2016 is Koen werkzaam bij DrugTarget ID, een spin-out van de Radboud Universiteit 
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Abstract DGCN for Donders Series
Donders Graduate School for Cognitive Neuroscience
For a successful research institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and 
Behaviour established the Donders Graduate School for Cognitive Neuroscience 
(DGCN), which was officially recognised as a national graduate school in 2009. The 
Graduate School covers training at both Master’s and PhD level and provides an 
excellent educational context fully aligned with the research programme of the 
Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine and 
related disciplines. Selective admission and assessment centers guarantee the 
enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD 
alumni show a continuation in academia with postdoc positions at top institutes 
worldwide, e.g. Stanford University, University of Oxford, University of Cambridge, 
UCL London, MPI Leipzig, Hanyang University in South Korea, NTNU Norway, 
University of Illinois, North Western University, Northeastern University in Boston, 
ETH Zürich, University of Vienna etc.. DGCN PhD graduates obtain positions outside 
the academia for example as: 
-  specialists in a medical environment, mainly in genetics, geriatrics, psychiatry 
and neurology,
-  specialists in a psychological environment, e.g. as specialist in neuropsychology, 
psychological diagnostics or therapy, or
-  in higher education, e.g. as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of 
research and development. Fewer graduates stay in a research environment as 
lab coordinators, technical support or policy advisors. Upcoming possibilities are 
positions in the IT sector and management position in pharmaceutical industry. In 
general, the PhDs graduates almost invariably continue with high-quality positions 
that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please 
visit:
http://www.ru.nl/donders/graduate-school/donders-graduate/

